P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1AP H A S E 1/ [ADDRESS_370710] u d y S p o ns or: Bi o N Tec h 
St u d y C o n d ucte d b y: [COMPANY_007] 
St u d y I nter ve nti o n N u m ber: P F -[ADDRESS_370711] u d y I nter ve nti o n N a me: C o m bi nati o n C O VI D- 1 9 a n d I nfl ue nza 
m o d R N A Vacci ne 
U S I N D N u m ber: [ADDRESS_370712] a C T / E U C T N u m ber: N ot a p plica ble 
Cli nic al Tri als. g o v I D: N C T [ADDRESS_370713] a n N u m ber: N ot a p plica ble 
Pr ot oc ol N u m ber: C 5 2 6 1 0 0 1 
P h ase: 1/ 2 
Brief Title: 
A St u d y  t o E val uate t he Safet y , T olera bilit y, a n d I m m u n o ge nicit y of C o m bi ne d M o difie d 
R N A Vacci ne Ca n di dates A gai nst C O VI D -1 9 a n d I nfl ue nza 
T his d oc u me nt a n d acc o m pa n yi n g materials c o ntai n c o nfi de ntial i nf or mati o n bel o n gi n g t o [COMPANY_007].  E xce pt as 
ot her wise a gree d t o i n writi n g, b y acce pti n g or re vie wi n g t hese d oc u me nts, y o u a gree t o h ol d t his i nf or mati o n 
i n c o nfi de nce a n d n ot c o p y or discl ose it t o ot hers (e xce pt w here re q uire d b y a p plica ble la w) or use it f or 
u na ut h orize d p ur p oses.  I n t he e ve nt of a n y act ual or s us pecte d breac h of t his o bli gati o n, [COMPANY_007] m ust be 
pr o m ptl y n otifie d. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 2D oc u me nt Hist or y 
D oc u me nt Versi o n D ate 
A me n d me nt [ADDRESS_370714] of c o u ntr y  healt h a ut h orities a n d I R Bs/ E Cs a n d a n y  P A C L (s). 
Pr ot oc ol A me n d me nt S u m m ar y of C h a n ges T a ble 
A m e n d me nt 6 ( 0 9 Fe b r u ar y 2 0 2 4) 
O ver all R ati o n al ef or t he A me n d me nt:   
Pr ot oc ol re visi o ns t o re m o ve partici pa nts ≥ [ADDRESS_370715] orat or y.  
Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
T hr o u g h o ut Re m o ve d refere nce t o i nitial -e nr oll me nt 
a n d e x pa n de d -e nr oll me nt gr o u ps T o ali g n wit h re m o val 
of t he ≥[ADDRESS_370716] t hat t his is a 
master pr ot oc ol T o ali g n wit h c urre nt 
g ui da nce N o ns u bsta ntial 
Thr o u g h o ut Re vise d te xt t o ali g n wit h t he re m o val 
of t he i nitial -e nr oll me nt a n d e x pa n de d -
e nr oll me nt gr o u ps T o ali g n wit h re m o val 
of t he ≥[ADDRESS_370717] u d y B S u bsta ntial 
T hr o u g h o ut Re m o ve d a n y te xt referri n g t o m ore 
t ha n 1d ose (e g ,“at least,” “t he first ,” 
“eac h d ose” ) T o e ns ure t hat 
ver bia ge reflects o nl y 
1vacci nati o n i n t he 
st u dies N o ns u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 3Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n 1. [ADDRESS_370718] u d y 
I nter ve nti o n(s) 
A d mi nistere d f or 
S u bst u d y B Re m o ve d ar ms c o ntai ni n g place b o fr o m 
S u bst u d y B i nter ve nti o ns T o ali g n wit h re m o val 
of p orti o ns of 
S u bst u d y B S u bsta ntial 
Secti o n s1. 1 S y n o psis, 
1 0. 1 1. 3 O bjecti ves, 
E n d p oi nts ,a n d 
Esti ma n ds 
( S u bst u d y A) ,a n d 
1 0. 1 1. 9 Statistical 
C o nsi derati o ns –
S u bst u d y A U p date d S u bst u d y A o bjecti ves, 
e n d p oi nts, a n d esti ma n ds t o m o ve 
Wee k [ADDRESS_370719] u d y 
I nter ve nti o n(s) a n d 
C o nc o mita nt T hera p y U p date d Ta ble [ADDRESS_370720] u d y Data A d de d w e bsite i nf or mati o n f or 
Cli nical Trials . g o v a n d [COMPANY_007]. T o ali g n wit h t he 
c urre nt pr ot oc ol 
t e m plate N o ns u bsta ntial 
Secti o n 1 0. 1 0. 4 
Rec or di n g/ Re p orti n g 
a n d F oll o w -U p of 
Me dical De vice 
Deficie ncies U p date d la n g ua ge t o t he c urre nt 
pr ot oc ol te m plate T o ali g n wit h t he 
c urre nt pr ot oc ol 
t e m plate N o ns u bsta ntial 
Secti o n 1 0. 5. 2 Fe male 
Partici pa nt 
Re pr o d ucti ve I ncl usi o n 
Criteria A d de d t he secti o n T o ali g n wit h u p dates 
t o t he pr ot oc ol 
t e m plate N o ns u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 4T A B L E O F C O N T E N T S 
LI S T O F T A B L E S ................................ ................................ ................................ ................... [ADDRESS_370721] u d y  Rati o nale ................................ ................................ ....................................... 4 3 
2. 2. Bac k gr o u n d ................................ ................................ ............................................. 4 5 
2. 2. 1. S A R S -C o V -2.............................................................................................. 4 5 
2. 2. 2. I nfl ue nza ................................ ................................ ..................................... 4 5 
2. 2. 3. Cli nical O ver vie w ................................ ....................................................... 4 6 
2. 2. 3. 1. S A R S -C o V -2............................................................................. 4 6 
2. 2. 3. 2. I nfl ue nza ................................ .................................................... 4 8 
2. 2. 3. 3. C o m bi ne d I nfl ue nza a n d C O VI D -1 9 Vacci nes ......................... 4 9 
2. 3. Be nefit/ Ris k Assess me nt ................................ ......................................................... 5 0 
2. 3. 1. Ris k Assess me nt ................................ ......................................................... 5 0 
2. 3. 2. Be nefit Assess me nt ................................ ..................................................... 5 2 
2. 3. 3. O verall Be nefit/ Ris k C o ncl usi o n ................................ ................................ [ADDRESS_370722] u d y  P o p ulati o n ................................ ................................ .... 5 3 
4. 2. 2. C h oice of C o ntrace pti o n/ Barrier Re q uire me nts ................................ ......... 5 3 
4. 3. J ustificati o n f or D ose ................................ .............................................................. 5 3 
4. 3. 1. Bi vale nt B N T 1 6 2 b 2 ( Ori gi nal/ O mi B A. 4/ B A. 5) ................................ ....... 5 3 
4. 3. 2. qI R V ................................ ................................ ........................................... 5 4 
4. 3. 3. qI R V/ Bi vale nt B N T 1 6 2 b 2 ( Ori gi nal/ O mi B A. 4/ B A. 5) ............................. 5 4 
4. 3. 4. tI R V/ Bi vale nt B N T 1 6 2 b 2 ( Ori gi nal/ O mi B A. 4/ B A. 5) .............................. 5 4 
4. 3. 5. bI R V/ Bi vale nt B N T 1 6 2 b 2 ................................ ................................ .......... 5 5 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 54. 4. E n d of St u d y  Defi niti o n ................................ .......................................................... [ADDRESS_370723] y le C o nsi derati o ns ................................ .......................................................... 5 6 
5. 3. 1. C o ntrace pti o n ................................ .............................................................. 5 6 
5. 4. Scr ee n Fail ures ................................ ................................ ........................................ 5 6 
5. 5. Criteria f or Te m p oraril y  Dela y i n g 
E nr oll me nt/ Ra n d o mizati o n/ A d mi nistrati o n of St u d y  I nter ve nti o n ........................... 5 6 
6. S T U D Y I N T E R V E N TI O N( S) A N D C O N C O MI T A N T T H E R A P Y ................................. [ADDRESS_370724] u d y  I nter ve nti o n(s) A d mi nistere d ................................ ........................................ [ADDRESS_370725] u d y ...................... 6 4 
6. 8. Treat me nt of O ver d ose ................................ ............................................................ 6 4 
6. 9. Pri or a n d C o nc o mita nt T hera p y................................ .............................................. 6 5 
7. DI S C O N TI N U A TI O N O F S T U D Y I N T E R V E N TI O N A N D P A R TI CI P A N T 
DI S C O N TI N U A TI O N/ WI T H D R A W A L ................................ ........................................... [ADDRESS_370726] u d y  I nter ve nti o n ................................ .................................... 6 5 
7. 2. Partici pa nt Disc o nti n ua ti o n/ Wit h dra wal Fr o m t he St u d y ....................................... [ADDRESS_370727] t o F oll o w -U p ................................ ................................ ................................... 6 6 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 68. S T U D Y A S S E S S M E N T S A N D P R O C E D U R E S ............................................................... 6 7 
8. 1. A d mi nistrati ve Pr oce d ures ................................ ...................................................... 6 7 
8. 2. Efficac y  a n d/ or I m m u n o ge nicit y  Assess me nts ....................................................... [ADDRESS_370728]............................................................. 7 9 
8. 4. 7. 1. Lac k of Efficac y ................................ ........................................ 8 0 
8. 4. 8. Me dical De vice Deficie ncies ................................ ................................ ...... 8 0 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 78. 4. 8. 1. Ti me Peri o d f or Detecti n g Me dical De vice Deficie ncies ......... [ADDRESS_370729] me nt ................................ .............................................. 8 3 
9. 2. A nal y sis Sets ................................ ................................ ........................................... 8 3 
9. 3. Statistical A nal y ses ................................ ................................ ................................. 8 3 
9. 3. 1. Ge neral C o nsi derati o ns ................................ ............................................... 8 3 
9. 3. 1. 1. A nal y ses f or Bi nar y  Data .......................................................... 8 4 
9. 3. 1. 2. A nal y ses f or C o nti n u o us Data ................................................... 8 4 
9. 4. I nteri m A nal ys es ................................ ................................ ..................................... 8 5 
9. 5. Sa m ple Size Deter mi nati o n ................................ ..................................................... 8 5 
1 0. S U P P O R TI N G D O C U M E N T A TI O N A N D O P E R A TI O N A L 
C O N SI D E R A TI O N S ................................ ................................ .......................................... 8 6 
1 0. 1. A p pe n di x 1: Re g ulat or y , Et hical, a n d St u d y  O versi g ht C o nsi derati o ns ............... [ADDRESS_370730] ure ................................ ............................................... 8 9 
1 0. 1. 5. 1. Data M o nit ori n g C o m mittee ................................................... 8 9 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370731] u d y  a n d Site Start a n d Cl os ure ................................ .............................. 9 2 
1 0. 1. 1 0. P u blicati o n P olic y ................................ ................................................... 9 3 
1 0. 1. 1 1. S p o ns or’s Me dicall y  Q ualifie d I n di vi d ual .............................................. 9 3 
1 0. 2. A p pe n di x 2: Cli nical La b orat or y  Tests ................................ ................................. 9 5 
1 0. 3. A p pe n di x 3: A d verse E ve nts: Defi niti o ns a n d Pr oce d ures f or Rec or di n g, 
E val uati n g, F oll o w -U p, a n d Re p orti n g ................................ ..................................... 9 6 
1 0. 3. 1. Defi niti o n of A E ................................ ....................................................... 9 6 
1 0. 3. 2. Defi niti o n of a n S A E ................................ ................................................ 9 7 
1 0. 3. 3. Rec or di n g/ Re p orti n g a n d F oll o w -U p of A Es a n d/ or S A Es D uri n g 
t he Acti ve C ollecti o n Peri o d ................................ ............................................ 9 9 
1 0. 3. 4. Re p orti n g of S A Es ................................ .................................................. 1 0 2 
1 0. 4. A p pe n di x 4: Ge netics ................................ .......................................................... 1 0 4 
1 0. 5. A p pe n di x 5: C o ntrace pti ve a n d Barrier G ui da nce .............................................. 1 0 5 
1 0. 5. 1. Male Partici pa nt Re pr o d ucti ve I ncl usi o n Criteria .................................. 1 0 5 
1 0. 5. 2. Fe male Partici pa nt Re pr o d ucti ve I ncl usi o n Criteria ............................... 1 0 5 
1 0. 5. 3. W o ma n of C hil d beari n g P ote nt ial .......................................................... 1 0 6 
1 0. 5. 4. C o ntrace pti o n Met h o ds ................................ ........................................... 1 0 7 
1 0. 6. A p pe n di x 6: L i ver Safet y : S u g geste d Acti o ns a n d F oll o w -U p Assess me nts ..... 1 0 9 
1 0. 7. A p pe n di x 7: Ki d ne y  Safet y  M o nit ori n g G ui deli nes ........................................... 1 1 1 
1 0. 7. 1. La b orat or y  Asses s me nt of C ha n ge i n Ki d ne y  F u ncti o n a n d 
Detecti o n of Ki d ne y  I nj ur y ................................ ............................................ 1 1 1 
1 0. 7. 2. A ge -S pecific Ki d ne y  F u ncti o n Calc ulati o n Rec o m me n dati o ns ............. 1 1 1 
1 0. 7. 2. 1. A d ults ( 1 8 Years a n d A b o ve) –2 0 2 1 C K D -E PI 
E q uati o ns......................................................................................... 1 1 1 
1 0. 7. 3. A d verse E ve nt Gra di n g f or Ki d ne y  Safet y La b orat or y  
A b n or malities ................................ ................................ ................................. 1 1 1 
1 0. 8. A p pe n di x 8: Criteria f or All o wi n g I ncl usi o n of Partici pa nts Wit h C hr o nic 
Sta ble HI V, H C V, or H B V I nfecti o n ................................ ...................................... 1 1 2 
1 0. 9. A p pe n di x 9: E C G Fi n di n gs of P ote ntial Cli nical C o ncer n ................................. 1 1 3 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 91 0. 1 0. A p pe n di x 1 0: A Es, A D Es, S A E s, S A D Es, U S A D Es, a n d De vice 
Deficie ncies: Defi niti o ns a n d Pr oce d ures f or Rec or di n g, E val uati n g, F oll o w -
U p, a n d Re p orti n g i n Me dical De vice St u dies........................................................ 1 1 5 
1 0. 1 0. 1. Defi niti o n of A E a n d A D E ................................ ................................... 1 1 5 
1 0. 1 0. 2. Defi niti o n of S A E, S A D E, a n d U S A D E .............................................. 1 1 5 
1 0. 1 0. 3. Defi niti o n of De vice Deficie nc y ........................................................... 1 1 6 
1 0. 1 0. 4. Rec or di n g/ Re p orti n g a n d F oll o w -U p of Me dical De vice 
Deficie ncies ................................ ................................ .................................... 1 1 6 
1 0. 1 0. 5. Re p orti n g of S A Es ................................ ................................................ 1 1 8 
1 0. 1 0. 6. Re p orti n g of S A D Es ................................ ............................................. 1 1 9 
1 0. 1 1. A p pe n di x 1 1: S u bst u d y  A ( P hase 1) ................................ ................................. 1 2 0 
1 0. 1 1. 1. S o A –S u bst u d y  A ( P hase 1) ................................ ................................ [ADDRESS_370732] u d y  A ................................................ 1 2 2 
1 0. 1 1. 2. 3. Be nefit/ Ris k Assess me nt f or S u bst u d y A ........................... 1 2 2 
1 0. 1 1. 3. O bjecti ves, E n d p oi nts, a n d Esti ma n ds ( S u bst u d y  A) ........................... [ADDRESS_370733] u d y  A E xcl usi o n Criteria ............................................ 1 2 8 
1 0. 1 1. 5. 3. Criteria f or Te m p oraril y  Dela y i n g 
E nr oll me nt/ Ra n d o mizati o n/ A d mi nistrati o n of St u d y  
I nter ve nti o n f or S u bst u d y  A ............................................................ [ADDRESS_370734] u d y  I nter ve nti o n(s) A d mi nistere d f or S u bst u d y  A ........... [ADDRESS_370735] u d y  A ..................................... 1 3 4 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370736] u d y  A I nter ve nti o n a n d Partici pa nt 
Disc o nti n uati o n/ Wit h dra wal ................................ .......................................... [ADDRESS_370737] u d y  A ....................................... 1 3 9 
1 0. 1 1. 9. Statistical C o nsi derati o ns –S u bst u d y  A ............................................... [ADDRESS_370738] u d y A ........................ 1 5 3 
1 0. 1 2. A p pe n di x 1 2: S u bst u d y  B ( P hase 1/ 2) .............................................................. 1 5 5 
1 0. 1 2. 1. S o A –S u bst u d y  B ( P hase 1/ 2) .............................................................. [ADDRESS_370739] u d y  B ................................................ 1 5 7 
1 0. 1 2. 2. 3. Be nefit/ Ris k Assess me nt f or S u bst u d y B ............................ 1 5 7 
1 0. 1 2. 3. O bjecti ves, E n d p oi nts, a n d Esti ma n ds ( S u bst u d y  B) ........................... [ADDRESS_370740] u d y B ........ 1 6 1 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370741] u d y  B E xcl usi o n Criteria ............................................ 1 6 3 
1 0. 1 2. 5. 3. Criteria f or Te m p oraril y  Dela y i n g 
E nr oll me nt/ Ra n d o mizati o n/ A d mi nistrati o n of St u d y  
I nter ve nti o n f or S u bst u d y  B ............................................................ [ADDRESS_370742] u d y  I nter ve nti o n(s) A d mi n istere d f or S u bst u d y  B ........... [ADDRESS_370743] u d y  B I nter ve nti o n a n d Partici pa nt 
Disc o nti n uati o n/ Wit h dra wal ................................ .......................................... [ADDRESS_370744] u d y  B ..................................... 1 8 2 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370745] u d y  B ............................... 1 8 5 
1 0. 1 2. 9. Statistical C o nsi derati o ns –S u bst u d y  B ............................................... [ADDRESS_370746] u d y B ........................ 1 9 0 
1 0. 1 3. A p pe n di x 1 3: Pr ot oc ol A me n d me nt Hist or y ..................................................... 1 9 1 
1 0. 1 4. A p pe n di x 1 4: A b bre viati o ns ................................ ............................................. [ADDRESS_370747] u d y  A: qI R V/ Bi vale nt B N T 1 6 2 b 2 ( Ori gi nal/ O mi B A. 4/ B A. 5) 
Dose -Le vel C o m bi nati o ns........................................................................ [ADDRESS_370748] u d y  B: All Vacci ne Gr o u ps .............................................................. [ADDRESS_370749] u d y  B: Vacci ne Details .......................................... [ADDRESS_370750] 1 A E b y  Ass u me d Tr ue E ve nt 
Rate ................................ ................................ ......................................... 1 9 0 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 3 1. P R O T O C O L S U M M A R Y 
1. 1. S y n o psis 
Pr ot oc ol Title: 
A P hase 1/ [ADDRESS_370751] C O VI D -1 9 a n d I n fl ue nza i n Healt h y 
I n di vi d uals 
Brief Title: 
A St u d y  t o E val uate t he Safet y , T olera bilit y, a n d I m m u n o ge nicit y of C o m bi ne d M o difie d 
RN A Vacci ne Ca n di dates A gai nst C O VI D -1 9 a n d I nfl ue nza 
Re g ul at or y A ge nc y I de ntific ati o n N u m ber(s): 
U S I N D N u m ber: [ADDRESS_370752] a C T / E U C T N u m ber: N ot a p plica ble 
Cli nic al Tri als. g o v I D: N C T [ADDRESS_370753] a n N u m ber: N ot a p plica ble 
Pr ot oc ol N u m ber: C 5 2 6 1 0 0 1 
P h ase: 1/ 2 
R ati o n ale: 
T his master pr ot oc ol descri bes t he i n vesti gati o nal pla n of a c o m bi nati o n vacci ne c o ntai ni n g 
m o difie d R N A c o m p o ne nts e nc o di n g pr otei ns of t he S A R S -C o V -2 pref usi o n s pi [INVESTIGATOR_2531] a n d 
i nfl ue nza H A a nti ge ns .T his c o m bi nati o n vacci ne ai ms t o si m plif y  vacci nati o n practices f or 
t he pre ve nti o n of 2p ote ntiall y  seri o us res pi[INVESTIGATOR_1305] y  ill nesses :i nfl ue nza a n d C O VI D - 1 9.    
B N T 1 6 2 b 2 ( C o mir nat y®) is a m o d R N A -base d vacci ne t hat, as of Ja n uar y  2 0 2 3 , has bee n 
gra nte d f ull mar keti n g a ut h orizati o n, c o n diti o nal mar keti n g a ut h orizati o n, E U A, or 
te m p orar y  a ut h orizati o n i n a t otal of m ore t ha n 1 8 4 c o u ntries f or t he pre ve nti o n of 
C O VI D -1 9 ca use d b y S A R S -C o V - 2.  T he ori gi nal versi o n of B N T 1 6 2 b 2 e nc o des t he 
ancestral W u ha n -H u -1strai n s pi [INVESTIGATOR_303615] y c o pr otei n.   I n t he U S, it has bee n f ull y  lice nse d f or use 
i n i n di vi d uals 1 2 y ears of a ge a n d a b o ve as of 0 8 J ul y  2 0 2 2.  Fr o m 18 A pril 2 0 2 3 u ntil 
1 1 Se pte m ber 2 0 2 3 ,t he bi vale nt ori gi nal */ O micr o n B A. 4/ B A. 5 C O VI D -1 9 vacci n e ha dbee n 
a ut h orize d f or use f or all d oses a d mi nistere d t o i n di vi d ua ls 6 m o nt hs of a ge a n d ol der .
All versi o ns of t he vacci ne e nc o de t he S A R S -C o V - 2 pref usi o n s pi [INVESTIGATOR_303616] n (s) i n m o d R N A 
e nca ps ulate d i n R N A -L N Ps , w hic h has de m o nstrate d p ote nt i m m u n o ge nicit y , hi g h V E, a n d a 
fa v ora ble safet y  pr ofile i n P hase 1, 2, a n d 3 h u ma n trials, as well as i n real -w orl d usa ge.  As 
S A R S -C o V -2 c o nti n ues t o circ ulate, at ver y  hi g h le vels, [COMPANY_007]/ Bi o N Tec h are i n vesti gati n g 
R N A -base d C O VI D- [ADDRESS_370754] C O VI D -1 9 ca use d b y  e mer ge nt 
a n d p ote ntiall y  m ore a nti ge nicall y di verse varia nts .  T heref ore, b i vale nt B N T 1 6 2 b 2 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 4 ( ori gi nal */ O mi B A. 4/ B A. 5) ,c o nsisti n g of t he ori gi nal S A R S -C o V -2pref usi o n s pi [INVESTIGATOR_303616] n 
m o d R N A, tar geti n g t he a ncestral strai n of t he vir us, i n c o m bi nati o n wit h m o d R N A e nc o di n g 
t he s pi [INVESTIGATOR_303616] n of t he O micr o n varia nt ( B A. 4/ B A. 5 s u bli nea ge) ,will be use d i n t his st u d y .
[COMPANY_007] als o has a q ua dri vale nt m o d R N A- base d i nfl ue nza vacci ne, q I R V, c urre ntl y i n P hase 3 
de vel o p me nt.  qI R V e nc o des t he H A a nti ge n of i nfl ue nza strai ns (  
) rec o m me n de d seas o nall y b y  W H O f or t he i nfl ue nza seas o n. Base d o n P hase [ADDRESS_370755] u d y ,b y  a ge strat u m, is µg f or partici pa nts 1 8 t hr o u g h 6 4 ye ars of a ge a n d  µg f or 
partici pa nts ≥6 5 y ears of a ge. 
T he W H O rec o m me n dati o n f or t he c o m p ositi o n of i nfl ue nza vacci nes i n t he 2 0 2 3 - 2 0 2 4 
n ort her n he mis p here i nfl ue nza seas o n i ncl u des b ot h a q ua dri vale nt vacci ne a n d a tri vale nt 
vacci ne , t he latter wit h o ut t he B/ Ya ma gata li nea ge, w hic h has n ot bee n see n i n circ ulati o n 
si nce Marc h [ADDRESS_370756] o ber 2 0 2 3 V R B P A C rec o m me n dati o ns, t he 
c o m mittee v ote d t o e xcl u de t he B/ Ya ma gata li nea ge a nti ge n c o m p o ne nt fr o m q ua dri vale nt 
i nfl ue nza vacci nes as s o o n as p ossi ble. T he st u d y  desi g n t heref ore i ncl u des a q ua dri vale nt 
i nfl ue nza vacci ne ( qI R V) a n d a tri vale nt i nfl ue nza vacci ne (tI R V) w he n c o m bi ne d wit h 
B N T 1 6 2 b 2 (t he [COMPANY_007]- Bi o N Tec h C O VI D- 1 9 vacci ne ). 
Gi ve n t hat a n n ual vacci ne pr o gra ms i n t he U S a n d li kel y  ot her parts of t he w orl d a gai nst b ot h 
i nfl ue nza a n d C O VI D - [ADDRESS_370757] i nfl ue nza w he n c o m bi ne d 
wit h B N T 1 6 2 b 2 (bi vale nt ori gi nal */ O mi B A. 4/ B A. 5 ). This e val uati o n will i nitiall y  be 
c o n d ucte d t hr o u g h t he f oll o wi n g s u bst u dies :
S u bst u d y  A: A P hase [ADDRESS_370758] u d y  i n u p t o a p pr o xi matel y  3 6 0 partici pa nts 
( 1 8 0 partici pa nts 1 8 t hr o u g h 6 4 ye ars of a ge a n d 1 8 0 partici pa nts ≥ 6 5 y ears of a ge) t o 
descri be t he safet y of q I R V a n d bi vale nt B N T 1 6 2 b 2 ( ori gi nal */ O mi B A. 4/ B A. 5) at 
3d ose -le vel c o m bi nati o ns. 
S u bst u d y  B: A P hase 1/ [ADDRESS_370759] u d y  t o descri be t he safet y a n d i m m u n o ge nicit y  of I R V 
( qI R V or tI R V) w he n a d mi nistere d i n c o m bi nati o n wit h bi vale nt B N T 1 6 2 b 2 
( ori gi nal */ O mi B A. 4/ B A. 5) , a n d lice nse d QI V gi ve n c o nc urre ntl y wit h bI R V/ bi vale nt 
B N T 1 6 2 b 2 ( ori gi nal */ O mi B A. 4/ B A. 5) i n healt h y  a d ults 1 8 t hr o u g h 6 4 ye ars of a ge. 
* Ori gi nal refers t o t he a ncestral strai n ( W u ha n -H u -1; U S A -W A 1/ 2 0 2 0), als o referre d t o i n 
t his pr ot oc ol as t he refere nce strai n. 
Base d o n preli mi nar y  data fr o m S u bst u d y  A, S u bst u d y  B will st u d y a d diti o nal c o m bi nati o n s
of C O VI D -1 9/i nfl ue nza m o d R N A vacci ne s, i n cl u di n g tI R V: µ g  
 pl us µ g bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) ,bI R V : µ g  pl us 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI C CI 
C CI C CI 
C CI 
C CI C CI C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 5 µ g bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) gi ve n c o nc urre ntl y wit h QI V i n t he 
o p p osite ar m , a n d a d diti o nal n o vel c o m bi nati o ns of qI R V µ g  
.T his is s u p p orte d b y  a n acce pta ble t olera bilit y  
pr ofile f or a d ose u p t o µ g of a c o m bi nati o n of i nfl ue nza m o d R N A a n d C O VI D - [ADDRESS_370760] u d y  A f or b ot h t he 1 8 -t hr o u g h 
6 4- ye ar a ge gr o u p a n d t he ≥6 5 -year a ge gr o u p b y  t he s p o ns or ’s I R C i n Marc h 2 0 2 3 a n d 
Ma y 2 0 2 3, c o nti n ue d use of C O VI D -1 9/i nfl ue nza c o m bi nati o n vacci nes u p t o µ g 
ma xi m u m R N A d ose was c o nsi dere d acce pta ble f or c o nti n u ati o n i nt o S u bst u d y  B .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
C CI C CI 
C CI 
C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 6 O bjecti ves, E n d p oi nts, a n d Esti m a n ds: 
S u bst u d y A ( P h ase 1) 
O bjecti ves Esti m a n ds E n d p oi nts 
Pri m ar y S afet y Pri m ar y S afet y Pri m ar y S afet y 
T o descri be t he safet y a n d t olera bilit y of 
qI R V/ bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) at vari o us 
d ose -le vel c o m bi nati o ns i n partici pa nts 
≥ 1 8 years of a ge I n partici pa nts 1 8 t hr o u g h 6 4 years of a ge a n d ≥ [ADDRESS_370761] u d y i nter ve nti o n, t he 
perce nta ge of partici pa nts re p orti n g: 
L ocal reacti o ns f or u p t o 7 da ys f oll o wi n g vacci nati o n 
S yste mic e ve nts f or u p t o 7 da ys f oll o wi n g vacci nati o n 
A E s fr o m vacci nati o n t hr o u g h 4 wee ks after vacci nati o n 
S A Es fr o m t he first vacci nati o n t hr o u g h 6 m o nt hs after 
vacci nati o n L ocal reacti o ns ( pai n at t he i njecti o n site, re d ness, a n d 
s welli n g) 
S yste mic e ve nts (fe ver, fati g ue, hea dac he, c hills, 
v o miti n g, diarr hea, ne w or w orse ne d m uscle pai n, a n d 
ne w or w orse ne d j oi nt pai n) 
A Es 
S A Es 
T he perce nta ge of partici pa nts wit h: 
A b n or mal tr o p o ni n I la b orat or y val ues 2 da ys a n d 1 wee k after 
vacci nati o n Tr o p o ni n I la b orat or y para meters detaile d i n t he pr ot oc ol 
T he perce nta ge of partici pa nts wit h: 
Ne w E C G a b n or malities 2 da ys a n d 1 wee k after vacci n ati o n E C G a b n or malities c o nsiste nt wit h pr o ba ble or p ossi ble 
m y o car ditis or pericar ditis as defi ne d i n t he pr ot oc ol 
Sec o n d ar y Sec o n d ar y Sec o n d ar y 
T o descri be t he i m m u ne res p o nses elicite d 
b y qI R V/ bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) at vari o us 
d ose -le vel c o m bi nati o ns i n partici pa nts 
≥ 1 8 years of a ge I n partici pa nts 1 8 t hr o u g h 6 4 years of a ge a n d ≥ [ADDRESS_370762] yi n g wit h t he ke y pr ot oc ol criteria (e val ua ble 
partici pa nts): 
G M Ts bef ore vacci nati o n a n d at 4 wee ks after vacci nati o n
G M F R fr o m bef ore vacci nati o n t o 4 wee ks after vacci nati o n 
T he pr o p orti o n of partici pa nts ac hie vi n g H AI ser oc o n versi o n a
f or eac h strai n at 4 wee ks after vacc i nati o n 
T he perce nta ge of partici pa nts wit h H AI titers ≥ 1: 4 0 f or eac h 
strai n bef ore vacci nati o n a n d at 4 wee ks after vacci nati o n 
T he perce nta ge of partici pa nts ac hie vi n g H AI ser oc o n versi o n f or 
all strai ns at 4 wee ks after vacci nati o n 
T he perce nta ge of partici pa nts wit h H AI titers ≥ 1: 4 0 f or all 
strai ns at 4 wee ks after vacci nati o n H AI titers f or t he matc he d seas o nal strai ns (  
rec o m me n de d b y W H O 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370763] u d y A ( P h ase 1) 
O bjecti ves Esti m a n ds E n d p oi nts 
I n partici pa nts 1 8 t hr o u g h 6 4 years of a ge a n d ≥ 6 5 years of a ge, 
se paratel y, ha vi n g recei ve d qI R V/ bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) a n d c o m pl yi n g wit h t h e ke y pr ot oc ol 
criteria (e val ua ble partici pa nts): 
G M Ts bef ore vacci nati o n a n d at 4 wee ks after vacci nati o n f or 
eac h strai n 
G M F R fr o m bef ore vacci nati o n t o 4 wee ks after vacci nati o n f or 
eac h strai n 
Perce nta ges of partici pa nts wit h ser ores p o nse bat 4 wee ks after 
vacci nati o n f or eac h strai n S A R S -C o V -2 O micr o n B A. 4/ B A. 5 –ne utralizi n g titers 
S A R S -C o V -2 refere nce -strai n –ne utralizi n g titers 
E x pl or at or y E x pl or at or y E x pl or at or y 
T o descri be t he i m m u ne res p o nses elicite d 
b y qI R V/ bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) at vari o us 
d ose -le vel c o m bi nati o ns i n partici pa nts 
≥ 1 8 years of a ge I n partici pa nts 1 8 t hr o u g h 6 4 years of a ge a n d ≥ [ADDRESS_370764] yi n g wit h t he ke y pr ot oc ol criteria (e val ua ble 
partici pa nts): 
G M Ts bef ore vacci nati o n a n d at 1 a n d 8 wee k safter vacci nati o n 
G M F R fr o m bef ore vacci nati o n t o 1 wee k after vacci nati o n 
T he pr o p orti o n of partici pa nts ac hie vi n g H AI ser oc o n versi o n a
f or eac h strai n at 1 a n d 8 wee k safter vacc i nati o n 
T he perce nta ge of partici pa nts wit h H AI titers ≥ 1: 4 0 f or eac h 
strai n bef ore vacci nati o n a n d at 1 a n d 8 wee k safter vacci nati o n 
T he perce nta ge of partici pa nts ac hie vi n g H AI ser oc o n versi o n f or 
all strai ns at 1 a n d 8 wee k safter vacci nati o n 
T he perce nta ge of partici pa nts wit h H AI titers ≥ 1: 4 0 f or all 
strai ns at 1 a n d 8 wee k safter vacci nati o n H AI titers f or t he matc he d seas o nal strai ns  ) 
rec o m me n de d b y W H O 
T o descri be t he i m m u ne res p o nses elicite d 
b y qI R V/ bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) at vari o us 
d ose -le vel c o m bi nati o ns i n partici pa nts 
≥ 1 8 years of a ge I n partici pa nts 1 8 t hr o u g h 6 4 years of a ge a n d ≥ 6 5 years of a ge, 
se paratel y, ha vi n g recei ve d qI R V/ bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) a n d c o m pl yi n g wit h t he ke y pr ot oc ol 
criteria (e val ua ble partici pa nts): 
G M Ts bef ore vacci nati o n a n d at 1a n d 8 wee k safter vacci nati o n 
f or eac h strai n 
G M F R fr o m bef ore vacci nati o n t o 1 a n d 8 wee k safter 
vacci nati o n f or eac h strai n 
Perce nta ges of partici pa nts wit h ser ores p o nse bat 1a n d 8 wee k s
after vacci nati o n f or eac h strai n S A R S -C o V -2 O micr o n B A. 4/ B A. 5 –ne utralizi n g titers 
S A R S -C o V -2 refere nce -strai n –ne utralizi n g titers 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370765] u d y A ( P h ase 1) 
O bjecti ves Esti m a n ds E n d p oi nts 
T o descri be t he i m m u ne res p o nse t o 
e m er gi n g V O Cs i n partici pa nts ≥ 1 8 years 
of a ge S A R S -C o V -2 ne utralizi n g titers f or V O Cs n ot alrea d y 
s pecifie d 
a. Ser oc o n versi o n is defi ne d as a n H AI titer < 1: 1 0 pri or t o vacci nati o n a n d ≥ 1: [ADDRESS_370766], or a n H AI titer of ≥ 1: [ADDRESS_370767]. 
b. Ser ores p o nse is defi ne d as ac hie vi n g a ≥ 4 -f ol d rise fr o m baseli ne ( bef ore t he st u d y vacci nati o n).  If t he baseli ne meas ure me nt is bel o w  t he L L O Q, t he 
p ost vacci nati o n meas ure of ≥ 4 × L L O Q is c o nsi dere d ser ores p o nse. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370768] u d y B ( P h ase 1/ 2) 
O bjecti ves Esti m a n ds E n d p oi nts 
Pri m ar y S afet y Pri m ar y S afet y Pri m ar y S afet y 
T o descri be t he safet y a n d t olera bilit y of st u d y 
i nter ve nti o ns i n partici pa nts [ADDRESS_370769] u d y i nter ve nti o n, t he perce nta ge of partici pa nts 
wit h: 
A b n or mal tr o p o ni n I la b orat or y val ues 2 da ys a n d 
1wee k after vacci nati o n Tr o p o ni n I la b orat or y para meters detaile d i n 
t he pr ot oc ol 
I n partici pa nts [ADDRESS_370770] u d y i nter ve nti o n, t he perce nta ge of partici pa nts 
wit h: 
Ne w E C G a b n or malities 2 da ys a n d 1 wee k after 
vacci nati o n E C G a b n or malities c o nsiste nt wit h pr o ba ble or 
p ossi ble m y ocar ditis or pericar ditis as defi ne d i n t he 
pr ot oc ol 
I n partici pa nts [ADDRESS_370771] u d y i nter ve nti o n, t he perce nta ge of partici pa nts 
re p orti n g: 
L ocal reacti o ns f or u p t o 7 da ys f oll o wi n g vacci nati o n i n 
t he ri g ht ar m o nl y 
S yste mic e ve nts f or u p t o 7 da ys f oll o wi n g vacci nati o n i n 
t he ri g ht ar m 
A Es fr o m vacci nati o n t hr o u g h 4   w ee ks after eac h 
vacci nati o n 
S A Es fr o m vacci nati o n t hr o u g h [ADDRESS_370772] 
vacci nati o n L ocal reacti o ns ( pai n at t he i njecti o n site, re d ness, a n d 
s welli n g) i n t he ri g ht ar m o nl y 
S yste mic e ve nts (fe ver, fati g ue, hea dac he, c hills, 
v o miti n g, diarr hea, ne w or w orse ne d m uscle pai n, a n d 
ne w or w orse ne d j oi nt pai n) 
A Es 
S A Es 
Sec o n d ar y I m m u n o ge nicit y aSec o n d ar y I m m u n o ge nicit y aSec o n d ar y I m m u n o ge nicit y a
T o descri be t he i m m u ne res p o nses t o S A R S- C o V -[ADDRESS_370773] yi n g wit h 
t he ke y pr ot oc ol criteria (e val ua ble partici pa nts): 
G M Ts bef ore vacci nati o n a n d at eac h bl o o d sa m pli n g 
ti me p oi nt after i nfl ue nza vacci nati o n   
G M F R fr o m bef ore vacci nati o n t o eac h bl o o d sa m pli n g 
ti me p oi nt after i nfl ue nza vacci nati o n 
T he pr o p orti o n of partici pa nts ac hie vi n g H AI 
ser oc o n versi o n bf or eac h strai n at eac h bl o o d sa m pli n g 
ti me p oi nt after i nfl ue nza vacci nati o n   
T he perce nta ge of partici pa nts wit h H AI titers ≥ 1: 4 0 f or 
eac h strai n bef ore vacci nati o n a n d at eac h bl o o d 
sa m pli n g ti me p oi nt after i nfl ue nza vacci n ati o n H AI titers f or t he matc he d seas o nal strai ns 
rec o m me n de d b y W H O 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370774] u d y B ( P h ase 1/ 2) 
O bjecti ves Esti m a n ds E n d p oi nts 
I n partici pa nts [ADDRESS_370775] yi n g wit h 
t he ke y pr ot oc ol criteria (e val ua ble partici pa nts): 
G M Ts bef ore vacci nati o n a n d at eac h bl o o d sa m pli n g 
ti me p oi nt after vacci nati o n f or eac h strai n 
G M F R fr o m bef ore S A R S -C o V - 2 vacci nati o n t o eac h 
bl o o d sa m pli n g ti me p oi nt after vacci nati o n f or eac h 
strai n 
Perce nta ges of partici pa nts wit h ser ores p o nse cat eac h 
bl o o d sa m pli n g ti me p oi nt after S A R S -C o V - 2 
vacci nati o n f or eac h strai n S A R S -C o V - 2 – ne utralizi n g titers b y strai n 
Terti ar y/ E x pl or at or y Terti ar y/ E x pl or at or y Terti ar y/ E x pl or at or y 
T o descri be t he i m m u ne res p o nse t o e mer gi n g varia nts 
( u n der m o nit ori n g, of i nterest, a n d/ or of c o ncer n) i n 
partici pa nts 1 8 t hr o u g h 6 4 years of a ge As detaile d i n t he S A P S A R S -C o V -2 ne utralizi n g titers f or e mer gi n g 
varia nts ( u n der m o nit ori n g, of i nterest ,a n d/ or of 
c o ncer n) 
T o descri be t he tr o p o ni n a n d E C G a b n or malities 
detecte d i n partici pa nts w h o are e val uate d f or p ossi ble 
car diac s y m pt o ms  As detaile d i n t he S A P Tr o p o ni n I la b orat or y para meters detaile d i n 
t he pr ot oc ol 
E C G a b n or malities c o nsiste nt wit h pr o ba ble or 
p ossi ble m y ocar ditis or pericar ditis as defi ne d i n t he 
pr ot oc ol 
a. T here are n o pri mar y i m m u n o ge nicit y o bjecti ves i n t his st u d y. 
b. Ser oc o n versi o n is defi ne d as a n H AI titer <1: 1 0 pri or t o vacci nati o n a n d ≥ 1: [ADDRESS_370776], or a n H AI titer of ≥ 1: [ADDRESS_370777]. 
c. Ser ores p o nse is defi ne d as ac hie vi n g a ≥ 4 -f ol d rise fr o m baseli ne ( bef ore t he st u d y vacci nati o n). If t he baseli ne meas ure me nt is bel o w  t he L L O Q, t he 
p ost vacci nati o n meas ure of ≥ 4 × L L O Q is c o nsi dere d ser ores p o nse. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 2 1 O ver all Desi g n: 
T his st u d y i ncl u des 2s u bst u dies ( S u bst u d ies A a n d B) . 
Su bst u dies A a n d B are desi g ne d t o descri be t he safet y , t olera bilit y , a n d i m m u n o ge nicit y of 
se veral vacci nes t hat i ncl u de c o m bi ne d or sta n dal o ne m o d R N A e nc o di n g 3or 4i nfl ue nza 
strai ns *a n d/ or m o d R N A e nc o di n g 1or m ore S A R S -C o V -[ADDRESS_370778] u d y  A: qI R V/ Bi vale nt B N T 1 6 2 b 2 
( O ri gi nal/ O mi B A. 4/ B A. 5) D ose -Le vel C o m bi nati o ns . T he st u d y  i nter ve nti o ns e val uate d i n 
S u bst u d y  B are s h o w n i n t he t a ble ti tle d S u bst u d y  B: All Vacci ne Gr o u ps .
Eac h of t hese s u bst u dies i ncl u des t he use of lice nse d/a ut h orize d sta n dal o ne i nfl ue nza vacci ne 
( QI V) a n d C O VI D -[ADDRESS_370779] u d y  B ,bi vale nt 
B N T 1 6 2 b 2 (ori gi na l/ O mi B A . 4 / B A. 5) re prese nts t he C O VI D- 1 9 c o m parat or .Bi vale nt 
B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) use d i n S u bst u dies A a n d B was rec o m me n de d b y  
A CI P i n [ADDRESS_370780] u d y  B, t he 
QI V c o m parat or is Fl ucel va x. 
* I nfl ue nza strai ns use d i n S u bst u d y  A a n d S u bst u d y  B were base d o n t he W H O 
rec o m me n dati o ns f or use i n t he n ort her n he mis p here i n [ADDRESS_370781] u d y A: qI R V/ Bi v ale nt B N T 1 6 2 b 2 ( Ori gi n al/ O mi B A. 4/ B A. 5) D ose -Le vel C o m bi n ati o ns 
D ose -Le vel 
C o m bi n ati o n qI R V D ose Bi v ale nt B N T 1 6 2 b 2 ( Ori gi n al/ 
O m i B A. 4/ B A. 5) D ose T ot al 
m o d R N A 
D ose 
1  µ g , ie, µ g , ie, 
 µ g of ori gi nal B N T 1 6 2 b 2 a n d 
 µ g of B N T 1 6 2 b 2 O micr o n 
( B. 1. 1. 5 2 9 s u bli nea ge B A. 4/ B A. 5) µ g 
2 µ g , ie, µ g , ie, 
 µ g of ori gi nal B N T 1 6 2 b 2 a n d 
 µ g of B N T 1 6 2 b 2 O micr o n 
( B. 1. 1. 5 2 9 s u bli nea ge B A. 4/ B A. 5) µ g 
3 µ g , ie, µ g , ie, 
 µ g of ori gi nal B N T 1 6 2 b 2 a n d 
 µ g of B N T 1 6 2 b 2 O micr o n 
( B. 1. 1. 5 2 9 s u bli nea ge B A. 4/ B A. 5) µ g 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI C CI 
C CI C CI 
C CI C CI C CI 
C CI 
C CI C CI C CI C CI 
C CI C CI 
C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370782] u d y B: All V acci ne Gr o u ps 
S u bst u d y B 
V acci ne 
Gr o u p qI R V/ Bi v ale nt 
B N T 1 6 2 b 2 
D ose -Le vel 
C o m bi n ati o ns aqI R V, tI R V, or bI R V Bi v ale nt 
B N T 1 6 2 b 2 bLice nse d QI V L N P 
D ose T ot al m o d R N A 
D ose A p pr o xi m ate 
N u m ber of 
P artici p a nts 
1 N/ A N/ A µ g Lice nse d QI V m g µ g 3 0 
2c N/ A µ g bI R V 
)µ g Lice nse d QI V m g µ g 3 0 
3 1 µ g qI R V 
(
)µ g N/ A m g µ g 1 2 0 
4d 2 µ g qI R V ( 
(  
)µ g N/ A m g  µ g 1 2 0 
5 3 µ g qI R V 
(  
)µ g N/ A m g µ g 1 2 0 
6 4 µ g qI R V 
(  
)µ g N/ A m g µ g 3 0 
7 5 µ g qI R V 
(  
)µ g N/ A m g µ g 3 0 
8 6 µ g qI R V 
(  
)µ g N/ A m g µ g 3 0 
9 7 µ g qI R V 
(  µ g N/ A m g µ g 3 0 
1 0 8 µ g qI R V 
(  
)µ g N/ A m g µ g 3 0 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
C CI 
C CI 
C CI 
C CI C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI C CI 
C CI C CI C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370783] u d y B: All V acci ne Gr o u ps 
S u bst u d y B 
V acci ne 
Gr o u p qI R V/ Bi v ale nt 
B N T 1 6 2 b 2 
D ose -Le vel 
C o m bi n ati o ns aqI R V, tI R V, or bI R V Bi v ale nt 
B N T 1 6 2 b 2 bLice nse d QI V L N P 
D ose T ot al m o d R N A 
D ose A p pr o xi m ate 
N u m ber of 
P artici p a nts 
1 1 c N/ A µ g tI R V 
(
)µ g N/ A m g µ g 3 0 
1 2 d N/ A qI R V 
(N/ A N/ A m g µ g 3 0 
a. F or qI R V/ bi vale nt B N T 1 6 2 b 2 ( o ri gi nal/ O mi B A . 4/ B A. 5) t hat is  mI R Vs e nc o di n g H A f or eac h A a n d B strai n will be t o ge nerate qI R V 
at t he d ose -le vel c o m bi nati o n s h o w n; t he res ulta nt qI R V will t he n be wit h bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) pri or t o a d mi nistrati o n.  Please 
see t he I P M f or f urt her details. 
b. F or bi vale nt B N T 1 6 2 b 2 f or m ulati o ns: µ g t otal d ose i ncl u des  µ g of O micr o n B A. 4/ B A. 5 a n d  µ g of t he a ncestral S A R S -C o V - 2 strai n; µ g t otal d ose i ncl u des 
µ g of O micr o n B A. 4/ B A. 5 a n d  µ g of t he a ncestral S A R S- C o V -2 strai n. Ori gi nal refers t o t he a ncestral strai n ( W u ha n- H u -1; U S A- W A 1/ 2 0 2 0), als o referre d t o i n 
t his pr ot oc ol as t he refere nce strai n. 
c. Gr o u ps 2 a n d 1 1 :bI R V/ bi vale nt B N T 1 6 2 b 2 ( o ri gi nal/ O mi B A. 4/ B A. 5 )a n d tI R V/ bi vale nt B N T 1 6 2 b 2 ( o ri gi nal/ O mi B A. 4/ B A. 5) are 
d. Gr o u ps 4 a n d 1 2 :qI R V/ bi vale nt B N T 1 6 2 b 2 ( o ri gi nal/ O mi B A. 4/ B A. 5 )a n d qI R V are 
N ote: T he f oll o wi n g i nfl ue nza strai ns are i ncl u de d i n t he I R V i n eac h gr o u p at t he d ose le vel n ote d: 
Gr o u p 
Gr o u ps t hr o u g h  a n d    
 
Gr o u p 
Gr o u p 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
C CI 
C CI C CI C CI C C 
I
C CI C CI 
C CI 
C CI C CI C CI C CI 
C CI C CI 
C CI 
C CI C CI C CI C CI 
C CI C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370784] u d y A ( P h ase 1) 
T his is a P hase [ADDRESS_370785] u d y t o descri be t he safet y a n d i m m u n o ge nicit y 
of u p t o 3 d ose- le vel c o m bi nati o ns of qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5).  
A p pr o xi matel y  3 6 0 partici pa nts will be e nr olle d acr oss 2 a ge strata: a p pr o xi matel y  
1 8 0 partici pa nts 1 8 t hr o u g h 6 4 ye ars of a ge a n d a p pr o xi matel y 1 8 0 partici pa nts ≥ 6 5 y ears of 
a ge will be ra n d o mize d e q uall y  (a p pr o xi matel y  3 0 partici pa nts per gr o u p) t o eac h gr o u p t o 
recei ve a d ose of eit her: 
qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal */ O mi B A. 4/ B A. 5), at [ADDRESS_370786] u d y  A: qI R V/ Bi vale nt B N T 1 6 2 b 2 
( Ori gi nal/ O mi B A. 4/ B A. 5) D ose -Le vel C o m bi nati o ns ,
  µ g qI R V, 
 µ g qI R V, or 
  µ g Bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) a d mi nistere d c o nc urre ntl y  i n 
t he o p p osite ar m t o lice nse d QI V 
* Ori gi nal refers t o t he a ncestral strai n ( W u ha n -H u -1; U S A -W A 1/ 2 0 2 0), als o referre d t o i n 
t his pr ot oc ol as t he refere nce strai n. 
Saf et y  a n d i m m u n o ge nicit y  data fr o m st u dies pre vi o usl y  c o n d ucte d i n partici pa nts of a 
si milar a ge ra n ge ha vi n g recei ve d [ADDRESS_370787] u d y  a nal y sis. 
E nr oll me nt i n eac h a ge strat u m will be c o ntr olle d s uc h t hat n o m ore t ha n 1 0 partici pa nts 
(se nti nel ≤ 1 0 partici pa nts) ca n be vacci nate d o n t he first da y ; vacci nati o n of t he re mai ni n g 
partici pa nts will c o m me nce n o s o o ner t ha n [ADDRESS_370788] y  t o gr o u ps recei vi n g t he c o m bi nati o n 
bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) a n d qI R V as detaile d i n t he pr ot oc ol .
After c o nfir mati o n of eli gi bilit y  b y  t he in vesti gat or, partici pa nts will be e nr olle d, 
ra n d o mize d, a n d will recei ve a d mi nistrati o n of [ADDRESS_370789] o ge nicit y  e -diar y  f or 7 da ys f oll o wi n g eac h 
vacci nati o n.  Bl o o d sa m ples of a p pr o xi matel y  5 0 m L  will be c ollecte d f or i m m u n o ge nicit y 
assess me nts pri or t o V acci nati o n 1 a n d at 1, 4, a n d 8 wee ks after vacci nati o n.  All 
partici pa nts will be as ke d t o pr o vi de a n a d diti o nal bl o o d sa m ple of a p pr o xi matel y  2. 5 m L at 
ti me p oi n ts s pecifie d i n t he pr ot oc ol f or assess me nt of tr o p o ni n I .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI C CI C CI 
C CI 
C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370790] 4wee k sf oll o wi n g vacci nati o n i n 
eac h a ge strat u m will be re vie we d b y t he s p o ns or’s I R C t o deter mi ne if e nr oll me nt i n eac h 
a ge strat u m of S u bst u d y  B ma y  pr ocee d.   Base d o n re vie w of safet y or i m m u n o ge nicit y data 
of a n y st u d y i nter ve nt i o n gr o u p, at [COMPANY_007]’s discreti o n, s u bse q ue nt c ollecti o n of bl o o d 
sa m ples fr o m partici pa nts i n t hat gr o u p ma y  be halte d a n d/ or bl o o d sa m ples ma y  n ot be 
a nal yz e d ,a n d st u d y  visits or ot her pr oce d ures ma y  be disc o nti n ue d. 
T he t otal d urati o n of t he st u d y  f or eac h partici pa nt will be u p t o a p pr o xi matel y  [ADDRESS_370791] u d y B ( P h ase 1/ 2) 
T his is a P hase 1/ [ADDRESS_370792] u d y  t o descri be t he safet y, t olera bilit y , a n d i m m u n o ge nicit y  of I R V
(qI R V , tI R V, or bI R V) w he n a d mi nistere d i n c o m bi nati o n wit h bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5).  B i vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) will be use d 
d uri n g t he s u b st u d y ,as detaile d i n t he ta ble title d S u bst u d y  B: All Vacci ne Gr o u ps .
S u bst u d y  B will be si n gle -bli n d (s p o ns or -u n bli n de d). I n S u bst u d y  B , u p t o a p pr o xi matel y 
[ADDRESS_370793] u d y B: E nr oll me nt C o h orts 
E nr oll me nt 
C o h ort T ot al 
N u m ber of 
P artici p a nts N u m ber of 
P artici p a nts 
per V acci ne 
Gr o u p V acci ne 
Gr o u p 
N u m ber V acci ne Gr o u p Descri pti o ns 
1 6 0 3 0 1 Lice nse d QI V (Fl ucel va x )a d mi nistere d 
c o nc urre ntl y i n t he o p p osite ar m t o  µ g 
bi vale nt B N T 1 6 2 b 2 ( ori gi nal */ O mi 
B A. 4/ B A. 5) 
2 Lice nse d QI V (Fl ucel va x )a d mi nistere d 
c o nc urre ntl y i n t he o p p osite ar m t o 
bI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi 
B A. 4/ B A. 5) 
2 3 6 0 U p t o 1 2 0 3 qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi 
B A. 4/ B A. 5) at d ose -le vel c o m bi nati o n 1 a
4 qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi 
B A. 4/ B A. 5) at d ose -le vel c o m bi nati o n 2 a
5 qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi 
B A. 4/ B A. 5) at d ose -le vel c o m bi nati o n 3 a0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370794] u d y B: E nr oll me nt C o h orts 
E nr oll me nt 
C o h ort T ot al 
N u m ber of 
P artici p a nts N u m ber of 
P artici p a nts 
per V acci ne 
Gr o u p V acci ne 
Gr o u p 
N u m ber V acci ne Gr o u p Descri pti o ns 
3 2 1 0 3 0 6 qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi 
B A. 4/ B A. 5) at d ose -le vel c o m bi nati o n 4 a
7 qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi 
B A. 4/ B A. 5) at d ose -le vel c o m bi nati o n 5 a
8 qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi 
B A. 4/ B A. 5) at d ose -le vel c o m bi nati o n 6 a
9 qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi 
B A. 4/ B A. 5) at d ose -le vel c o m bi nati o n 7 a
1 0 qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi 
B A. 4/ B A. 5) at d ose -le vel c o m bi nati o n 8 a
1 1 tI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi 
B A. 4/ B A. 5) 
[ADDRESS_370795] u d y B: All Vacci ne Gr o u ps. 
N ote: * Ori gi nal refers t o t he a ncestral strai n ( W u ha n -H u -1; U S A -W A 1/ 2 0 2 0), als o referre d t o i n t his 
pr ot oc ol as t he refere nce strai n. 
E nr oll me nt of partici pa nts ( Gr o u ps 2, 6, 7, 8, 9, 1 0, 1 1, a n d 1 2) will be c o ntr olle d s uc h t hat 
n o m ore t ha n 1 0 partici pa nts (se nti nel partici pa nts) ca n be vacci nate d o n t he first da y ; 
vacci nati o n of t he re mai ni n g partici pa nts will c o m me nce n o s o o ner t ha n [ADDRESS_370796] u d y  B will be re vie we d b y t he s p o ns or’s I R C, a n d if t hese data are 
dee me d acce pta ble, t he I R C will e val uate w hic h gr o u ps ( as detaile d i n t he ta ble title d 
S u bst u d y  B : E nr oll me nt C o h orts a b o ve )are acce pta b le f or f urt her st u d y . 
I m m u n o ge nicit y Bl o o d Dr a ws i n S u bs t u d y B :
Bl o o d sa m ples of a p pr o xi matel y  1 5 m L will be c ollecte d f or i m m u n o ge nicit y  assess me nts 
pri or t o vacci nati o n a n d at 4 wee ks after vacci nati o n. U p t o 2 0 partici pa nts i n Gr o u ps 3, 4, 
a n d 5 i n t he 1 8 -t hr o u g h 6 4 -ye ar a ge strat u m will be as ke d t o c o nse n t t o alter nati vel y 
pr o vi di n g 5 0 -m L , rat her t ha n 1 5 -m L , bl o o d sa m ples at t he sa me ti me p oi nts, w hic h will be 
use d f or i m m u n o ge nicit y assess me nts as well as assa y de vel o p me nt / mai nte na nce .  
F or S u bst u d y  B bl o o d dra ws (as detaile d a b o ve), t he hi g her - v ol u me bl o o d dra ws of [ADDRESS_370797] o ge nicit y  e -diar y  f or 7 da ys f oll o wi n g eac h 
vacci nati o n .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370798] vacci nati o n. I n  a d diti o n, A Es will be c ollecte d t hat 
occ ur u p t o 4 8 h o u rs after bl o o d dra ws. 
N u m ber of P artici p a nts: 
U p t o a p pr o xi matel y  [ADDRESS_370799] u d y A ( P h ase 1) 
U p t o a p pr o xi matel y  3 6 0 partici pa nts ( n = 3 0 per d ose le vel per gr o u p ) will be e nr olle d acr oss 
2 a ge strata: a p p r o xi matel y  1 8 0 partici pa nts 1 8 t hr o u g h 6 4 ye ars of a ge a n d a p pr o xi matel y  
1 8 0 partici pa nts ≥[ADDRESS_370800] u d y B ( P h ase 1/ 2) 
U p t o a p pr o xi matel y  [ADDRESS_370801] u d y B. 
N ote : “ E nr olle d” mea ns a partici pa nt, or t heir le gall y  a ut h orize d re prese ntati ve, has a gree d t o 
partici pate i n a cli nical st u d y  f oll o wi n g c o m pleti o n of t he i nf or me d c o nse nt pr ocess a n d 
ra n d o mizati o n. 
St u d y P o p ul ati o n: 
S u bst u d y A ( P h ase 1) 
I ncl usi o n Criteri a 
I n cl usi o n criteria f or S u bst u d y  A ca n als o be f o u n d i n t he pr ot oc ol .
Partici pa nts are eli gi ble t o be i ncl u de d i n S u bst u d y  A o nl y if all of t he f oll o wi n g criteria 
a p pl y :
A ge a n d Se x: 
1. Male or fe male partici pa nts ≥ 1 8 y ears of a ge ( or t he mi ni m u m a ge of c o nse n t i n 
acc or da nce wit h l ocal re g ulati o ns) at Visit 1 ( Da y 1). 
Refer t o A p pe n di x 5 f or re pr o d ucti ve criteria f or male a n d fe male partici pa nts i n 
t he pr ot oc ol .
Dise ase C h ar acteristics: 
N ot a p plica ble. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 2 8 Ot her I ncl usi o n Criteri a: 
2. Partici pa nts w h o are willi n g a n d a ble t o c o m pl y wit h all sc he d ule d visits, i n vesti gati o nal 
pla n, la b orat or y  tests, lifest y le c o nsi derati o ns, a n d ot her st u d y  pr oce d ures. 
3. Healt h y partici pa nts w h o are deter mi ne d b y me dical hist or y, p h ys ical e xa mi nati o n 
(if re q uire d), a n d cli nical j u d g me nt of t he i n vesti gat or t o be eli gi ble f or i ncl usi o n i n t he 
st u d y .
N ote: Healt h y partici pa nts wit h pree xisti n g sta ble disease, defi ne d as disease n ot 
re q uiri n g si g nifica nt c ha n ge i n t hera p y or h os pi[INVESTIGATOR_1314] o n f or w orse ni n g disease 
d uri n g t he 6 wee ks bef ore e nr oll me nt, ca n be i ncl u de d.  S pecific criteria f or 
partici pa nts wit h k n o w n sta ble i nfecti o n wit h HI V, H C V, or H B V ca n be f o u n d i n 
t he pr ot oc ol .
4. Ca pa ble of gi vi n g si g ne d i nf or me d c o nse nt as descri be d i n t he pr ot oc ol, w hic h i ncl u des 
c o m plia nce wit h t he re q uire me nts a n d restricti o ns liste d i n t he I C D a n d i n t his pr ot oc ol. 
5. F or p artici p a nts 1 8 t hr o u g h 6 4 ye ars of a ge: partici pa nts w h o ha ve recei ve d [ADDRESS_370802] d ose bei n g 1 5 0 da ys t o 3 6 5 da y s b ef ore Visit 1 
( Da y 1). 
F or p artici p a nts ≥ 6 5 ye ars of a ge: partici pa nts w h o ha ve recei ve d [ADDRESS_370803] d ose bei n g a bi vale nt vacci ne, 9 0 da y s t o 
3 6 5 da y s bef ore Visit 1 ( Da y  1). 
N ote: D oc u me nte d c o nfir mati o n of pri or d oses of m o d R N A S A R S -C o V - [ADDRESS_370804] be o btai ne d pri or t o ra n d o mizati o n. 
6. F or p artici p a nts ≥ 6 5 ye ars of a ge: recei pt of lice nse d i nfl ue nza vacci nati o n f or t he 
2 0 2 2- 2 0 2 3 n ort her n he mis p here seas o n ≥ [ADDRESS_370805] y :
Me dic al C o n diti o ns: 
1. Hist or y  of se vere a d verse reacti o n ass ociate d wit h a n y  vacci ne a n d/ or se vere aller gic 
reacti o n (e g, a na p h yl a xis) t o a n y  c o m p o ne nt of t he st u d y  i nter ve nti o n(s). 
2. I m m u n oc o m pr o mise d i n di vi d uals wit h k n o w n or s us pecte d i m m u n o deficie nc y , as 
deter mi ne d b y hist or y  a n d/ or la b orat or y / p h y sical e xa mi nati o n. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 2 9 3. Blee di n g diat hesis or c o n diti o n ass ociate d wit h pr ol o n ge d blee di n g t hat w o ul d, i n t he 
o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or, c o ntrai n dicate i ntra m usc ular i njecti o n. 
4. W o me n w h o are pre g na nt or breastfee di n g. 
5. Aller g y  t o e g g pr otei ns (e g g or e g g pr o d ucts) or c hic ke n pr otei ns. 
6. Ot her me dical or ps y c hiatric c o n diti o n i ncl u di n g rece nt ( wit hi n t he past year) or acti ve 
s uici dal i deati o n/ be ha vi or or la b orat or y  a b n or malit y  t hat ma y  i ncrease t he ris k of st u d y  
partici pati o n or, i n t he i n vesti gat or’s j u d g me nt, ma ke t he partici pa nt i na p pr o pr iate f or 
t he st u d y .
Pri or/ C o nc o mit a nt T her a p y: 
7. Recei pt of c hr o nic s ys te mic treat me nt wit h k n o w n i m m u n os u p pressa nt me dicati o ns 
(i ncl u di n g c y t ot o xic a ge nts or s y ste mic c ortic oster oi ds), or ra di ot hera p y , wit hi n [ADDRESS_370806] u d y. 
N ote: S y ste mic c ortic oster oi ds are defi ne d as t h ose a d mi nistere d f or ≥ 1 4 da y s at a d ose 
of ≥ 2 0 m g/ da y  of pre d nis o ne or e q ui vale nt (e g, f or ca ncer or a n a ut oi m m u ne 
disease) or pla n ne d recei pt t hr o u g h o ut t he st u d y.  I n hale d/ ne b ulize d, i ntra -
artic u lar, i ntra b ursal, or t o pi[INVESTIGATOR_2855] (s ki n or e y es) c ortic oster oi ds are per mitte d. 
8. Recei pt of bl o o d/ plas ma pr o d ucts, i m m u n o gl o b uli n, or m o n ocl o nal a nti b o dies, fr o m 
[ADDRESS_370807] u d y .
9. F or p arti ci p a nts 1 8 t hr o u g h 6 4 ye ars of a ge: vacci nati o n wit h a n y i n vesti gati o nal or 
lice nse d i nfl ue nza vacci ne wit hi n 6 m o nt hs ( 1 7 5 da y s) bef ore st u d y  i nter ve nti o n 
a d mi nistrati o n. 
Pri or/ C o nc urre nt Cli nic al St u d y E x perie nce: 
[ADDRESS_370808] u d y .
Di a g n ostic Assess me nts: 
N ot a p plica ble. 
Ot her E xcl usi o n Criteri a: 
[ADDRESS_370809] u d y  a n d t heir fa mil y  
me m bers. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370810] u d y res ults.  Partici pa nts wit h a 
scree ni n g 1 2 -lea d E C G t hat s h o ws a n a vera ge Q Tc F i nter val > [ADDRESS_370811] u d y B ( P h ase 1/ 2) 
I ncl usi o n Criteri a 
I n cl usi o n criteria f or S u bst u d y  B ca n als o be f o u n d i n t he pr ot oc ol .
Partici pa nts are eli gi ble t o be i ncl u de d i n S u bst u d y  B o nl y  if all of t he f oll o wi n g criteria 
a p pl y :
A ge a n d Se x: 
1. Male or fe male partici pa nts 1 8 t hr o u g h 6 4 ye ars of a ge ( or t he mi ni m u m a ge of c o nse nt 
i n acc or da nce wit h l ocal re g ulati o ns) at Visit 2 0 1 ( Da y  1). 
Refer t o A p pe n di x 5 f or re pr o d ucti ve criteria f or male a n d fe male partici pa nts i n t he 
pr ot oc ol .
Dise ase C h ar acteristics: 
N ot a p plica ble .
Ot her I ncl usi o n Criteri a: 
2. Partici pa nts w h o are willi n g a n d a ble t o c o m pl y wit h all sc he d ule d visits, i n vesti gati o nal 
pla n, la b orat or y  tests, lifest y le c o nsi derati o ns, a n d ot her st u d y  pr oce d ures. 
3. Healt h y partici pa nts w h o are deter mi ne d b y me dic al hist or y , p h y sical e xa mi nati o n 
(if re q uire d), a n d cli nical j u d g me nt of t he i n vesti gat or t o be eli gi ble f or i ncl usi o n i n t he 
st u d y .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 3 1 N ote: Healt h y partici pa nts wit h pree xisti n g sta ble disease, defi ne d as disease n ot re q uiri n g 
si g nifica nt c ha n ge i n t hera p y  or h os pi[INVESTIGATOR_1314] o n f or w orse ni n g disease d uri n g t he [ADDRESS_370812] d ose bei n g a n u p date d ( bi vale nt) vacci ne gi ve n at least 1 5 0 da y s 
bef ore Visit 2 0 1 ( Da y  1). A n y  d ose of m o d R N A C O VI D - 1 9 vacci ne recei ve d after 
0 1 Se pte m ber 2 0 2 2 ma y  be c o nsi dere d t o be a bi vale nt vacci ne i n t he U S. 
N ote: D oc u me nte d c o nfir mati o n of pri or d oses of S A R S -C o V -2vacci ne recei ve d m ust be 
o btai ne d pri or t o ra n d o mizati o n. 
E xcl usi o n Criteri a 
E xcl usi o n criteria f or S u bst u d y  B ca n als o be f o u n d i n t he pr ot oc ol .
Partici pa nts are e xcl u de d fr o m S u bst u d y  B if a n y of t he f oll o wi n g criteria a p pl y :
Me dic al C o n diti o ns: 
1. Me dical or ps yc hiatric c o n diti o n, i ncl u di n g rece nt ( wit hi n t he past year) or acti ve s uici dal 
i deati o n/ be ha vi or or la b orat or y  a b n or malit y , t hat ma y  i ncrease t he ris k of st u d y  
partici pati o n or, i n t he i n vesti gat or’s j u d g me nt, ma ke t he partici pa nt i na p pr o priate f or t he 
st u d y .
2. Hist or y  of se vere a d verse reacti o n ass ociate d wit h a n y  vacci ne a n d/ or se vere aller gic 
reacti o n ( e g , a na p h y la xis) t o a n y  c o m p o ne nt of t he st u d y  i nter ve nti o n(s). 
3. I m m u n oc o m pr o mise d i n di vi d uals wit h k n o w n or s us pecte d i m m u n o deficie nc y , as 
deter mi ne d b y  hist or y  a n d/ or la b orat or y / p h y sical e xa mi nati o n. 
4. Blee di n g diat hesis or c o n diti o n ass ociate d wit h pr ol o n ge d blee di n g t hat w o ul d, i n t he 
o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or, c o ntrai n dicate i ntra m usc ular i njecti o n. 
5. W o me n w h o are pre g na nt or breastfee di n g .
6. Hist or y  of m y o car ditis or pericar ditis .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 3 2 Pri or/ C o nc o mit a nt T her a p y: 
7. Recei pt of c hr o nic me dicati o ns wit h k n o w n s y ste mic i m m u n os u p pressa nt effects 
(i ncl u di n g c y t ot o xic a ge nts or s y ste mic c ortic oster oi ds), or ra di ot hera p y , wit hi n [ADDRESS_370813] u d y. 
N ote: S y ste mic c ortic oster oi ds are defi ne d as t h ose a d mi nistere d f or ≥ 1 4 da y s at a d ose of 
≥2 0 m g/ da y  of pre d nis o ne or e q ui vale nt (e g, f or ca ncer or a n a ut oi m m u ne disease) or 
pla n ne d recei pt t hr o u g h o ut t he st u d y .  I n hale d/ ne b ulize d, i ntra -artic ular, i ntra b ursal, or 
t o pi[INVESTIGATOR_2855] (s ki n or e y es) c ortic oster oi ds are per mitte d. 
8. Recei pt of bl o o d/ plas ma pr o d ucts, i m m u n o gl o b uli n, or m o n ocl o nal a nti b o dies use d f or 
t he trea t me nt or pre ve nti o n of C O VI D -[ADDRESS_370814] u d y .
9. Vacci nati o n wit h a n y  i n vesti gati o nal or lice nse d i nfl ue nza vacci ne wit hi n 6 m o nt hs 
( 1 7 5 d a y s) bef ore st u d y i nter ve nti o n a d mi nistrati o n, or o n g oi n g rec ei pt of c hr o nic 
a nti viral t hera p y wit h acti vit y  a gai nst i nfl ue nza. 
Pri or/ C o nc urre nt Cli nic al St u d y E x perie nce: 
[ADDRESS_370815] u d y  i nter ve nti o n wit hi n 
2 8 da y s pri or t o, a n d/ or d uri n g, partici pati o n i n t his st u d y .
N ote: I n a d diti o n t o a d mi nistrati o n of i n vesti gati o nal pr o d ucts, st u d y  i nter ve nti o ns ma y  
i ncl u de a d diti o nal pr oce d ures, s uc h as c ollecti o n of bi ol o gical sa m ples. T heref ore, 
partici pa nts ma y  n ot be i n a n ot her st u d y  w here b y pr oce d ures, s uc h as res pi[INVESTIGATOR_1305] y  
ill ness visits, ma y  i nterfere wit h c o m plia nce wit h t his st u d y ’s pr ot oc ol. 
Di a g n ostic Assess me nts: 
N ot a p plica ble. 
Ot her E xcl usi o n Criteri a: 
[ADDRESS_370816] or y  of heart disea se of c o ncer n: hist or y  of m y ocar ditis, pericar ditis, 
car di o m y o pat h y, c or o nar y arter y disease (i ncl u di n g hist or y of m y ocar dial i nfarcti o n, 
u nsta ble a n gi na), N Y H A Class III a n d a b o ve heart fail ure, or si g nifica nt arr h y t h mias. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370817] u d y  res ults.  Partici pa nts wit h a 
scree ni n g 1 2 -lea d E C G t hat s h o ws a n a vera ge Q Tc F i nter val > [ADDRESS_370818] u d y  
partici pati o n. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370819] u d y Ar ms a n d D ur ati o n: 
St u d y I nter ve nti o ns A d mi nistere d 
S u bst u d y A ( P h ase 1) 
T he t otal d urati o n of S u bst u d y  Af or eac h partici pa nt will be u p t o a p pr o xi matel y  [ADDRESS_370820] u d y  A will i ncl u de: 
I nter ve nti o n 
N a m eBi vale nt B N T 1 6 2 b 2 
( ori gi nal a/ O mi B A . 4/ B A. 5) 
( ori gi nal B N T 1 6 2 b 2 a n d 
B N T 1 6 2 b 2 O micr o n 
[ B. 1. 1. 5 2 9 s u bli nea ge 
B A. 4/ B A. 5]) 
 qI R V qI R V/ bi vale nt 
B N T 1 6 2 b 2 
( ori gi nal/ 
O m i B A. 4/ B A. 5) QI V 
A r m  N a m e
( gr o u p of 
p artici p a nts 
recei vi n g a 
s pecific st u d y 
i nter ve nti o n or 
n o st u d y 
i nter ve nti o n) qI R V/ bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O m iB A . 4/ B A. 5 )
or 
Lice nse d QI V + bi vale nt 
B N T 1 6 2 b 2 ( ori gi nal/ 
O m i B A. 4/ B A. 5) qI R V/ bi vale nt 
B N T 1 6 2 b 2 
( ori gi nal/ 
O m iB A . 4/ B A. 5) 
or 
µ g qI R V 
or 
µ g qI R V qI R V/ bi vale nt 
B N T 1 6 2 b 2 
( ori gi nal/ 
O m iB A . 4/ B A. 5) Lice nse d QI V + 
bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi 
B A. 4/ B A. 5) 
T ar gete d 
I nfl ue nz a 
Str ai ns N/ A F or eac h seas o n, 
strai ns as 
rec o m me n de d b y 
W H O f or 
rec o m bi na nt or 
cell -base d 
i nfl ue nza vacci nes F or eac h seas o n, 
strai ns as 
rec o m me n de d b y 
W H O f or 
rec o m bi na nt or 
cell -base d 
i nfl ue nza vacci nes F or eac h seas o n, 
strai ns as 
rec o m me n de d b y 
W H O 
T y pe Vacci ne Vacci ne Vacci ne  Vacci ne 
D ose 
F o r m ul ati o n m o d R N A m o d R N A m o d R N A 
U nit D ose 
Stre n gt h(s) As detaile d i n t he I P M As detaile d i n t he 
I P M As detaile d i n t he 
I P M As detaile d i n t he 
I P M 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 3 5 D os a ge Le vel(s) µ g or  µ g 
( µ g o ri gi nal B N T 1 6 2 b 2 
a n d 
µ g B N T 1 6 2 b 2 O micr o n 
[B. 1. 1. 5 2 9 s u bli nea ge 
B A. 4/ B A. 5]) 
( µ g o ri gi nal B N T 1 6 2 b 2 
a n d 
µ g B N T 1 6 2 b 2 O micr o n 
[B. 1. 1. 5 2 9 s u bli nea ge 
B A. 4/ B A. 5]) µ g 
(  μ g per strai n) 
 µ g 
μ g per strai n) D ose -le vel 
c o m bi nati o n [ADDRESS_370821] u d y A :
qI R V/ Bi vale nt 
B N T 1 6 2 b 2 
( Ori gi nal/ 
O m i B A. 4/ B A. 5) 
D ose -Le vel 
C o m bi nati o ns 
 µ g 
qI R V  µ g 
( μ g per strai n) 
B N T 1 6 2 b 2 µ g 
( µ g o ri gi nal 
B N T 1 6 2 b 2 a n d 
µ g B N T 1 6 2 b 2 
O m icr o n 
[B. 1. 1. 5 2 9 s u bli ne 
a ge B A. 4/ B A. 5 ]) 
D ose -le vel 
c o m bi nati o n [ADDRESS_370822] u d y A :
qI R V/ Bi vale nt 
B N T 1 6 2 b 2 
( Ori gi nal/ 
O m i B A. 4/ B A. 5) 
D ose -Le vel 
C o m bi nati o ns 
µ g 
qI R V µ g 
( μ g per strai n) 
B N T 1 6 2 b 2 µ g 
( µ g o ri gi nal 
B N T 1 6 2 b 2 a n d 
µ g B N T 1 6 2 b 2 
O m icr o n 
[B. 1. 1. 5 2 9 s u bli ne 
a ge B A. 4/ B A. 5 ]) 
D ose -le vel 
c o m bi nati o n [ADDRESS_370823] u d y A :
qI R V/ Bi vale nt 
B N T 1 6 2 b 2 
( Ori gi nal/ 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI C CI 
C CI 
C CI 
C CI C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 3 6 O m i B A. 4/ B A. 5) 
D ose -Le vel 
C o m bi nati o ns 
µ g 
qI R V µ g 
( μ g per strai n) 
B N T 1 6 2 b 2 µ g 
(  µ g o ri gi nal 
B N T 1 6 2 b 2 a n d 
µ g B N T 1 6 2 b 2 
O m icr o n 
[B. 1. 1. 5 2 9 s u bli ne 
a ge B A. 4/ B A. 5 ]) 
R o ute of 
A d mi nistr ati o n I ntra m usc ular i njecti o n I ntra m usc ular 
i njecti o n I ntra m usc ular 
i njecti o n I ntra m usc ular 
i njecti o n 
Use E x peri me ntal E x peri me ntal E x peri me ntal C o m parat or 
I M P or 
NI M P/ A x M P I M P I M P I M P I M P 
S o urci n g Pr o vi de d ce ntrall y b y 
[COMPANY_007] Pr o vi de d ce ntrall y 
b y [COMPANY_007] St u d y i nter ve nti o n 
will be ge nerate d 
b y mi xi n g t he 
f oll o wi n g at t he 
site at t he 
d ose -le vel 
c o m bi nati o ns 
detaile d a b o ve: 
qI R V 
Bi vale nt 
B N T 1 6 2 b 2 
( ori gi nal/ O mi 
B A. 4/ B A. 5) Pr o vi de d ce ntrall y 
b y [COMPANY_007] 
P ac k a gi n g a n d 
L a beli n g St u d y i nter ve nti o n will be 
pr o vi de d i n a glass vial as 
o pe n -la bel s u p pl y.  Eac h 
vial will be la bele d per 
c o u ntr y re q uire me nt. St u d y i nter ve nti o n 
will be pr o vi de d i n 
a glass vial as 
o pe n -la bel s u p pl y.  
Eac h vial will be 
la bele d per c o u ntr y 
re q uire me nt. St u d y i nter ve nti o n 
will be pr o vi de d as 
eit her a P F S or a 
glass vial as 
o pe n -la bel s u p pl y.  
Eac h vial will be 
la bele d per c o u ntr y 
re q uire me nt. 
a. Ori gi nal refers t o t he a ncestral strai n ( W u ha n -H u -1; U S A -W A 1/ 2 0 2 0), als o referre d t o i n t his pr ot oc ol as 
t he refere nce strai n. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370824] u d y A ( P h ase 1) 
St u d y  ar ms f or S u bst u d y  A will i ncl u de: 
St u d y Ar ms 
Gr o u p 
N u m ber 1 2 3 4 5 6
Ar m Title qI R V/ bi vale nt 
B N T 1 6 2 b 2 
( ori gi nal/ O mi 
B A. 4/ B A. 5) 
D ose -le vel 
c o m bi nati o n [ADDRESS_370825] u d y A: 
qI R V/ Bi vale nt 
B N T 1 6 2 b 2 
( Ori gi nal/ O mi 
B A. 4/ B A. 5) 
D ose -Le vel 
C o m bi nati o ns qI R V/ bi vale nt 
B N T 1 6 2 b 2 
( ori gi nal/ O mi 
B A. 4/ B A. 5) 
D ose -le vel 
c o m bi nati o n [ADDRESS_370826] u d y A: 
qI R V/ Bi vale nt 
B N T 1 6 2 b 2 
( Ori gi nal/ O mi 
B A. 4/ B A. 5) 
D ose -Le vel 
C o m bi nati o ns qI R V/ bi vale nt 
B N T 1 6 2 b 2 
( ori gi nal/ O mi 
B A. 4/ B A. 5) 
D ose -le vel 
c o m bi nati o n [ADDRESS_370827] u d y A: 
qI R V/ Bi vale nt 
B N T 1 6 2 b 2 
( Ori gi nal/ O mi 
B A. 4/ B A. 5) 
D ose -Le vel 
C o m bi nati o ns  µg qI R V µg qI R V Lice nse d QI V + 
bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) 
Ar m T y pe E x peri me ntal E x peri me ntal E x peri me ntal E x peri me ntal E x peri me ntal E x peri me ntal 
Ar m 
Descri pti o n Partici pa nts will 
recei ve 
qI R V/ bi vale nt 
B N T 1 6 2 b 2 
( ori gi nal/ O mi 
B A. 4/ B A. 5) at 
d ose -le vel 
c o m bi nati o n [ADDRESS_370828] u d y A : 
qI R V/ Bi vale nt 
B N T 1 6 2 b 2 
( Ori gi nal/ O mi 
B A. 4/ B A. 5) 
D ose -Le vel 
C o m bi nati o ns Partici pa nts 
will recei ve 
qI R V/ bi vale nt 
B N T 1 6 2 b 2 
( ori gi nal/ O mi 
B A. 4/ B A. 5) at 
d ose -le vel 
c o m bi nati o n [ADDRESS_370829] u d y A: 
qI R V/ Bi vale nt 
B N T 1 6 2 b 2 
( Ori gi nal/ O mi 
B A. 4/ B A. 5) 
D ose -Le vel 
C o m bi nati o ns Partici pa nts 
will recei ve 
qI R V/ bi vale nt 
B N T 1 6 2 b 2 
( ori gi nal/ O mi 
B A. 4/ B A. 5) at 
d ose -le vel 
c o m bi nati o n [ADDRESS_370830] u d y A: 
qI R V/ Bi vale nt 
B N T 1 6 2 b 2 
( Ori gi nal/ O mi 
B A. 4/ B A. 5) 
D ose -Le vel 
C o m bi nati o ns Partici pa nts 
will recei ve 
µg of 
qI R V Partici pa nts 
will recei ve 
µg of 
qI R V Partici pa nts will recei ve 
µg of 
bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) 
a d mi nistere d c o nc urre ntl y 
i n t he o p p osite ar m t o 
QI V 
Ass oci ate d 
I nter ve nti o n 
L a bels qI R V/ bi vale nt 
B N T 1 6 2 b 2 
( ori gi nal/ O mi 
B A. 4/ B A. 5) qI R V/ bi vale nt 
B N T 1 6 2 b 2 
( ori gi nal/ O mi 
B A. 4/ B A. 5) qI R V/ bi vale nt 
B N T 1 6 2 b 2 
( ori gi nal/ O mi 
B A. 4/ B A. 5) qI R V qI R V Bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) 
a n d QI V 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI C CI 
C CI C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370831] u d y B ( P h ase 1/ 2) 
T he t otal d urati o n of S u bst u d y B f or eac h partici pa nt will be u p t o a p pr o xi matel y  [ADDRESS_370832] u d y B will i ncl u de: 
I nter ve nti o n N a me B N T 1 6 2 b 2 a
 qI R V qI R V b/ B N T 1 6 2 b 2 atI R V c/ B N T 1 6 2 b 2 abI R V c/ B N T 1 6 2 b 2 aQI V 
Ar m N a me 
( gr o u p of p artici p a nts 
recei vi n g a s pecific 
st u d y i nter ve nti o n or 
n o st u d y i nter ve nti o n) Lice nse d QI V + 
B N T 1 6 2 b 2 aqI R V qI R V/ B N T 1 6 2 b 2 atI R V/ B N T 1 6 2 b 2 abI R V/ B N T 1 6 2 b 2 a+ 
lice nse d QI V Lice nse d QI V + 
B N T 1 6 2 b 2 a
or 
Lice nse d QI V + 
bI R V/ B N T 1 6 2 b 2 a
T ar gete d I nfl ue nz a 
Str ai ns N/ A Strai ns as 
rec o m me n de d b y 
W H O f or rec o m bi na nt 
or cell -base d i nfl ue nza 
vacci nes Strai ns as 
rec o m me n de d b y 
W H O f or rec o m bi na nt 
or cell -base d i nfl ue nza 
vacci nes Strai ns as 
rec o m me n de d b y 
W H O f or rec o m bi na nt 
or cell -base d i nfl ue nza 
vacci nes Strai ns as 
rec o m me n de d b y 
W H O f or rec o m bi na nt 
or cell -base d i nfl ue nza 
vacci nes F or eac h seas o nal strai n 
as rec o m me n de d b y 
W H O 
T y pe mo d R N A vacci ne m o d R N A vacci ne m o d R N A vacci ne m o d R N A vacci ne m o d R N A vacci ne Vacci ne 
D ose F or m ul ati o n m o d R N A m o d R N A m o d R N A m o d R N A m o d R N A 
U nit D ose Stre n gt h(s) µ g 
B N T 1 6 2 b 2 aµ g qI R V f or 
partici pa nts 
1 8 t hr o u g h 6 4 years of 
a ge (as detaile d i n t he 
I M P) µ g or µ g or 
µ g i n d ose -le vel 
c o m bi nati o ns as 
descri be d i n t he ta bles 
title d S u bst u d y B: All 
I Vacci ne Gr o u ps µ g tI R V/ µ g 
B N T 1 6 2 b 2 a  µ g bI R V/ µ g 
B N T 1 6 2 b 2 a  µ g bI R V/ µ g 
B N T 1 6 2 b 2 a
As detaile d i n t he I P M 
R o ute of 
A d mi nistr ati o n I ntra m usc ular i njecti o n I ntra m usc ular 
i njecti o n I ntra m usc ular 
i njecti o n I ntra m usc ular 
i njecti o n I ntra m usc ular 
i njecti o n I ntra m usc ular i njecti o n 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI C CI C CI C CI C CI C CI C CI C CI C CI C CI C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 3 9 Use E x peri me ntal E x peri me ntal E x peri me ntal E x peri me ntal E x peri me ntal E x peri me ntal 
I M P or NI M P/ A x M P I M P I M P I M P I M P I M P I M P 
P ac k a gi n g a n d 
L a beli n g St u d y i nter ve nti o n will be 
pr o vi de d i n a glass vial as 
o pe n -la bel s u p pl y.  Eac h 
vial will be la bele d per 
c o u ntr y re q uire me nt. St u d y i nter ve nti o n 
will be pr o vi de d i n a 
glass vial as 
o pe n -la bel s u p pl y.  
Eac h vial will be 
la bele d per c o u ntr y 
re q uire me nt. St u d y i nter ve nti o n 
will be pr o vi de d i n a 
glass vial as 
o pe n -la bel s u p pl y.  
Eac h vial will be 
la bele d per c o u ntr y 
re q uire me nt. St u d y i nter ve nti o n 
will be pr o vi de d i n a 
glass vial as 
o pe n -la bel s u p pl y.  
Eac h vial will be 
la bele d per c o u ntr y 
re q uire me nt. St u d y i nter ve nti o n 
will be pr o vi de d i n a 
glass vial as 
o pe n -la bel s u p pl y.  
Eac h vial will be 
la bele d per c o u ntr y 
re q uire me nt. St u d y i nter ve nti o n will 
be pr o vi de d as eit her a 
P F S or a glass/ plastic 
vial as o pe n -la bel 
s u p pl y.  Eac h P F S or vial 
will be la bele d per 
c o u ntr y re q uire me nt. 
a. Bi vale nt B N T 1 6 2 b 2 ( ori gi nal */ O mi B A. 4/ B A. 5) w ill be use d d uri n g S u bst u d y B . * Ori gi nal refers t o t he a ncestral strai n ( W u ha n -H u -1; U S A -W A 1/ 2 0 2 0), 
als o referre d t o i n t his pr ot oc ol as t he refere nce strai n. 
b. Will ha ve f or m ulati o ns t hat are  per t he I P M a n d 
c.F or m ulati o ns will be 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370833] atistic al Met h o ds: 
S u bst u d y A ( P h ase 1) 
Si nce t his s u bst u d y  is descri pti ve i n nat ure, t he pla n ne d sa m ple size f or t he s u bst u d y  is n ot 
base d o n a n y statistical h y p ot hesis testi n g. 
Safet y  a n d i m m u n o ge nicit y  data fr o m st u dies pre vi o usl y  c o n d ucte d i n partici pa nts of a 
si milar a ge ra n ge ha vi n g recei v e d [ADDRESS_370834] u d y will be e val uate d b y descri pti ve s u m mar y  statistics 
f or l ocal reacti o ns, s ys te mic e ve nts, a n d A E s/ S A Es f or eac h vacci ne gr o u p b y  a ge strat u m 
(1 8 t hr o u g h 6 4 a n d ≥ 6 5 years of a ge) a n d o verall ( ≥ 1 8 y ears of a ge) .  A b n or mal tr o p o ni n I 
la b orat or y  para meters a n d E C G a b n or malities c o nsiste nt wit h pr o ba ble or p ossi ble 
m y ocar ditis or pericar ditis will als o be descri p ti vel y  s u m marize d f or b y  a ge strat u m 
( 1 8 t hr o u g h 6 4 a n d ≥ 6 5 years of a ge) a n d o verall ( ≥ 1 8 y ears of a ge). 
T he sec o n dar y  (i m m u n o ge nicit y ) o bjecti ve will be e val uate d descri pti vel y  b y  a ge strat u m 
( 1 8 t hr o u g h 6 4 a n d ≥ 6 5 years of a ge) b y  G M T a n d G M F R of b ot h H AI  a n d S A R S -C o V - 2 
ne utralizi n g titers, as well as: 
t he perce nta ge of partici pa nts ac hie vi n g ser oc o n versi o n meas ure d b y H AI, a n d 
pr o p orti o n of partici pa nts wit h H AI titers ≥ 1: 4 0, f or eac h strai n at t he vari o us ti me 
p oi nts. 
t he perce nta ge of partici pa nts wit h ser ores p o nse of S A R S -C o V -[ADDRESS_370835] u d y B ( P h ase 1/ 2) 
T here is n o f or mal sa m ple size calc ulati o n f or t he pla n ne d sa m ple size i n S u bst u d y  B, as 
t here is n o f or mal h y p ot hesis testi n g. 
T he i m m u n o ge nicit y o bjecti ve s will be e val uate d descri pti vel y b y G M T, G M F R, perce nta ge 
of partici pa nts ac hie vi n g ser oc o n versi o n, perce nta ge of partici pa nts wit h ser ores p o nse ,a n d 
t he ass ociate d 9 5 % C Is, at t he vari o us ti me p oi nts. 
T he pri mar y  safet y o bjecti ve will be e val uate d b y de scri pti ve s u m mar y  statistics f or l ocal 
reacti o ns, s ys te mic e ve nts, a n d A Es/ S A Es f or eac h st u d y  i nter ve nti o n. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 4 1 Et hic al C o nsi der ati o ns: 
T he a vaila ble safet y a n d i m m u n o ge nicit y data fr o m o n g oi n g cli nical trials a n d real -w orl d 
effecti ve ness a n d safet y data f o r B N T 1 6 2 b 2, c o m bi ne d wit h a vaila ble n o ncli nical data wit h 
B N T 1 6 2 vacci nes, as well as data fr o m n o ncli nical a n d cli nical trials wit h qI R V, s u p p ort a 
fa v ora ble be nefit/ris k pr ofile a n d s u p p ort cli nical de vel o p me nt of a vacci ne c o m bi ni n g t hese 
c o m p o ne nts. Ta ki n g i nt o acc o u nt t he meas ures t o mi ni mize ris k t o st u d y  partici pa nts, t he 
p ote ntial ris ks i de ntifie d i n ass ociati o n wit h t he st u d y  i nter ve nti o n are j ustifie d b y  t he 
a ntici pate d be nefits t hat ma y  be aff or de d t o healt h y  partici pa nts. 
As I R V f or m ulati o ns ( bI R V, tI R V ,a n d q I R V) a n d bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi 
B A. 4/ B A. 5) ha ve t he sa me m o d R N A a n d L N P platf or m as B N T 1 6 2 b 2, t heir safet y pr ofiles 
are e x pecte d t o be si milar t o t hat of B N T 1 6 2 b 2.  Base d o n t he e x perie nce wit h B N T 1 6 2 b 2, 
t he p ote ntial ris ks f or I R V f or m ulati o ns c o m bi ne d wit h bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi 
B A. 4/ B A. 5) i ncl u de t he f oll o wi n g: 
L ocal reacti o ns, s uc h as i njecti o n site re d ness, i njecti o n site s welli n g, a n d i njecti o n 
site pai n, a n d s y ste mic e ve nts , s uc h as fe ver, fati g ue, hea dac he, c hills , m uscle pai n, 
a n d j oi nt pai n. 
Ver y  rare cases of m y ocar ditis a n d pericar ditis ha ve bee n re p orte d after a ut h orizati o n 
i n reci pie nts of B N T 1 6 2 b 2. 
Cases of a na p h yl a xis ha ve bee n re p orte d; h o we ver, t he fre q ue nc y  is n ot esti ma ble 
fr o m t he a vaila ble data. 
T he st u d y pr oce d ure –relate d ris ks i ncl u de t he f oll o wi n g :
Ve ni p u nct ure will be perf or me d d uri n g t he st u d y. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370836] u d y B Sc he m a: 
S u bst u d y B E nr oll me nt C o h ort 1 E nr oll me nt C o h ort 2 E nr oll me nt C o h ort 3 
A ge Strat u m 
1 8 -6 4 Years Vacci ne gr o u p a1
( n =~3 0) 
Vacci ne gr o u p a2 
( n = ~ 3 0) Vacci ne gr o u p a3 
( n = ~≤ 1 2 0 )
Vac ci ne gr o u p a4 
( n = ~ ≤ 1 2 0 )
Vacci ne gr o u p a5 
( n = ~≤ 1 2 0 )Vacci ne gr o u p a6
( n = ~3 0) 
Vacci ne gr o u p a7 
( n = ~3 0) 
Vacci ne gr o u p a8 
( n = ~3 0) 
Vacci ne gr o u p a9 
( n = ~3 0) 
Vacc i ne gr o u p a1 0 
( n = ~3 0) 
Vacci ne gr o u p a1 1 
( n = ~3 0) 
Vacci ne gr o u p a1 2 
( n = ~3 0) 
Se nti nel b
≤ 1 0 partici pa nts 
fr o m gr o u p 2F ull 
~5 0 partici pa nts F ull 
~ 3 3 0 partici pa nts Se nti nel b
≤ 1 0 partici pa nts 
per gr o u p F ull 
~ [ADDRESS_370837] vacci nati o n safet y data fr o m se nti n el partici pa nts 
bef ore f ull e nr oll me nt of t he r e m ai ni n g partici pa nts i n eac h vacci ne gr o u p , wit h t he e xce pti o n of Gr o u ps 
1, 3, 4, a n d 5, as e nr oll me nt of t h ose gr o u ps occ urre d u n der a pri or pr ot oc ol versi o n .
N ote: T he arr o w  re prese nt st he 2 4 -h o ur safet y pa use .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 4 3 1. 3. Sc he d ule of Acti vities 
T he S o A  ta ble pr o vi des a n o ver vie w of t he pr ot oc ol visits a n d pr oce d ures.  Refer t o t he 
S T U D Y  A S S E S S M E N T S A N D P R O C E D U R E S secti o n of t he pr ot oc ol f or detaile d 
i nf or mati o n o n eac h pr oce d ure a n d assess me nt re q uire d f or c o m plia nce wit h t he pr ot oc ol. 
T he i n vesti gat or ma y  sc he d ule visits ( u n pla n ne d visits) i n a d diti o n t o t h ose liste d i n t he S o A 
ta ble, i n or der t o c o n d uct e val uati o ns or assess me nts re q uire d t o pr otect t he well -bei n g of t he 
partici pa nt. 
See Secti o n [ADDRESS_370838] u d y R ati o n ale 
T his master pr ot oc ol descri bes t he i n vesti gati o nal pla n of a c o m bi nati o n vacci ne c o ntai ni n g 
m o difie d R N A c o m p o ne nts e nc o di n g pr otei ns o f t he S A R S -C o V -2 pref usi o n s pi [INVESTIGATOR_2531] a n d 
i nfl ue nza H A a nti ge ns. T his c o m bi nati o n vacci ne ai ms t o si m plif y  vacci nati o n practices f or 
t he pre ve nti o n of 2 p ote ntiall y  seri o us res pi[INVESTIGATOR_1305] y  ill nesses: i nfl ue nza a n d C O VI D - 1 9.    
B N T 1 6 2 b 2 ( C o mir nat y®) is a m o d R N A -base d vacci ne t hat, as of Ja n uar y  2 0 2 3 , has bee n 
gra nte d f ull mar keti n g a ut h orizati o n, c o n diti o nal mar keti n g a ut h orizati o n, E U A, or 
te m p orar y  a ut h orizati o n i n a t otal of m ore t ha n 1 8 4 c o u ntries f or t he pre ve nti o n of 
C O VI D -1 9 ca use d b y S A R S -C o V - 2. 1T he ori gi nal versi o n of B N T 1 6 2 b 2 e nc o des t he 
a ncestral W u ha n -H u - 1 strai n s pi [INVESTIGATOR_303615] y c o pr otei n. I n t he U S, it has bee n f ull y  lice nse d f or use 
i n i n di vi d uals 1 2 y ears of a ge a n d a b o ve as of 0 8 J ul y  2 0 2 2. 2
Fr o m 1 8 A pril 2 0 2 3 u ntil 1 1 Se pte m ber 2 0 2 3, t he bi vale n t ori gi nal */ O micr o n B A. 4/ B A. 5 
C O VI D -1 9 vacci ne ha d bee n a ut h orize d f or use f or all d oses a d mi nistere d t o i n di vi d uals 6 
m o nt hs of a ge a n d ol der. 3
* Ori gi nal refers t o t he a ncestral strai n ( W u ha n -H u -1; U S A -W A 1/ 2 0 2 0), als o referre d t o i n 
t his pr ot oc ol as t he refere nce strai n .
A bi vale nt f or m ulati o n of t he vacci ne B N T 1 6 2 b 2 ( b i vale nt B N T 1 6 2 b 2 
[ ori gi nal / O mi B A. 4/ B A. 5 ]) has bee n gra nte d E U A i n t he U S as a si n gle b o oster d ose i n 
i n di vi d uals [ADDRESS_370839] rece nt b o oster d ose wit h a n 
a ut h orize d or a p pr o ve d m o n o vale nt C O VI D -1 9 vacci ne. 4
All versi o ns of t he vacci ne e nc o de t he S A R S -C o V - 2 pref usi o n s pi [INVESTIGATOR_303616] n (s) i n m o d R N A 
e nca ps ulate d i n R N A -L N P s, w hic h has de m o nstrate d p ote nt i m m u n o ge nicit y , hi g h V E, a n d a 
fa v ora ble safet y pr ofile i n P hase 1, 2, a n d 3 h u ma n trials, 5as well as i n real -w orl d usa ge. 6  As 
S A R S -C o V -2 c o nti n ues t o circ ulate, 7at ver y  hi g h le vels, [COMPANY_007]/ Bi o N Tec h are i n vesti gati n g 
R N A -base d C O VI D -[ADDRESS_370840] C O VI D -1 9 ca use d b y  e mer ge nt 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 4 4 a n d p ote ntiall y  m ore a nti ge nicall y di verse vari a nts .  T heref ore, b i vale nt B N T 1 6 2 b 2 
(ori gi nal / O mi B A. 4/ B A. 5) ,c o nsisti n g of t he ori gi nal S A R S -C o V - 2 pref usi o n s pi [INVESTIGATOR_303616] n 
m o d R N A, tar geti n g t he a ncestral strai n of t he vir us, i n c o m bi nati o n wit h m o d R N A e nc o di n g 
t he s pi [INVESTIGATOR_303616] n of t he O micr o n varia nt ( B A. 4/ B A. 5 s u bli nea ge) ,will be use d i n t his st u d y .
[COMPANY_007] als o has a q ua dri vale nt m o d R N A -base d i nfl ue nza vacci ne, q I R V, i n P ha se 3 
de vel o p me nt.  qI R V e nc o des H A of strai ns ( ) seas o nall y 
rec o m me n de d b y  W H O f or t he i nfl ue nza seas o n .8Base d o n P hase [ADDRESS_370841] u d ie d i n t he P hase 3 C 4 7 8 1 0 0 4 pr ot oc ol 
b y a ge strat u m is µg f or partici pa nts 1 8 t hr o u g h 6 4 years of a ge a n d  µ g f or partici pa nts 
≥6 5 y ears of a ge. 
T he W H O rec o m me n dati o n f or t he c o m p ositi o n of i nfl ue nza vacci nes i n t he 2 0 2 4 - 2 0 2 5 
n ort her n he mis p here i nfl ue nza seas o n i ncl u des b ot h a q ua dri vale nt vacci ne a n d a tri vale nt 
vacci ne , t he latter wit h o ut t he B/ Ya ma gata li nea ge, w hic h has n ot bee n see n i n circ ulati o n 
si nce Marc h [ADDRESS_370842] o ber 2 0 2 3 V R B P A C rec o m me n dati o ns, t h e 
c o m mittee v ote d t o e xcl u de t he B/ Ya ma gata li nea ge a nti ge n c o m p o ne nt fr o m q ua dri vale nt 
i nfl ue nza vacci nes as s o o n as p ossi ble .9T he st u d y  desi g n t heref ore i ncl u des a q ua dri vale nt 
i nfl ue nza vacci ne ( qI R V) a n d a tri vale nt i nfl ue nza vacci ne (tI R V) w he n c o m b i ne d wit h 
B N T 1 6 2 b 2 (t he [COMPANY_007]- Bi o N Tec h C O VI D- 1 9 vacci ne ). 
Gi ve n t hat a n n ual vacci ne pr o gra ms i n t he U S a n d li kel y  ot her parts of t he w orl d a gai nst b ot h 
i nfl ue nza a n d S A R S- C o V -[ADDRESS_370843] i nfl ue nza w he n 
c o m bi ne d wit h B N T 1 6 2 b 2 ( bi vale nt ori gi nal/ O mi B A. 4/ B A. 5 ). T his e val uati o n will i nitiall y  
be c o n d ucte d t hr o u g h t he f oll o wi n g s u bst u dies: 
S u bst u d y  A: AP hase [ADDRESS_370844] u d y  i n u p t o a p pr o xi matel y  3 6 0 partici pa nts 
( 1 8 0 partici pa nts 1 8 t hr o u g h 6 4 ye ars of a ge a n d 1 8 0 partici pa nts ≥6 5 y ears of a ge) t o 
descri be t he safet y of q I R V a n d bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) at 
3d ose -le vel c o m bi nati o ns as s h o w n i n Ta ble 1.
S u bst u d y  B: This is a n e x pl orat or y P hase 1/ [ADDRESS_370845] u d y  t o descri be t he safet y  a n d 
i m m u n o ge nicit y of I R V (qI R V , tI R V , or bI R V )w he n a d mi nistere d i n c o m bi n ati o n 
wit h bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5), a n d l ice nse d QI V gi ve n 
c o nc urre n tl y wit h bI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5 ) i n healt h y  
a d ults [ADDRESS_370846] u d y  a d diti o nal c o m bi nati o ns of C O VI D - 1 9 /i nfl ue nza m o d R N A 
vacci nes ,i ncl u di n g tI R V:  µ g (  
) pl us  µ g bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5); 
bI R V:  µ g ( )pl us µ g bi vale nt 
B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) gi ve n c o nc urre ntl y wit h QI V i n t he o p p osite 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI C CI 
C CI C CI 
C CI 
C CI C CI C CI 
C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 4 5 ar m ;a n d a d diti o nal n o vel c o m bi nati o ns of qI R V :µ g (  
). 
F oll o wi n g a t h or o u g h re vie w of safet y  data fr o m S u bst u d y  A f or b ot h t he 
1 8- t hr o u g h 6 4 -ye ar a ge gr o u p a n d t he ≥ 6 5 -ye ar a ge gr o u p b y  t he s p o ns or’s I R C i n 
Marc h 2 0 2 3 a n d Ma y  2 0 2 3, c o nti n ue d use of C O VI D - 1 9/i nfl ue nza c o m bi nati o n vacci nes 
u p t o µ g ma xi m u m R N A d ose was c o nsi dere d acce pta ble f or c o nti n uati o n i nt o 
S u bst u d y  B. 
* Ori gi nal refers t o t he a ncestral strai n ( W u ha n -H u -1; U S A -W A 1/ 2 0 2 0), als o referre d t o i n 
t his pr ot oc ol as t he refere nce strai n. 
2. 2. B ac k gr o u n d 
2. 2. 1. S A R S -C o V - [ADDRESS_370847] u dies of S A R S -C o V -2 a n d 
S A R S -C o V, a cl osel y  relate d c or o na vir us t hat ca use d t he 2 0 0 3 S A R S pa n de mic, 
de m o nstrate d t hat effecti ve a nti b o d y  pr otecti o n c o ul d be ac hie ve d t hr o u g h s pi [INVESTIGATOR_2531] -s pecific 
a nti b o dies. 1 0 ,1 1   T heref ore, v acci nes tar geti n g t he s pi [INVESTIGATOR_303616] n of S A R S -C o V -2 ha ve bee n 
use d as a critical miti gati o n strate g y  of t he C O VI D -1 9 pa n de mic. H o we ver, wa ni n g 
effecti ve ness of t he a ut h oriz e d vacci nes has bee n s h o w n t o occ ur o ver ti me a n d is s us pecte d 
t o be d ue t o wa ni n g of vacci ne -i n d uce d i m m u nit y  as well as t he e mer ge nce of V O Cs. 
2. 2. 2. I nfl ue nz a 
I n fl ue nza is a maj or ca use of m or bi dit y  a n d m ortalit y  w orl d wi de, occ urri n g i n a n n ual 
seas o nal e pi [INVESTIGATOR_303617] a n d occasi o nall y i n gl o bal pa n de mics. 1 2   S y m pt o matic i nfl ue nza i nfecti o n 
ca uses a fe brile ill ness wit h res pi[INVESTIGATOR_1305] y  a n d s ys te mic s y m pt o ms, 1 3 alt h o u g h it ma y  ofte n be 
as y m pt o matic. 1 4   T he ris k of c o m plicati o ns a n d h os pi[INVESTIGATOR_1314] o n fr o m i nfl ue nza are hi g her i n 
pe o ple ≥ 6 5 y ears of a ge, y o u n g c hil dre n, a n d pe o ple wit h certai n u n derl yi n g me dical 
c o n diti o ns.  I n t he U S, a n a vera ge of > [ADDRESS_370848] 
3 0 0, 0 0 0 t o o ver 6 0 0, 0 0 0. 1 6 
I n fl ue nza vir uses are part of t he Ort h o myx oviri d ae fa mil y  a n d are di vi de d i nt o 3 ge nera or 
t y pes ( A, B, a n d C) base d u p o n a nti ge nic differe nces i n t he n ucle o pr otei n a n d t he matri x 
pr otei n.  I nfl ue nza A vir uses are f urt her clas sifie d i nt o s u bt y pes base d u p o n t he me m bra ne 
gl yc o pr otei ns, H A a n d N A. 1 7   T he R N A ge n o me is se g me nte d, w hic h all o ws ge netic 
reass ort me nt a m o n g vir uses of t he sa me t y pe. 1 7   T his ge netic i nsta bilit y  ca n res ult i n t he 
p he n o me n o n k n o w n as a nti ge nic s hift, i n v ol vi n g a maj or c ha n ge i n 1 or b ot h of t he H As a n d 
NAs, w hic h, if efficie ntl y  tra ns missi ble, ca n res ult i n a pa n de mic.  M ore c o m m o n are 
m ulti ple p oi nt m utati o ns i n t he ge n o me, lea di n g t o m ore mi n or c ha n ges i n t he H A a n d N A, 
k n o w n as a nti ge nic drift. 1 5   T his ge netic i nsta bilit y is w hat necessitates vacci nes t hat are 
tail ore d a n n uall y. 1 5 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI C CI 
C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370849] u d y  C 4 5 9 1 0 0 1 ( N C T 0 4 3 6 8 7 2 8) is a n o n g oi n g P hase 1/ 2 / 3 trial i n ~ [ADDRESS_370850] u d y  
p o p ulati o n: eli gi ble partici pa nts ≥ [ADDRESS_370851] I g G -bi n di n g res p o nse t o S 1 a n d a S A R S -C o V -2ne utralizi n g res p o nse.  
I m m u n o ge nicit y s u bsta ntiall y  i ncrease d f oll o wi n g t he sec o n d d ose of vacci ne.  B N T 1 6 2 b 2 
i n d uces a str o n g a nti ge n -s pecific T h 1 -s ke we d C D 4 + res p o nse a n d a str o n g a nti ge n-s pecific 
C D 8 + res p o nse. 
I n a mi d –N o ve m ber 2 0 2 0 a nal ys is of 3 6, 6 2 1 partici pa nts ra n d o mize d 1: [ADDRESS_370852] 
7 da y s after t he sec o n d d ose of vacci ne was 9 5. 0 %, wit h [ADDRESS_370853] b o gr o u p. 
I n a s u bse q ue nt a nal ys is of 9 2 7 c o nfir me d s y m pt o matic cases of C O VI D -1 9, a n efficac y  rate 
of 9 1. 3 % was o bser ve d f or B N T 1 6 2 b 2 i n pre ve nti n g s uc h cases occ urri n g bet wee n 7 da y s 
a n d 6 m o nt hs after t he sec o n d d ose. 1 9   F urt her m ore, fr o m t he sa me a nal ys is, B N T 1 6 2 b 2 wa s 
s h o w n t o ha ve a n efficac y of: 
1 0 0 % i n pre ve nti n g se vere disease as defi ne d b y t he C D C. 
9 5. 3 % i n pre ve nti n g se vere disease as defi ne d b y t he F D A. 
1 0 0 % i n pre ve nti n g C O VI D -[ADDRESS_370854] 1 6 y ears of a ge ra n d o mize d 1: [ADDRESS_370855] b o wit h a me dia n of 2 m o nt hs of f oll o w- u p after t he sec o n d d ose 
de m o nstrate d a fa v ora ble safet y pr ofile.  A vaila ble safet y data fr o m all p artici pa nts e nr olle d 
t hr o u g h t he 1 4 N o ve m ber 2 0 2 0 data c ut off ( N = 4 3, 2 5 2), w hic h i ncl u des late e nr oll me nt of 
a d diti o nal a d olesce nt a n d a d ult partici pa nts, were c o nsiste nt wit h t he safet y pr ofile f or t he 
a p pr o xi matel y  [ADDRESS_370856] u d y  C 4 5 9 1 0 0 1, t he F D A iss ue d 
t he E U A f or a si n gle b o oster d ose of B N T 1 6 2 b 2 3 0 µ g f or: 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 4 7 1. i n di vi d uals 6 5 y ears of a ge a n d ol der; 
2. i n di vi d uals 1 8 t hr o u g h 6 4 y ears of a ge at hi g h ris k of se vere C O VI D- 1 9; a n d 
3. i n di vi d uals [ADDRESS_370857] u d y  E is a n o n g oi n g P hase 3 trial i n a p pr o xi matel y  2 9 0 0 partici pa nts 
1 8 ye ars of a ge a n d ol der w h o ha ve pre vi o usl y  rece i ve d 3 d oses of B N T 1 6 2 b 2 ( 3 0- μ g d ose).   
Partici pa nts i n t his s u bst u d y  recei ve d a f o urt h d ose of eit her B N T 1 6 2 b 2 or B N T 1 6 2 b 2 
O micr o n ( B A. 1 s u bli nea ge) or a c o m bi nati o n of b ot h at a t otal d ose le vel of eit her [ADDRESS_370858] u d y  vacci nati o n (t o t he data c ut off date) was acce pta ble a n d c o nsiste nt 
wit h t he k n o w n safet y pr ofi le of B N T 1 6 2 b 2 a n d t he pre vi o usl y re p orte d A E pr ofile f or 
O micr o n B A. 1 –m o difie d B N T 1 6 2 b 2 vacci nes. I n  partici pa nts > [ADDRESS_370859] o ge nicit y  wit h t he 3 0- μ g  d ose le vel.   Fr o m t he 
i m m u n o ge nicit y data, i n partici pa nts > [ADDRESS_370860] O micr o n B A. 1 a n d 
refere nce -strai n vacci ne - elicite d i m m u ne res p o nse t o b ot h m o n o vale nt a n d bi vale nt 
O micr o n B A. 1 – m o difie d vacci nes w he n a d mi nistere d as a f o urt h d ose t o 
B N T [ADDRESS_370861] C O VI D- 1 9. T his nee d has bee n 
ree m p hasize d b y t he F D A si nce J u ne 2 0 2 2 w he n it cal le d f or trials wit h m o difie d vacci nes 
c o ntai ni n g a n O micr o n B A. 4/ B A. 5 c o m p o ne nt at e mer ge nce of t hat strai n. 2 2 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370862] u d y ( N C T 0 5 4 7 2 0 3 8). T his is a n 
o n g oi n g P hase 2/ 3, ra n d o mize d, acti ve -c o ntr olle d st u d y  t o e val uate t he safet y , t olera bilit y, 
a n d i m m u n o ge nicit y of ne w bi vale nt varia nt vacci nes at t he sta n dar d or hi g her d ose. T he 
st u d y  e val uates bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) gi ve n as a f o urt h d ose i n 
partici pa nts 1 2 t hr o u g h 1 7, 1 8 t hr o u g h 5 5, a n d > 5 5 y ears of a ge. Preli mi nar y  data 
de m o nstrate d t hat t he safet y  pr ofile wit hi n 1 m o nt h after vacci nati o n ( D ose 4) wit h bi vale nt 
B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) at t he [ADDRESS_370863] u d y 
vacci nati o n f or B N T 1 6 2 b 2 -e x perie nce d partici pa nts 1 8 t hr o u g h 5 5 ye ars a n d > 5 5 y ears of 
a ge w h o recei ve d a f o urt h d ose wit h bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) [ADDRESS_370864] vacci ne- elicite d i m m u ne res p o nse. S u peri orit y  of bi va le nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) 3 0 μ g t o B N T 1 6 2 b 2 3 0 μ g i n t he > [ADDRESS_370865] t o a nti – O micr o n B A. 4/ B A. 5 ne utralizi n g titers was met. 
N o ni nferi orit y base d o n ser ores p o nse f or bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) 
3 0 μ g t o B N T 1 6 2 b 2 3 0 μ g i n t he > 5 5 -year a ge gr o u p was als o met. A d diti o nall y ,
n o ni nferi orit y  of a nti –refere nce -strai n i m m u ne res p o nse base d o n t he G M R of bi vale nt 
B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) 3 0 μ g t o B N T 1 6 2 b 2 3 0 μ g i n t he > [ADDRESS_370866] C O VI D- 1 9 d ue 
t o O micr o n B A. 4/ B A. 5 wit h bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) c o m pare d t o 
B N T 1 6 2 b 2 as a f o urt h d ose. 
2. 2. 3. 2. I nfl ue nz a 
I n fl ue nza m o d R N A has bee n e val uate d i n 2 Pf izer -s p o ns ore d cli nical trials: C 4 7 8 1 0 0 1 a n d 
C 4 7 8 1 0 0 4.  
C 4 7 8 1 0 0 1:  T his is a P hase 1 /[ADDRESS_370867] v isit 
(Se pte m ber 2 0 2 1) t o last partici pa nt l ast visit ( Ja n uar y  2 0 2 3) .  T he st u d y  e val uate d 
m o n o vale nt, bi vale nt, a n d q ua dri vale nt i nfl ue nza vacci nes i n healt h y  a d ults 
[ADDRESS_370868] u d y  e val uate d m o n o vale nt R N A e nc o di n g i nfl ue nza strai ns i n d oses u p t o µg, 
bi vale nt R N A e nc o di n g 2i nfl ue nza strai ns i n d oses u p t o  µ g/strai n ( = µg t otal R N A 
d ose), q ua dri vale nt R N A e nc o di n g 4 i nfl ue nza strai ns i n d oses u p t o µ g/strai n 
( = µg t otal R N A d ose), a n d c o m bi nati o ns of m o n o vale nt a n d bi vale nt R N A vacci nes 
gi ve n c o nc o mita ntl y  or sta g gere d wit h lice nse d i nfl ue nza vacci nes. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
C CI C CI 
C CI 
C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370869] u d y  ha v e de m o nstrate d t hat a si n gle d ose of qI R V 
µ g or µ g ) was well t olerate d a n d elicite d i m m u ne res p o nses a gai nst i nfl ue nza i n 
partici pa nts 1 8 t hr o u g h 8 5 y ears of a ge. T o get her, t hese data s u p p orte d pr o gressi o n t o 
P hase 3 cli nical de vel o p me nt of qI R V ( µ g) f or a d ults ≥ 6 5 y ears of a ge a n d qI R V ( µ g) 
f or a d ults [ADDRESS_370870] u d y  C 4 7 8 1 0 0 4 was desi g ne d t o e val uate t he efficac y a n d 
i m m u n o ge nicit y t o deter mi ne effecti ve ness, al o n g wit h safet y a nal ys es t o assess t olera bilit y  
a n d ris k, of qI R V w he n a d mi nistere d t o a lar ge c o h ort of a d ults at t he a ge gr o u p –selecte d 
d ose le v els. 
C 4 7 8 1 0 0 4:  AP hase [ADDRESS_370871] u d y is e val uati n g d oses of µg a n d µg 
q ua dri vale nt m o d R N A i nfl ue nza vacci nes i n a d ults 1 8 t hr o u g h 6 4 y ears of a ge a n d ≥[ADDRESS_370872] u dies a n d n o n –[COMPANY_007] -s p o ns ore d st u dies wit h m o d R N A i nfl ue nza, 
see t he I B. 
T he latest safet y  a n d im m u n o ge nicit yres ults ca n be f o u n d i n t he I B f or qI R V.  
T he rati o nale f or t he d ose le vel select e d f or eac h st u d y  i nter ve nti o n use d i n t his st u d y  is 
pr o vi de d i n Secti o n 4. [ADDRESS_370873] b ot h of t hese pat h o ge ns c o ul d pr o vi de si g nifica nt 
a d va nta ges t o b ot h patie nts a n d care gi vers i n ter ms of si m plif y i n g care. T his cli nical 
de vel o p me nt pr o gra m is i nte n de d t o deter mi ne if 2 m o difie d m o d R N A vacci nes desi g ne d t o 
tar get i nfl ue nza a n d t he S A R S -C o V -2 vir us ca n de m o nstrate a n acce pta ble safet y a n d 
i m m u n o ge nicit y pr ofile. 
T he differ e nt vacci ne gr o u ps t o be e val uate d i n t his cli nical trial will deter mi ne t he 
i m m u n o ge nicit y a n d safet y pr ofile of differe nt d oses of t he i nfl ue nza a n d S A R S -C o V - 2 
a nti ge ns, of differe nt met h o ds of vacci ne c o m bi nati o n  
 
 
 T he s u m mar y  of t hese gr o u ps is 
i ncl u de d i n Ta ble 2.0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI C CI 
C CI C CI 
C CI C CI 
C CI 
C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 5 0 2. 3. Be nefit/ Ris k Assess me nt 
T he a vaila ble safet y a n d i m m u n o ge nicit y data fr o m o n g oi n g cli nical trials a n d real -w orl d 
effecti ve ness a n d safet y data f or B N T 1 6 2 b 2, c o m bi ne d wit h a vaila ble n o ncli nical data wit h 
B N T 1 6 2 vacci nes, as well as data fr o m n o ncli nical a n d cli nical trials wit h qI R V , s u p p ort a 
fa v ora ble be nefit/ris k pr ofile a n d s u p p ort cli nical de vel o p me nt of a vacci n e c o m bi ni n g t hese 
c o m p o ne nts.  Ta ki n g i nt o acc o u nt t he meas ures t o mi ni mize ris k t o st u d y  partici pa nts, t he 
p ote ntial ris ks i de ntifie d i n ass ociati o n wit h t he st u d y  i nter ve nti o n are j ustifie d b y  t he 
a ntici pate d be nefits t hat ma y  be aff or de d t o healt h y part ici pa nts. 
Cli nical i n vesti gati o n is j ustifie d, gi ve n: 
T he t hreat p ose d b y c o nti n u o us ne w o ut brea ks of S A R S -C o V- 2 i nfecti o ns w orl d wi de .
T he t hreat p ose d b y t he S A R S -C o V -2 varia nts e mer gi n g w orl d wi de. 
T he p ote ntial nee d f or e n ha nci n g i m m u ne res p o nses t o o verc o me wa ni n g i m m u nit y .
T he p ote ntial a d va nta ges a n d c o n ve nie nce t o i n di vi d uals i n de vel o pi n g a c o m bi ne d 
vacci ne a gai nst S A R S- C o V - 2 a n d i nfl ue nza t hat w o ul d ali g n wit h t he rece nt F D A 
rec o m me n dati o ns f or a n a n n ual C O VI D - 1 9 vacci nati o n a p pr oac h ,si milar t o t hat f or 
i nfl ue nza .
M ore detaile d i nf or mati o n a b o ut t he k n o w n a n d e x pecte d be nefits a n d ris ks a n d reas o na bl y 
e x pecte d A E s of I R V ( qI R V , bI R V ,or t I R V)/ B N T 1 6 2 b 2 ( ori gi nal / O mi B A. 4/ B A. 5 ), I R V, 
a n d B N T [ADDRESS_370874] u d y  B is 
t he lice nse d Fl ucel va x U S PI .
2. 3. 1. Ris k Assess me nt 
P ote nti al Ris k of Cli nic al Si g nific a nce S u m m ar y of D at a/ R ati o n ale f or Ris k Miti g ati o n Str ate g y 
St u d y I nter ve nti o n(s): I R V/ Bi v ale nt B N T 1 6 2 b 2 ( Ori gi n al/ O m i B A. 4/ B A. 5) , 
I R V, a n d B N T 1 6 2 b 2 O m icr o n ( B A. 4/ B A. 5) 
F or I R V: 
L ocal a n d s yste mic reacti o ns t o t he 
vacci ne ma y occ ur (i njecti o n site 
re d ness, i njecti o n site s welli n g, a n d 
i njecti o n site pai n; fe ver, fati g ue, 
hea dac he, c hills, v o m iti n g, diarr hea , 
m uscle pai n, a n d j oi nt pai n) f oll o w i n g 
vacci nati o n. T hese are c o m m o n a d verse reacti o ns 
see n wit h ot her vacci nes, [ADDRESS_370875] u d y wit h B N T 1 6 2 b 2 
( C 4 5 9 1 0 0 1) w ere mi l d t o m o derate pai n 
at t he i njecti o n site, fati g ue, a n d 
hea dac he. [ADDRESS_370876] o ge nicit y e- diar y, 
whic h all o ws t he 
i n vesti gat or t o m o nit or l ocal 
reacti o ns a n d s yste mic 
e ve nts i n real ti me after 
eac h vacci nati o n t hr o u g h a n 
electr o nic p ortal. Se vere 
reacti o ns will re q uire a n 
u nsc he d ule d tele p h o ne call, 
a n d visit if re q uire d, t o be 
c o n d ucte d per pr ot oc ol. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 5 1 P ote nti al Ris k of Cli nic al Si g nific a nce S u m m ar y of D at a/ R ati o n ale f or Ris k Miti g ati o n Str ate g y 
a n d [ADDRESS_370877] 
3 0 mi n utes after 
vacci nati o n. 
T he safet y pr ofile of a n o vel vacci ne is 
n ot yet f ull y c haracterize d. Alt h o u g h I R Vs are n o vel vacci nes, t he y 
are base d o n t he sa me platf or m 
( m o d R N A) as t he C O VI D -1 9 vacci ne 
BN T 1 6 2 b 2, w hic h has bee n s h o w n t o 
ha ve a p ositi ve be nefit/ris k pr ofile. A E a n d S A E re p orts w ill be 
c ollecte d fr o m t he si g ni n g 
of t he I C D t hr o u g h 4 w ee ks 
a n d 6 m o nt hs after 
vacci nati o n (f or all 
s u bst u dies) .
All partici pa nts will be 
o bser ve d f or at least 
3 0 mi n utes after 
vacci nati o n. 
F or B N T 1 6 2 b 2 O micr o n ( B A. 4/ B A. 5) 
T his vacci ne has t he sa me m o d R N A 
platf or m ( wit h se q ue nce c ha n ges 
li mite d t o t h ose t hat are 
O m icr o n -s pecific) a n d L N P f or m ulati o n 
as B N T 1 6 2 b 2; t heref ore, t he safet y 
pr ofile is e x pecte d t o be si milar t o t hat 
of B N T 1 6 2 b 2, ie, local reacti o ns, s uc h 
as i njecti o n site re d ness, i njecti o n site 
s welli n g, a n d i njecti o n site pai n, a n d 
s yste mic e ve nts , s uc h as fe ver, fati g ue, 
hea dac he, c hills, v o m iti n g, diarr hea, 
m uscle pai n, a n d j oi nt pai n. 
Ot her ke y ris ks i de ntifie d f or 
B N T 1 6 2 b 2 are l y m p ha de n o pat h y; 
h y perse nsiti vit y reacti o ns, s uc h as ras h, 
pr urit us, urticaria, a n gi oe de ma, a n d 
a na p h yla xis; a n d m y ocar ditis a n d 
pericar ditis. T hese are c o m m o n a d verse reacti o ns 
see n wit h ot her vacci nes as well as t he 
C O VI D -[ADDRESS_370878] u d y 
( w it h B N T 1 6 2 b 2 ) s h o we d l o w i nci de nce 
of se vere or seri o us e ve nts a n d n o 
cli nicall y c o ncer ni n g safet y o bser vati o ns 
acr oss t he safet y p o p ulati o n a n d wit hi n 
de m o gra p hic s u b gr o u ps base d o n a ge, 
se x, race/et h nicit y, c o u ntr y, a n d baseli ne 
S A R S -C o V -[ADDRESS_370879] c o m m o n e ve nts bei n g pai n at t he 
i njecti o n site, fati g ue, a n d hea dac he. 
A na p h yla xis: Fre q ue nc y n ot k n o w n. 
M y ocar ditis a n d pericar ditis: Ver y rare 
cases of m y ocar ditis a n d pericar ditis 
ha ve bee n re p orte d f oll o wi n g 
vacci nati o n wit h m o d R N A 
S A R S -C o V - [ADDRESS_370880] o ge nicit y e -diar y t o 
m o nit or l ocal reacti o ns a n d 
s yste mic e ve nts i n real ti me 
after vacci nati o n .
C ollecti o n of A Es fr o m t he 
si g ni n g of t he I C D t hr o u g h 
4we e ks after vacci nati o n ,
a n d S A Es t hr o u g h 6 m o nt hs 
after V isit 1/ [ADDRESS_370881] a healt hcare 
pr ofessi o nal if a case is 
s us pecte d. 
F or a na p h yla xis, t here is a n 
o n -site 3 0 -mi n ute 
o bser vati o n peri o d after 
vacci nati o n. 
I nstr ucti o ns f or ha n dli n g 
s us pecte d cases of 
m y ocar ditis a n d pericar ditis 
are f o u n d i n 
Secti o n 1 0. 1 1. 8. 8. 1 0 a n d 
Secti o n 1 0. 1 2. 8. 1 2 .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 5 2 P ote nti al Ris k of Cli nic al Si g nific a nce S u m m ar y of D at a/ R ati o n ale f or Ris k Miti g ati o n Str ate g y 
f oll o wi n g sta n dar d treat me nt a n d rest.  
Healt hcare pr ofessi o nals s h o ul d be alert 
t o t he si g ns a n d s y m pt o ms of 
m y ocar ditis a n d pericar ditis i n vacci ne 
reci pie nts. 
P osta ut h orizati o n safet y data 
s ur veilla nce has c o nfir me d t he safet y 
pr ofile o bser ve d i n St u d y C 4 5 9 1 0 0 1 a n d 
has res ulte d i n i de ntificati o n of s o me 
a d diti o nal a d verse reacti o ns (ris ks) as 
n ote d i n t he S R S D. 
St u d y I nter ve nti o n(s): QI V –Fl uz o ne S D a n d QI V –Fl ucel v a x 
L ocal a n d s yste mic reacti o ns t o t he 
vacci ne ma y occ ur (i njecti o n site 
re d ness, i njecti o n site s welli n g, a n d 
i njecti o n site pai n; fe ver, fati g ue, 
hea dac he, c hills, v o miti n g, diarr hea, 
ne w or w orse ne d m uscle pai n, 
ne w or w orse ne d j oi nt pai n , G uillai n -
Barr és y n dr o me, a n d s y nc o pe )
f oll o wi n g vacci nati o n .T hese are c o m m o n a d verse reacti o ns 
see n wit h ot her vacci nes. [ADDRESS_370882] u d y  B are detaile d i n Secti o n 1 0. 1 2. 2. 3 .
2. 3. 3. O ver all Be nefit/ Ris k C o ncl usi o n 
Ta ki n g i nt o acc o u nt t he meas ures t o mi ni mize ris k t o st u d y  partici pa nts as state d i n 
Secti o n 2. 3. [ADDRESS_370883] u d y  i nter ve nti o ns 
are j ustifie d b y t he a ntici pate d be nefits t hat ma y be aff or de d t o healt h y partici pa nts. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370884] u d y P o p ul ati o n 
See Secti o n 5 .
4. 2. 2. C h oice of C o ntr ace pti o n/ B arrier Re q uire me nts 
H u ma n re pr o d ucti ve safet y  data are n ot a vaila ble f or t he m o d R N A i nfl ue nza vacci nes use d i n 
t his st u d y , b ut t here is n o s us pi[INVESTIGATOR_37180] o n of h u ma n tera t o ge nicit y  base d o n t he i nte n de d 
p har mac ol o g y  of t he c o m p o u n d.  T he use of a hi g hl y effecti ve met h o d of c o ntrace pti o n is 
re q uire d f or se x ual i nterc o urse i n v ol vi n g a W O C B P (see Secti o n 1 0. 5 ). 
4. 3. J ustific ati o n f or D ose 
4. 3. 1. Bi v ale nt B N T 1 6 2 b 2 ( Ori gi n al / O mi B A. 4/ B A. 5 )
Base d o n data fr o m t he P hase 1 c o m p o ne nt of cli nical trial C 4 5 9 1 0 0 1 a n d a vaila ble 
n o ncli nical data, t he m o d R N A B N T 1 6 2 b 2 vacci ne ca n di date was selecte d at a d ose of 3 0 µ g 
f or P hase 2 a n d 3 e val uati o n of safet y, i m m u n o ge nicit y , a n d efficac y  after 2 d oses 
a d mi nistere d 3 wee ks a part.  T his is t he d ose t hat was s h o w n t o be effecti ve a n d has bee n 
a p pr o ve d i n m ulti ple c o u ntries w orl d wi de. 
I n N o ve m ber 2 0 2 1 ,t he F D A iss ue d a n E U A f or asi n gle b o oster d ose of bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) at a d ose le vel of 3 0 µ g ( 1 5 µg ori gi nal B N T 1 6 2 b 2 a n d 
1 5 µ g B N T 1 6 2 b 2 O micr o n [ B. 1. 1. 5 2 9 s u bli nea ge B A. 4/ B A. 5]) i n i n di vi d uals ≥[ADDRESS_370885] u d y  w he n bi vale nt B N T 1 6 2 b 2 
( o ri gi nal/ O mi B A. 4/ B A. 5) is a d mi nistere d al o ne .2 7 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370886] u d ie d i n t he P hase 3 
C 4 7 8 1 0 0 4 pr ot oc ol b y  a ge strat u m is µg f or partici pa nts 1 8 t hr o u g h 6 4 years of a ge a n d 
µ g f or partici pa nts ≥[ADDRESS_370887] u dies A a n d B w he n a d mi nistere d al o ne or i n c o m bi nati o n wit h bi vale nt 
B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5). 
4. 3. 3. qI R V/ Bi v ale nt B N T 1 6 2 b 2 ( O ri gi n al/ O mi B A. 4/ B A. 5) 
qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) at d ose -le vel c o m bi nati o ns n ot 
e xcee di n g µ g will be e val uate d i n Su bst u dies A a n d B .
I n S u b st u d y  A, d ose -le vel c o m bi nati o ns [ADDRESS_370888] u d y  B will e val uate vari o us d ose -le vel c o m bi nati o n si n partici pa nts 1 8 t hr o u g h 6 4 ye ars 
of a ge (Ta ble 2) (as detaile d i n Secti o n 1 0. 1 2. 4. 1 ). T hese d ose -le vel c o m bi nati o ns i n 
S u bst u d y  B were  
 
 
 
Base d o n P hase [ADDRESS_370889] u d y ,b y  a ge strat u m ,is µ g f or partici pa nts 1 8 t hr o u g h 
6 4 ye ars of a ge a n d µ g f or partici pa nts ≥ 6 5 y ears of a ge ; he nce, t he c orres p o n di n g d ose 
le vel will be use d i n qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) a d mi nistere d 
d uri n g S u bst u d y B t o partici pa nts [ADDRESS_370890] u d y  a d diti o nal c o m bi nati o ns of C O VI D - 1 9 /i nfl ue nza 
m o d R N A . T his is s u p p orte d b y  a n acce pta ble t olera bilit y  pr ofile f or a d ose u p t o µ g of a 
c o m bi nati o n of i nfl ue nza m o d R N A a n d C O VI D -[ADDRESS_370891] b ot h C O VI D- 1 9 a n d i nfl ue nza strai ns. 
4. 3. 4. tI R V /Bi v ale nt B N T 1 6 2 b 2 ( Ori gi n al/ O mi B A. 4/ B A. 5) 
tI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) at d ose- le vel c o m bi nati o ns n ot 
e xcee di n g  µ g will be e val uate d i n t his st u d y  as e x pl orat or y o bjecti ves , base d o n 
i m m u n o ge nicit y data fr o m S u bst u d y  A a n d S u bst u d y  B .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
C CI 
C CI 
C CI 
C CI C CI C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370892] u d y  a differe nt c o m bi nati o n 
of C O VI D - 1 9 /i nfl ue nza m o d R N A vacci ne i n t he f or m of tI R V: µ g (  
,a n d  a n d µ g  bi vale nt B N T 1 6 2 b 2 
(ori gi nal/ O mi B A. 4/ B A. 5). T his is s u p p orte d b y  a n acce pta ble t olera bilit y pr ofile f or a d ose 
u p t o µ g of a c o m bi nati o n of i nfl ue nza m o d R N A a n d C O VI D - [ADDRESS_370893] b ot h C O VI D-1 9 a n d i nfl ue nza strai ns . 
4. 3. 5. bI R V /Bi v ale nt B N T 1 6 2 b 2 
bI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) at d ose -le vel c o m bi nati o ns n ot 
e xcee di n g µ g will be e val uate d i n S u bst u d y  B as e x pl orat or y o bjecti ves , base d o n 
i m m u n o ge nicit y data fr o m S u bst u d y  A. 
Base d o n preli mi nar y data fr o m S u bst u d y  A, S u bst u d y  B will st u d y  a differe nt c o m bi nati o n 
of C O VI D - 1 9 /i nfl ue nza m o d R N A vacci ne i n t he f or m of bI R V gi ve n c o nc urre ntl y wit h QI V 
i n t he o p p osite ar m: µ g (  a n d µ g bi vale nt 
B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5). T his is s u p p orte d b y  a n acce pta ble t olera bilit y  pr ofile 
f or a d o se u p t o  µ g ma xi m u m a n d o p p ort u nit y  t o i ncrease t he i m m u ne res p o nse. 
4. 4. E n d of St u d y Defi niti o n 
T he e n d of t he st u d y is defi ne d as t he date of t he last visit of t he last partici pa nt i n 
S u bst u d y B. 
A partici pa nt is c o nsi dere d t o ha ve c o m plete d t he st u d y  if he/s he has c o m plete d all peri o ds of 
t he st u d y , i ncl u di n g t he last visit. 
5. S T U D Y P O P U L A TI O N 
T his st u d y  ca n f ulfill its o bjecti ves o nl y  if a p pr o priate partici pa nt s are e nr olle d , i ncl u di n g 
partici pa nts acr oss di verse a n d re prese ntati ve racial a n d et h nic bac k gr o u n ds. If a 
prescree n i n g t o ol is utilize d f or st u d y recr uit me nt p ur p oses , it will i ncl u de c ollecti o n of 
i nf or mati o n t hat reflects t he e nr oll me nt of a di verse partici pa nt p o p ulati o n i ncl u di n g, w here 
per mitte d u n der l ocal re g ulati o ns, a ge, se x, race, a n d et h nicit y . T he f oll o wi n g eli gi bilit y  
criteria are desi g ne d t o select partici pa nt s f or w h o m partici pati o n i n t he st u d y  is c o nsi dere d 
a p pr o priate. All rele va nt me dical a n d n o n me dical c o n diti o ns s h o ul d be ta ke n i nt o 
c o nsi derati o n w he n deci di n g w het her a partic ular partici pa nt is s uita ble f or t his pr ot oc ol .
Pr os pecti ve a p pr o val of pr ot oc ol de viati o ns t o recr uit me nt a n d e nr oll me nt criteria ,als o 
k n o w n as pr ot oc ol wai vers or e xe m pti o ns, is n ot per mitte d .
N ote : “E nr olle d ”mea ns a partici pa nt ’s, or t heir le gall y a ut h orize d re prese ntati ve’s, 
a gree me nt t o partici pate i n a cli nical st u d y  f oll o wi n g c o m pleti o n of t he i nf or me d c o nse nt 
pr ocess a n d ra n d o mizati o n. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI C CI 
C CI C CI 
C CI 
C CI 
C CI 
C CI C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370894] yle C o nsi der ati o ns 
5. 3. 1. C o ntr ace pti o n 
T he i n vesti gat or or t heir desi g nee, i n c o ns ultati o n wit h t he partici pa nt, will c o nfir m t hat t he 
partici pa nt is utilizi n g a n a p pr o priate met h o d of c o ntrace pti o n f or t he i n di vi d ual partici pa nt 
a n d t heir part ner(s) fr o m t he per mitte d list of c o ntrace pti o n met h o ds (see A p pe n di x 5,
Secti o n 1 0. 5. 4 ) a n d will c o nfir m t hat t he partici pa nt has bee n i nstr ucte d i n its c o nsiste nt a n d 
c orrect use. At ti me p oi nts i n dica te d i n t he S o As , t he i n vesti gat or or desi g nee will i nf or m t he 
partici pa nt of t he nee d t o use acce pta ble eff ecti ve c o ntrace pti o n c o nsiste ntl y a n d c orrectl y 
a n d d oc u me nt t he c o n versati o n a n d t he partici pa nt ’s af fir mati o n i n t he partici pa nt’s c hart. 
Partici pa nts nee d t o af fir m t heir c o nsiste nt a n d c orrect use of at least [ADDRESS_370895] u d y  (scree n fail ures) ma y  
be rescree ne d. 
5. 5. Criteri a f or Te m p or aril y Del a yi n g E nr oll me nt/ R a n d o miz ati o n/ A d mi nistr at i o n of 
St u d y I nter ve nti o n 
See Secti o n [ADDRESS_370896] u d y  A .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370897] u d y  B .
6. S T U D Y I N T E R V E N TI O N( S ) A N D C O N C O MI T A N T T H E R A P Y 
St u d y  i nter ve nti o ns are all pres pecifie d i n vesti gati o nal a n d me dical de vices, a n d ot her 
i nter ve nti o ns (e g, s ur gical a n d be ha vi oral) ,i nte n de d t o be a d mi nistere d t o t he st u d y  
partici pa nts d uri n g t he st u d y c o n d uct. 
F or t he p ur p oses of t his pr ot oc ol, st u d y  i nter ve nti o n refers t o: 
qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal / O mi B A. 4/ B A. 5), w hic h is a c o m bi nati o n of t he 
f oll o wi n g, a d mi nistere d at t he d ose -le vel c o m bi nati o ns s h o w n i n Ta ble 1f or 
S u bst u d y A a n d Ta ble 2f or S u bst u d y  B .
qI R V e nc o di n g H A of 4 strai ns as seas o nall y rec o m me n de d f or t he i nfl ue nza 
seas o n ( )or , wit h t he 
strai n c o m bi nati o ns as s h o w n i n Ta ble 1f or S u bst u d y  A a n d Ta ble 2f or 
S u bst u d y B. 
Bi vale nt B N T 1 6 2 b 2 (ori gi nal / O mi B A. 4/ B A. 5), w hic h c o ntai ns ori gi nal 
B N T 1 6 2 b 2 a n d B N T 1 6 2 b 2 O micr o n ( B. 1. 1. 5 2 9 s u bli nea ge B A. 4/ B A. 5) , at a 
d ose of eit her: 
 µg, ie,  µ g of ori gi nal B N T 1 6 2 b 2 a n d  µ g of B N T 1 6 2 b 2 O micr o n 
( B. 1. 1. 5 2 9 s u bli nea ge B A. 4/ B A. 5) , or 
 µg, ie,  µ g of ori gi nal B N T 1 6 2 b 2 a n d µ g of B N T 1 6 2 b 2 O micr o n 
( B. 1. 1. 5 2 9 s u bli nea ge B A. 4/ B A. 5) 
tI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5), w hic h is a c o m bi nati o n of t he 
f oll o wi n g, a d mi nistere d at t he d ose -le vel c o m bi nati o ns s h o w n i n Ta ble 2:
 µ g tI R V e nc o di n g H A of 3strai ns as seas o nall y rec o m me n de d f or t he 
i nfl ue nza seas o n ( a n d  
)
 µ g Bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5), w hic h c o ntai ns ori gi nal 
B N T 1 6 2 b 2 a n d B N T 1 6 2 b 2 O micr o n ( B. 1. 1. 5 2 9 s u bli nea ge B A. 4/ B A. 5) 
bI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5), w hic h is a c o m bi nati o n of t he 
f oll o wi n g, a d mi nistere d at t he d ose -le vel c o m bi nati o ns s h o w n i n Ta ble 2:
 µ g bI R V e nc o di n g H A of  as seas o nall y  rec o m me n de d f or t he 
i nfl ue nza seas o n )0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI C CI 
C CI C CI C CI 
C CI C CI C CI 
C CI 
C CI C CI C CI 
C CI 
C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 5 8   µ g Bi vale n t B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5), w hic h c o ntai ns ori gi nal 
B N T 1 6 2 b 2 a n d B N T 1 6 2 b 2 O micr o n ( B. 1. 1. 5 2 9 s u bli nea ge B A. 4/ B A. 5) 
 µ g qI R V, ie, e nc o di n g H A of 4 strai ns as seas o nall y  rec o m me n de d f or t he 
i nfl ue nza seas o n )
 µ g qI R V, ie, e nc o di n g H A of 4 strai ns as seas o nall y  rec o m me n de d f or t he 
i nfl ue nza seas o n )
Lice nse d QI V 
Ta ble 3de sc ri bes the vacci ne details f or eac h of t he c o nstit ue nt parts of t he st u d y  
i nter ve nti o ns. 
T a ble 1. S u bst u d y A: qI R V/ Bi v ale nt B N T 1 6 2 b 2 ( Ori gi n al/ O mi B A. 4/ B A. 5) 
D ose -Le vel C o m bi n ati o ns 
Su bst u d y A
V acci ne Gr o u p qI R V D ose Bi v ale nt B N T 1 6 2 b 2 
( Ori gi n al */ O m iB A. 4/ B A. 5) D ose T ot al 
m o d R N A D ose 
1 µ g , ie, 
 µ g , ie, 
 µ g of ori gi nal B N T 1 6 2 b 2 a n d 
 µ g of B N T 1 6 2 b 2 O micr o n 
( B. 1. 1. 5 2 9 s u bli nea ge B A . 4/ B A. 5) µ g 
2 µ g , ie, 
 µ g , ie, 
 µ g of ori gi nal B N T 1 6 2 b 2 a n d 
 µ g of B N T 1 6 2 b 2 O micr o n 
( B. 1. 1. 5 2 9 s u bli nea ge B A. 4/ B A. 5) µ g 
3 µ g , ie, 
  µ g , ie, 
 µ g of ori gi nal B N T 1 6 2 b 2 a n d 
 µ g of B N T 1 6 2 b 2 O micr o n 
( B. 1. 1. 5 2 9 s u bli nea ge B A. 4/ B A. 5) µ g 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
C CI 
C CI C CI 
C CI 
C CI 
C CI 
C CI C CI 
C CI 
C CI C CI 
C CI 
C CI 
C CI C CI 
C CI 
C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370898] u d y B: All V acci ne Gr o u ps 
S u bst u d y B 
V acci ne 
Gr o u p qI R V/ Bi v ale nt 
B N T 1 6 2 b 2 
D ose -Le vel 
C o m bi n ati o ns aqI R V, tI R V, or bI R V Bi v ale nt 
B N T 1 6 2 b 2 bLice nse d QI V L N P 
D ose T ot al m o d R N A 
D ose A p pr o xi m ate 
N u m ber of 
P artici p a nts 
1 N/ A N/ A µ g Lice nse d QI V m g µ g 3 0 
2cN/ A µ g bI R V 
(µ g Lice nse d QI V m g µ g 3 0 
3 1 µ g qI R V 
(
)µ g N/ A m g µ g 1 2 0 
4d2 µ g qI R V ( 
(  
)µ g 
 N/ A m g µ g 1 2 0 
5 3 µ g qI R V 
(  
)µ g N/ A m g µ g 1 2 0 
6 4 µ g qI R V 
(  
)µ g N/ A m g µ g 3 0 
7 5  µ g qI R V 
(  
)µ g N/ A m g µ g 3 0 
8 6 µ g qI R V 
(  
)µ g N/ A m g µ g 3 0 
9 7 µ g qI R V 
(  
)µ g N/ A m g µ g 3 0 
1 0 8 µ g qI R V 
(  
)µ g N/ A m g µ g 3 0 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
C CI 
C CI 
C CI 
C CI C CI 
C CI C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI C CI 
C CI C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370899] u d y B: All V acci ne Gr o u ps 
S u bst u d y B 
V acci ne 
Gr o u p qI R V/ Bi v ale nt 
B N T 1 6 2 b 2 
D ose -Le vel 
C o m bi n ati o ns aqI R V, tI R V, or bI R V Bi v ale nt 
B N T 1 6 2 b 2 bLice nse d QI V L N P 
D ose T ot al m o d R N A 
D ose A p pr o xi m ate 
N u m ber of 
P artici p a nts 
1 1 cN/ A µ g tI R V 
(
)µ g N/ A m g µ g 3 0 
1 2 dN/ A qI R V N/ A N/ A m g µ g 3 0 
a. F or qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) t hat mI R Vs e nc o di n g H A f or eac h A a n d B strai n will be t o ge nerate qI R V 
at t he d ose -le vel c o m bi nati o n s h o w n; t he res ulta nt qI R V will t he n be wit h bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) pr i or t o a d mi nistrati o n.  Please 
see t he I P M f or f urt her details. 
b. F or bi vale nt B N T 1 6 2 b 2 f or m ulati o ns: µ g t otal d ose i ncl u des µ g of O micr o n B A. 4/ B A. 5 a n d  µ g of t he a ncestral S A R S -C o V - 2 strai n; µ g t otal d ose i ncl u des 
µ g of O micr o n B A. 4/ B A. 5 a n d µ g of t he a ncestral S A R S- C o V -2 strai n. Ori gi nal refers t o t he a ncestral stra i n ( W u ha n -H u - 1; U S A- W A 1/ 2 0 2 0), als o referre d t o i n 
t his pr ot oc ol as t he refere nce strai n. 
c. Gr o u ps 2 a n d 1 1: bI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) a n d tI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) are 
d. Gr o u ps 4 a n d 1 2: qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) a n d qI R V are 
N ote: T he f oll o wi n g i nfl ue nza strai ns are i ncl u de d i n t he I R V i n eac h gr o u p at t he d ose le vel n ote d: 
Gr o u p 
Gr o u ps t hr o u g h a n d  :  
 
Gr o u p 
Gr o u p 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
C CI 
C CI C CI C CI C CI 
C CI C CI 
C CI C CI C CI C CI 
C CI C CI 
C CI 
C CI 
C CI 
C CI C CI C CI C CI 
C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370900] u d y B: V acci ne Det ails 
V acci ne Pre p ar ati o n V acci ne A nti ge n Str ai n 
P F -0 7 8 2 9 8 5 5 I nfl ue nza m o d R N A S us pe nsi o n f or 
I njecti o n, 0. 1 m g/ m L I nfl ue nza S us pe nsi o n f or aI nfl ue nza A 
P F -0 7 9 6 6 7 3 1 I nfl ue nza m o d R N A S us pe nsi o n f or 
I njecti o n, 0. 1 m g/ m L I nfl ue nza A 
P F -0 7 8 3 6 2 5 8 I nfl ue nza m o d R N A S us pe nsi o n f or 
I njecti o n, 0. 1 m g / m L I nfl ue nza A 
P F -0 7 8 7 1 8 5 3 I nfl ue nza m o d R N A S us pe nsi o n f or 
I njecti o n, 0. 1 m g/ m L I nfl ue nza A 
P F -0 7 8 7 2 9 6 3 I nfl ue nza m o d R N A S us pe nsi o n f or 
I njecti o n, 0. 1 m g/ m L I nfl ue nza B 
P F -0 7 8 3 6 2 5 9 I nfl ue nza m o d R N A S us pe nsi o n f or 
I njecti o n, 0. 1 m g/ m L I nfl ue nza B 
P F -0 7 8 7 1 9 9 2 Q ua dri vale nt I nfl ue nza m o d R N A 
S us pe nsi o n f or I njecti o n, 0. 0 6 m g/ m L b2 0 2 2/ 2 0 2 3 nort her n 
he mis p here, µ g d ose 
P F -0 7 8 7 1 9 9 2 Q ua dri vale nt I nfl ue nza m o d R N A 
S us pe nsi o n f or I njecti o n, 0. 1 2 m g/ m L b2 0 2 2/ 2 0 2 3 nort her n 
he mis p here µ g d ose 
B N T 1 6 2 b 2 bi vale nt [ W T a n d O micr o n ( B A. 4/ B A. 5) 
varia nt] 1 0 0 µg/ m L 2 0 2 2/ [ADDRESS_370901] u d y I nter ve nti o n(s) A d mi nistere d 
See Secti o n [ADDRESS_370902] u d y  staff (e g, p h ys icia n, n urse, p h y sicia n ’s 
assista nt, n urse practiti o ner, p har macist, or me dical assista nt) as all o we d b y l ocal, state, a n d 
i nstit uti o nal g ui da nce. 
St u d y  i nter ve nti o n a d mi nistrati o n details will be rec or de d o n t he C R F. 
See Secti o n 1 0. 1 1. 6. 1. 1 ( S u bst u d y  A) f or st u d y  i nte r ve nti o n a d mi nistrati o n details. 
See Secti o n 1 0. 1 2. 6. 1. 1 ( S u bst u d y  B) f or st u d y  i nter ve nti o n a d mi nistrati o n details. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
C
CI 
C C 
IC CI 
C CI 
C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 6 2 6. 1. 2. Me dic al De vices 
QI V ma y  be pr o vi de d as P F S sa n d, i n w hic h case, s h o ul d be c o nsi dere d a me dical de vice. 
All me dical de vice deficie ncies (i ncl u di n g malf u ncti o n, use err or, a n d i na de q uate la beli n g) 
s hall be d oc u me nte d a n d re p orte d b y t he i n vesti gat or t hr o u g h o ut t he c li nical i n vesti gati o n 
(see Secti o n 8. 4. 8 ) a n d a p pr o priatel y ma na ge d b y t he s p o ns or. 
6. 2. Pre p ar ati o n , H a n dli n g , St or a ge , a n d Acc o u nt a bilit y 
1. T he i n vesti gat or or desi g nee m ust c o nfir m t hat a p pr o priate c o n diti o ns (e g, te m perat ure) 
ha ve bee n mai ntai ne d d uri n g tra nsit f or all st u d y  i nter ve nti o n srecei ve d a n d a n y  
discre pa ncies are re p orte d a n d res ol ve d bef ore use of t he st u d y  i nter ve nti o n. 
2. O nl y  partici pa nts e nr olle d i n t he st u d y  ma y  recei ve st u d y  i nter ve nti o n a n d o nl y  
a ut h orize d site staff ma y  s u p pl y , pre pare, a n d/ or a d mi nister st u d y  i nter ve nti o n. 
3. All st u d y  i nter ve nti o n sm ust be st ore d i n a sec ure, e n vir o n me ntall y  c o ntr olle d, a n d 
m o nit ore d ( ma n ua l or a ut o mate d rec or di n g ) area i n acc or da nce wit h t he la bele d st ora ge 
c o n diti o ns wit h access li mite d t o t he i n vesti gat or a n d a ut h orize d site staff. At a 
mi ni m u m, dail y  mi ni m u m a n d ma xi m u m te m perat ures f or all site st ora ge l ocati o ns m ust 
be d oc u me nte d a n d a vaila ble u p o n re q uest. Data f or n o n w or ki n g da y s m ust i n dicate t he 
mi ni m u m a n d ma xi m u m te m perat ure ssi nce pre vi o usl y  d oc u me nte d u p o n ret ur n t o 
b usi ness. 
4. A n y  e xc ursi o ns fr o m t he st u d y  i nter ve nti o n la bel st ora ge c o n diti o ns s h o ul d be re p orte d t o 
[COMPANY_007] u p o n disc o ver y  al o n g wit h acti o ns ta ke n. T he site s h o ul d acti vel y p urs ue o pti o ns 
f or ret ur ni n g t he st u d y i nter ve nti o n t o la bele d st ora ge c o n diti o ns, as s o o n as p ossi ble. 
O nce a n e xc ursi o n is i de ntifie d, t he st u d y i nter ve nti o n m ust be q uara nti ne d a n d n ot use d 
u ntil [COMPANY_007] pr o vi des per missi o n t o use t he st u d y  i nter ve nti o n. S pecific details re gar di n g 
t he e xc ursi o n defi niti o n a n d i nf or mati o n t o re p ort f or eac h e xc ursi o n will be pr o vi de d t o 
t he site i n t he I P M. 
5. A n y  st ora ge c o n diti o ns state d i n t he S R S D will be s u p erse de d b y t he st ora ge c o n diti o ns 
state d o n t he la bel. See t he I P M f or st ora ge c o n diti o ns of t he pre pare d st u d y i nter ve nti o n .
6. St u d y  i nter ve nti o ns s h o ul d be st ore d i n t heir ori gi nal c o ntai ners. 
7. T he i n vesti gat or, i nstit uti o n, hea d of t he me dical i nstit uti o n ( w here a p plica ble) ,or 
a ut h orize d site staff is res p o nsi ble f or st u d y  i nter ve nti o n acc o u nta bilit y , rec o nciliati o n, 
a n d rec or d mai nte na nce (ie, recei pt, rec o nciliati o n, a n d fi nal dis p ositi o n rec or ds) , s uc h as 
t he I P A L or s p o ns or -a p pr o ve d e q ui vale nt . All s t u d y  i nter ve nti o n s will be acc o u nte d f or 
usi n g a st u d y  i nter ve nti o n acc o u nta bilit y f or m/rec or d. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370903] u d y  staff (e g, p h y sicia n, n urse, p h y sicia n’s assista nt, n urse 
practiti o ner, p har mac y  assista nt/tec h nicia n, or p har macist) as all o we d b y  l oca l, state, a n d 
i nstit uti o nal g ui da nce. A sec o n d staff me m ber (e g, p h y sicia n, n urse, p h y sicia n’s assista nt, 
n urse practiti o ner, p har mac y  assista nt/tec h nicia n, or p har macist) will verif y  t he dis pe nsi n g. 
See Secti o n [ADDRESS_370904] u d y I nter ve nti o n 
All ocati o n (ra n d o mizati o n) of partici pa nts t o vacci ne gr o u ps will pr ocee d t hr o u g h t he use of 
a n I R T s ys te m (I W R) .  T he site pers o n nel (st u d y c o or di nat or or s pecifie d desi g nee) will be 
re q uire d t o e nter or select i nf or mati o n i ncl u di n g, b ut n ot li mite d t o, t he user’s I D a n d 
pass w or d, t he pr ot oc ol n u m ber, a n d t he partici pa nt n u m ber.  T he s ite pers o n nel will t he n be 
pr o vi de d wit h a ra n d o mizati o n n u m ber.  T he I R T s y ste m will pr o vi de a c o nfir mati o n re p ort 
c o ntai ni n g t he partici pa nt n u m ber, ra n d o mizati o n n u m ber, a n d st u d y i nter ve nti o n all ocati o n 
assi g ne d.  T his re p ort will be pr o vi de d t o bli n de d or u n bli n de d site staff as a p pr o priate o n t he 
r ole/ per missi o n t he user is gra nte d a n d m ust be st ore d i n t he site’s bli n de d or u n bli n de d files 
as a p pr o priate. 
St u d y  i nter ve nti o n will be dis pe nse d at t he st u d y  visits s u m marize d i n t he S o As .
6. 4. Bli n di n g 
See Secti o n [ADDRESS_370905] u d y  B bli n di n g arra n ge me nts. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370906] u d y  i nter ve nti o n wit hi n 
a 2 4 - h o ur ti me peri o d will be c o nsi dere d a n o ver d ose. 
[COMPANY_007] d oes n ot rec o m me n d s pecific treat me nt f or a n o ver d ose. 
I n t he e ve nt of a n o ver d ose, t he i n vesti gat or s h o ul d: 
1. C o ntact t he st u d y me dical m o nit or wit hi n 2 4 h o urs. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 6 5 2. Cl osel y  m o nit or t he partici pa nt f or a n y A E s/ S A Es a n d la b orat or y  a b n or malities as 
me dicall y  a p pr o priate a n d at least u ntil t he ne xt sc he d ule d f oll o w - u p. 
3. D oc u me nt t he q ua ntit y of t he e xcess d ose as well as t he d urati o n of t he o ver d ose i n t he 
C R F. 
4. O ver d ose is re p orta ble t o [COMPANY_007] Safet y  o nl y w he n ass oci ate d wit h a n S A E. 
6. 9. Pri or a n d C o nc o mit a nt T her a p y 
See Secti o n [ADDRESS_370907] u d y  B pri or a n d c o nc o mita nt t hera p y .
7. DI S C O N TI N U A TI O N O F S T U D Y I N T E R V E N TI O N A N D P A R TI CI P A N T 
DI S C O N TI N U A TI O N/ WI T H D R A W A L 
7. 1. Disc o nti n u ati o n of St u d y I nter ve nti o n 
Si nce t his is a si n gle -d ose st u d y , t his secti o n is n ot a p plica ble. 
7. 2. P artici p a nt Disc o nti n u ati o n/ Wit h dr a w al Fr o m t he St u d y 
A partici pa nt ma y  wit h dra w fr o m t he st u d y  at a n y ti me at their o w n re q uest . Reas o ns f or 
disc o nti n uati o n fr o m t he st u d y  i ncl u de t he f oll o wi n g :
Ref use d f urt her st u d y pr oce d ures; 
L ost t o f oll o w - u p; 
Deat h; 
St u d y  ter mi nate d b y s p o ns or; 
React o ge nicit y e ve nt; 
A E s; 
Partici pa nt re q uest; 
I n vesti gat or re q uest; 
Select pr ot oc ol de viati o ns ( e g, recei pt of a C O VI D -[ADDRESS_370908] u d y -s pecifie d ti me p oi nts ). See Secti o n [ADDRESS_370909] u d y  rec or ds a n d n otif y  t he s p o ns or acc or di n gl y .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370910] u d y  a n d als o wit h dra ws c o nse nt (see Secti o n 7. 2 )f or 
discl os ure of f ut ure i nf or mati o n, n o f urt her e val uati o ns will be perf or me d a n d n o a d diti o nal 
data will be c ollecte d. T he s p o ns or ma y  retai n a n d c o nti n ue t o use a n y  data c ollecte d bef ore 
s uc h wit h dra wal of c o nse nt. 
7. 2. 1. Wit h dr a w al of Co nse nt 
Partici pa nt s w h o re q uest t o disc o nti n ue recei pt of st u d y  i nter ve nti o n will re mai n i n t he st u d y  
a n d m ust c o nti n ue t o be f oll o we d f or pr ot oc ol -s pecifie d f oll o w -u p pr oce d ures. T he o nl y 
e xce pti o n t o t his is w he n a partici pa nt s pecificall y wit h dra ws c o nse nt f or a n y f urt her c o ntact 
wit h t he m or pers o ns pre vi o usl y  a ut h orize d b y  t he partici pa nt t o pr o vi de t his i nf or mati o n. 
Partici pa nt s s h o ul d n otif y  t he i n vesti gat or i n writi n g of t he decisi o n t o wit h dra w c o nse nt 
fr o m f ut ure f oll o w -u p, w he ne ver p ossi ble. T he wit h dra wal of c o ns e nt s h o ul d be e x plai ne d i n 
detail i n t he me dical rec or ds b y  t he i n vesti gat or , as t o w het her t he wit h dra wal is o nl y  fr o m 
f urt her recei pt of st u d y  i nter ve nti o n or als o fr o m st u d y  pr oce d ures a n d/ or p ost vacci nati o n 
st u d y  f oll o w -u p, a n d e ntere d o n t he a p pr o priate C R F pa ge. I n t he e ve nt t hat vital stat us 
( w het her t he partici pa nt is ali ve or dea d) is bei n g meas ure d, p u blicl y a vaila ble i nf or mati o n 
s h o ul d be use d t o deter mi ne vital stat us o nl y  as a p pr o priatel y directe d i n acc or da nce wit h 
l ocal la w .
7. 3. L ost t o F ol l o w - U p 
A partici pa nt will be c o nsi dere d l ost t o f oll o w -u p if t he partici pa nt re peate dl y  fails t o ret ur n 
f or sc he d ule d visits a n d is u na ble t o be c o ntacte d b y  t he st u d y  site. 
T he f oll o wi n g acti o ns m ust be ta ke n if a partici pa nt fails t o ret ur n t o t he cl i nic f or a re q uire d 
st u d y  visit: 
T he site m ust atte m pt t o c o ntact t he partici pa nt a n d resc he d ule t he misse d visit as s o o n as 
p ossi ble . C o u nsel t he partici pa nt o n t he i m p orta nce of mai ntai ni n g t he assi g ne d visit 
sc he d ule ,a n d ascertai n w het her t he partici pa nt wis hes t o a n d/ or s h o ul d c o nti n ue i n t he 
st u d y ;
Bef ore a partici pa nt is dee me d l ost t o f oll o w- u p, t he i n vesti gat or or desi g nee m ust ma ke 
e ver y  eff ort t o re gai n c o ntact wit h t he partici pa nt ( w here p ossi ble, 3 tele p h o ne calls a n d, 
if necessar y , a certifie d letter t o t he partici pa nt’s last k n o w n maili n g a d dress or l ocal 
e q ui vale nt met h o ds). T hese c o ntact atte m pts s h o ul d be d oc u me nte d i n t he partici pa nt’s 
me dical rec or d ;
S h o ul d t he partici pa nt c o nti n ue t o be u nreac ha ble, t he partici pa nt will be c o nsi dere d t o 
ha ve wit h dra w n fr o m t he st u d y .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 6 7 8. S T U D Y A S S E S S M E N T S A N D P R O C E D U R E S 
8. 1. A d mi nistr ati ve Pr oce d ures 
T he i n vesti gat or ( or a n a p pr o priate dele gate at t he i n vesti gat or site) m ust o btai n a si g ne d a n d 
date d I C D bef ore perf or mi n g a n y  st u d y -s pecific pr oce d ures. 
T he date of birt h will be c ollecte d t o criticall y  e val uate t he i m m u ne res p o nse a n d safet y  
pr ofile b y a ge. 
St u d y  pr oce d ures a n d t heir ti mi n g are s u m marize d i n t he S o As .Pr ot oc ol wai vers or 
e xe m pti o ns ar e n ot all o we d. 
A d here nce t o t he st u d y desi g n re q uire me nts, i ncl u di n g t h ose s pecifie d i n t he S o As , is 
esse ntial a n d re q uire d f or st u d y c o n d uct. 
All scree ni n g e val uati o ns m ust be c o m plete d a n d re vie we d t o c o nfir m t hat p ote ntial 
par tici pa nts meet all eli gi bilit y  criteria. T he i n vesti gat or will mai ntai n a scree ni n g l o g t o 
rec or d details of all partici pa nts scree ne d a n d t o c o nfir m eli gi bilit y  or rec or d reas o ns f or 
scree ni n g fail ure, as a p plica ble. 
E ver y ef f ort s h o ul d be ma de t o e ns ure t hat pr ot oc o l- re q uire d tests a n d pr oce d ures are 
c o m plete d as descri be d. H o we ver , it is a ntici pate d t hat fr o m ti me t o ti me t here ma y  be 
circ u msta nces o utsi de t he c o ntr ol of t he i n vesti gat or t hat ma ke it u nfeasi ble t o perf or m t he 
test. I n  t hese cases, t he i n vesti gat or m ust ta ke all ste ps necessar y  t o e ns ure t he safet y a n d 
well -bei n g of t he partici pa nt . W he n a pr ot oc ol -re q uire d test ca n n ot be perf or me d, t he 
i n vesti gat or will d oc u me nt t he reas o n f or t he misse d test a n d a n y c orrecti ve a n d pre ve nti ve 
acti o ns t hat t he y  ha ve ta ke n t o e ns ure t hat re q uire d pr ocesses are a d here d t o as s o o n as 
p ossi ble. T he st u d y  tea m m ust be i nf or me d of t hese i nci de nts i n a ti mel y  ma n ner .
F or sa m ples bei n g c ollecte d a n d s hi p pe d, detaile d c ollecti o n, pr ocessi n g, st ora ge, a n d 
s hi p me nt i nstr ucti o ns a n d c o ntact i nf or mati o n will be pr o vi de d t o t he i n vesti gat or site pri or 
t o i nitiati o n of t he st u d y .
8. 2. Effic ac y a n d/ or I m m u n o ge nicit y Assess me nts 
See Secti o n [ADDRESS_370911] u d y  B i m m u n o ge nicit y  assess me nts. 
8. 2. 1. Bi ol o gic al S a m ples 
Bl o o d a n d mi dt ur bi nate s wa b sa m ples will be use d o nl y  f or scie ntific researc h.   Eac h sa m ple 
will be la bele d wit h a c o de s o t hat t he la b orat or y  a nal ys t testi n g t he sa m ples will n ot k n o w 
t he partici pa nt’s i de ntit y,  st u d y  visit, or st u d y  c o h ort ass ociate d wit h t he sa m ple. Sa m ples 
t hat re mai n after perf or mi n g assa y s o utli ne d i n t he pr ot o c ol ma y be st ore d b y  [COMPANY_007]. U nless 
a ti me li mitati o n is re q uire d b y  l ocal re g ulati o ns or et hical re q uire me nts, t he sa m ples will be 
st ore d f or u p t o [ADDRESS_370912] u d y a n d t he n destr o ye d. If all o we d b y t he 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370913] ore d sa m ples ma y be use d f or a d diti o nal testi n g t o better u n dersta n d t he i m m u ne 
res p o nses t o t he vacci ne(s) u n der st u d y i n t his pr ot oc ol, t o i nf or m t he de vel o p me nt of ot her 
vacci nes or vacci ne -relate d pr o d ucts, a n d/ or f or vacci ne -relate d assa y  w or k s u p p orti n g 
vacci ne pr o gra ms. N o testi n g of t he partici pa nt’s D N A will be perf or me d. 
T he partici pa nt ma y  re q uest t hat t heir sa m ples, if still i de ntifia ble, be destr o y e d at a n y  ti me; 
h o we ver, a n y data alrea d y c ollecte d fr o m t h ose sa m ples will still be use d f or t his researc h. 
T he bi ol o gi cal sa m ples ma y  be s hare d wit h ot her researc hers as l o n g as c o nfi de ntialit y  is 
mai ntai ne d a n d n o testi n g of t he partici pa nt’s D N A is perf or me d .
8. 3. S afet y Assess me nts 
Pla n ne d ti me p oi nts f or all safet y  assess me nts are pr o vi de d i n t he S o As .U nsc he d ule d safet y 
meas ure me nts m a y  be o btai ne d at a n y  ti me d uri n g t he st u d y  t o assess a n y  percei ve d safet y  
iss ues. 
A cli nical assess me nt, i ncl u di n g me dical hist or y , will be perf or me d o n all partici pa nts at t heir 
first visit t o esta blis h a baseli ne .  Si g nifica nt me dical hist or y  a n d o bser vati o ns fr o m a n y  
p h y sical e xa mi nati o n, if perf or me d, will be d oc u me nte d i n t he C R F. 
A Es a n d S A Es are c ollecte d, rec or de d, a n d re p orte d as defi ne d i n Secti o n 8. [ADDRESS_370914] o ge nicit y e -di ar y re p orts of l ocal reacti o ns ,s y ste mic 
e ve nts (i ncl u di n g fe ver) ,a n d use of a nti p yr etic me dicati o n t hat occ ur i n t he [ADDRESS_370915] u d y  A, a p h y sical e xa mi nati o n will be perf or me d at t he scree ni n g visit a n d, if 
cli nicall y  i n dicate d, pri or t o t he partici pa nt’s first vacci nati o n (at Visit [ADDRESS_370916] u d y  A ).   I n 
Su bst u d y  B, a p h ys ical e xa mi nati o n will be perf or me d at t he scree ni n g visit a n d, if cli nicall y 
i n dicate d, pri or t o t he partici pa nt’s first vacci nati o n (at Visit 2 0 1) .
P h y sical e xa mi nati o n fi n di n gs c ollecte d d uri n g t he st u d y  will be c o nsi dere d s o urce data a n d 
will n ot be re q uire d t o be re p orte d , u nless ot her wise n ote d. A n y u nt o war d p h y sical 
e xa mi nati o n fi n di n gs t hat are i de ntifie d d uri n g t he acti ve c ollecti o n peri o d a n d meet t he 
defi niti o n of a n A E or S A E (A p pe n di x 3 )m ust be re p orte d acc or di n g t o t he pr ocesses i n 
Secti o ns 8. 4. [ADDRESS_370917] u d y  A, t he partici pa nt’s oral te m perat ure , p ulse rate, a n d seate d bl o o d press ure will 
be meas ure d at scree ni n g, pri or t o vacci nati o n at Visit 1 , Visit 2 ,a n d Visit 3.  A d diti o nall y , 
wei g ht a n d hei g ht will be meas ure d at scree ni n g. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370918] u d y  B, t he partici pa nt’s oral te m perat ure , p ulse rate, a n d seate d bl o o d press ure will 
be meas ure d at scree ni n g, pri or t o vacci nati o n at Visit 2 0 1, at Visit 2 0 2, a n d at Visit 2 0 3 .
A d dit i o nall y , wei g ht a n d hei g ht will be meas ure d at scree ni n g. 
A n y  u nt o war d vital si g n fi n di n gs t hat are i de ntifie d d uri n g t he acti ve c ollecti o n peri o d a n d 
meet t he defi niti o n of a n A E or S A E ( A p pe n di x 3 ) m ust be re p orte d acc or di n g t o t he 
pr ocesses i n Secti o ns 8. 4. [ADDRESS_370919] u d y  A / B S o A f or t he ti mi n g a n d fre q ue nc y .All pr ot oc ol -re q uire d la b orat or y  
assess me nts, as defi ne d i n A p pe n di x [ADDRESS_370920] u d y A/ B S o A .U nsc he d ule d cli nical la b orat or y  meas ure me nts ma y  be 
o btai ne d at a n y ti me d uri n g t he st u d y t o assess a n y percei ve d safet y iss ues .
T he i n vesti gat or m ust re vie w t he la b orat or y  re p ort, d oc u me nt t his re vie w , a n d rec or d a n y 
cli nicall y  si g nifica nt c ha n ges occ urri n g d uri n g t he st u d y  i n t he A E secti o n of t he C R F .
Cli nicall y  si g nifica nt a b n or mal la b orat or y  test fi n di n gs are t h ose t hat are n ot ass ociate d wit h 
t he u n derl yi n g disease, u nless j u d ge d b y  t he i n vesti gat or t o be m ore se vere t ha n e x pecte d f or 
t he partici pa nt ’s c o n diti o n. 
All la b orat or y  tests wit h val ues c o nsi dere d cli nicall y  si g nifica nt a n d a b n or mal d uri n g 
partici pati o n i n t he st u d y  or wit hi n [ADDRESS_370921] u d y  me dical m o nit or .
If s uc h val ues d o n ot ret ur n t o n or mal/ baseli ne wit hi n a peri o d of ti me j u d ge d reas o na ble b y  
t he i n vesti gat or , t he eti ol o g y  s h o ul d be i de ntifie d a n d t he s p o ns or n otifie d. 
See Secti o n [ADDRESS_370922] a b n or malities. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370923] o ge nicit y e -diar y  after eac h vacci nati o n 
gi ve n at Visit s 1 a n d 2 0 1 t hr o u g h a n a p plicati o n i nstalle d o n a pr o visi o ne d de vice or o n t he 
partici pa nt’s o w n pers o nal de vice.  All partici pa nts will be as ke d t o m o nit or a n d rec or d l ocal 
reacti o ns, s ys te mic e ve nts, a n d use of a nti p y retic me dicati o n f or [ADDRESS_370924] o ge nicit y e -diar y  
all o ws rec or di n g of t hese assess me nts o nl y  wit hi n a fi xe d ti me wi n d o w, t h us pr o vi di n g t he 
acc urate re prese ntati o n of t he partici pa nt’s e x perie nce at t hat ti me.  Data o n l ocal reacti o ns 
a n d s y ste mic e ve nts re p orte d i n t he react o ge nicit y e-diar y  will be tra nsferre d electr o nicall y  t o 
a t hir d -part y ve n d or, w here t he y will be a vaila ble f or re vie w b y i n vesti gat ors a n d t he [COMPANY_007] 
cli nicia ns at all ti mes via a n i nter net - base d p ortal. 
At i nter vals a gree d t o b y t he ve n d or a n d [COMPANY_007], t hese data will be tra nsferre d electr o nicall y 
i nt o [COMPANY_007] ’s data base f or a nal ys is a n d re p orti n g.  T hese data d o n ot nee d t o be re p orte d b y  
t he i n vesti gat or i n t he C R F , u nless t he partici pa nt misse d a n e- diar y  e ntr y  a n d t he partici pa nt 
e x perie nce d a pr o m pte d l ocal reacti o n or s ys te mic e ve nt, i n w hic h case a n y misse d e ntries 
s h o ul d be i ncl u de d i n t he A E C R F. 
I n vesti gat ors ( or desi g nee) will be re q uire d t o re vie w t he react o ge nicit y  e -diar y  data o nli ne at 
fre q ue nt i nter vals as part of t he o n g oi n g safet y re vie w. 
T he i n vesti gat or or desi g nee m ust o btai n st o p dates fr o m t he partici pa nt f or a n y  o n g oi n g 
l ocal reacti o ns, s y ste mic e ve nts, or use of a nti p y retic me dicati o n o n t he last da y  t hat t he 
react o ge nicit y  e -diar y  was c o m plete d.  T he st o p dates s h o ul d be d oc u me nte d i n t he s o urce 
d oc u me nts a n d t he i nf or mati o n e ntere d i n t he C R F. 
8. 3. 5. 1. Gr a di n g Sc ales 
T he gra di n g scales use d i n t his st u d y  t o assess l ocal reacti o ns a n d s yste mic e ve nts as 
descri be d bel o w are deri ve d fr o m t he F D A C B E R g ui deli nes o n t o xicit y  gra di n g scales f or 
healt h y  a d ult v ol u nteers e nr olle d i n pre ve nti ve vacci ne cli n ical trials. 2 3 
8. 3. 5. 2. L oc al Re acti o ns 
F oll o wi n g vacci nati o n ( w here Da y  1 is t he da y  of vacci nati o n) , partici pa nts will be as ke d t o 
assess re d ness, s welli n g, a n d pai n at t he i njecti o n site a n d t o rec or d t he s y m pt o ms i n t he 
react o ge nicit y  e -diar y dail y .  I n S u bst u d ies Aa n d B ,l oc al re acti o ns will be assesse d at t he 
i njecti o n site o n t he ri g ht ar m o nl y after v acci n ati o n sgi ve n at Visit s [ADDRESS_370925] o ge nicit y  e -diar y  peri o d f oll o wi n g 
vacci nati o n, t he partici pa nt will be re q ueste d t o re p ort t hat i nf or mati o n.  T he i n vesti gat or will 
e nter t his a d diti o nal i nf or mati o n i n t he C R F. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 7 1 Partici pa nts will be pr o vi de d wit h a mea s uri n g de vice.  Re d ness a n d s welli n g will be 
meas ure d a n d rec or de d i n meas uri n g de vice u nits (ra n ge: 1t o 2 1) a n d t he n cate g orize d 
d uri n g a nal ys is as a bse nt, mil d, m o derate, or se vere base d o n t he gra di n g scale i n Ta ble 4.  
Meas uri n g de vice u nits ca n be c o n verte d t o ce nti meters acc or di n g t o t he f oll o wi n g f or m ula: 
1meas uri n g de vice u nit = 0. [ADDRESS_370926] 
s h o ul d occ ur t o ascertai n f urt her details a n d deter mi ne w het her a site visit is cli nicall y  
i n dicate d.  O nl y a n i n vesti gat or or me dicall y q ualifie d pers o n is a ble t o classif y  a 
partici pa nt’s l ocal reacti o n as Gra de 4.  If a partici pa nt e x perie nces a c o nfir me d Gr a de [ADDRESS_370927] i m me diatel y  n otif y  t he s p o ns or. 
T a ble 4. L oc al Re acti o n Gr a di n g Sc ale 
Mil d 
( Gr a de 1) M o der ate 
( Gr a de 2) Se vere 
( Gr a de 3) P ote nti all y 
Life -T hre ate ni n g 
( Gr a de 4) 
Pai n at t he 
i njecti o n site D oes n ot i nterfere 
wit h acti vit y I nterferes wit h acti vit y Pre ve nts dail y 
acti vit y E m er ge nc y r o o m visit 
or h os pi[INVESTIGATOR_1314] o n f or 
se vere pai n 
Re d ness > 2. 0 c m t o 5. 0 c m 
( 5 t o 1 0 meas uri n g 
de vice u nits) > 5. 0 c m t o 1 0. 0 c m 
( 1 1 t o 2 0 meas uri n g 
de vice u nits) > 1 0 c m 
(≥ 2 1 meas uri n g 
de vice u nits) Necr osis or e xf oliati ve 
der matitis 
S welli n g > 2. 0 c m t o 5. 0 c m 
( 5 t o 1 0 meas uri n g 
de vice u nits) > 5. 0 c m t o 1 0. 0 c m 
( 1 1 t o 2 0 meas uri n g 
de vice u nits) > 1 0 c m 
(≥ 2 1 meas uri n g 
de vice u nits) Necr osis 
8. 3. 5. 3. S yste mic E ve nts 
D uri n g t he react o ge nicit y e -diar y  re p orti n g peri o d, partici pa nts will be as ke d t o assess 
v o miti n g, diarr hea, hea dac he, fati g ue, c hills, ne w or w orse ne d m uscle pai n, a n d ne w or 
w orse ne d j oi nt pai n a n d t o rec or d t he s y m pt o ms i n t he react o ge nicit y e - di ar y .  T he s y m pt o ms 
will be assesse d b y t he partici pa nt as a bse nt, mil d, m o derate, or se vere acc or di n g t o t he 
gra di n g scale i n Ta ble 5.
If a Gra de [ADDRESS_370928] 
s h o ul d occ ur t o ascertai n f urt her details a n d deter mi ne w het her a site visit is cli nicall y  
i n dicate d.  O nl y a n i n vesti gat or or me dicall y q ualifie d pers o n is a ble t o classif y  a 
partici pa nt’s s ys te mi c e ve nt as Gra de 4.  If a partici pa nt e x perie nces a c o nfir me d Gra de [ADDRESS_370929] i m me diatel y n otif y  t he s p o ns or. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 7 2 T a ble 5. S yste mic E ve nt Gr a di n g Sc ale 
Mil d 
( Gr a de 1) M o der ate 
( Gr a de 2) Se vere 
( Gr a de 3 )P ote nti all y Life -
T hre ate ni n g 
( Gr a de 4) 
V o m iti n g 1- 2 ti mes i n 
2 4 h o urs > [ADDRESS_370930] o ols 
i n 2 4 h o urs E m er ge nc y r o o m visit 
or h os pi[INVESTIGATOR_1314] o n f or 
se vere diarr hea 
Hea dac he D oes n ot i nterfere 
wit h acti vit y S o m e i nterfere nce 
wit h acti vit y Pre ve nts dail y r o uti ne 
acti vit y E m er ge nc y r o o m visit 
or h os pi[INVESTIGATOR_1314] o n f or 
se vere hea da c he 
Fati g ue/tire d ness D oes n ot i nterfere 
wit h acti vit y S o m e i nterfere nce 
wit h acti vit y Pre ve nts dail y r o uti ne 
acti vit y E m er ge nc y r o o m visit 
or h os pi[INVESTIGATOR_1314] o n f or 
se vere fati g ue 
C hills D oes n ot i nterfere 
wit h acti vit y S o m e i nterfere nce 
wit h acti vit y Pre ve nts dail y r o uti ne 
acti vit y E m er ge nc y r o o m visit 
or h os pi[INVESTIGATOR_1314] o n f or 
se vere c hills 
N e w  or w orse ne d 
m uscle pai n D oes n ot i nterfere 
wit h acti vit y S o m e i nterfere nce 
wit h acti vit y Pre ve nts dail y r o uti ne 
acti vit y E m er ge nc y r o o m visit 
or h os pi[INVESTIGATOR_1314] o n f or 
se vere ne w or w orse ne d 
m uscle pai n 
N e w  or w orse ne d 
j oi nt pai n D oes n ot i nterfere 
wit h acti vit y S o m e i nterfere nce 
wit h acti vit y Pre ve nts dail y r o uti ne 
acti vit y E m er ge nc y r o o m visit 
or h os pi[INVESTIGATOR_1314] o n f or 
se vere ne w or w orse ne d 
j oi nt pai n 
8. 3. 5. 4. Fe ver 
I n or der t o rec or d i nf or mati o n o n fe ver, a t her m o meter will be gi ve n t o partici pa nts wit h 
i nstr ucti o ns o n h o w t o meas ure oral te m perat ure at h o me.  Te m perat ure will be c ollecte d i n 
t he react o ge nicit y e -diar y i n t he e ve ni n g dail yf or 7 da y s f oll o wi n g vacci n ati o n ( w here Da y  1 
is t he da y  of vacci nati o n ). It  will als o be c ollecte d at a n y  ti me d uri n g t he react o ge nicit y 
e- diar y  data c ollecti o n peri o ds w he n fe ver is s us pecte d.  Fe ver is defi ne d as a n oral 
te m perat ure ≥ 3 8. 0° C ( ≥1 0 0. 4° F).  T he hi g hest te m perat ure f or eac h da y  will be rec or de d i n 
t he react o ge nicit y e -diar y.  Te m perat ure will be meas ure d a n d rec or de d t o [ADDRESS_370931].  
Te m perat ures rec or de d i n de grees Fa hre n heit will be pr o gra m maticall y  c o n verte d t o de grees 
Celsi us a n d t he n cate g orize d acc or di n g t o t he scale s h o w n i n Ta ble 6d uri n g a nal ys is. 
If a fe ver of ≥ 3 9. 0° C ( ≥ 1 0 2. 1° F) is re p orte d i n t he react o ge nicit y  e -diar y , a tele p h o ne c o ntact 
s h o ul d occ ur t o ascertai n f urt her details a n d deter mi ne w het her a site visit is cli nicall y  
i n dicate d.  O nl y a n i n vesti gat or or me dicall y q ualifie d pers o n is a ble t o c o nfir m a 
partici pa nt’s fe ver as > 4 0. 0° C ( > 1 0 4. 0° F).  If a partici pa nt e x perie nces a c o nfir me d fe ver 
> 4 0. 0° C ( > 1 0 4. 0° F), t he i n vesti gat or m ust i m me diatel y  n otif y  t he s p o ns or .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 7 3 T a ble 6. Sc ale f or Fe ver 
≥ 3 8. 0 -3 8. 4° C ( 1 0 0. 4 -1 0 1. 1° F) 
> 3 8. 4 -3 8. 9° C ( 1 0 1. 2 -1 0 2. 0° F) 
> 3 8. 9 -4 0. 0° C ( 1 0 2. 1 -1 0 4. 0° F) 
> 4 0. 0° C ( > 1 0 4. 0° F) 
8. 3. 5. 5. A nti p yretic Me dic ati o n 
T he use of a nti p y retic me dicati o n t o treat s y m pt o ms ass ociate d wit h st u d y  i nter ve nti o n 
a d mi nistrati o n will be rec or de d i n t he react o ge nicit y  e- diar y  dail y d uri n g t he re p orti n g peri o d 
( Da y  1 t hr o u g h Da y 7). 
8. 3. 6. Pre g n a nc y Testi n g 
Pre g na nc y  tests ma y  be uri ne or ser u m tests , b ut m ust ha ve a se nsiti vit y  of at least 
2 5 mI U/ m L. Pre g na nc y  tests will be perf or me d i n W O C B P  at t he ti mes liste d i n t he S o As ,
i m me diatel y  bef ore t he a d mi nistrati o n of t he st u d y i nter ve nti o n d ose . A ne gati ve pre g na nc y  
test res ult will be re q uire d pri or t o t he partici pa nt ’s recei vi n g t he st u d y  i nter ve nti o n . 
Pre g na nc y  tests ma y  als o be re peate d if re q ueste d b y  I R Bs/ E Cs or if re q uire d b y  l ocal 
re g ulati o ns. I n t he case of a p ositi ve c o nfir me d pre g na nc y , t he partici pa nt will be wit h dra w n 
fr o m a d mi nistrati o n of st u d y  i nter ve nti o n b ut ma y re mai n i n t he st u d y .
8. 4. A d verse E ve nts ,Seri o us A d verse E ve nts , a n d Ot her S afet y Re p orti n g 
T he defi niti o ns of a n A E a n d a n S A E ca n be f o u n d i n A p pe n di x 3 .
A E s ma y  arise fr o m s y m pt o ms or ot her c o m plai nts re p orte d t o t he i n vesti gat or b y  t he 
partici pa nt ( or , w he n a p pr o priate, b y  a care gi ver , s urr o gate, or t he partici pa nt ’s le gall y  
a ut h orize d re prese ntati ve), or t he y  ma y  arise fr o m cli nical fi n di n gs of t he i n vesti gat or or 
ot her healt hcare pr o vi ders (cli nical si g ns, test res ults, etc). 
T he i n vesti gat or a n d a n y q ualifie d desi g nees are res p o nsi ble f or detecti n g, d oc u me nti n g, a n d 
rec or di n g e ve nts t hat meet t he defi niti o n of a n A E or S A E a n d re mai n res p o nsi ble t o p urs ue 
a n d o btai n a de q uate i nf or mati o n b ot h t o deter mi ne t he o utc o me a n d t o assess w het her t he 
e ve nt meets t he criteria f or classificati o n as a n S A E or ca use d t he partic i pa nt t o disc o nti n ue 
t he st u d y  (see Secti o n 7. 1 ). 
D uri n g t he acti ve c ollecti o n peri o d as descri be d i n Secti o n 8. 4. 1 , e ac h partici pa nt will be 
q uesti o ne d a b o ut t he occ urre nce of AEs i n a n o nlea di n g ma n ner .
I n a d diti o n, t he i n vesti gat or ma y  be re q ueste d b y  [COMPANY_007] Safet y t o o btai n s pecific f oll o w - u p 
i nf or ma ti o n i n a n e x pe dite d fas hi o n. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370932] u d y A
T he ti me peri o d f or acti vel y  eliciti n g a n d c ollecti n g A E s a n d S A Es ( “ acti ve c ollecti o n 
peri o d ”) f or eac h partici pa nt be gi ns fr o m t he ti me t he partici pa nt pr o vi des i nf or me d c o nse nt, 
w hic h is o btai ne d bef ore t he partici pa nt ’s partici pati o n i n t he st u d y  (ie, bef ore u n der g oi n g 
a n y  st u d y -relate d pr oce d ure a n d/ or recei vi n g st u d y  i nter ve nti o n ), t hr o u g h a n d i ncl u di n g 
Vi sit 4 ( 4 -wee k f oll o w -u p visit).  A d diti o nall y , a n y  A Es occ urri n g u p t o [ADDRESS_370933] be rec or de d o n t he C R F. 
S A Es will be c ollecte d fr o m t he ti me t he partici pa nt pr o vi des i nf or me d c o nse nt t o 
a p pr o xi matel y  6 m o nt hs after t he partici pa nt’s last st u d y  vacci nati o n ( Visit 6). 
S u bst u d y B 
T he ti me peri o d f or acti vel y  eliciti n g a n d c ollecti n g A Es a n d S A Es (“acti ve c ollecti o n 
peri o d”) f or eac h partici pa nt be gi ns fr o m t he ti me t he partici pa nt pr o vi des i nf or me d c o nse nt, 
w hic h is o btai ne d bef ore t he partici pa nt’s partici pati o n i n t he st u d y  (ie, bef ore u n der g oi n g 
a n y  st u d y -relate d pr oce d ure a n d/ or recei vi n g st u d y  i nter ve nti o n), t hr o u g h a n d i ncl u di n g 
Visit [ADDRESS_370934] u d y  B (if eli gi ble as per Secti o n 1 0. 1 2. 1 ) m ust be rec or de d o n t he C R F. 
S A Es will be c ollecte d fr o m t he ti me t he partici pa nt pr o vi des i nf or me d c o nse nt t o 
a p pr o xi matel y  6 m o nt hs after t he partici pa nt’s first st u d y  vacci nati o n ( Visi t 2 0 5). 
F oll o w -u p b y  t he i n vesti gat or c o nti n ues t hr o u g h o ut t he acti ve c ollecti o n peri o d a n d u ntil t he 
A E or S A E or its se q uelae res ol ve or sta bilize at a le vel acce pta ble t o t he i n vesti gat or .
W he n a cli nicall y  i m p orta nt A E re mai ns o n g oi n g at t he e n d of t he acti ve c ollecti o n peri o d, 
f oll o w -u p b y  t he i n vesti gat or c o nti n ues u ntil t he A E or S A E or its se q uelae res ol ve or 
sta bilize at a le vel acce pta ble t o t he i n vesti gat or a n d [COMPANY_007] c o nc urs wit h t hat assess me nt. 
F or partici pa nts w h o are scree n fail ures, t he act i ve c ollecti o n peri o d e n ds w he n scree n fail ure 
stat us is deter mi ne d. 
If t he partici pa nt wit h dra ws fr o m t he st u d y  a n d als o wit h dra ws c o nse nt f or t he c ollecti o n of 
f ut ure i nf or mati o n, t he acti ve c ollecti o n peri o d e n ds w he n c o nse nt is wit h dra w n. 
If a partici pa nt per ma ne ntl y disc o nti n ues or te m p oraril y disc o nti n ues st u d y beca use of a n A E 
or S A E, t he A E or S A E m ust be rec or de d o n t he C R F a n d t he S A E re p orte d usi n g t he 
Va cci ne S A E Re p ort F or m .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370935] u d y .
8. 4. 2. Met h o d of Detecti n g A E s a n d S A Es 
The met h o d o f rec or di n g , e val uati n g, a n d assessi n g ca usalit y  of A Es a n d S A E sa n d t he 
pr oce d ures f or c o m pleti n g a n d tra ns mitti n g S A E re p orts are pr o vi de d i n A p pe n di x 3 .
Care will be ta ke n n ot t o i ntr o d uce bias w he n detecti n g A E s a n d/ or S A Es. O pe n -e n de d a n d 
n o nlea di n g ver bal q uesti o ni n g of t he partici pa nt is t he preferre d met h o d t o i n q uire a b o ut 
A E occ urre nces. 
8. 4. 3. F oll o w - U p of A Es a n d S A Es 
After t he i nitial A E or S A E re p ort, t he i n vesti gat or is re q uire d t o pr oacti vel y  f oll o w eac h 
partici pa nt at s u bse q ue nt visits/c o ntacts. F or eac h e ve nt, t he i n vesti gat or m ust p urs ue a n d 
o btai n a de q uate i nf or mati o n u ntil res ol uti o n, sta bilizati o n, t he e ve nt is ot her wise e x plai ne d, 
or t he partici pa nt is l ost t o f oll o w -u p (as defi ne d i n Secti o n 7. 3 ). 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370936] y  wit h c o u ntr y -s pecific re g ulat or y  re q uire me nts relati n g t o safet y 
re p orti n g t o t he re g ulat or y  a ut h orit y,  I R B s/ E Cs , a n d i n vesti gat ors. 
I n vesti gat or safet y  re p orts m ust be pre pare d f or S U S A R sacc or di n g t o l ocal re g ulat or y  
re q uire me nts a n d s p o ns or p olic y  a n d f or war de d t o i n vesti gat ors as necessar y .
A n i n vesti gat or w h o recei ves S U S A R sor ot her s pecific safet y i nf or mati o n (e g, s u m mar y  or 
listi n g of S A Es) fr o m t he s p o ns or will re vie w a n d t he n file it al o n g wit h t he S R S D (s) f or t he 
st u d y a n d will n otif y  t he I R B/ E C, if a p pr o priate acc or di n g t o l ocal re q uire me nts. 
8. 4. 5. E n vir o n me nt al E x p os ure, E x p os ure D uri n g Pre g n a nc y or Bre astfee di n g, a n d 
Occ u p ati o n al E x p os ure 
E n vir o n me ntal e x p os ure occ urs w he n a pers o n n ot e nr olle d i n t he st u d y as a partici pa nt 
recei ves u n pla n ne d direct c o ntact wit h or e x p os ure t o t he st u d y  i nter ve nti o n. S uc h e x p os ure 
ma y  or ma y  n ot lea d t o t he occ urre nce of a n A E or S A E. Pers o ns at ris k f or e n vir o n me ntal 
e x p os ure i ncl u de healt hcare pr o vi ders, fa mil y me m bers, a n d ot hers w h o ma y be e x p ose d . A n 
e n vir o n me ntal e x p os ure ma y i ncl u de E D P , E D B ,a n d occ u pati o nal e x p os ure .
A n y  s uc h ex p os ure st o t he st u d y  i nter ve nti o nu n der st u d y  are re p orta ble t o [COMPANY_007] Safet y  
wit hi n 2 4 h o urs of i n vesti gat or a ware ness. 
8. 4. 5. 1. E x p os ure D uri n g Pre g n a nc y 
A n E D P  occ urs if: 
A fe male partici pa nt is f o u n d t o be pre g na nt w hile recei vi n g or after disc o nti n ui n g st u d y  
i nter ve nti o n .
A male partici pa nt w h o is recei vi n g or has disc o nti n ue d st u d y  i nter ve nti o n i nse mi nates a 
fe male part ner .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 7 7 A fe male n o n partici pa nt is f o u n d t o be pre g na nt w hile bei n g e x p ose d or ha vi n g bee n 
e x p ose d t o st u d y  i nter ve nti o n beca use of e n vir o n me ntal e x p os ure. Bel o w are e xa m ples 
of e n vir o n me ntal E D P :
A fe male fa mil y  me m ber or healt hcare pr o vi der re p orts t hat s he is pre g na nt after 
ha vi n g bee n e x p ose d t o t he st u d y  i nter ve nti o n b y  i n halati o n or s ki n c o ntact. 
A male fa mil y me m ber or healt hcare pr o vi der w h o has bee n e x p ose d t o t he st u d y  
i nter ve nti o n b y  i n halati o n or s ki n c o ntact t he n i nse mi nates his fe male part ner pri or t o 
or ar o u n d t he ti me of c o nce pti o n. 
T he i n vesti gat or m ust re p ort E D P  t o [COMPANY_007] Safet y wit hi n 2 4 h o urs of t he i n vesti gat or ’s 
a ware ness, irres pecti ve of w het her a n SA E has occ urre d. T he i nitial i nf or mati o n s u b mitte d 
s h o ul d i ncl u de t he a ntici pate d date of deli ver y  (see bel o w f or i nf or mati o n relate d t o 
ter mi nati o n of pre g na nc y). 
If E D P occ urs i n a partici pa nt /partici pa nt’s part ner, t he i n vesti gat or m ust re p ort t his 
i nf or mati o n t o [COMPANY_007] Safet y  o n t he Vacci ne S A E Re p ort F or m a n d a n E D P Su p ple me ntal 
For m, re gar dless of w het her a n S A E has occ urre d. Details of t he pre g na nc y will be 
c ollecte d after t he start of st u d y  i nter ve nti o n a n d u ntil [ADDRESS_370937] u d y  
i nter ve nti o n. 
If E D P occ urs i n t he setti n g of e n vir o n me ntal e x p os ure, t he i n vesti gat or m ust re p ort 
i nf or mati o n t o [COMPANY_007] Safet y  usi n g t he Vacci ne S A E Re p ort F or m a n d E D P Su p ple me ntal 
For m. Si nce t he e x p os ure i nf or mati o n d oes n ot pertai n t o t he partici pa nt e nr olle d i n t he 
st u d y , t he i nf or mati o n is n ot rec or de d o n a C R F; h o we ver, a c o p y  of t he c o m plete d 
Vacci ne S A E Re p ort F or m is mai ntai ne d i n t he i n vesti gat or site file. 
F oll o w -u p is c o n d ucte d t o o btai n ge neral i nf or mati o n o n t he pre g na nc y  a n d its o utc o me f or 
all E D P  re p orts wit h a n u n k n o w n o utc o me. T he i n vesti gat or will f oll o w t he pre g na nc y  u ntil 
c o m pleti o n ( or u ntil pre g na nc y  ter mi nati o n) a n d n otif y  [COMPANY_007] Safet y of t he o utc o me as a 
f oll o w - u p t o t he i nitial E D P  Su p ple me ntal For m. I n t he case of a li ve birt h, t he str uct ural 
i nte grit y of t he ne o nate ca n be assesse d at t he ti me of birt h. I n t he e ve nt of a ter mi nati o n, t he 
reas o n(s) f or ter mi nati o n s h o ul d be s pecifie d a n d, if cli nicall y  p ossi bl e, t he str uct ural 
i nte grit y of t he ter mi nate d fet us s h o ul d be assesse d b y gr oss vis ual i ns pecti o n ( u nless 
pre pr oce d ure test fi n di n gs are c o ncl usi ve f or a c o n ge nital a n o mal y a n d t he fi n di n gs are 
re p orte d). 
A b n or mal pre g na nc y  o utc o mes are c o nsi dere d S A Es. If t he o utc o me of t he pre g na nc y  meets 
t he criteria f or a n S A E (ie, ect o pic pre g na nc y , s p o nta ne o us a b orti o n, i ntra uteri ne fetal 
de mise, ne o natal deat h, or c o n ge nital a n o mal y) , t he i n vesti gat or s h o ul d f oll o w t he pr oce d ures 
f or re p orti n g S A Es. A d diti o nal i nf o r mati o n a b o ut pre g na nc y  o utc o mes t hat are re p orte d t o 
[COMPANY_007] Safet y  as S A Es f oll o ws: 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 7 8 S p o nta ne o us a b orti o n i ncl u d i n g miscarria ge a n d misse d a b orti o n s h o ul d be re p orte d 
as a n S A E ;Ne o natal deat hs t hat occ ur wit hi n [ADDRESS_370938] u d y  i nter ve nti o n. 
A d diti o nal i nf or mati o n re gar di n g t he E D P  ma y  be re q ueste d b y  t he s p o ns or . F urt her 
f oll o w - u p of birt h o utc o mes will be ha n dle d o n a case- b y -case basis (e g, f oll o w - u p o n 
preter m i nfa nts t o i de ntif y de vel o p me ntal dela y s). I n  t he case of pater nal e x p os ure, t he 
i n vesti gat or will pr o vi de t he part ici pa nt wit h t he Pre g na nt Part ner Release of I nf or mati o n 
F or m t o deli ver t o his part ner . T he i n vesti gat or m ust d oc u me nt i n t he s o urce d oc u me nts t hat 
t he partici pa nt was gi ve n t he Pre g na nt Part ner Release of I nf or mati o n F or m t o pr o vi de t o his 
part ner .
8. 4. 5. 2. E x p o s ure D uri n g Bre astfee di n g 
A n E D B occ urs if: 
A fe male partici pa nt is f o u n d t o be breastfee di n g w hile recei vi n g or after 
disc o nti n ui n g st u d y  i nter ve nti o n .
A fe male n o n partici pa nt is f o u n d t o be breastfee di n g w hile bei n g e x p ose d or ha vi n g 
bee n e x p ose d t o st u d y  i nter ve nti o n (ie, e n vir o n me ntal e x p os ure). A n e xa m ple of 
e n vir o n me ntal E D B is a fe male fa mil y me m ber or healt hcare pr o vi der w h o re p orts 
t hat s he is breastfee di n g after ha vi n g bee n e x p ose d t o t he st u d y  i nter ve nti o n b y 
i n halati o n or s ki n c o ntact .
T he i n vesti gat or m ust re p ort E D B t o [COMPANY_007] Safet y  wit hi n 2 4 h o urs of t he i n vesti gat or ’s 
a ware ness, irres pecti ve of w het her a n S A E has occ urre d. T he i nf or mati o n m ust be re p orte d 
usi n g t he Va cci ne S A E Re p ort F or m . W he n E D B occ urs i n t he setti n g of e n vir o n me ntal 
e x p os ure, t he e x p os ure i nf or mati o n d oes n ot pertai n t o t he partici pa nt e nr olle d i n t he st u d y , 
s o t he i nf or mati o n is n ot rec or de d o n a C R F . H o we ver , a c o p y  of t he c o m plete d Va cci ne 
S A E Re p ort F or m is mai ntai ne d i n t he i n vesti gat or site file. 
A n E D B re p ort is n ot create d w he n a [COMPANY_007] dr u g s pecificall y a p pr o ve d f or use i n 
breastfee di n g w o me n (e g, vita mi ns) is a d mi nistere d i n acc or d a nce wit h a ut h orize d use. 
H o we ver , if t he i nfa nt e x perie nces a n S A E ass ociate d wit h s uc h a dr u g, t he S A E is re p orte d 
t o get her wit h t he E D B .
8. 4. 5. 3. Occ u p ati o n al E x p os ure 
T he i n vesti gat or m ust re p ort a n y  i nsta nce of occ u pati o nal e x p os ure t o [COMPANY_007] Safet y wit hi n 
2 4 h o urs of t he i n vesti gat or ’s a ware ness usi n g t he Va cci ne S A E Re p ort F or m , re gar dless of 
w het her t here is a n ass ociate d S A E. Si nce t he i nf or mati o n a b o ut t he occ u pati o nal e x p os ure 
d oes n ot pertai n t o a partici pa nt e nr olle d i n t he st u d y , t he i nf or mati o n is n ot rec or de d o n a 
C R F; h o we ver , a c o p y  of t he c o m p lete d Va cci ne S A E Re p ort F or m m ust be mai ntai ne d i n t he 
i n vesti gat or site file .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370939] 
T he f oll o wi n g e ve nts are c o nsi dere d A E SI s: 
F or S u bst u d y  A: 
A c o nfir me d dia g n osis of i nfl ue nza. 
C o nfir me d dia g n osis of m y ocar ditis or pericar ditis occ urri n g wit hi n 4 wee ks after 
vacci nati o n.  See Secti o n 1 0. 1 1. 8. 8. 1 0 .
C o nfir me d C O VI D -[ADDRESS_370940] u d y  (cli nical 
si g ns/s y m pt o ms per C D C [ADDRESS_370941] 
res ult ). 
F or S u bst u d y  B: 
A c o nfir me d dia g n osis of i nfl ue nza. 
C o nfir me d dia g n osis of m y ocar ditis or pericar ditis occ urri n g wit hi n 6 wee ks after 
vacci nati o n .  See Secti o n 1 0. 1 2. 8. 1 2. 
C o nfir me d C O VI D -[ADDRESS_370942] u d y  (cli nical 
si g ns/s y m pt o ms per C D C [ADDRESS_370943] res ult) 
(e xcl u di n g Gr o u p 1 2) .
P ote ntial me nstr ual c y cle dist ur ba nces. See Secti o n 1 0. 1 2. 8. 1 1 .
A E SI sare e xa mi ne d as part of r o uti ne safet y data re vie w pr oce d ures t hr o u g h o ut t he cli nical 
trial a n d as part of si g nal detec ti o n pr ocesses. S h o ul d a n a g gre gate a nal y sis i n dicate t hat 
t hese pres pecifie d e ve nts occ ur m ore fre q ue ntl y t ha n e x pecte d, e g ,base d o n e pi [INVESTIGATOR_32450] o gical 
data, literat ure, or ot her data, t he n t his will be s u b mitte d a n d re p orte d i n acc or da nce wit h 
[COMPANY_007]’s safet y re p orti n g re q uire me nts. A g gre gate a nal ys es of safet y data will be perf or me d 
o n a re g ular basis per i nter nal S O Ps .
All A E SI s m ust be re p orte d as a n A E or S A E f oll o wi n g t he pr oce d ures descri be d i n 
Secti o n 8. 4. [ADDRESS_370944] be re p orte d usi n g t he Va cci ne S A E Re p ort F or m .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370945] re p ort si g ns, s y m pt o ms, a n d/ or cli nical se q uelae res ulti n g fr o m lac k of 
efficac y.  Lac k of ef ficac y  or fail ure of e x pecte d p har mac ol o gical acti o n is re p orta ble t o 
[COMPANY_007] Safet y  o nl y if ass oci a te d wit h a n S A E .
8. 4. 8. Me dic al De vice Deficie ncies 
Me dical de vices bei n g pr o vi de d f or use i n t his st u d y are t h ose liste d i n Secti o n 6. 1. [ADDRESS_370946] u d y  wit h s uc h de vices. 
T he defi niti o n of a me dical de vice deficie nc y  ca n be f o u n d i n Secti o n 1 0. 1 0 .
N ote: A Es a n d/ or S A Es t hat are ass ociate d wit h a me dical de vice d eficie nc y will f oll o w t he 
sa me pr ocesses as ot her A Es or S A Es, as o utli ne d i n Secti o n s 8. 4. [ADDRESS_370947] u dies. 
T he u n bli n de d site staff, or res p o nsi ble pers o n acc or di n g t o l ocal re q uire me nts (e g, t he hea d 
of t he me dical i nstit uti o n), will c o m pl y  wit h t he a p plica ble l ocal re g ulat or y re q uire me nts 
relati n g t o t he re p orti n g of de vice deficie ncies t o t he I R B/ E C. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 8 1 N ote: T here are a d diti o nal re p orti n g o bli gati o ns f or me dical de vice deficie ncies t hat are 
p ote ntiall y  relate d t o S A Es (ie, a n S A D E) t hat m ust f ulfill t he le gal res p o nsi bilit y  t o n otif y  
a p pr o priate re g ulat or y  a ut h orities a n d ot her e ntities a b o ut certai n safet y i nf or mati o n relati n g 
t o me dical de vices bei n g use d i n cli nical st u dies. 
A n y  de vice deficie nc y  t hat is ass ociate d wit h a n S A E m ust be re p orte d t o t he s p o ns or 
wit hi n 2 4 h o urs after t he i n vesti gat or deter mi nes t hat t he e ve nt meets t he defi niti o n of a 
de vice deficie nc y .
T he s p o ns or s hall re vie w all de vice deficie ncies a n d deter mi ne a n d d oc u me nt i n writi n g 
w het her t he y  c o ul d ha ve le d t o a n S A E. T hese s hall be re p orte d t o t he re g ulat or y  
a ut h orities a n d I R Bs/ E Cs as re q uire d b y nati o nal re g ulati o ns. 
8. 4. 9. V acci n ati o n Err ors 
Va cci nati o n err ors ma y  res ult fr o m t he a d mi nistrati o n or c o ns u m pti o n of t he st u d y  
i nter ve nti o n b y  t he wr o n g part ici pa nt , or at t he wr o n g ti me, or at t he wr o n g d osa ge stre n gt h. 
Va cci nati o n err ors are rec or de d a n d re p orte d as f oll o ws: 
Rec or de d o n t he 
V acci n ati o n Err or Pa ge 
of t he C R F Rec or de d o n t he 
A d verse E ve nt Pa ge 
of t he C R F Re p orte d o n t he V acci ne 
S A E Re p ort F or m t o [COMPANY_007] 
S afet y Wit hi n 2 4 H o urs of 
A w are ness 
All (re gar dless of w het her 
ass ociate d wit h a n A E) A n y  A E or S A E ass ociate d 
wit h t he vacci nati o n err or O nl y  if ass ociate d wit h a n 
S A E 
Va cci nati o n err ors i ncl u de: 
Vacci nati o n err ors i n v ol vi n g partici pa nt e x p os ure t o t he st u d y  i nter ve nti o n ;
P ote ntial vacci nati o n err ors or uses o utsi de of w hat is f oresee n i n t he pr ot oc ol t hat d o 
or d o n ot i n v ol ve t he st u d y partici pa nt ;
T he a d mi nistrati o n of e x pi[INVESTIGATOR_1312] d st u d y  i nter ve nti o n; 
T he a d mi nistrati o n of a n i nc orrect st u d y  i nter ve nti o n; 
T he a d mi nistrati o n of a n i nc orrect d osa ge; 
T he a d mi nistrati o n of st u d y  i nter ve nti o n t hat has u n der g o ne te m perat ure e xc ursi o n 
fr o m t he s pecifie d st ora ge ra n ge, u nless it is deter mi ne d b y  t he s p o ns or t hat t he st u d y  
i nter ve nti o n u n der q ues ti o n is acce pta ble f or use. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370948] u d y partici pa nt are t o be ca pt ure d o n t he vacci nati o n 
err or pa ge of t he C R F , w hic h is a s pecific versi o n of t he A E pa ge. 
W het her or n ot t he vacci nati o n err or is acc o m pa nie d b y  a n A E, as d eter mi ne d b y  t he 
i n vesti gat or , t he vacci nati o n err or is rec or de d o n t he vacci nati o n err or pa ge of t he C R F a n d, 
if a p plica ble, a n y ass ociate d A E(s), seri o us a n d n o nseri o us, are rec or de d o n t he A E pa ge of 
t he C R F .
I n t he e ve nt of a vacci nati o n d osi n g err or , t he s p o ns or s h o ul d be n otifie d wit hi n [ADDRESS_370949] u d y  B. 
8. 9. He alt h Ec o n o mics 
Healt h ec o n o mics/ me dical res o urce utilizati o n a n d healt h ec o n o mics para meters are n ot 
e val uate d i n S u bst u d y  A or S u bst u d y  B .
9. S T A TI S TI C A L C O N SI D E R A TI O N S 
Met h o d ol o g y f or s u m mar y  a n d statistical a nal ys es of t he data c ollecte d i n t his st u d y  is 
descri be d here a n d f urt her detaile d i n t he S A P, w hic h will be mai ntai ne d b y t he s p o ns or. T he 
S A P ma y  m o dif y  w hat is o utli ne d i n t he pr ot oc ol w here a p pr o priate; h o we ver, a n y maj or 
m o dificati o ns of t he pri mar y  e n d p oi nt defi niti o ns or t heir a nal ys es will als o be ref lecte d i n a 
pr ot oc ol a me n d me nt. 
9. 1. St atistic al H y p ot heses 
T here are n o statistical h y p ot heses i n eit her S u bst u d y  A or S u bst u d y  B .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370950] u d y  B are detaile d i n Secti o n 1 0. 1 2. 9. 3 .
9. 3. 1. Ge ner al C o nsi der ati o ns 
CIs f or all e n d p oi nts i n t he statistical a nal ys is will be prese nte d as 2-si de d at t he 9 5 % le vel 
u nless s pecifie d ot her wise. 
T he safet y a nal ys es are base d o n t he safet y p o p ulati o n. Partici pa nts will be s u m marize d b y  
vacci ne gr o u p acc or di n g t o t he st u d y  i nter v e nti o ns t he y  act uall y recei ve d. C o m pletel y  
missi n g react o ge nicit y e -diar y  data will n ot be i m p ute d; missi n g A E dates will be ha n dle d 
acc or di n g t o t he [COMPANY_007] safet y  r ules. Missi n g e- diar y  da ta n ot rec or de d i n t he e- diar y will be 
rec or de d o n t he A E C R F . Theref ore, t he pri mar y  a nal ys is will use react o ge nicit y  rec or de d as 
A Es i n t he C R F t o i m p ute t he missi n g e- diar y  data. 
F or all t he i m m u n o ge nicit y  e n d p oi nts, t he a nal y sis will be base d o n t he e val ua ble 
i m m u n o ge nicit y p o p ulati o n. A nti b o d y  titers bel o w t he L L O Q or de n ote d as B L Q will be set 
t o 0. 5 × L L O Q f or i m m u n o ge nicit y a nal ys is.  N o ot her missi n g assa y  data will be i m p ute d i n 
t he a nal ys es.  All i m m u n o ge nicit y  a nal ys es will be perf or me d after t he i m p utati o n of t he 
a nti b o d y  c o nce n trati o ns or a nti b o d y  titers t hat are bel o w t he L L O Q. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 8 4 A n a d diti o nal a nal ys is ma y  be perf or me d base d o n t he mI T T i m m u n o ge nicit y  p o p ulati o n if 
t here is a lar ge e n o u g h differe nce i n sa m ple size bet wee n t he mI T T i m m u n o ge nicit y  
p o p ulati o n a n d t he e val ua ble i m m u n o ge nicit y  p o p ulati o n. Partici pa nts will be s u m marize d 
acc or di n g t o t he vacci ne gr o u p t o w hic h t he y  were ra n d o mize d.  Missi n g ser ol o g y  data will 
n ot be i m p ute d. 
9. 3. 1. 1. A n al yses f or Bi n ar y D at a 
Descri pti ve statistics f or bi nar y  varia bles (e g, pr o p orti o ns) are t he perce nta ge ( %), t he 
n u merat or ( n) a n d t he de n o mi nat or ( N) use d i n t he perce nta ge calc ulati o n, a n d t he 9 5 % C Is 
w here a p plica ble. 
T he e xact 9 5 % CI sf or bi nar y  e n d p oi nts f or eac h gr o u p will be c o m p ute d usi n g t he 
Fdistri b uti o n ( Cl o p per -Pears o n). 
9. 3. 1. 2. A n al yses f or C o nti n u o us D at a 
U nless ot her wise state d, descri pti ve statistics f or c o nti n u o us varia bles are n, mea n, me dia n, 
sta n dar d de viati o n, mi ni m u m, a n d ma xi m u m. 
9. 3. 1. 2. 1. Ge o metric Me a n Titers 
T he G M Ts will be calc ulate d as t he mea n of t he assa y  res ults after ma ki n g t he l o ga rit h m 
tra nsf or mati o n a n d t he n e x p o ne ntiati n g t he mea n t o e x press res ults o n t he ori gi nal scale. 
T w o -si de d 9 5 % C Is will be o btai ne d b y  ta ki n g l o g tra nsf or ms of assa y  res ults, calc ulati n g t he 
9 5 % CI  wit h refere nce t o t he St u de nt t distri b uti o n, a n d t he n e x p o ne ntiati n g t he c o nfi de nce 
li mits. 
9. 3. 1. 2. 2. Ge o metric Me a n F ol d Rises 
F ol d rises are defi ne d as rati os of t he res ults after vacci nati o n t o t he res ults bef ore 
vacci nati o n. T he calc ulati o ns of f ol d ri ses are li mite d t o partici pa nts wit h n o n missi n g val ues 
at b ot h ti me p oi nts. 
G M F Rs will be calc ulate d as t he mea n of t he differe nce of l o garit h micall y t ra nsf or me d assa y  
res ults (later ti me p oi nt mi n us earlier ti me p oi nt) a n d e x p o ne ntiati n g t he mea n. T he 
ass oc iate d 2 -si de d 9 5 % C Is will be o btai ne d b y c o nstr ucti n g C Is usi n g t he St u de nt 
t distri b uti o n f or t he mea n differe nce o n t he l o garit h m scale a n d e x p o ne ntiati n g t he 
c o nfi de nce li mits. 
9. 3. 1. 2. 3. Re verse C u m ul ati ve Distri b uti o n C ur ve s
E m pi[INVESTIGATOR_10477] R C D Cs will pl ot pr o p orti o n s of partici pa nts wit h val ues e q ual t o or e xcee di n g a 
s pecifie d assa y  val ue vers us t he i n dicate d assa y  val ue, f or all o bser ve d assa y  val ues.  Data 
p oi nts will be j oi ne d b y  a ste p f u ncti o n wit h t he li ne first g oi n g d o w n a n d t he n t o t he ri g ht t o 
t he ne xt ass a y  val ue. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370951] u d y B. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 8 6 1 0. S U P P O R TI N G D O C U M E N T A TI O N A N D O P E R A TI O N A L C O N SI D E R A TI O N S 
1 0. 1. A p pe n di x 1: Re g ul at or y, Et hic al, a n d St u d y O versi g ht C o nsi der ati o ns 
[ADDRESS_370952] u d y  will be c o n d ucte d i n acc or da nce wit h t he pr ot oc ol a n d wit h t he f oll o wi n g: 
C o nse ns us et hical pri nci ples deri ve d fr o m i nter nati o nal g ui deli nes , i ncl u di n g t he 
Declarati o n of Helsi n ki a n d CI O M S I nter nati o nal Et hical G ui de li nes ;
A p plica ble I C H G C P gui deli nes ;
A p plica ble la ws a n d re g ulati o ns , i ncl u di n g a p plica ble pri vac y  la ws .
T he pr ot oc ol, pr ot oc ol a me n d me nts, I C D, S R S D(s) , a n d ot her rele va nt d oc u me nts 
(e g, a d vertise me nts) m ust be re vie we d a n d a p pr o ve d b y  t he s p o ns or ,s u b mitte d t o a n I R B/ E C 
b y  t he i n vesti gat or, a n d re vie we d a n d a p pr o ve d b y  t he I R B/ E C bef ore t he st u d y  is i nitiate d. 
A n y  a me n d me nts t o t he pr ot oc ol will re q uire I R B/ E C a p pr o val bef ore i m ple me ntati o n of 
c ha n ges ma de t o t he st u d y desi g n, e xce pt f or c ha n ges necessar y  t o eli mi nate a n i m me diate 
hazar d t o st u d y  partici pa nts. 
Pr ot oc ols a n d a n y s u bsta ntial a me n d me nts t o t he pr ot oc ol will re q uire healt h a ut h orit y  
a p pr o val pri or t o i nitiati o n e xce pt f or c ha n ges necessar y t o eli mi nate a n i m me diate hazar d t o 
st u d y  par tici pa nts. 
T he i n vesti gat or will be res p o nsi ble f or t he f oll o wi n g: 
Pr o vi di n g writte n s u m maries of t he stat us of t he st u d y  t o t he I R B/ E C a n n uall y  or 
m ore fre q ue ntl y  i n acc or da nce wit h t he re q uire me nts, p olicies, a n d pr oce d ures 
esta blis he d b y  t he I R B/ E C ;
N ot if y i n g t he I R B/ E C of S A Es or ot her si g nifica nt safet y fi n di n gs as re q uire d b y 
I R B/ E C pr oce d ures ;
Pr o vi di n g o versi g ht of t he c o n d uct of t he st u d y at t he site a n d a d here nce t o 
re q uire me nts of 2 1 C F R, I C H G C P g ui deli nes, t he I R B/ E C, E ur o pea n Re g ulati o n 
5 3 6/ [ADDRESS_370953] u dies, E ur o pea n M D R 2 0 1 7/ 7 4 5 f or cli nical de vice researc h, 
a n d all ot her a p plica ble l ocal re g ulati o ns .
1 0. 1. 1. 1. Re p orti n g of S afet y Iss ues a n d Seri o us Bre a c hes of t he Pr ot oc ol or I C H G C P 
I n t he e ve nt of a n y pr o hi biti o n or restricti o n i m p ose d (ie, cli nical h ol d) b y a n a p plica ble 
re g ulat or y  a ut h orit y i n a n y area of t he w orl d, or if t he i n vesti gat or is a ware of a n y ne w 
i nf or mati o n t hat mi g ht i nfl ue nce t he e val uati o n of t he be nefits a n d ris ks of t he st u d y  
i nter ve nti o n , [COMPANY_007] s h o ul d be i nf or me d i m me dia t el y .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370954] u d y .
1 0. 1. 3. I nf or me d C o nse nt Pr oces s
T he i n vesti gat or or t he i n vesti gat or’s re prese ntati ve will e x plai n t he nat ure of t he st u d y , 
i ncl u di n g t he ris ks a n d be nefits, t o t he partici pa nt a n d a ns wer all q uesti o ns re gar di n g t he 
st u d y . T he partici pa nt s h o ul d be gi ve n s uf ficie nt ti me a n d o p p ort u nit y  t o as k q uesti o ns a n d 
t o deci de w het her or n ot t o partici pate i n t he trial. 
Partici pa nts m ust be i nf or me d t hat t heir partici pati o n is v ol u ntar y . Partici pa nts will be 
re q uire d t o si g n a state me nt of i nf or me d c o nse nt t hat meets t he re q uire me nts o f 2 1 C F R 5 0, 
l ocal re g ulati o ns, I C H g ui deli nes, pri vac y  a n d data pr otecti o n re q uire me nts, w here 
a p plica ble, a n d t he I R B/ E C or st u d y  ce nter .
T he i n vesti gat or m ust e ns ure t hat eac h partici pa nt is f ull y  i nf or me d a b o ut t he nat ure a n d 
o bjecti ves of t he st u d y , t he s hari n g of data relate d t o t he st u d y ,a n d p ossi ble ris ks ass ociate d 
wit h partici pati o n, i ncl u di n g t he ris ks ass ociate d wit h t he pr ocessi n g of t he partici pa nt ’s 
pers o nal data. 
T he partici pa nt m ust be i nf or me d t hat t heir pers o nal st u d y -relate d data will b e use d b y t he 
s p o ns or i n acc or da nce wit h l ocal data pr otecti o n la w. T he le vel of discl os ure m ust als o be 
e x plai ne d t o t he partici pa nt. 
T he partici pa nt m ust be i nf or me d t hat t heir me dical rec or ds ma y  be e xa mi ne d b y  Cli nical 
Q ualit y  A ss ura nce a u dit ors or ot her a ut h orize d pers o n nel a p p oi nte d b y  t he s p o ns or , b y  
a p pr o priate I R B/ E C me m bers, a n d b y i ns pect ors fr o m re g ulat or y a ut h orities. 
T he i n vesti gat or f urt her m ust e ns ure t hat eac h st u d y  partici pa nt is f ull y  i nf or me d a b o ut t heir 
ri g ht t o access a n d c orrect t hei rpers o nal data a n d t o wit h dra w c o nse nt f or t he pr ocessi n g of 
t heir pers o nal data. 
T he me dical rec or d m ust i ncl u de a state me nt t hat writte n i nf or me d c o nse nt was o btai ne d 
bef ore t he partici pa nt was e nr olle d i n t he st u d y  a n d t he date o n w hic h t he writte n c o n se nt was 
o btai ne d. T he a ut h orize d pers o n o btai ni n g t he i nf or me d c o nse nt m ust als o si g n t he I C D. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370955] c urre nt versi o n of t he I R B/ E C -a p pr o ve d I C D(s) 
d uri n g t heir partici pati o n i n t he st u d y as re q uire d per l ocal re g ul ati o ns .
A c o p y of t he I C D(s) m ust be pr o vi de d t o t he partici pa nt. 
Partici pa nts w h o are rescree ne d are re q uire d t o si g n a ne w I C D. 
1 0. 1. 3. 1. Electr o nic C o nse nt 
Partici pa nts ma y  be a ble t o e x perie nce t he i nf or me d c o nse nt pr ocess b y  electr o nic mea ns 
(e C o nse nt). T he e C o nse nt pr ocess i ncl u des a n electr o nic prese ntati o n of t he I C D(eI C D), 
cli nical trial e d ucati o nal c o m p o ne nts (as a p plica ble), a n d electr o nic si g nat ures (if all o we d b y 
l ocal re g ulati o ns). T he use of e C o nse nt d oes n ot re place or alter t he I C D c o nte nt o r i nf or me d 
c o nse nt pr ocess as descri be d a b o ve. T he e C o nse nt pr ocess c o m plies wit h a p plica ble 
re g ulati o ns a n d s p o ns or p olicies t o e ns ure relia bilit y  a n d data pri vac y . 
[ADDRESS_370956] y  wit h all a p plica ble la ws, i ncl u di n g la ws re gar d i n g t he i m ple me ntati o n 
of or ga nizati o nal a n d tec h nical meas ures t o e ns ure pr otecti o n of partici pa nt data. 
Partici pa nts ’ pers o nal data will be st ore d at t he st u d y  site i n e ncr y pte d electr o nic a n d/ or pa per 
f or m a n d will be pass w or d pr otecte d or sec ure d i n a l oc ke d r o o m t o e ns ure t hat o nl y  
a ut h orize d st u d y  staff ha ve access. T he st u d y site will i m ple me nt a p pr o priate tec h nical a n d 
or ga nizati o nal meas ures t o e ns ure t hat t he pers o nal data ca n be rec o vere d i n t he e ve nt of 
disaster .I n t he e ve nt of a p ote ntial pers o nal data breac h, t he st u d y site will be res p o nsi ble f or 
deter mi ni n g w het her a pers o nal data breac h has i n fact occ urre d a n d, if s o, pr o vi di n g breac h 
n otificati o ns as re q uire d b y  la w .
To  pr otect t he ri g hts a n d free d o ms of partic i pa nts wit h re gar d t o t he pr ocessi n g of pers o nal 
data, partici pa nts will be assi g ne d a si n gle, partici pa nt -s pecific n u merical c o de. A n y 
partici pa nt rec or ds or data sets t hat are tra nsferre d t o t he s p o ns or will c o ntai n t he n u merical 
c o de; partici pa nt na mes will n ot be tra nsferre d. All ot her i de ntifia ble data tra nsferre d t o t he 
s p o ns or will be i de ntifie d b y  t his si n gle, partici pa nt -s pecific c o de. T he st u d y  site will 
mai ntai n a c o nfi de ntial list of partici pa nt s w h o partici pate d i n t he st u d y , li n ki n g eac h 
pa rtici pa nt ’s n u merical c o de t o t heir act ual i de ntit y a n d me dical rec or d I D .I n  case of data 
tra nsfer , t he s p o ns or will pr otect t he c o nfi de ntialit y  of partici pa nt s’ pers o nal data c o nsiste nt 
wit h t he c li nical st u d y  agree me nt a n d a p plica ble pri vac y  la ws. 
I n f o r mati o n tec h n ol o g y  s y ste ms use d t o c ollect, pr ocess, a n d st ore st u d y -relate d data are 
sec ure d b y t ec h nical a n d or ga nizati o nal sec urit y m eas ures desi g ne d t o pr otect s uc h data 
a gai nst acci de ntal or u nla wf ul l oss, alterati o n, or u na ut h orize d discl os ure or acc ess. 
T he s p o ns or mai ntai ns S O Ps o n h o w t o res p o n d i n t he e ve nt of u na ut h orize d access, use, or 
discl os ure of s p o ns or i nf or mati o n or s y ste ms. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370957] u d y  
acc or di n g t o t he c harter . T h e rec o m me n dati o ns ma de b y t he I R C will be f or war de d t o t he 
a p pr o priate a ut h orize d [COMPANY_007] pers o n nel f or re vie wa n d fi nal decisi o n. [COMPANY_007] will 
c o m m u nicate s uc h decisi o ns, w hic h ma y  i ncl u de s u m maries of a g gre gate a nal y ses of safet y 
data, t o re g ulat or y  a ut h orities a n d i n vesti gat ors, as a p pr o priate. 
T he res p o nsi bilities of t he I R C will i ncl u de at a mi ni m u m: 
Re vie w of safet y data i n t he case of a st o p pi n g r ule bei n g met i n Su bst u d y  A a n d 
S u bst u d y  B .
Re vie w of safet y data a n d i m m u n o ge nicit y acc u m ulate d f or at least 4wee k sf oll o wi n g 
vacci nati o n i n Su bst u d y A a n d Su bst u d y  B. 
[ADDRESS_370958] u dies o n w w w .cli nicaltrials . g o v ( Cli nical T rials. g o v), t he E u dra C T / C TI S, a n d/ or 
w w w . pfizer .c o m , a n d ot her p u blic re gistries a n d we bsites i n acc or da nce wit h a p plica ble l ocal 
la ws/re g ulati o ns. I n a d diti o n, [COMPANY_007] re p orts st u d y  res ults o utsi de of t he re q uire me nts of l ocal 
la ws/re g ulati o ns p urs ua nt t o its S O Ps. 
I n all cases, st u d y res ults are re p orte d b y [COMPANY_007] i n a n o bjecti ve, acc urate, bala nce d, a n d 
c o m plete ma n ner a n d are re p orte d re gar dless of t h e o utc o me of t he st u d y or t he c o u ntr y i n 
w hic h t he st u d y  was c o n d ucte d. 
w w w.cli nicaltrials. g o v 
[COMPANY_007] p osts cli nical trial res ults o n w w w .cli nicaltrials . g o v f or [COMPANY_007] -s p o ns ore d i nter ve nti o nal 
st u dies (c o n d ucte d i n patie nts) t hat e val uate t he safet y  a n d/ o r ef ficac y  of a pr o d uct, 
re gar dless of t he ge o gra p hical l ocati o n i n w hic h t he st u d y  is c o n d ucte d. T hese r es ults are 
s u b mitte d f or p osti n g i n acc or da nce wit h t he f or mat a n d ti meli nes set f ort h b y  U S la w. 
E u dra C T / C TI S
[COMPANY_007] p osts cli nical trial r es ults o n E u dra C T / C TI Sf or [COMPANY_007] -s p o ns ore d i nter ve nti o nal st u dies 
i n acc or da nce wit h t he f or mat a n d ti meli nes set f ort h b y  E U re q uire me nts. 
w w w. pfizer.c o m 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370959] u d y  res ults 
are p oste d t o w w w.cli nicaltrials . g o v .C S R s y n o pses will ha ve pers o nall y  i de ntif ia ble 
i nf or mati o n a n o n y m ize d. 
D oc u me nts wit hi n mar keti n g a p plicati o ns 
[COMPANY_007] c o m plies wit h a p plica ble l ocal la ws/re g ulati o ns t o p u blis h cli nical d oc u me nts i ncl u de d 
i n mar keti n g a p plicati o ns. Cli nical d oc u me nts i ncl u de s u m mar y  d oc u me nts a n d C S Rs 
i ncl u di n g t he pr ot oc ol a n d pr ot oc ol a me n d me nts, sa m ple C R Fs, a n d S A P s. Cli nical 
d oc u me nts will ha ve per s o nall y  i de ntifia ble i nf or mati o n a n o n y mize d. 
Data shari n g 
[COMPANY_007] pr o vi des researc hers sec ure access t o partici pa nt -le vel data or f ull C S Rs f or t he 
p ur p oses of “b o na -fi de scie ntific researc h ” t hat c o ntri b ute st o t he scie ntific u n dersta n di n g of 
t he disease, tar get, or c o m p o u n d class. [COMPANY_007] will ma ke data fr o m t hese trials a vaila ble 
[ADDRESS_370960], i ncl u di n g i n di vi d uals 
re q uesti n g access f or c o m mercial/c o m petiti ve or le gal p ur p oses. 
[ADDRESS_370961] u d y will be rec or de d o n pri nte d or elec tr o nic C R F u nless 
tra ns mitte d t o t he s p o ns or or desi g nee electr o nicall y  (e g, la b orat or y  data). T he i n vesti gat or is 
res p o nsi ble f or verif y i n g t hat data e ntries are acc urate a n d c orrect b y  p h y sicall y  or 
electr o nicall y  si g ni n g t he C R F .
G ui da nce o n c o m pleti o n of C R Fs will be pr o vi de d i n t he C R F C o m pleti o n Re q uire me nts 
d oc u me nt .
T he i n vesti gat or m ust e ns ure t hat t he C R Fs are sec urel y st ore d at t he st u d y site i n e ncr y pte d 
electr o nic a n d/ or pa per f or m a n d are pass w or d pr otecte d or sec ure d i n a l oc ke d r o o m t o 
pre ve nt access b y u na ut h orize d t hir d parties. 
Q T L s are pre defi ne d para meters t hat are m o nit ore d d uri n g t he st u d y . I m p orta nt de viati o ns 
fr o m t he Q T Ls a n d a n y re me dial acti o ns ta ke n will be s u m marize d i n t he C S R .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370962] u d y -relat e d m o nit ori n g, a u dits, I R B/ E C re vie w , a n d 
re g ulat or y  a ge nc y  i ns pecti o ns a n d pr o vi de direct access t o s o urce rec or ds a n d d oc u me nts. 
T his verificati o n ma y  als o occ ur after st u d y c o m pleti o n. It  is i m p orta nt t hat t he 
i n vesti gat or(s) a n d t heir rele va nt pers o n nel are a vaila ble d uri n g t he m o nit ori n g visits a n d 
p ossi ble a u dits or i ns pecti o ns a n d t hat s uf ficie nt ti me is de v ote d t o t he pr ocess. 
M o nit ori n g details descri bi n g strate g y , i ncl u di n g defi niti o n of st u d y -critical data ite ms a n d 
pr ocesses (e g, -ris k -base d i nitiati ves i n o perati o ns a n d q ualit y  s uc h as ris k ma na ge me nt a n d 
miti gati o n strate gies a n d anal yt ical ris k - b ase d mo nit ori n g), met h o ds, res p o nsi bilities ,a n d 
re q uire me nts, i ncl u di n g ha n dli n g of n o nc o m plia nce iss ues a n d m o nit ori n g tec h ni q ues 
(ce ntral, virt ual , or o n -site m o nit ori n g) , are pr o vi de d i n t he data ma na ge me nt pla n a n d 
mo nit ori n g pla n mai ntai ne d a n d utilize d b y  t he s p o ns or or desi g nee. 
T he s p o ns or or desi g nee is res p o nsi ble f or t he data ma na ge me nt of t his st u d y ,i ncl u di n g 
q ualit y  c hec ki n g of t he data. 
Rec or ds a n d d oc u me nts, i ncl u di n g si g ne d I C Ds, pertai ni n g t o t he c o n d uct of t his st u d y  m ust 
be retai ne d b y t he i n vesti gat or f or [ADDRESS_370963] ore d sec urel y f or as l o n g as t he y  are 
mai ntai ne d. 
W he n partici pa nt data are t o be delete d, t he i n vesti gat or will e ns ure t hat all c o pi[INVESTIGATOR_1309] s uc h 
data are pr o m ptl y  a n d irre v oca bl y delete d fr o m all s yste ms. 
T he i n v esti gat or(s) will n otif y t he s p o ns or or its a ge nts i m me diatel y  of a n y  re g ulat or y  
i ns pecti o n n otificati o n i n relati o n t o t he st u d y . F urt her m ore, t he i n vesti gat or will c o o perate 
wit h t he s p o ns or or its a ge nts t o pre pare t he i n vesti gat or site f or t he i ns pect i o n a n d will all o w 
t he s p o ns or or its a ge nt, w he ne ver feasi ble, t o be prese nt d uri n g t he i ns pecti o n. T he 
i n vesti gat or site a n d i n vesti gat or will pr o m ptl y  res ol ve a n y  discre pa ncies t hat are i de ntifie d 
bet wee n t he st u d y data a n d t he partici pa nt ’s me dical rec or ds. T he i n vesti gat or will pr o m ptl y  
pr o vi de c o pi[INVESTIGATOR_1309] t he i ns pecti o n fi n di n gs t o t he s p o ns or or its a ge nt. Bef ore res p o nse 
s u b missi o n t o t he re g ulat or y  a ut h orities, t he i n vesti gat or will pr o vi de t he s p o ns or or its 
a ge nts wit h a n o p p ort u nit y t o re vie w a n d c o m me nt o n res p o nses t o a n y s uc h fi n di n gs. 
[ADDRESS_370964] be a vaila ble. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370965] mai ntai n acc urate d oc u me ntati o n (s o urce data) t hat s u p p orts t he 
i nf or mati o n e ntere d i n t he C R F .
T he s p o ns or or desi g nee will perf or m m o nit ori n g t o c o nfir m t ha t data e ntere d i nt o t he C R F 
b y  a ut h orize d site pers o n nel are acc urate, c o m plete, a n d verifia ble fr o m s o urce d oc u me nts; 
t hat t he safet y a n d ri g hts of partici pa nts are bei n g pr otecte d; a n d t hat t he st u d y is bei n g 
c o n d ucte d i n acc or da nce wit h t he c urre ntl y a p pr o ve d pr ot oc ol a n d a n y  ot her st u d y  
a gree me nts, I C H G C P g ui deli nes , a n d all a p plica ble re g ulat or y  re q uire me nts. 
[ADDRESS_370966] partici pa nt ’s first visit .
T he s p o ns or desi g nee reser ves t he ri g h t t o cl ose t he st u d y  site or ter mi nate t he st u d y  at a n y  
ti me f or a n y reas o n at t he s ole discreti o n of t he s p o ns or , i ncl u di n g ( b ut n ot li mite d t o) 
re g ulat or y  a ut h orit y decisi o n, c ha n ge i n o pi [INVESTIGATOR_9384] o n of t he I R B/ E C, or c ha n ge i n be nefit -ris k 
assess me nt .St u d y  sites will be cl ose d u p o n st u d y c o m pleti o n. A st u d y  site is c o nsi dere d 
cl ose d w he n all re q uire d d oc u me nts a n d st u d y  s u p plies ha ve bee n c ollecte d a n d a st u d y -site 
cl os ure visit has bee n perf or me d. 
T he i n vesti gat or ma y  i nitiate st u d y -site cl os ure at a n y  ti me u p o n n otificati o n t o t he s p o ns or 
or desi g nee/ C R O if re q ueste d t o d o s o b y  t he res p o nsi ble I R B/ E C or if s uc h ter mi nati o n is 
re q uire d t o pr otect t he healt h of st u d y  partici pa nts .
Reas o ns f or t he earl y cl os ure of a st u d y site b y t he s p o ns or ma y i ncl u d e b ut are n ot li mite d 
t o: 
Fail ure of t he i n vesti gat or t o c o m pl y  wit h t he pr ot oc ol, t he re q uire me nts of t he 
I R B/ E C or l ocal healt h a ut h orities, t he s p o ns or ’s pr oce d ures, or t he I C H G C P 
g ui deli nes ;
I n a de q uate recr uit me nt of partici pa nts b y  t he i n vesti gat or; 
Disc o nti n uati o n of f urt her st u d y  i nter ve nti o n de vel o p me nt .
If t he st u d y is pre mat urel y ter mi nate d or s us pe n de d, t he s p o ns or s hall pr o m ptl y i nf or m t he 
in vesti gat ors, t he E Cs /I R Bs, t he re g ulat or y  a ut h orities, a n d a n y  C R O (s) use d i n t he st u d y  of 
t he reas o n f or ter mi nati o n or s us pe nsi o n, as s pecifie d b y  t he a p plica ble re g ulat or y  
re q uire me nts. T he in vesti gat or s hall pr o m ptl y  i nf or m t he partici pa nt a n d s h o ul d ass ure 
a p pr o priate partici pa nt t hera p y  a n d/ or f oll o w - u p. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370967] will c o ntr ol as t o ter mi nati o n ri g hts. 
1 0. 1. 1 0. P u blic ati o n P olic y 
F or m ultice nter trials, t he pri mar y  p u blicati o n will be a j oi nt p u blicati o n de vel o pe d b y t he 
i n vesti gat or a n d [COMPANY_007] re p orti n g t he pri mar y  e n d p oi nt(s) of t he st u d y  c o veri n g all st u d y  sites. 
T he i n vesti gat or a grees t o refer t o t he pri mar y  p u blicati o n i n a n y  s u bse q ue nt p u blicati o ns. 
[COMPANY_007] will n ot pr o vi de a n y fi na ncial c o m pe nsati o n f or t he i n vesti gat or’s partici pati o n i n t he 
pre parati o n of t he pri mar y c o n gress a bstract, p oster, prese ntati o n, or pri mar y ma n uscri pt f or 
t he st u d y .
I n vesti gat ors are free t o p u blis h i n di vi d ual ce nter res ults t hat t he y  dee m t o be cli nicall y  
mea ni n gf ul after p u blicati o n of t he o verall res ults of t he st u d y  or [ADDRESS_370968] u d y res ults (c ollecti vel y, “ p u blicati o n”) bef ore it is 
s u b mitte d or ot her wise discl ose d a n d will s u b mit all p u blicati o ns t o [COMPANY_007] [ADDRESS_370969] u d y  res ults.  F or j oi nt p u blicati o ns, s h o ul d t here be disa gree me nt re gar di n g i nter pretati o n 
a n d/ or prese ntati o n of s pecific a nal ys is res ults, res ol uti o n of, a n d res p o nsi bilit y  f or, s uc h 
disa gree me nts will be t he c ollecti ve res p o nsi bilit y  of all a ut h ors of t he p u blicati o n. 
F or all p u blicati o ns relati n g t o t he st u d y, t he i n vesti gat or a n d [COMPANY_007] will c o m pl y wit h 
rec o g nize d et hical sta n dar ds c o ncer ni n g p u blicati o ns a n d a ut h ors hi p, i ncl u di n g t h ose 
esta blis he d b y  t he I nter nati o nal C o m mittee of Me dical J o ur nal E dit ors. T he i n vesti gat or will 
discl ose a n y relati o ns hi p wit h [COMPANY_007] a n d a n y rele va nt p ote ntial c o nflicts of i nterest, i ncl u di n g 
a n y  fi na ncial or pers o nal relati o ns hi p wit h [COMPANY_007], i n a n y  p u blicati o ns. All a ut h or s will ha ve 
access t o t he rele va nt statistical ta bles, fi g ures, a n d re p orts (i n t heir ori gi nal f or mat) re q uire d 
t o de vel o p t he pu blicati o n .
1 0. 1. 1 1. S p o ns or’s Me dic all y Q u alifie d I n di vi d u al 
T he c o ntact i nf or mati o n f or t he s p o ns or ’s M QI f or t he st u d y  is d oc u me nte d i n t he st u d y  
c o ntact list l ocate d i n t he su p p orti n g st u d y d oc u me ntati o n/st u d y  p ortal or ot her electr o nic 
s y ste m .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 9 4 To  facilitate access t o t heir i n vesti gat or a n d t he s p o ns or ’s M QI f or st u d y -relate d me dical 
q uesti o ns or pr o ble ms fr o m n o nst u d y  healt hcare pr ofessi o nals , partici pa nts are pr o vi de d wit h 
a n E C C at t he ti me of i nf or me d c o nse nt. T he E C C c o ntai ns, at a mi ni m u m, (a) pr ot oc ol a n d 
st u d y  i nter ve nti o n i de ntifiers, ( b) partici pa nt’ s st u d y  i de ntificati o n n u m ber , (c) site 
e mer ge nc y p h o ne n u m ber acti ve 2 4 h o urs/ da y , 7 da y s per wee k, a n d ( d) [COMPANY_007] Call Ce nter 
n u m ber .
T he E C C is i nte n de d t o a u g me nt, n ot re place, t he esta blis he d c o m m u nicati o n pat h wa y s 
bet wee n t he partici pa nt a n d t heir i n vesti gat or a n d site staf f, a n d bet wee n t he i n vesti gat or a n d 
s p o ns or st u d y  tea m. T he E C C is o nl y  t o be use d b y  healt hcare pr ofessi o nals n ot i n v ol ve d i n 
t he researc h st u d y , as a mea ns of reac hi n g t he i n vesti gat or or site staf f relate d t o t he care of a 
partici pa nt. T he [COMPANY_007] Call Ce nter n u m ber is t obe use d w he n t he i n vesti gat or a n d site staff 
are u na vaila ble .T he [COMPANY_007] Call Ce nter n u m ber is n ot f or use b y  t he partici pa nt directl y;  if a 
partici pa nt calls t hat n u m ber directl y , t he y will be directe d bac k t o t he i n vesti gat or site. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 9 5 1 0. 2. A p pe n di x 2: Cli nic a l L a b or at or y Tests 
T he f oll o wi n g safet y la b orat or y test will be perf or me d at ti mes defi ne d i n Secti o n [ADDRESS_370970] u d y B 
H e m at ol o g y C he mistr y 
N/ A Car diac tr o p o ni n I 
Please refer t o t he la b orat or y  n or mal ra n ges ( pr o vi de d se paratel y) f or gra di n g scales f or 
a b n or malities. 
T he i n vesti gat or m ust re vie w t he la b orat or y  re p ort, d oc u me nt t his re vie w , a n d rec or d a n y 
cli nicall y  rele va nt c ha n ges occ urri n g d uri n g t he st u d y  i n t he A E secti o n of t he C R F .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 9 6 1 0. 3. A p pe n di x 3: A d v erse E ve nts: Defi niti o ns a n d Pr oce d ures f or Rec or di n g, 
E v al u ati n g, F oll o w - U p, a n d Re p orti n g 
1 0. 3. 1. Defi niti o n of A E 
A E Defi niti o n 
A n A E is a n y u nt o war d me dical occ urre nce i n a patie nt or cli nical st u d y partici pa nt, 
te m p orall y ass ociate d wit h t he use of st u d y  i nter ve nti o n, w het her or n ot c o nsi dere d 
relate d t o t he st u d y i nter ve nti o n. 
Note : A n A E ca n t heref ore be a n y u nfa v ora ble a n d u ni nte n de d si g n (i ncl u di n g a n 
a b n or mal la b orat or y  fi n di n g), s y m pt o m, or disease ( ne w or e xacer bate d) te m p orall y  
ass ociate d wit h t he use of st u d y  i nter ve nti o n. 
E ve nts Meeti n g t he A E Defi niti o n 
A n y  a b n or mal la b orat or y test res ults ( he mat ol o g y , cli nical c he mistr y , or uri nal y sis) 
or ot her safet y assess me nts (e g, E C G, ra di ol o gical sca ns, vital si g n meas ure me nts), 
i ncl u di n g t h ose t hat w orse n fr o m baseli ne, c o nsi dere d cli nicall y si g nifica nt i n t he 
me dical a n d scie ntific j u d g me nt of t he i n vesti gat or .A n y a b n or mal la b orat or y test 
res ults t hat meet a n y of t he c o n diti o ns bel o w m ust be rec or de d as a n A E: 
Is ass ociate d wit h acc o m pa n y i n g s y m pt o ms .
Re q uires a d diti o nal dia g n ostic testi n g or me dical/s ur gical i nter ve nti o n .
Lea ds t o a c ha n ge i n st u d y  d osi n g ( o utsi de of a n y  pr ot oc ol -s pecifie d d ose 
a dj ust me nts) or disc o nti n uati o n fr o m t he st u d y , si g nifica nt a d diti o nal 
c o nc o mita nt dr u g treat me nt, or ot her t hera p y. 
E xacer bati o n of a c hr o nic or i nter mitte nt pree xisti n g c o n diti o n, i ncl u di n g a n 
i ncrease i n eit her fre q ue nc y  a n d/ or i nte nsit y  of t he c o n diti o n. 
Ne w c o n diti o n detecte d or dia g n ose d after st u d y i nter ve nti o n a d mi nistrati o n ,e ve n 
t h o u g h it ma y  ha ve bee n prese nt bef ore t he start of t he st u d y .
Si g ns, s y m pt o ms, or t he cli nical se q uelae of a s us pecte d dr u g -dr u g i nteracti o n. 
Si g ns, s y m pt o ms, or t he cli nical se q uelae of a s us pecte d o ver d ose of eit her st u d y  
i nter ve nti o n or a c o nc o mita nt me dicati o n. O v er d ose per se will n ot be re p orte d as 
a n A E or S A E u nless it is a n i nte nti o nal o ver d ose ta ke n wit h p ossi ble 
s uici dal/self- har mi n g i nte nt. S uc h o ver d oses s h o ul d be re p orte d re gar dless of 
se q uelae. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 9 7 E ve nts N O T Meeti n g t he A E Defi niti o n 
A n y  cli nicall y  si g nifica nt a b n or mal la b orat or y  fi n di n gs or ot her a b n or mal safet y 
assess me nts t hat are ass ociate d wit h t he u n derl yi n g disease, u nless j u d ge d b y  t he 
i n vesti gat or t o be m ore se vere t ha n e x pecte d f or t he partici pa nt’s c o n diti o n. 
T he disease/ dis or der bei n g st u die d or e x pecte d pr o gressi o n, si g ns, or s y m pt o ms of 
t he disease/ dis or der bei n g st u die d, u nless m ore se vere t ha n e x pecte d f or t he 
partici pa nt’s c o n diti o n. 
Me dical or s ur gical pr oce d ure (e g, e n d osc o p y, a p pe n dect o m y): t he c o n diti o n t hat 
lea ds t o t he pr oce d ure is t he A E. 
Sit uati o ns i n w hic h a n u nt o war d me dical occ urre nce di d n ot occ ur (s ocial a n d/ or 
c o n ve nie nce a d missi o n t o a h os pi[INVESTIGATOR_307]). 
A ntici pate d da y -t o -d a y  fl uct uati o ns of pree xisti n g disease(s) or c o n diti o n(s) prese nt 
or detecte d at t he start of t he st u d y  t hat d o n ot w orse n. 
1 0. 3. 2. Defi niti o n of a n S A E 
A n S A E is defi ne d as a n y u nt o w ar d me dic al occ urre nce t h at, at a n y d ose , meets o ne or 
m o re of t he criteri a liste d bel o w :
a. Res ults i n de at h 
b. Is life -t hre ate ni n g 
T he ter m “life -t hreate ni n g ”i n t he defi niti o n of “seri o us ”refers t o a n e ve nt i n w hic h t he 
partici pa nt was at ris k of deat h at t he ti me of t he e ve nt. It  d oes n ot refer t o a n e ve nt t hat 
h y p ot heticall y  mi g ht ha ve ca use d deat h if it were m ore se vere. 
c. Re q uires i n p atie nt h os pit aliz ati o n or pr ol o n g ati o n of e xisti n g h os pit aliz ati o n 
I n ge neral, h os pi[INVESTIGATOR_1314] o n si g nifies t hat t he partici pa nt has bee n a d mitte d ( us uall y  
i n v ol vi n g at least a n o ver ni g ht sta y ) at t he h os pi[INVESTIGATOR_6879] e mer ge nc y war d f or o bser vati o n 
a n d/ or treat me nt t hat w o ul d n ot ha ve bee n a p pr o priate i n t he p h y sicia n ’s office or 
o ut patie nt setti n g. C o m plicati o ns t hat occ ur d uri n g h os pi[INVESTIGATOR_1314] o n are A Es. If a 
c o m plicati o n pr ol o n gs h os pi[INVESTIGATOR_1314] o n or f ulfills a n y ot her seri o us criteria, t he e ve nt is 
seri o us. W he n i n d o u bt as t o w het her “h os pi[INVESTIGATOR_1314] o n ” occ urre d or was necessar y , t he 
A E s h o ul d be c o nsi dere d seri o us. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 9 8 H os pi[INVESTIGATOR_1314] o n f or electi ve treat me nt of a pree xisti n g c o n diti o n t hat di d n ot w orse n 
fr o m baseli ne is n ot c o nsi dere d a n A E. 
d. Res ults i n persiste nt or si g ni fic a nt dis a bilit y/i nc a p acit y 
T he ter m disa bilit y mea ns a s u bsta ntial disr u pti o n of a pers o n’s a bilit y  t o c o n d uct 
n or mal life f u ncti o ns. 
T his defi niti o n is n ot i nte n de d t o i ncl u de e x perie nces of relati vel y mi n or me dical 
si g nifica nce ,s uc h as u nc o m plicate d h ea dac he, na usea, v o miti n g, diarr hea, i nfl ue nza, 
a n d acci de ntal tra u ma (e g, s prai ne d a n kle) ,t hat ma y  i nterfere wit h or pre ve nt 
e ver y d a y  life f u ncti o ns b ut d o n ot c o nstit ute a s u bsta ntial disr u pti o n. 
e. Is a c o n ge nit al a n o m al y/ birt h defect 
f. Is a s us pecte d tr a ns missi o n vi a a [COMPANY_007] pr o d uct of a n i nfecti o us a ge nt, p at h o ge nic 
or n o n p at h o ge nic 
T he e ve nt ma y  be s us pecte d fr o m cli nical s y m pt o ms or la b orat or y  fi n di n gs i n dicati n g a n 
i nfecti o n i n a partici pa nt e x p ose d t o a [COMPANY_007] pr o d uct. T he ter ms “s us pecte d 
tra ns missi o n” a n d “tra ns missi o n” are c o nsi dere d s y n o n y m o us. T hese cases are 
c o nsi dere d u ne x pecte d a n d ha n dle d as seri o us e x pe dite d cases b y p har mac o vi gila nce 
pers o n nel. S uc h cases are als o c o nsi dere d f or re p orti n g as pr o d uct defects, if 
a p pr o priate. 
g. Ot her sit u ati o ns: 
Me dical or scie ntific j u d g me nt s h o ul d be e xercise d b y  t he i n vesti gat or i n deci di n g 
w het her S A E re p orti n g is a p pr o priate i n ot her sit uati o ns, s uc h as si g nifica nt me dical 
e ve nts t hat ma y  je o par dize t he partici pa nt or ma y  r e q uire me dical or s ur gical 
i nter ve nti o n t o pre ve nt o ne of t he ot her o utc o mes liste d i n t he a b o ve defi niti o n. 
T hese e ve nts s h o ul d us uall y  be c o nsi dere d seri o us. 
E xa m ples of s uc h e ve nts i ncl u de i n vasi ve or mali g na nt ca ncers, i nte nsi ve treat me nt 
i n a n e mer ge n c y  r o o m or at h o me f or aller gic br o nc h os pas m, bl o o d d y scrasias or 
c o n v ulsi o ns t hat d o n ot res ult i n h os pi[INVESTIGATOR_1314] o n , or de vel o p me nt of dr u g de pe n de nc y 
or dr u g a b use. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 9 9 1 0. 3. 3. Rec or di n g / Re p orti n g a n d F oll o w - U p of A Es a n d/ or S A E sD uri n g t he Acti ve 
C olle cti o n Peri o d 
A E a n d S A E Rec or di n g / Re p orti n g 
T he ta ble bel o w s u m marizes t he re q uire me nts f or rec or di n g A Es o n t he C R F a n d f or 
re p orti n g S A E so n t he Vacci ne S A E Re p ort F or m t o [COMPANY_007] Safet y t hr o u g h o ut t he acti ve 
c ollecti o n peri o d . T hese re q uire me nts are deli neate d f or 3 t y pes of e ve nts: ( 1) S A Es; 
( 2) n o nseri o us A Es ; a n d ( 3) e x p os ure t o t he st u d y  i nter ve nti o n u n der st u d y d uri n g 
pre g na nc y  or breastfee di n g, a n d occ u pati o nal e x p os ure. 
It s h o ul d be n ote d t hat t he Vacci ne S A E Re p ort F or m f or re p orti n g of S A E i n f or mati o n is 
n ot t he sa me as t he A E pa ge of t he C R F. W he n t he sa me data are c ollecte d, t he f or ms m ust 
be c o m plete d i n a c o nsiste nt ma n ner. A Es s h o ul d be rec or de d usi n g c o ncise me dical 
ter mi n ol o g y  a n d t he sa me A E ter m s h o ul d be use d o n b ot h t he C R F a n d t h e Vacci ne S A E 
Re p ort F or m f or re p orti n g of S A E i nf or mati o n. 
S afet y E ve nt Rec or de d o n t he C R F Re p orte d o n t he V acci ne 
S A E Re p ort F or m t o 
[COMPANY_007] S afet y Wit hi n 
[ADDRESS_370971] u d y 
d uri n g pre g na nc y  or 
breastfee di n g All A E s or S A Es ass ociate d 
wit h E D P or ED B 
N ote: I nsta nces of E D P or 
E D B n ot ass ociate d wit h a n 
A E or S A E are n ot ca pt ure d 
i n t he C R F All i nsta nces of E D P are 
re p orte d ( w het her or n ot 
t here is a n ass ociate d S A E) * 
All i nsta nces of E D B are 
re p orte d ( w het her or n ot 
t here is a n ass ociate d 
S A E) * * 
E n vir o n me ntal or 
occ u pati o nal e x p os ure t o 
t he pr o d uct u n der st u d y t o 
a n o n partici pa nt ( n ot 
i n v ol vi n g E D P or E D B) N o ne. E x p os ure t o a st u d y  
n o n partici pa nt is n ot 
c ollecte d o n t he C R F T he e x p os ure ( w het her or 
n ot t here is a n ass ociate d 
A E or S A E) m ust be 
re p orte d * * * 
*E D P ( w it h or wit h o ut a n ass ociate d A E or S A E): a n y pre g na nc y i nf or mati o n is re p orte d t o [COMPANY_007] 
Safet y usi n g t he Vacci ne S A E Re p ort F or m a n d E D P S u p ple me ntal F or m; if t he E D P is ass ociate d 
wit h a n S A E, t he n t he S A E is re p orte d t o [COMPANY_007] Safet y usi n g t he Vacci ne S A E Re p ort F or m .
* * E D B is re p orte d t o [COMPANY_007] Safet y usi n g t he Vacci ne S A E Re p ort F or m ,w hic h w o ul d als o i ncl u de 
details of a n y S A E t hat mi g ht be ass ociate d w it h t he E D B. 
* * * E n vir o n me nt al or occ u p ati o n al e x p os ure: A E s or S A Es ass ociate d wit h occ u pati o nal e x p os ure are 
re p orte d t o [COMPANY_007] Safet y usi n g t he Vacci ne S A E Re p ort F or m .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 0 0 W he n a n A E or S A E occ urs, it is t he res p o nsi bilit y  of t he i n vesti gat or t o re vie w all 
d oc u me ntati o n (e g, h os pi[INVESTIGATOR_75512] o gress n otes, la b orat or y  re p orts, a n d dia g n ostic 
re p orts) relate d t o t he e ve nt. 
T he i n vesti gat or will t he n rec or d all rele va nt A E or S A E i nf or mati o n i n t he C R F. 
It is n ot acce pta ble f or t he i n ves ti gat or t o se n d p h ot oc o pi[INVESTIGATOR_1309] t he partici pa nt’s 
me dical rec or ds t o [COMPANY_007] Safet y  i n lie u of c o m pleti o n of t he Vacci ne S A E Re p ort 
F or m / A E or S A E C R F pa ge. 
T here ma y  be i nsta nces w he n c o pi[INVESTIGATOR_75513] f or certai n cases are 
re q ueste d b y [COMPANY_007] Safet y.I n t his case, all partici pa nt i de ntifiers, wit h t he 
e xce pti o n of t he partici pa nt n u m ber, will be re dacte d o n t he c o pi[INVESTIGATOR_1309] t he me dical 
rec or ds bef ore s u b missi o n t o [COMPANY_007] Safet y .
T he i n vesti gat or will atte m pt t o esta blis h a dia g n osis of t he e ve nt base d o n si g ns, 
s y m pt o ms, a n d/ or ot her cli nical i nf or mati o n. W he ne ver p ossi ble, t he dia g n osis 
( n ot t he i n di vi d ual si g ns/s y m pt o ms) will be d oc u me nte d as t he A E or S A E. 
Assess me nt of I nte nsit y 
T he i n vesti gat or will ma ke a n assess me nt of i nte nsit y f or eac h A E a n d S A E re p orte d d uri n g 
t he st u d y  a n d assi g n it t o 1 of t he f oll o wi n g cate g ories: 
G R A D E If re q uire d o n t he A E pa ge of t he C R F, t he i n vesti gat or will use t he a djecti ves 
MI L D, M O D E R A T E, S E V E R E, or LI F E -T H R E A T E NI N G t o descri be t he 
ma xi m u m i nte nsit y  of t he A E.   F or p ur p oses of c o nsiste nc y , t hese i nte nsit y  
gra des are defi ne d as f oll o ws: 
1 MI L D D oes n ot i nterfere wit h partici pa nt ’s us ual 
f u ncti o n. 
2 M O D E R A T E I nterferes t o s o me e xte nt wit h partici pa nt ’s us ual 
f u ncti o n. 
3 S E V E R E I nterferes si g nifica ntl y wit h partici pa nt ’s us ual 
f u ncti o n. 
4 LI F E -T H R E A T E NI N G Life -t hreate ni n g c o nse q ue nces; ur ge nt 
i nter ve nti o n i n dicate d. 
A n e ve nt is defi ne d as “seri o us” w he n it meets at least 1 of t he pre defi ne d o utc o mes as 
descri be d i n t he defi niti o n of a n S A E, N O T w he n it is rate d as se vere. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 0 1 Assess me nt of C a us alit y 
T he i n vesti gat or is o bli gate d t o assess t he relati o ns hi p bet wee n st u d y i nter ve nti o n 
a n d eac h occ urre nce of eac h A E or S A E. T he i n vesti gat or will use cli nical 
j u d g me nt t o deter mi ne t he relati o ns hi p. 
A “reas o na ble p ossi bilit y” of a relati o ns hi p c o n ve ys t hat t here are facts, e vi de nce, 
a n d/ or ar g u me nts t o s u g gest a ca usal relati o ns hi p, rat her t ha n a relati o ns hi p ca n n ot 
be r ule d o ut. 
Alter nati ve ca uses, s uc h as u n derl yi n g disease(s), c o nc o mita nt t hera p y, a n d ot her 
ris k fact ors, as well as t he te m p oral relati o ns hi p of t he e ve nt t o st u d y  i nter ve nti o n 
a d mi nistrati o n ,will be c o nsi dere d a n d i n vesti gate d. 
T he i n vesti gat or will als o c o ns ult t he I B a n d/ or pr o d uct inf or mati o n, f or mar kete d 
pr o d ucts, i n t heir assess me nt. 
F or eac h A E or S A E, t he i n vesti gat or m ust d oc u me nt i n t he me dical n otes t hat t he y  
ha ve re vie we d t he A E or S A E a n d ha ve pr o vi de d a n assess me nt of ca usalit y. 
T here ma y  be sit uati o ns i n w hic h a n S A E has occ urre d a n d t he i n vesti gat or has 
mi ni mal i nf or mati o n t o i ncl u de i n t he i nitial re p ort t o t he s p o ns or. H o we ver, it is 
ver y i m p ort a nt t h at t he i n vesti g at or al w a ys m a ke a n assess me nt of c a us alit y f or 
e ver y e ve nt b ef ore t he i niti al tr a ns missi o n of t he S A E d at a t o t he s p o ns or .
T he i n vesti gat or ma y  c ha n ge t heir o pi [INVESTIGATOR_9384] o n of ca usalit y  i n li g ht of f oll o w -u p 
i nf or mati o n a n d se n d a nS A E f oll o w -u p re p ort wit h t he u p date d ca usalit y  
assess me nt. 
T he ca usalit y  assess me nt is o ne of t he criteria use d w he n deter mi ni n g re g ulat or y  
re p orti n g re q uire me nts. 
If t he i n vesti gat or d oes n ot k n o w w het her or n ot t he st u d y  i nter ve nti o n ca use d t he 
e ve nt, t he n t he e ve nt will be ha n dle d as “relate d t o st u d y  i nter ve nti o n ” f or re p orti n g 
p ur p oses, as defi ne d b y  t he s p o ns or .I n a d diti o n, if t he i n vesti gat or deter mi nes t hat 
a n S A E is ass ociate d wit h st u d y  pr oce d ures, t he i n vesti gat or m ust rec or d t his ca usal 
relati o ns hi p i n t he s o urce d oc u me nts a n d C R F, a n d re p ort s uc h a n assess me nt i n t he 
de dicate d sect i o n of t he Vacci ne S A E Re p ort F or m a n d i n acc or da nce wit h t he S A E 
re p orti n g re q uire me nts. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 0 2 F oll o w - U p of A Es a n d S A Es 
T he i n vesti gat or is o bli gate d t o perf or m or arra n ge f or t he c o n d uct of s u p ple me ntal 
meas ure me nts a n d/ or e val uati o ns, as me dicall y  i n dicate d or as re q ueste d b y  t he 
s p o ns or ,t o el uci date t he nat ure a n d/ or ca usalit y of t he A E or S A E as f ull y as 
p ossi ble. T his ma y  i ncl u de a d diti o nal la b orat or y  tests or i n vesti gati o ns, 
hist o pat h ol o gical e xa mi nati o ns, or c o ns ultati o n wit h ot her healt hcare pr o vi ders .
If a partici pa nt dies d uri n g partici pati o n i n t he st u d y or d uri n g a rec o g nize d 
f oll o w -u p peri o d, t he i n vesti gat or will pr o vi de [COMPANY_007] Safet y wit h a c o p y of a n y 
p ost m orte m fi n di n gs ,i ncl u di n g hist o pat h ol o g y .
Ne w or u p date d i nf or mat i o n will be rec or de d i n t he ori gi nall y  s u b mitte d d oc u me nts .
T he i n vesti gat or will s u b mit a n y  u p date d S A E data t o t he s p o ns or wit hi n 2 4 h o urs of 
recei pt of t he i nf or mati o n. 
1 0. 3. 4. Re p orti n g of S A Es 
S A E Re p orti n g t o [COMPANY_007] S afet y vi a a n Electr o nic D C T 
T he pri mar y  mec ha nis m f or re p orti n g a n S A E t o [COMPANY_007] Safet y will be t he electr o nic 
D C T .
If t he electr o nic s ys te m is u na vaila ble, t he n t he site will use t he pa per S A E D C T 
(see ne xt secti o n) t o re p ort t he e ve nt wit hi n 2 4 h o urs. 
T he site will e nter t he S A E da ta i nt o t he electr o nic D C T (e g , e S A E or P S S A) or 
pa per f or m (as a p plica ble) as s o o n as t he data bec o me a vaila ble. 
After t he st u d y is c o m plete d at a gi ve n site, t he electr o nic D C T will be ta ke n off -li ne 
t o pre ve nt t he e ntr y  of ne w data or c ha n ges t o e xisti n g data. 
If a site recei ves a re p ort of a ne w S A E fr o m a st u d y  partici pa nt or recei ves u p date d 
data o n a pre vi o usl y  re p orte d S A E after t he electr o nic D C T has bee n ta ke n off- li ne, 
t he n t he site ca n re p ort t his i nf or mati o n o n a pa per S A E f or m (see ne xt secti o n) or t o 
[COMPANY_007] Safet y  b y  tele p h o ne. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 0 3 S A E Re p orti n g t o [COMPANY_007] S afet y vi a t he V acci ne S A E Re p ort F or m 
Facsi mile tra ns missi o n of t he Vacci ne S A E Re p ort F or m is t he preferre d met h o d t o 
tra ns mit t his i nf or mati o n t o [COMPANY_007] Safet y .
I n circ u msta nces w he n t he facsi mile is n ot w or ki n g, a n alter nati ve met h o d s h o ul d be 
use d, e g, sec ure d ( Tra ns p ort La y er Sec urit y) or pass w or d - pr otecte d e mail.  If n o ne 
of t hese met h o ds ca n be use d, n otificati o n b y  tele p h o ne is acce pta ble wit h a c o p y  of 
t he Vacci ne S A E Re p ort F or m se nt b y  o ver ni g ht mail or c o urier ser vice. 
I nitial n otificati o n via tele p h o ne d oes n ot re place t he nee d f or t he i n vesti gat or t o 
c o m plete a n d si g n t he Vacci ne S A E Re p ort F or m pa ges wit hi n t he desi g nate d 
re p orti n g ti me fra mes. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 0 4 1 0. 4. A p pe n di x 4: Ge netics 
Use/ A n al ysis of D N A 
Ge netic variati o n ma y  i m pact a partici pa nt’s res p o nse t o st u d y  i nter ve nti o n a n d 
s usce pti bilit y  t o a n d se verit y  a n d pr o gressi o n of disease. T heref ore, w here l ocal 
re g ulati o ns a n d I R Bs/ E Cs all o w, a bl o o d sa m ple will be c ollecte d f or D N A a n d/ or R N A 
a nal ys is. I nfl ue nza strai n se q ue nci n g of L CI cases a n d S A R S -C o V -2 strai n se q ue nci n g 
of c o nfir me d C O VI D -1 9 cases usi n g ne xt -ge nerati o n se q ue nci n g tec h n ol o g y ma y  als o be 
c o n d ucte d fr o m t he mi dt ur bi nate s wa b sa m ples c ollecte d. 
T he res ults of ge net ic a nal y ses ma y  be re p orte d i n t he C S R or i n a se parate st u d y  
s u m mar y , or ma y  be use d f or i nter nal decisi o n- ma ki n g wit h o ut bei n g i ncl u de d i n a st u d y  
re p ort. 
T he s p o ns or will st ore t he D N A a n d/ or R N A sa m ples i n a sec ure st ora ge s pace wit h 
a de q uate meas ures t o pr otect c o nfi de ntialit y. 
T he sa m ples will be retai ne d as i n dicate d: 
Sa m ples f or s pecifie d ge netic a nal ys is (see Secti o n 8. 6. 1 )wi ll be st ore d f or u p t o 
1 5 ye ars or ot her peri o d as per l ocal re q uire me nts. 
Sa m ples f or ge netic researc h will be la bele d wit h a c o de. T he ke y  bet wee n t he c o de a n d 
t he partici pa nt’s pers o nall y  i de ntif y i n g i nf or mati o n (e g, na me, a d dress) will be hel d 
sec urel y at t he st u d y  site. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 0 5 1 0. 5. A p pe n di x 5: C o ntr ace pti ve a n d B arrier G ui d a nce 
[ADDRESS_370972] u d y  
i nter ve nti o n(s) :
Refrai n fr o m d o nati n g s per m .
P L U S eit her :
Be a bsti ne nt fr o m heter ose x ual i nterc o urse as t heir prefe rre d a n d us ual lifest y le 
(a bsti ne nt o n a l o n g -ter m a n d persiste nt basis) a n d a gree t o re mai n a bsti ne nt. 
O R 
M ust a gree t o use c o ntrace pti o n/ barrier as detaile d bel o w: 
A gree t o use a male c o n d o m a n d s h o ul d als o be a d vise d of t he be nefit f or a 
fe male part ner t o use a hi g hl y effecti ve met h o d of c o ntrace pti o n as a c o n d o m ma y 
brea k or lea k w he n ha vi n g se x ual i nterc o urse wit h a w o ma n of c hil d beari n g 
p ote ntial w h o is n ot c urre ntl y  pre g na nt. 
O R 
Be vasect o mize d, wit h t he a bse nce of s per m ha vi n g bee n c o nfir me d. 
1 0. 5. 2. Fe m ale P artici p a nt Re pr o d ucti ve I ncl usi o n Criteri a 
T he criteria bel o w are part of incl usi o n criteri o n 1 ( A ge a n d Se x; Secti o n 5. 1 ) a n d s pecif y  t he 
re pr o d ucti ve re q uire me n ts f o r i ncl u di n g fe male partici pa nts. Refer t o Secti o n [ADDRESS_370973] 1of t he f oll o wi n g c o n diti o ns a p plies: 
Is n ot a W O C B P (see defi niti o ns bel o w i n Secti o n 1 0. 5. 3 ). 
O R 
Is a W O C B P a n d a grees t o use a n acce pta ble c o ntrace pti ve met h o d d uri n g t he 
i nter ve nti o n peri o d (f or a mi ni m u m of [ADDRESS_370974] u d y 
i nter ve nti o n).  T he i n vesti gat or s h o ul d e val uate t he effecti ve ness of t he c o ntrace pti ve 
met h o d i n relati o ns hi p t o t he first d ose of st u d y i nter ve nti o n. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370975] me n o pa usal 
u nless per ma ne ntl y sterile (see bel o w). 
If fertilit y  is u nclear (e g, a me n orr hea i n a d olesce nts or at hletes) a n d a me nstr ual c y cle ca n n ot 
be c o nfir me d bef ore t he first d ose of st u d y  i nter ve nti o n, a d diti o nal e val uati o n s h o u l d be 
c o nsi dere d. 
Wo me n i n t he f oll o wi n g cate g ories are n ot c o nsi dere d W O C B P: 
1. Pre me n o pa usal fe male wit h 1 of t he f oll o wi n g: 
D oc u me nte d h ys terect o m y ;
D oc u me nte d bilateral sal pi n gect o m y ;
D oc u me nte d bilateral o o p h orect o m y. 
F or i n di vi d uals wit h per ma ne nt i nfer tilit y  d ue t o a me dical ca use ot her t ha n t he a b o ve 
(e g, m ulleria n a ge nesis, a n dr o ge n i nse nsiti vit y ), i n vesti gat or discreti o n s h o ul d be a p plie d t o 
deter mi ni n g st u d y e ntr y. 
N ote: D oc u me ntati o n f or a n y of t he a b o ve cate g ories ca n c o me fr o m t he site pers o n nel ’s 
re vie w of t he partici pa nt ’s me dical rec or ds, me dical e xa mi nati o n, or me dical hist or y  
i nter vie w . T he met h o d of d oc u me ntati o n s h o ul d be rec or de d i n t he partici pa nt’ s me dical 
rec or d f or t he st u d y. 
2. P ost me n o pa usal fe male :
A p ost me n o pa usal state is defi ne d as n o me nses f or 1 2 m o nt hs wit h o ut a n alter nati ve 
me dical ca use. I n a d diti o n: 
A hi g h F S H le vel i n t he p ost me n o pa usal ra n ge m ust be use d t o c o nfir m a 
p ost me n o pa usal state i n w o me n u n der 6 0 ye ars of a ge a n d n ot usi n g h or m o nal 
c o ntrace pti o n or H R T. 
A f e male o n H R T a n d w h ose me n o pa usal stat us is i n d o u bt will be re q uire d t o use 
o ne of t he hi g hl y  effecti ve n o nestr o ge n h or m o nal c o ntrace pti o n met h o ds if s he 
wis h es t o c o nti n ue her H R T d uri n g t he st u d y . Ot her wise, s he m ust disc o nti n ue 
H R T t o all o w c o nfir mati o n of p ost me n o pa usal stat us bef ore st u d y e nr oll me nt. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 0 7 1 0. 5. 4. C o ntr ace pti o n Met h o ds 
C o ntrace pti ve use b y me n or w o me n s h o ul d be c o nsiste nt wit h l ocal a vaila bilit y /re g ulati o ns 
re gar di n g t he use of c o ntrace pti ve met h o ds f or t h ose partici pati n g i n cli nical trials. 
T he f oll o wi n g c o ntrace pti ve met h o ds are a p pr o priate f or t his st u d y :
Hi g hl y Effecti ve Met h o ds That Ha ve L o w User De pe n de nc y 
1. I m pla nta ble pr o gest o ge n -o nl y  h or m o ne c o ntrace pti o n ass ociate d wit h i n hi biti o n of 
o v ulati o n. 
2. I ntra uteri ne de vice. 
3. I ntra uteri ne h or m o ne -re leasi n g s ys te m. 
4. Bilateral t u bal occl usi o n. 
5. Vasect o mize d part ner: 
Vasect o mize d part ner is a hi g hl y effecti ve c o ntrace pti ve met h o d pr o vi de d t hat t he 
part ner is t he s ole se x ual part ner of t he W O C B P a n d t he a bse nce of s per m has bee n 
c o nfir me d. If n ot, a n a d diti o nal hi g hl y  effecti ve met h o d of c o ntrace pti o n s h o ul d be 
use d. T he s per mat o ge nesis c y cle is a p pr o xi matel y  9 0 da y s. 
Hi g hl y Effecti ve Met h o ds That Are User De pe n de nt 
6. C o m bi ne d (estr o ge n -a n d pr o gest o ge n -c o ntai ni n g) h or m o nal c o ntrace pti o n ass o ciate d 
wit h i n hi biti o n of o v ulati o n: 
Oral; 
I ntra va gi nal; 
Tra ns der mal. 
7. Pr o gest o ge n - o nl y h or m o ne c o ntrace pti o n ass ociate d wit h i n hi biti o n of o v ulati o n: 
Oral; 
I njecta ble. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370976] o ge n - o nl y oral h or m o nal c o ntrace pti o n w here i n hi biti o n of o v ulati o n is n ot t he 
pri mar y  m o de of acti o n. 
1 0. Male or fe male c o n d o m, wit h or wit h o ut s per mici de. 
1 1. Cer vical ca p, dia p hra g m ,or s p o n ge wit h s per mic i de. 
1 2. A c o m bi nati o n of male c o n d o m wit h eit her cer vical ca p, dia p hra g m, or s p o n ge wit h 
s per mici de ( d o u ble -barrier met h o ds). 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 0 9 1 0. 6. A p pe n di x 6: Li ver S afet y: S u g geste d Acti o ns a n d F oll o w -Up Assess me nts 
P ote nti al C ases of Dr u g -I n d uce d Li ver I nj ur y 
H u ma ns e x p ose d t o a dr u g w h o s h o w n o si g n of li ver i nj ur y  (as deter mi ne d b y  ele vati o ns i n 
tra nsa mi nases) are ter me d “ t olerat ors, ” w hile t h ose w h o s h o w tra nsie nt li ver i nj ur y  b ut a da pt 
are ter me d “a da pt ors. ” I n s o me partici pa nt s, tra nsa mi nase ele vati o ns are a har bi n ger of a 
m ore seri o us p ote ntial o utc o me. T hese partici pa nt s fail t o a da pt a n d t heref ore are 
“s usce pti ble” t o pr o gressi ve a n d seri o us li ver i nj ur y , c o m m o nl y  referre d t o as DI LI. 
Partici pa nt s w h o e x perie nce a tra nsa mi nase ele vati o n a b o ve 3 × U L N s h o ul d be m o nit ore d 
m ore fre q ue ntl y  t o deter mi ne if t he y  are “a da pt or s” or are “s usce pti ble. ”
L F T s are n ot re q uire d as a r o uti ne safet y  m o nit ori n g pr oce d ure i n t his st u d y . H o we ver , 
s h o ul d a n i n vesti gat or dee m it necessar y  t o a ssess L F T s beca use a partici pa nt prese nts wit h 
cli nical si g ns/s y m pt o ms, s uc h L F T  res ults s h o ul d be ma na ge d a n d f oll o we d as descri be d 
bel o w .
I n t he maj orit y  of DI LI cases, ele vati o ns i n A S T a n d/ or A L T prece de T b ili ele vati o ns 
( > 2 × U L N) b y se veral da ys or wee ks. T he i ncrease i n T b ili t y pi[INVESTIGATOR_1306] y occ urs w hile 
A S T/ A L T is/are still ele vate d a b o ve 3 × U L N (ie, A S T/ A L T a n d T bili val ues will be ele vate d 
wit hi n t he sa me la b orat or y sa m ple). I n rare i nsta nces, b y t he ti me T bili ele vati o ns are 
detecte d, A S T/ A L T val ues mi g ht ha ve decrease d. T his occ urre nce is still re gar de d as a 
p ote ntial DI LI. T heref ore, a b n or mal ele vati o ns i n eit her A S T  O R A L T i n a d diti o n t o Tbili 
t hat meet t he criteria o utli ne d bel o w are c o nsi dere d p ote ntial DI LI (assesse d per H y ’s la w 
criter ia) cases a n d s h o ul d al wa y s be c o nsi dere d i m p orta nt me dical e ve nts, e ve n bef ore all 
ot her p ossi ble ca uses of li ver i nj ur y  ha ve bee n e xcl u de d. 
T he t hres h ol d of la b orat or y  a b n or malities f or a p ote ntial DI LI case de pe n ds o n t he 
partici pa nt ’s i n di vi d ual baseli ne val ues a n d u n derl y i n g  c o n diti o ns. Partici pa nt s w h o prese nt 
wit h t he f oll o wi n g la b orat or y  a b n or malities s h o ul d be e val uate d f urt her as p ote ntial DI LI 
( H y’ s la w) cases t o defi niti vel y  deter mi ne t he eti ol o g y  of t he a b n or mal la b orat or y  val ues: 
Partici pa nt swit h A S T/ A L T a n d T bili baseli ne val ues wit hi n t he n or mal ra n ge w h o 
s u bse q ue ntl y  prese nt wit h A S T O R A L T val ues ≥3 × U L N A N D a T bili val ue 
≥2 × U L N wit h n o e vi de nce of he m ol ys is a n d a n al kali ne p h os p hatase val ue 
< 2 ×U L N or n ot a vaila ble. 
F or partici pa nt s wit h baseli ne A S T O R A L T O R T b ili val ues a b o ve t he U L N, t he 
f oll o wi n g t hres h ol d val ues are use d i n t he defi niti o n me nti o ne d a b o ve, as nee de d, 
de pe n di n g o n w hic h val ues are a b o ve t he U L N at baseli ne: 
Pree xisti n g A S T or A L T baseli ne val ues a b o ve t he n or ma l ra n ge: A S T or A L T 
val ues ≥ 2 ti mes t he baseli ne val ues A N D ≥ 3 ×U L N; or ≥ 8 ×U L N ( w hic he ver is 
s maller). 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 1 0 Pree xisti n g val ues of T bili a b o ve t he n or mal ra n ge: T bili le vel i ncrease d fr o m 
baseli ne val ue b y a n a m o u nt of ≥1 × U L N or if t he val ue reac hes ≥ 3 × U L N 
( w hic he ver is s maller). 
Rises i n A S T/ A L T a n d T bili se parate d b y m ore t ha n a fe w wee ks s h o ul d be assesse d 
i n di vi d uall y  base d o n cli nical j u d g me nt; a n y  case w here u ncertai nt y  re mai ns as t o w het her it 
re prese nts a p ote ntial H y ’s la w case s h o ul d be re vie w e d wit h t he s p o ns or .
T he partici pa nt s h o ul d ret ur n t o t he i n vesti gat or site a n d be e val uate d as s o o n as p ossi ble, 
prefera bl y wit hi n [ADDRESS_370977] or y , a n d p h ysical assess me nt. 
I n a d diti o n t o re peati n g meas ure me nts of A S T  a n d A L T a n d T bili f or s us pecte d H y ’s la w 
cases , a d diti o nal la b orat or y  tests s h o ul d i ncl u de al b u mi n, C K, direct a n d i n direct bilir u bi n, 
G G T , P T/I N R, t otal bile aci ds, a n d al kali ne p h os p hatase. C o nsi derati o n s h o ul d als o be gi ve n 
t o dra wi n g a se parate t u be of cl otte d bl o o d a n d a n a ntic oa g ulate d t u be of bl o o d f or f urt her 
testi n g, as nee de d, f or f urt her c o nte m p ora ne o us a nal y ses at t he ti me of t he rec o g nize d i nitial 
a b n or malities t o deter mi ne eti ol o g y . A detaile d hist or y , i ncl u di n g rele va nt i nf or mati o n, s uc h 
as re vie w of et ha n ol, aceta mi n o p he n / paraceta m ol (eit her b y  itself or as a c of or m ulate d 
pr o d uct i n prescri pti o n or o ver -t he -c o u nter me dicati o ns), recreati o nal dr u g, or s u p ple me nt 
( her bal) use a n d c o ns u m pti o n, fa mil y  hist or y , se x ual hist or y , tra vel hist or y , hist or y  of c o ntact 
wit h a ja u n dice d pers o n, s ur ger y , bl o o d tra nsf usi o n, hist or y  of li ver or aller gic disease, a n d 
p ote ntial occ u pati o nal e x p os ure t o c he micals, s h o ul d be c ollecte d. F urt her test i n g f or ac ute 
he patitis A, B, C, D, a n d E i nfecti o n ,li ver i ma gi n g (e g, biliar y  tract) ,a n d c ollecti o n of ser u m 
sa m ple s f or aceta mi n o p he n / paraceta m ol dr u g a n d/ or pr otei n a d d uct le vels ma y  be warra nte d. 
All cases de m o nstrate d o n re peat testi n g as meeti n g t h e la b orat or y  criteria of A S T/ A L T a n d 
T b ili ele vati o n defi ne d a b o ve s h o ul d be c o nsi dere d p ote ntial DI LI ( H y ’s la w) cases if n o 
ot her reas o n f or t he L F T  a b n or malities has y et bee n f o u n d. S uc h p ote nti al DI LI ( H y’s l a w) 
c ases are t o be re p orte d as S A Es, irre s pecti ve of a v ail a bilit y of all t he res ults of t he 
i n vesti g ati o ns perf or me d t o deter mi ne eti ol o g y of t he L F T a b n or m alities. 
A p ote ntial DI LI ( H y ’s la w) case bec o mes a c o nfir me d case o nl y after all res ults of 
reas o na ble i n vesti gati o ns ha ve bee n recei ve d a n d ha ve e xcl u de d a n alter nati ve eti ol o g y. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 1 1 1 0. 7. A p pe n di x 7: Ki d ne y S afet y M o nit ori n g G ui deli nes 
[ADDRESS_370978] baseli ne s er u m 
creati ni ne (Scr meas ure me nt t o e G F R [ Scr- base d e G F R ]or [e Cr Cl ]). Baseli ne a n d 
p ost baseli ne Sc y s ma kes it feasi ble t o disti n g uis h A KI fr o m ot her ca uses of Scr i ncrease. If 
Scr i ncrease is c o nfir me d after baseli ne, t he n refle x meas ure me nt of Sc y s is i n dicate d t o 
esti mate t he c o m bi ne d Scr -S c y s e G F R calc ulati o n (f or a d ults o nl y). 
Re gar dless of w het her ki d ne y  f u ncti o n m o nit ori n g tests are re q uire d as a r o uti ne safet y 
m o nit ori n g pr oce d ure i n t he st u d y , if t he i n vesti gat or or s p o ns or dee ms it necessar y  t o f urt her 
assess ki d ne y  safet y  a n d q ua ntif y  ki d ne y  f u ncti o n, t he n t hese test res ults s h o ul d be ma na ge d 
a n d f oll o we d per sta n dar d of care. 
1 0. 7. 2. A ge -S pecific Ki d ne y F u ncti o n C alc ul ati o n Rec o m me n d ati o ns 
1 0. 7. 2. 1. A d ults ( 1 8 Ye ars a n d A b o ve) – 2 0 2 1 C K D- E P I E q u ati o ns 
2 0 2 1 C K D - E PI 
[INVESTIGATOR_303618] y Scr 
( m g/ d L) Sc ys 
( m g/ L) Rec o m me n de d e G F R E q u ati o n 
Fe male if ≤ 0. 7 N/ A e G F R = 1 4 3 × ( Scr/ 0. 7) -0. 2 4 1  ×  ( 0. 9 9 3 8) A ge 
Fe male if > 0. 7 N/ A e G F R = 1 4 3 × ( Scr/ 0. 7) -1. 2 0 0  ×  ( 0. 9 9 3 8) A ge 
Male if ≤ 0. 9 N/ A e G F R = 1 4 2 × ( Scr/ 0. 9) -0. 3 0 2  × ( 0. 9 9 3 8) A ge 
Male if > 0. 9 N/ A e G F R = 1 4 2 × ( Scr/ 0. 9) -1. 2 0 0  ×  ( 0. 9 9 3 8) A ge 
2 0 2 1 C K D -E PI 
[INVESTIGATOR_185572]- Sc ys 
Co m bi ne d Scr 
( m g/ d L) Sc ys 
( m g/ L) Rec o m me n de d e G F R E q u ati o n 
Fe male if ≤ 0. 7 if ≤ 0. 8 e G F R = 1 3 0 × ( Scr/ 0. 7) -0. 2 1 9  × ( Sc ys/ 0. 8) - 0. 3 2 3  × ( 0. 9 9 6 1) A ge 
Fe male if ≤ 0. 7 if > 0. 8 e G F R = 1 3 0 × ( Scr/ 0. 7) -0. 2 1 9  × ( Sc ys/ 0. 8) - 0. 7 7 8  × ( 0. 9 9 6 1) A ge 
Fe male if > 0. 7 if ≤ 0. 8 e G F R = 1 3 0 × ( Scr/ 0. 7) -0. 5 4 4  × ( Sc ys/ 0. 8) - 0. 3 2 3  × ( 0. 9 9 6 1) A ge 
Fe male if > 0. 7 if > 0. 8 e G F R = 1 3 0 × ( Scr/ 0. 7) -0. 5 4 4  × ( Sc ys/ 0. 8) - 0. 7 7 8  × ( 0. 9 9 6 1) A ge 
Male if ≤ 0. 9 if ≤ 0. 8 e G F R = 1 3 5 × ( Scr/ 0. 9) -0. 1 4 4  × ( Sc ys/ 0. 8) - 0. 3 2 3  × ( 0. 9 9 6 1) A ge 
Male if ≤ 0. 9 if > 0. 8 e G F R = 1 3 5 × ( Scr/ 0. 9) -0. 1 4 4  × ( Sc ys/ 0. 8) - 0. 7 7 8  × ( 0. 9 9 6 1) A ge 
Male if > 0. 9 if ≤ 0. 8 e G F R = 1 3 5 × ( Scr/ 0. 9) -0. 5 4 4  × ( Sc ys/ 0. 8) - 0. 3 2 3  × ( 0. 9 9 6 1) A ge 
Male if > 0. 9 if > 0. 8 e G F R = 1 3 5 × ( Scr/ 0. 9) -0. 5 4 4  × ( Sc ys/ 0. 8) - 0. 7 7 8  × ( 0. 9 9 6 1) A ge 
I n ker L A et al. N E n gl J Me d. 2 0 2 1; 3 8 5: 1 7 3 7 -4 9. 
1 0. 7. 3. A d verse E ve nt Gr a di n g f or Ki d ne y S afet y L a b or at or y A b n or m alities 
A E gra di n g f or decli ne i n ki d ne y  f u ncti o n (ie, e G F R or e Cr Cl) will be acc or di n g t o 
C T C A E/ K DI G O criteria. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 1 2 1 0. 8. A p pe n di x 8: Criteri a f or All o wi n g I ncl usi o n of P artici p a nts Wit h C hr o nic St a ble 
HI V, H C V, or H B V I nfecti o n 
P ote ntial partici pa nts wit h c hr o nic sta ble H I V, H C V, or H B V i nfecti o n ma y  be c o nsi dere d 
f or i ncl usi o n if t he y  f ulfill t he f oll o wi n g res pecti ve criteria. 
K n o w n HI V i nfecti o n 
C o nfir me d sta ble HI V disease defi ne d as d oc u me nte d viral l oa d < 5 0 c o pi[INVESTIGATOR_014]/ m L  a n d C D 4 
c o u nt > 2 0 0 cells/ m m 3wit hi n [ADDRESS_370979] 6 m o nt hs. 
K n o w n H C V i nfecti o n 
Hist or y of c hr o nic H C V wit h e vi de nce of s ustai ne d vir ol o gical res p o nse ( defi ne d as 
u n detecta ble H C V R N A) f or ≥ 1 2 wee ks f oll o wi n g H C V treat me nt or wit h o ut e vi de nce of 
H C V R N A vire mia ( u n detecta ble H C V viral l oa d). 
K n o w n H B V i nfecti o n 
C o nfir me d i nacti ve c hr o nic H B V i nfecti o n, defi ne d as H b s A g prese nt f or ≥ 6 m o nt hs a n d 
t he f oll o wi n g: 
Hbe A g ne gati ve, a nti -H b e p ositi ve 
Ser u m H B V D N A < 2 0 0 0 I U/ m L 
Persiste ntl y  n or mal A L T a n d/ or A S T le vels 
I n t h ose w h o ha ve ha d a li ver bi o ps y  perf or me d, fi n di n gs t hat c o nfir m t he a bse nce of 
si g nifica nt necr oi nfla m mati o n 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 1 3 1 0. 9. A p pe n di x 9: E C G Fi n di n gs of P ote nti al Cli nic al C o ncer n 
E C G Fi n di n gs Th at M a y Q u alif y as A Es 
Mar ke d si n us bra d yc ar dia (rate < 4 0 b p m) lasti n g mi n utes .
Ne w P R i nter val pr ol o n gati o n > 2 8 0 ms. 
Ne w pr ol o n gati o n of Q Tc F t o > 4 8 0 ms (a bs ol ute) or b y  ≥ 6 0 ms fr o m baseli ne .
Ne w -onset atrial fl utter or fi brillati o n, wit h c o ntr olle d ve ntric ular res p o nse rate: 
ie, rate < 1 2 0 b p m .
Ne w -onset ty pe I sec o n d - d e gree ( We nc ke bac h) A V bl oc k of > 3 0 sec o n ds ’d urati o n .
Fre q ue nt P V Cs, tri plets, or s h ort i nter vals ( < 3 0 sec o n ds) of c o nsec uti ve ve ntric ular 
c o m ple xes .
E C G Fi n di n gs Th at M a y Q u alif y as S A Es 
Q Tc F pr ol o n gati o n > 5 0 0 ms .
Ne w S T -T c ha n ges s u g gesti ve of m y ocar dial isc he mia .
Ne w - o nset L B B B ( Q R S c o m ple x > 1 2 0 ms) .
Ne w -onset ri g ht bu n dle bra nc h bl oc k ( Q R S c o m ple x > 1 2 0 ms) .
S y m pt o matic bra d yc ar dia .
As y st ole: 
I n a wa ke, s y m pt o m -free partici pa nts i n si n us r h y t h m, wit h d oc u me nte d peri o ds 
of as ys t ole ≥3. 0 sec o n ds or a n y esca pe rate < 4 0 b p m, or wit h a n esca pe r h yt h m 
t hat is bel o w t he A V n o de ; 
I n a wa ke, s y m pt o m -free partici pa nts wit h atrial fi brillati o n a n d bra d yc ar dia wit h 
[ADDRESS_370980] 5 sec o n ds or l o n ger ; 
Atrial fl utter or fi brillati o n, wit h ra pi d ve ntric ular res p o nse rate: ra pi d = rate 
> 1 2 0 b p m. 
S ustai ne d su pra ve ntric ular tac h yc ar dia (rate > 1 2 0 b p m) ( “s ustai ne d ”= s h ort 
d urati o n wit h rele va nt s y m pt o ms or lasti n g > 1 mi n ute) .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 1 4 Ve ntric ular r h y t h ms > 3 0 sec o n ds ’ d urati o n, i ncl u di n g i di o ve nt ric ular r h yt h m 
(H R < 4 0 b p m), accelerate d i di o ve ntric ular r h yt h m ( H R 4 0 b p m t o < 1 0 0 b p m), a n d 
m o n o m or p hic/ p ol y m or p hic ve ntric ular tac h ycar dia ( H R > 1 0 0 b p m [s uc h as torsa des 
de p oi ntes ]). 
T y pe II sec o n d - d e gree ( M o bitz II) A V bl oc k .
C o m plete (t hir d -de gree) heart bl oc k .
E C G Fi n di n gs Th at Qu alif y as S A Es 
C ha n ge i n patter n s u g gesti ve of ne w m y ocar dial i nfarcti o n .
S ustai ne d ve ntric ular ta c h y arr h y t h mias ( > 3 0 sec o n ds ’d urati o n) .
Sec o n d -or t hir d - de gree A V bl oc k re q uiri n g pace ma ker place me nt. 
As y st olic pa uses re q uiri n g pace ma ker place me nt .
Atrial fl utter or fi brillati o n wit h ra pi d ve ntric ular res p o nse re q uiri n g car di o versi o n .
Ve ntric ular fi brillati o n/ fl utter .
At t he discreti o n of t he i n vesti gat or, a n y arr h yt h mia classifie d as a n a d verse 
e x perie nce .
The e n u merate d list of maj or e ve nts of p ote ntial cli nical c o ncer n are rec o m me n de d as “alerts ”or 
n otificati o ns fr o m t he c ore E C G la b orat or y t o t he i n vesti gat or a n d [COMPANY_007] st u d y tea m ,a n d n ot t o be 
c o nsi dere d as all -i ncl usi ve of w hat t o be re p orte d as A Es / S A Es. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 1 5 1 0. 1 0. A p pe n di x 1 0 : A Es, A D Es, S A Es, S A D Es, U S A D Es, a n d De vice Deficie ncies: 
Defi niti o ns a n d Pr oce d ures f or Rec or di n g, E v al u ati n g, F oll o w -U p, a n d Re p orti n g i n 
Me dic al De vice St u dies 
Defi niti o ns of a Me dic al De vice Deficie nc y 
T he defi niti o ns a n d pr oce d ures detaile d i n t his a p pe n di x are i n acc or da nce wit h I S O 1 4 1 5 5 
a n d t he E ur o pea n M D R 2 0 1 7/ 7 4 5 f or cli nical de vice researc h (if a p plica ble). 
B ot h t he i n vesti gat or a n d t he s p o ns or will c o m pl y  wit h all l ocal re p orti n g re q uire me nts f o r 
me dical de vices. 
T he detecti o n a n d d oc u me ntati o n pr oce d ures descri be d i n t his pr ot oc ol a p pl y  t o all s p o ns or 
me dical de vices pr o vi de d f or use i n t he st u d y (see Secti o n 6. 1. [ADDRESS_370981] of s p o ns or 
me dical de vices). 
1 0. 1 0. 1. Defi niti o n of A E a n d A D E 
A E a n d A D E Defi niti o n 
A n A E is defi ne d i n A p pe n di x 3 ( Secti o n 1 0. 3. 1 ). 
A n A D E is defi ne d as a n A E relate d t o t he use of a n i n vesti gati o nal me dical de vice. 
T his defi niti o n i ncl u des a n y  A Es res ulti n g fr o m i ns ufficie nt or i na de q uate 
i nstr ucti o ns f or use, de pl o y me nt, i m pla ntati o n, i nstallati o n, or o perati o n, or a n y  
malf u ncti o n of t he i n vesti gati o nal me dical de vice as well as a n y e ve nt res ulti n g 
fr o m use err or or fr o m i nte nti o nal mis use of t he i n vesti gati o nal me dical de vice. 
1 0. 1 0. 2. Defi niti o n of S A E, S A D E, a n d U S A D E 
S A E Defi niti o n 
A n S A E is defi ne d i n A p pe n di x 3 ( Secti o n 1 0. 3. 2 ). 
S A D E Defi niti o n 
A n S A D E is defi ne d as a n A D E t hat has res ulte d i n a n y  of t he c o nse q ue nces 
c haracteristic of a n S A E. 
A n y  de vice deficie nc y  t hat mi g ht ha ve le d t o a n S A E if a p pr o priate acti o n ha d n ot 
bee n ta ke n, i nter ve nti o n ha d n ot occ urre d, or circ u msta nces ha d bee n less f ort u nate. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 1 6 U S A D E Defi niti o n 
A U S A D E (als o i de ntifie d as U A D E i n U S Re g ulati o ns 2 1 C F R 8 1 3. 3) is a nS A D E 
t hat b y  its nat ure, i nci de nce, se verit y , or o utc o me has n ot bee n i de ntifie d i n t he 
c urre nt versi o n of t he ris k a nal ys is ma na ge me nt file. 
1 0. 1 0. 3. Defi niti o n of De vice Deficie nc y 
De vice Deficie nc y Defi niti o n 
A de vice deficie nc y  is a n i na de q uac y  of a me dical de vice wit h res pect t o its i de ntit y , 
q ualit y , d ura bilit y, relia bilit y , safet y, or perf or ma nce. De vice deficie ncies i ncl u de 
malf u ncti o ns, use err ors, a n d i na de q uate i nf or mati o n s u p plie d b y  t he ma n ufact urer. 
1 0. 1 0. 4. Rec or di n g/ Re p orti n g a n d F oll o w -U p of Me dic al De vice Deficie ncies 
De vice Deficie nc y Rec or di n g 
W he n a de vice deficie nc y  occ urs, it is t he res p o nsi bilit y  of t he u n bli n de d site staff t o 
re vie w all d oc u me ntati o n (e g, h os pi[INVESTIGATOR_75512] o gress n otes, la b orat or y  re p orts, a n d 
dia g n ostic re p orts) relate d t o t he e ve nt. 
T he u n bli n de d site staff will t he n rec or d all rele va nt de vice deficie nc y  i nf or mati o n 
i n t he partici pa nt’s me dical rec or ds, i n acc or da nce wit h t he i n vesti gat or’s n or mal 
cli nical practice. 
If a n A E (eit her seri o us or n o nseri o us) ass ociate d wit h t he de vice deficie nc y occ urs, 
t he n t he A E m ust be e ntere d i nt o t he A E secti o n of t he C R F. 
T he u n bli n de d site staff will n otif y  t he s p o ns or st u d y  tea m b y  tele p h o ne or e mail 
wit hi n 1 b usi ness da y  of deter mi ni n g t hat t he i nci de nt meets t he pr ot oc ol defi niti o n 
of a me dical de vice deficie nc y .
T he s p o ns or st u d y  tea m will ca pt ure t he re q uire d i nf or mati o n o n t he Me dical De vice 
C o m plai nt f or m al o n g wit h a n y  ass ociate d A E (eit her seri o us o r n o nseri o us) w he n 
a p plica ble a n d se n d t o t he a p pr o priate pr o d uct q ualit y  c o m plai nt gr o u p. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 1 7 If t he u n bli n de d site staff deter mi nes t hat t he me dical de vice deficie nc y  ma y  ha ve 
i nj ure d t he partici pa nt (ie, t he me dical de vice deficie nc y  is ass ociate d wit h a n A E or 
S A E), t he n t he u n bli n de d site staff will atte m pt t o esta blis h a dia g n osis of t he e ve nt 
base d o n si g ns, s y m pt o ms, a n d/ or ot her cli nical i nf or mati o n.  W he ne ver p ossi ble, 
t he dia g n osis will be d oc u me nte d i n t he partici pa nt’s me dical rec or d a n d rec or de d a s 
t he A E or S A E rat her t ha n t he i n di vi d ual si g ns/s y m pt o ms. All rele va nt details 
relate d t o t he r ole of t he de vice i n re gar d t o t he S A E m ust be i ncl u de d i n t he 
Vacci ne S A E Re p ort F or m as o utli ne d i n Secti o ns 8. 4. 1. 1 a n d 8. 4. 1. 2 . 
T here ma y  be i nsta nces w he n c o pi[INVESTIGATOR_75513] f or certai n cases are 
re q ueste d b y [COMPANY_007] Safet y. I n t his case, all partici pa nt i de ntifiers, wit h t he 
e xce pti o n of t he partici pa nt n u m b er, will be re dacte d o n t he c o pi[INVESTIGATOR_1309] t he me dical 
rec or ds bef ore s u b missi o n t o [COMPANY_007] Safet y . Refer t o Secti o n [ADDRESS_370982] be ta ke n w he n me dical rec or ds are se nt t o t he s p o ns or or s p o ns or desi g nee. 
F or de vice deficie ncies, it is ver y  i m p orta nt t hat t he u n bli n de d site staff descri bes 
a n y  c orrecti ve or re me dial acti o ns ta ke n t o pre ve nt rec urre nce of t he i nci de nt. 
A re me dial acti o n is a n y acti o n ot her t ha n r o uti ne mai nte na nce or ser vici n g of a 
me dical de vice w here s uc h acti o n is necessar y  t o pre ve nt rec urre nce of a de vice 
deficie nc y .  T his i ncl u des a n y  a me n d me nt t o t he de vice desi g n t o pre ve nt 
rec urre nce. 
Assess me nt of C a us alit y Occ urri n g i n C o nj u ncti o n Wit h a Me dic al De vice Deficie nc y 
If a n A E or S A E has occ urre d i n c o nj u ncti o n wit h a me dical de vice deficie nc y , t he 
i n vesti gat or m ust assess t he relati o ns hi p bet wee n eac h occ urre nce of t he A E or S A E 
a n d t he me dical de vice deficie nc y . T he i n vesti gat or will use cli nical j u d g me nt t o 
deter mi ne t he relati o ns hi p. 
A “reas o na ble p ossi bilit y” of a relati o ns hi p c o n ve ys t hat t here are facts, e vi de nce, 
a n d/ or ar g u me nts t o s u g gest a ca usal relati o ns hi p, rat her t ha n a relati o ns hi p ca n n ot 
be r ule d o ut. 
Alter nati ve ca uses, s uc h as u n derl yi n g disease(s), c o nc o mita nt t hera p y, a n d ot her 
ris k fact ors, as well as t he te m p oral relati o ns hi p of t he e ve nt t o st u d y  i nter ve nti o n 
a d mi nistrati o n will be c o nsi dere d a n d i n vesti gate d. 
T he i n vesti gat or will als o c o ns ult t he I B a n d/ or pr o d uct i nf or mati o n, f or mar kete d 
pr o d ucts i n t heir assess me nt. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 1 8 F or eac h de vice deficie nc y , t he i n vesti gat or m ust d oc u me nt i n t he me dical n otes 
t hat t he y  ha ve re vie we d t he de vice deficie nc y  a n d ha ve pr o vi de d a n assess me nt of 
ca usalit y .
T here ma y  be sit uati o ns i n w hic h a n S A E has occ urre d a n d t he i n vesti gat or has 
mi ni mal i nf or mati o n t o i ncl u de i n t he i nitial re p ort t o t he s p o ns or. H o we ver, it is 
ver y  i m p orta nt t hat t he i n vesti gat or al wa y s ma ke a n assess me nt of ca usalit y f or 
e ver y  e ve nt bef ore t he i nitial tra ns missi o n of t he S A E data t o t he s p o ns or. 
T he i n vesti gat or ma y  c ha n ge t heir o pi [INVESTIGATOR_9384] o n of ca usalit y  i n li g ht of f oll o w -u p 
i nf or mati o n a n d se n d a n S A E f oll o w- u p re p ort wit h t he u p date d ca usalit y  
assess me nt. 
T he ca u salit y  assess me nt is o ne of t he criteria use d w he n deter mi ni n g re g ulat or y  
re p orti n g re q uire me nts. 
F oll o w - U p of Me dic al De vice Deficie nc y 
F oll o w -u p a p plies t o all partici pa nts, i ncl u di n g t h ose w h o disc o nti n ue st u d y  
i nter ve nti o n. 
T he i n vesti gat or is o bli gate d t o perf or m or arra n ge f or t he c o n d uct of s u p ple me ntal 
meas ure me nts a n d/ or e val uati o ns, as me dicall y  i n dicate d or as re q ueste d b y  t he 
s p o ns or t o el uci date t he nat ure a n d/ or ca usalit y of t he de vice deficie nc y  as f ull y  as 
p ossi ble. T his ma y i ncl u de a d diti o nal la b orat or y  tests or i n vesti gati o ns, 
hist o pat h ol o gical e xa mi nati o ns, or c o ns ultati o n wit h ot her healt hcare pr o vi ders. 
Ne w or u p date d i nf or mati o n re gar di n g t he nat ure of t he de vice deficie nc y  will be 
rec or de d i n t he ori gi nall y c o m plete d Me dical D e vice C o m plai nt f or m b y  t he s p o ns or 
st u d y  tea m .
Ne w or u p date d i nf or mati o n re gar di n g a n y S A E t hat was p ote ntiall y ass ociate d wit h 
t he me dical de vice deficie nc y  will be s u b mitte d t o [COMPANY_007] Safet y  o n t he Vacci ne S A E 
Re p ort F or m wit hi n [ADDRESS_370983] be perf or me d acc or di n g t o t he pr ocesses 
descri be d i n Secti o n 1 0. 3. 4 .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 1 9 1 0. 1 0. 6. Re p orti n g of S A D Es 
S A D E Re p orti n g t o [COMPANY_007] S afet y 
N ote: T here are a d diti o nal re p orti n g o bli gati o ns f or me dical de vice deficie ncies t hat are 
p ote ntiall y  relate d t o S A Es (ie, a n S A D E) t hat m ust f ulfill t he le gal res p o nsi bilit y  t o n otif y  
a p pr o priate re g ulat or y  a ut h orities a n d ot her e ntities a b o ut certai n safet y i nf or mati o n relati n g 
t o me dical de vices bei n g use d i n cli nical st u dies. 
A n y  de vice deficie nc y  t hat is ass ociate d wit h a n S A E m ust be re p orte d t o t he 
s p o ns or wit hi n 2 4 h o urs after t he i n vesti gat or deter mi nes t hat t he e ve nt meets t he 
defi niti o n of a de vice deficie nc y .
T he s p o ns or s hall re vie w all de vice deficie ncies a n d deter mi ne a n d d oc u me nt i n 
writi n g w het her t he y  c o ul d ha ve le d t o a n S A E.  T hese s hall be re p orte d t o t he 
re g ulat or y  a ut h orities a n d I R Bs/ E Cs as re q uire d b y  nati o nal re g ulati o ns. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 2 0 1 0. 1 1. A p pe n di x 1 1 : S u bst u d y A ( P h ase 1) 
1 0. 1 1. 1. S o A –S u bst u d y A ( P h ase 1) 
Visit N u m ber Scree ni n g [ADDRESS_370984] 
Visit Wi n d o w ( D a ys) [ADDRESS_370985] or y data (i ncl u di n g c o nfir me d 
C O VI D -[ADDRESS_370986] res ult 
[N A A T or a nti ge n test ])X
O btai n details of me dicati o ns 
c urre ntl y ta ke n X
Perf or m p h ysical e xa mi nati o n X
Perf or m cli nical assess me nt aX
Meas ure hei g ht a n d w ei g ht X
Meas ure vital si g ns (i ncl u di n g oral 
t e m perat ure) X  X  X  X 
Perf or m [ADDRESS_370987] bl o o d sa m ple f or tr o p o ni n I 
la b orat or y testi n g ~ 2. 5 m L ~ 2. 5 m L b~ 2. 5 
m L ~ 2. [ADDRESS_370988] (if a p pr o priate) X  X 
C o nfir m use of c o ntrace pti ves 
(if a p pr o priate) X  X  X  X  X 
C ollect pri or C O VI D -[ADDRESS_370989] u d y i nter ve nti o n all ocati o n X
Nasal ( mi dt ur bi nate) s wa b f or 
S A R S -C o V -[ADDRESS_370990] bl o o d sa m ple f or 
i m m u n o ge nicit y assess me nt ~ 5 0 m L b~ 5 0 m L ~ 5 0 m L ~ [ADDRESS_370991] u d y i nter ve nti o n X0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370992] 
Visit Wi n d o w ( D a ys) [ADDRESS_370993] o ge nicit y e -diar y data 
( dail y re vie w is o pti mal d uri n g t he 
acti ve diar y peri o d) 
Re vie w o n g oi n g react o ge nicit y e -diar y 
s y m pt o ms a n d o btai n st o p dates X  X 
C ollect A Es a n d S A Es as a p pr o priate cX  X  X  X  X  X  X 
C ollect e -diar y or assist t he partici pa nt 
wit h deleti n g a p plicati o n X  X 
a. I ncl u di n g, if i n dicate d, a p h ysical e xa mi nati o n. 
b. Pri or t o vacci nati o n at Visit 1. 
c.  A E s are c ollecte d fr o m t he c o m pleti o n of i nf or me d c o nse nt t hr o u g h Visit 4.  S A Es are c ollecte d fr o m t he 
c o m pleti o n of i nf or me d c o nse nt t hr o u g h t he e n d of st u d y partici pati o n.  A d diti o nall y, a n y A Es occ urri n g 
u p t o [ADDRESS_370994] be rec or de d. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_370995] u d y t o descri be t he safet y a n d i m m u n o ge nicit y 
of u p t o 3 d ose -le vel c o m bi nati o ns of qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal / O mi B A. 4/ B A. 5 ). 
[ADDRESS_370996] u d y A 
See Secti o n 2. 2 .
1 0. 1 1. 2. 3. Be nefit/ Ris k Assess me nt f or S u bst u d y A 
See Secti o n 2. 3. [ADDRESS_370997] u d y  A ma y  be: 
Recei pt of a d ose of a n efficaci o us or p ote ntiall y efficaci o us C O VI D -[ADDRESS_370998] t he S A R S -C o V - 2 W T (a ncestral) strai n a n d V O Cs 
d uri n g a gl o bal pa n de m ic. 
Recei pt of a p ote ntiall y efficaci o us i nfl ue nza vacci ne at n o c ost t o t he partici pa nt, a n d 
pr o visi o n of t he i m m u n o ge nicit y  res ults i n partici pa nts. 
Access t o C O VI D -1 9 dia g n ostic testi n g. 
C o ntri b uti n g t o researc h t o hel p ot hers i n a ti me of gl o bal pa n de mic. 
Please see Secti o n 2. [ADDRESS_370999] u d y  A. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 2 3 1 0. 1 1. 3. O bjecti ves, E n d p oi nts, a n d Esti m a n ds ( S u bst u d y A) 
O bjecti ves Esti m a n ds E n d p oi nts 
Pri m ar y S afet y Pri m ar y S afet y Pri m ar y S afet y 
T o descri be t he safet y a n d t olera bilit y of 
qI R V/ bi vale nt B N T 1 6 2 b 2 
(ori gi nal / O mi B A. 4/ B A. 5) at vari o us 
d ose -le vel c o m bi nati o ns i n partici pa nts 
≥ 1 8 years of a ge I n partici pa nts 1 8 t hr o u g h 6 4 years of a ge a n d ≥ [ADDRESS_371000] u d y 
i nter ve nti o n, t he perce nta ge of partici pa nts re p orti n g: 
L ocal reacti o ns f or u p t o 7 da ys f oll o wi n g vacci nati o n 
S yste mic e ve nts f or u p t o 7 da ys f oll o wi n g vacci nati o n 
A E s fr o m t he first vacci nati o n t hr o u g h 4 wee ks after vacci nati o n 
S A Es fr o m t he first vacci nati o n t hr o u g h 6 m o nt hs after 
vacci nati o n L ocal reacti o ns ( pai n at t he i njecti o n site, re d ness, a n d 
s welli n g) 
S yste mic e ve nts (fe ver, fati g ue, hea dac he, c hills, 
v o miti n g, diarr hea, ne w or w orse ne d m uscle pai n, a n d 
ne w or w orse ne d j oi nt pai n) 
A Es 
S A Es 
T he perce nta ge of partici pa nts wit h: 
A b n or mal tr o p o ni n I la b orat or y val ues 2 da ys a n d 1 wee k after 
vacci nati o n Tr o p o ni n I la b orat or y para meters detaile d i n Secti o n 1 0. 2 
T he perce nta ge of partici pa nts wit h: 
Ne w E C G a b n or malities 2 da ys a n d 1 wee k after vacci nati o n E C G a b n or malities c o nsiste nt wit h pr o ba ble or p ossi ble 
m y o car ditis or pericar ditis as defi ne d i n 
Secti o n 1 0. 1 1. 8. 4. 1 
Sec o n d ar y Sec o n d ar y Sec o n d ar y 
T o descri be t he i m m u ne res p o nses 
elicite d b y qI R V/ bi vale nt B N T 1 6 2 b 2 
(ori gi nal / O mi B A. 4/ B A. 5) at vari o us 
d ose -le vel c o m bi nati o ns i n partici pa nts 
≥ 1 8 years of a ge I n partici pa nts 1 8 t hr o u g h 6 4 years of a ge a n d ≥ [ADDRESS_371001] yi n g wit h t he ke y pr ot oc ol criteria (e val ua ble 
partici pa nts): 
G M Ts bef ore vacci nati o n a n d at 4 wee ks after vacci nati o n 
G M F R fr o m bef ore vacci nati o n t o 4 wee ks after vacci nati o n 
T he pr o p orti o n of partici pa nts ac hie vi n g H AI ser oc o n versi o n af or 
eac h strai n at 4 wee ks after vacci nati o n 
T he perce nta ge of partici pa nts wit h H AI titers ≥ 1: 4 0 f or eac h 
strai n bef ore vacci nati o n a n d at 4 wee ks after vacci nati o n 
T he perce nta ge of partici pa nts ac hie vi n g H AI ser oc o n versi o n f or 
all strai ns at 4 wee ks after vacci nati o n 
T he perce nta ge of partici pa nts wit h H AI titers ≥ 1: 4 0 f or all strai ns 
at 4 wee ks after vacci nati o n H AI titers f or t he matc he d seas o nal strai ns ( ) 
rec o m me n de d b y W H O 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 2 4 O bjecti ves Esti m a n ds E n d p oi nts 
I n partici pa nts 1 8 t hr o u g h 6 4 years of a ge a n d ≥ 6 5 years of a ge ,
se paratel y, ha vi n g recei ve d qI R V/ bi vale nt B N T 1 6 2 b 2 
(ori gi nal / O mi B A. 4/ B A. 5 ) a n d c o m pl yi n g wit h t he ke y pr ot oc ol 
cr iteria (e val ua ble partici pa nts): 
G M Ts bef ore vacci nati o n a n d at 4 wee ks after vacci nati o n f or 
eac h strai n 
G M F R fr o m bef ore vacci nati o n t o 4 wee ks after vacci nati o n f or 
eac h strai n 
Perce nta ges of partici pa nts wit h ser ores p o nse bat 4 wee ks after 
vacci nati o n f or eac h strai n S A R S -C o V -2 O micr o n B A. 4/ B A. 5 –ne utralizi n g titers 
S A R S -C o V -2 refere nce -strai n –ne utralizi n g titers 
E x pl or at or y E x pl or at or y E x pl or at or y 
T o descri be t he i m m u ne res p o nses 
elicite d b y qI R V/ bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) at vari o us 
d ose -le vel c o m bi nati o ns i n partici pa nts 
≥1 8 years of a ge I n partici pa nts 1 8 t hr o u g h 6 4 years of a ge a n d ≥ [ADDRESS_371002] yi n g wit h t he ke y pr ot oc ol criteria (e val ua ble 
partici pa nts): 
G M Ts bef ore vacci nati o n a n d at 1 a n d 8 wee k safter vacci nati o n 
G M F R fr o m bef ore vacci nati o n t o 1 a n d 8 wee k safter vacci nati o n 
T he pr o p orti o n of partici pa nts ac hie vi n g H AI ser oc o n v ersi o n af or 
eac h strai n at 1 a n d 8 wee k safter vacc i nati o n 
T he perce nta ge of partici pa nts wit h H AI titers ≥ 1: 4 0 f or eac h 
strai n bef ore vacci nati o n a n d at 1 a n d 8 wee k safter vacci nati o n 
T he perce nta ge of partici pa nts ac hie vi n g H AI ser oc o n versi o n f or 
all strai ns at 1 a n d 8 wee k safter vacci nati o n 
T he perce nta ge of partici pa nts wit h H AI titers ≥ 1: 4 0 f or all strai ns 
at 1 a n d 8 wee k safter vacci nati o n H AI titers f or t he matc he d seas o nal strai ns 
(  rec o m me n de d b y W H O 
T o descri be t he i m m u ne res p o nses 
elicite d b y qI R V/ bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) at vari o us 
d ose -le vel c o m bi nati o ns i n partici pa nts 
≥ 1 8 years of a ge I n partici pa nts 1 8 t hr o u g h 6 4 years of a ge a n d ≥ 6 5 years of a ge, 
se paratel y, ha vi n g recei ve d qI R V/ bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) a n d c o m pl yi n g wit h t he ke y pr ot oc ol 
criteria (e val ua ble partici pa nts): 
G M Ts bef ore vacci nati o n a n d at 1 a n d 8 wee k safter vacci nati o n 
f or eac h strai n 
G M F R fr o m bef ore vacci nati o n t o 1 a n d 8 wee k safter vacci nati o n 
f or eac h strai n 
Perce nta ges of partici pa nts wit h ser ores p o nse bat 1 a n d 8 wee k s
after vacci nati o n f or eac h strai n S A R S -C o V -2 O micr o n B A. 4/ B A. 5 –ne utralizi n g titers 
S A R S -C o V -2 refere nce -strai n –ne utralizi n g titers 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 2 5 O bjecti ves Esti m a n ds E n d p oi nts 
T o descri be t he i m m u ne res p o nse t o 
e m er gi n g V O Cs i n partici pa nts ≥1 8 years 
of a ge S A R S -C o V - 2 ne utralizi n g titers f or V O Cs n ot alrea d y 
s pecifie d 
a. Ser oc o n versi o n is defi ne d as a n H AI titer < 1: 1 0 pri or t o vacci nati o n a n d ≥ 1: [ADDRESS_371003], or a n H AI titer of ≥ 1: [ADDRESS_371004] a ≥ 4 -f ol d rise fr o m baseli ne ( bef ore t he st u d y vacci nati o n).  If t he baseli ne meas ure me nt is bel o w t he L L O Q, t he 
p ost va cci nati o n meas ure of ≥ 4 × L L O Q is c o nsi dere d ser ores p o nse. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371005] u d y t o descri be t he safet y a n d i m m u n o ge nicit y 
of u p t o 3 d ose- le vel c o m bi nati o ns of qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal / O mi B A. 4/ B A. 5). 
Bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) use d was rec o m me n de d b y  A CI P i n 
2 0 2 2- 2 0 2 3. 2 9 ,3 0 A p pr o xi matel y  3 6 0 partici pa nts will be e nr olle d acr oss 2a ge strata :
a p pr o xi matel y  1 8 0 partici pa nts 1 8 t hr o u g h 6 4 ye ars of a ge a n d a p pr o xi matel y  
1 8 0 partici pa nts ≥6 5 y ears of a ge .  Partici pa nts i n eac h strat u m will be ra n d o mize d e q uall y  
( 3 0 partici pa nts per gr o u p) t o eac h gr o u p t o recei ve a d ose of eit her: 
qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal */ O mi B A. 4/ B A. 5), at 1 of t he 3 d ose -le vel 
c o m bi nati o ns s h o w n i n Ta ble 1,
  µ g qI R V, 
  µ g qI R V, or 
  µ g Bi vale nt B N T 1 6 2 b 2 ( ori gi nal / O mi B A. 4/ B A. 5) a d mi nistere d c o nc urre ntl y  i n t he 
o p p osite ar m t o lice nse d QI V. 
* Ori gi nal refers t o t he a ncestral strai n ( W u ha n -H u -1; U S A -W A 1/ 2 0 2 0), als o referre d t o i n 
t his pr ot oc ol as t he refere nce strai n. 
E nr oll me nt i nt o eac h of t he 2 a ge strata ( 1 8 t hr o u g h 6 4 a n d ≥ 6 5 y ears of a ge) ma y  occ ur 
i n de pe n de ntl y. 
Safet y  a n d i m m u n o ge nicit y  data fr o m st u dies pre vi o usl y  c o n d ucte d i n partici pa nts of a 
si milar a ge ra n ge ha vi n g recei ve d [ADDRESS_371006] u d y  a nal y sis. 
E nr oll me n t i n eac h a ge strat u m will be c o ntr olle d s uc h t hat n o m ore t ha n 1 0 partici pa nts 
(c o nsi dere d t he se nti nel partici pa nts) ca n be vacci nate d o n t he first da y ; vacci nati o n of t he 
re mai ni n g partici pa nts will c o m me nce n o s o o ner t ha n [ADDRESS_371007] y t o gr o u ps recei vi n g c o m bi nati o n bi vale nt B N T 1 6 2 b 2 
(ori gi nal/ O mi B A. 4/ B A. 5) a n d qI R V as detaile d i n Secti o n [ADDRESS_371008] o ge nicit y  e -diar y  f or 7 da ys f oll o wi n g eac h 
vacci nati o n.  Bl o o d sa m ples of a p pr o xi matel y  5 0 m L  will be c ollecte d f or i m m u n o ge nicit y 
assess me nts pri or t o Vacci nati o n 1 a n d at 1, 4 ,a n d 8 wee ks after vacci nati o n.  All 
partici pa nts will be as ke d t o pr o vi de a n a d diti o nal bl o o d sa m ple of a p pr o xi matel y  2. 5 m L  at 
ti me p oi nts s pecifie d i n Secti o n 1 0. 1 1. 1 f or assess me nt of tr o p o ni n I .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI C CI C CI 
C CI 
C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371009] 4wee k sf oll o wi n g vacci nati o n i n 
eac h a ge strat u m will be re vie we d b y t he s p o ns or’s I R C t o deter mi ne if e nr ol lme nt i n eac h 
a ge strat u m i n S u bst u d y  B ma y  pr ocee d .Base d o n re vie w of safet y or i m m u n o ge nicit y data 
of a n y st u d y i nter ve nti o n gr o u p, at [COMPANY_007]’s discreti o n, s u bse q ue nt c ollecti o n of bl o o d 
sa m ples fr o m partici pa nts i n t hat gr o u p ma y  be halte d a n d/ or bl o o d sa m ples ma y  n ot be 
a nal yz e d ,a n d st u d y  visits or ot her pr oce d ures ma y  be disc o nti n ue d. 
T he t otal d urati o n of t he st u d y  f or eac h partici pa nt will be u p t o a p pr o xi matel y  [ADDRESS_371010] u d y  if he/s he has c o m plete d all 
peri o ds of t he s u bst u d y, i ncl u di n g t he last visit. 
[ADDRESS_371011] y :
A ge a n d Se x: 
1. Male or fe male partici pa nts ≥1 8 y ears of a ge ( or t he mi ni m u m a ge of c o nse nt i n 
acc or da nce wit h l ocal re g ulati o ns) at Visit 1 ( Da y 1). 
Refer t o A p pe n di x 5 f or re pr o d ucti ve criteria f or male ( Secti o n 1 0. 5. 1 ) a n d fe male 
(Secti o n 1 0. 5. 2 ) partici pa nts. 
Dise ase C h ar acteristics: 
N ot a p plica ble. 
Ot her I ncl usi o n Criteri a: 
2. Partici pa nts w h o are willi n g a n d a ble t o c o m pl y wit h all sc he d ule d visits, i n vesti gati o nal 
pla n, la b orat or y  tests, lifest y le c o nsi derati o ns, a n d ot her st u d y  pr oce d ures. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371012] or y, p h ys ical e xa mi nati o n 
(if re q uire d), a n d cli nical j u d g me nt of t he i n vesti gat or t o be eli gi ble f or i ncl usi o n i n t he 
st u d y .
N ote: Healt h y partici pa nts wit h pree xisti n g sta ble disease, defi ne d as dise ase n ot 
re q uiri n g si g nifica nt c ha n ge i n t hera p y or h os pi[INVESTIGATOR_1314] o n f or w orse ni n g disease 
d uri n g t he 6 wee ks bef ore e nr oll me nt, ca n be i ncl u de d. S pecific criteria f or 
partici pa nts wit h k n o w n sta ble i nfecti o n wit h HI V, H C V, or H B V ca n be f o u n d i n 
Secti o n 1 0. 8 .
4. Ca pa ble of gi vi n g si g ne d i nf or me d c o nse nt as descri be d i n t he pr ot oc ol, w hic h i ncl u des 
c o m plia nce wit h t he re q uire me nts a n d restri cti o ns liste d i n t he I C D a n d i n t his pr ot oc ol. 
5. F or p artic ip a nts 1 8 t hr o u g h 6 4 ye ars of a ge: partici pa nts w h o ha ve recei ve d [ADDRESS_371013] o 3 6 5 da y s bef ore Visit 1 
( Da y  1). 
F or p artici p a nts ≥ 6 5 ye ars of a ge: partici pa nts w h o ha ve recei ve d [ADDRESS_371014] d ose bei n g a bi vale nt vacci ne, 9 0 d a y s t o 
3 6 5 da y s bef ore Visit 1 ( Da y 1). A n y f o urt h or fift h d ose ( b o oster d ose) of m o d R N A 
S A R S -C o V - 2 vacci ne recei ve d after 0 1 Se pte m ber 2 0 2 2 ma y  be c o nsi dere d t o be a 
bi vale nt vacci ne i n t he U S. 
N ote: D oc u me nte d c o nfir mati o n of pri or d oses of m o d R N A S A R S -C o V - [ADDRESS_371015] be o btai ne d pri or t o ra n d o miza ti o n. 
6. F or p artici p a nts ≥ 6 5 ye ars of a ge: recei pt of lice nse d i nfl ue nza vacci nati o n f or t he 
2 0 2 2- 2 0 2 3 n ort her n he mis p here seas o n ≥[ADDRESS_371016] y :
Me dic al C o n diti o ns: 
1. Hist or y  of se vere a d verse reacti o n ass ociate d wit h a n y  vacci ne a n d/ or se vere aller gic 
reacti o n (e g, a na p h yl a xis) t o a n y  c o m p o ne nt of t he st u d y  i nter ve nti o n(s). 
2. I m m u n oc o m pr o mise d i n di vi d uals wit h k n o w n or s us pecte d i m m u n o deficie nc y, as 
deter mi ne d b y hist or y  a n d/ or la b orat or y / p h y sical e xa mi nati o n. 
3. Blee di n g diat hesis or c o n diti o n ass ociate d wit h pr ol o n ge d blee di n g t hat w o ul d, i n t he 
o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or, c o ntrai n dicate i ntra m usc ular i njecti o n. 
4. W o me n w h o are pre g na nt or breastfee di n g. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 2 9 5. Aller g y  t o e g g pr otei ns (e g g or e g g pr o d ucts) or c hic ke n pr otei ns. 
6. Ot her me dical or ps y c hiatric c o n diti o n i ncl u di n g rece nt ( wit hi n t he past year) or acti ve 
s uici dal i deati o n/ be ha vi or or la b orat or y  a b n or malit y  t hat m a y  i ncrease t he ris k of st u d y  
partici pati o n or, i n t he i n vesti gat or’s j u d g me nt, ma ke t he partici pa nt i na p pr o priate f or t he 
st u d y .
Pri or/ C o nc o mit a nt T her a p y: 
7. Recei pt of c hr o nic s ys te mic treat me nt wit h k n o w n i m m u n os u p pressa nt me dicati o ns 
(i ncl u di n g c y t ot o xi c a ge nts or s y ste mic c ortic oster oi ds), or ra di ot hera p y , wit hi n [ADDRESS_371017] u d y. 
N ote : S y ste mic c ortic oster oi ds are defi ne d as t h ose a d mi nistere d f or ≥ 1 4 da y s at a d ose 
of ≥ 2 0 m g/ da y  of pre d nis o ne or e q ui vale nt (e g, f or ca ncer or a n a ut oi m m u ne disease) or 
pla n ne d recei pt t hr o u g h o ut t he st u d y . I n hale d/ ne b ulize d, i ntra -artic ular, i ntra b ursal, or 
t o pi[INVESTIGATOR_2855] (s ki n or e y es) c ortic oster oi ds are per mitte d. 
8. Recei pt of bl o o d/ plas ma pr o d ucts, i m m u n o gl o b uli n, or m o n ocl o nal a nti b o dies, fr o m 
[ADDRESS_371018] u d y .
9. F or p artic ip a nts 1 8 t hr o u g h 6 4 ye ars of a ge: vacci nati o n wit h a n y i n vesti gati o nal or 
lice nse d i nfl ue nza vacci ne wit hi n 6 m o nt hs ( 1 7 5 da y s) bef ore st u d y  i n ter ve nti o n 
a d mi nistrati o n. 
Pri or/ C o nc urre nt Cli nic al St u d y E x perie nce: 
[ADDRESS_371019] u d y .
Di a g n ostic Assess me nts: 
N ot a p plica ble. 
Ot her E xcl usi o n Criteri a: 
[ADDRESS_371020] or y  of heart disease. 
1 4. A n y  a b n or mal scree ni n g tr o p o ni n I  la b orat or y  val ue. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371021] u d y  res ults.  Partic i pa nts wit h a 
scree ni n g 1 2 -lea d E C G t hat s h o ws a n a vera ge Q Tc F i nter val > [ADDRESS_371022] u d y  
partici pati o n. 
1 0. 1 1. 5. 3. Criteri a f or Te m p or aril y Del a yi n g 
E nr oll me nt/ R a n d o miz ati o n/ A d mi nistr ati o n of St u d y I nter ve nti o n f or S u bst u d y A 
T he f oll o wi n g c o n diti o ns ma y  all o w a partici pa nt t o be ra n d o mize d o nce t he c o n diti o ns ha ve 
res ol ve d a n d t he partici pa nt is ot her wise c o nsi dere d eli gi ble.  Partici pa nts meeti n g t hese 
criteria at Visit 1 will be c o nsi dere d scree n fail ures if e nr oll me nt has cl ose d o nce t he 
c o n diti o n(s) has/ ha ve res ol ve d. 
1. A p ositi ve S A R S -C o V -[ADDRESS_371023] res ult ( N A A T or ra pi d a nti ge n test) wit hi n t he pre vi o us 
2 8 da y s. 
2. C urre nt fe brile ill ness ( oral te m perat ure ≥ 3 8. 0° C [ ≥ 1 0 0. 4° F]) or ot her ac ute ill ness wit hi n 
[ADDRESS_371024] u d y  i nter ve nti o n a d mi nistrati o n.  T his i ncl u des s y m pt o ms t hat c o ul d 
re prese nt a p ote ntial C O VI D- 1 9 ill ness (refer t o Secti o n 8. 4. 7 ). 
N ote: T he partici pa nt s h o ul d be directe d t o see k a d diti o nal testi n g t hr o u g h his/ her 
pri mar y  healt hcare pr o vi der at a lice nse d cli nical la b orat or y  w he n e x hi biti n g p ote ntial 
C O VI D - [ADDRESS_371025] u d y  i nter ve nti o n 
a d mi nistrati o n at Visit 1. 
5. Recei pt of s h ort -ter m ( < 1 4 da y s) s y ste mic c ortic oster oi ds.  St u d y  i nter ve nti o n 
a d mi nistrati o n s h o ul d be dela y e d u ntil s y ste mic c ortic oster oi d use has bee n disc o nti n ue d 
f or at least 2 8 da y s.  I n hale d/ ne b ulize d, i ntra -artic ular, i ntra b ursal, or t o pi[INVESTIGATOR_2855] (s ki n or 
e y es) c ortic oster oi ds are per mitte d. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371026] u d y I nter ve nti o n(s) A d mi nistere d f or S u bst u d y A 
St u d y  i nter ve nti o ns f or S u bst u d y  A will i ncl u de: 
I nter ve nti o n 
N a me Bi vale nt B N T 1 6 2 b 2 
(ori gi nal / O mi B A. 4/ B A. 5) 
(ori gi nal aB N T 1 6 2 b 2 a n d 
B N T 1 6 2 b 2 Omicr o n 
[ B. 1. 1. 5 2 9 s u bli nea ge 
B A. 4/ B A. 5]) qI R V qI R V/ bi vale nt B N T 1 6 2 b 2 
(ori gi nal / O mi B A. 4/ B A. 5 )QI V 
Ar m N a me 
( gr o u p of 
p artici p a nts 
recei vi n g a 
s pecific st u d y 
i nter ve nti o n or 
n o st u d y 
i nter ve nti o n) qI R V/ bi vale nt B N T 1 6 2 b 2 
(ori gi nal / O mi B A. 4/ B A. 5 )
or 
Lice nse d QI V + 
bi vale nt B N T 1 6 2 b 2 
(ori gi nal / O mi B A. 4/ B A. 5) qI R V/ bi vale nt B N T 1 6 2 b 2 
(ori gi nal / O mi B A. 4/ B A. 5 )
or 
µ g qI R V 
or 
µ g qI R V qI R V/ bi vale nt B N T 1 6 2 b 2 
(ori gi nal / O mi B A. 4/ B A. 5) Lice nse d QI V 
+ bi vale nt 
B N T 1 6 2 b 2 
( ori gi nal/ O mi 
B A. 4/ B A. 5) 
T ar gete d 
I nfl ue nz a 
Str ai ns N/ A F or eac h seas o n , strai ns as 
rec o m me n de d b y W H O 
f or rec o m bi na nt or cell -
base d i nfl ue nza vacci nes F or eac h seas o n ,strai ns as 
rec o m me n de d b y W H O f or 
rec o m bi na nt or cell -base d 
i nfl ue nza vacci nes F or eac h 
seas o n ,
strai ns as 
rec o m me n de d 
b y W H O 
T y pe Vacci ne Vacci ne Vacci ne Vacci ne 
D ose 
F or m ul ati o n m o d R N A m o d R N A m o d R N A 
U nit D ose 
Stre n gt h(s) As detaile d i n t he I P M  As detaile d i n t he I P M  As detaile d i n t he I P M  As detaile d i n 
t he I P M 
D os a ge 
Le vel(s) µ g or µ g 
(  µ g o ri gi nal 
B N T 1 6 2 b 2 a n d 
 µ g B N T 1 6 2 b 2 
O m icr o n 
[B. 1. 1. 5 2 9 s u bli nea ge 
B A. 4/ B A. 5]) 
µ g o ri gi nal 
B N T 1 6 2 b 2 a n d 
µ g B N T 1 6 2 b 2 
O m icr o n 
[B. 1. 1. 5 2 9 s u bli nea ge 
B A. 4/ B A. 5]) µ g 
(
µ g 
( )D ose -le vel c o m bi nati o n 1 as 
descri be d in Ta ble 1
µ g 
qI R V µ g 
( )
B N T 1 6 2 b 2 µ g 
( µ g o ri gi nal B N T 1 6 2 b 2 a n d 
µ g B N T 1 6 2 b 2 O m icr o n 
[B. 1. 1. 5 2 9 s u bli nea ge 
B A. 4/ B A. 5 ]) 
D ose -le vel c o m bi nati o n 2 as 
descri be d in Ta ble 10 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
C CI 
C CI 
C CI C CI 
C CI 
C CI 
C CI 
C CI C CI 
C CI 
C CI 
C CI C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 3 2 µ g 
qI R V µ g 
)
B N T 1 6 2 b 2 µ g 
(  µ g o ri gi nal B N T 1 6 2 b 2 a n d 
µ g B N T 1 6 2 b 2 O m icr o n 
[B. 1. 1. 5 2 9 s u bli nea ge 
B A. 4/ B A. 5 ]) 
D ose -le vel c o m bi nati o n 3 as 
descri be d in Ta ble 1
µ g 
qI R V µ g 
( )
B N T 1 6 2 b 2 µ g 
( µ g o ri gi nal B N T 1 6 2 b 2 a n d 
µ g B N T 1 6 2 b 2 O m icr o n 
[B. 1. 1. 5 2 9 s u bli nea ge 
B A. 4/ B A. 5 ]) 
R o ute of 
A d mi nistr ati o n I ntra m usc ular i njecti o n I ntra m usc ular i njecti o n I ntra m usc ular i njecti o n I ntra m usc ular 
i njecti o n 
Use E x peri me ntal E x peri me ntal E x peri me ntal C o m parat or 
I M P or 
NI M P/ A x M P I M P I M P I M P I M P 
S o urci n g Pr o vi de d ce ntrall y b y 
Pf izer Pr o vi de d ce ntrall y b y 
Pf izer St u d y i nter ve nti o n will be 
ge nerate d b y   
 at t he d ose -
le vel c o m bi nati o ns detaile d 
a b o ve: 
qI R V 
Bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) Pr o vi de d 
ce ntrall y b y 
Pf izer 
P ac k a gi n g a n d 
L a beli n g St u d y i nter ve nti o n will be 
pr o vi de d i n a glass vial as 
o pe n -la bel s u p pl y.  Eac h 
vial will be la bele d per 
c o u ntr y re q uire me nt. St u d y i nter ve nti o n will be 
pr o vi de d i n a glass vial as 
o pe n -la bel s u p pl y.  Eac h 
vial will be la bele d per 
c o u ntr y re q uire me nt. St u d y 
i nter ve nti o n 
will be 
pr o vi de d as 
eit her a P F S 
or a glass vial 
as o pe n -la bel 
s u p pl y.  Eac h 
vial will be 
la bele d per 
c o u ntr y 
re q uire me nt. 
a.  Ori gi nal refers t o t he a ncestral strai n ( W u ha n -H u -1; U S A -W A 1/ 2 0 2 0), als o referre d t o i n t his pr ot oc ol as t he 
refere nce strai n. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371027] u d y Ar ms 
Gr o u p 
N u m ber 1 2 3 4 5 6
Ar m Title qI R V/ bi vale nt 
B N T 1 6 2 b 2 
(ori gi nal / O mi 
B A. 4/ B A. 5) 
D ose -l e vel 
co m bi nati o n 1 as 
descri be d in 
Ta ble 1qI R V/ bi vale nt 
B N T 1 6 2 b 2 
(ori gi nal / O mi 
B A. 4/ B A. 5) 
D ose -l e vel 
co m bi nati o n 2 as 
descri be d in 
Ta ble 1qI R V/ bi vale nt 
B N T 1 6 2 b 2 
(ori gi nal / O mi 
B A. 4/ B A. 5) 
D ose -l e vel 
co m bi nati o n 3 as 
descri be d i n 
Ta ble 1µg qI R V µg qI R V Lice nse d QI V + 
bi vale nt B N T 1 6 2 
b 2 ( ori gi nal /
Omi B A. 4/ B A. 5) 
Ar m T y pe E x peri me ntal E x peri me ntal E x peri me ntal E x peri me ntal E x peri me ntal E x peri me ntal 
Ar m 
Descri pti o n Partici pa nts will 
recei ve 
qI R V/ bi vale nt 
B N T 1 6 2 b 2 
(ori gi nal / O mi 
B A. 4/ B A. 5) 
at d ose -le vel 
c o m bi nati o n 1 as 
descri be d in 
Ta ble 1Partici pa nts will 
recei ve 
qI R V/ bi vale nt 
B N T 1 6 2 b 2 
(ori gi nal / O mi 
B A. 4/ B A. 5) 
at d ose -le vel 
c o m bi nati o n 2 as 
descri be d in 
Ta ble 1Partici pa nts will 
recei ve 
qI R V/ bi vale nt 
B N T 1 6 2 b 2 
(ori gi nal / O mi 
B A. 4/ B A. 5) 
at d ose -le vel 
c o m bi nati o n 3 as 
descri be d in 
Ta ble 1Partici pa nts 
will recei ve 
µg of 
qI R V Partici pa nts 
will recei ve 
µg of 
qI R V Partici pa nts will 
recei ve µg of 
bi vale nt B N T 1 6 2 
b 2 ( ori gi nal / O mi 
B A. 4/ B A. 5) 
a d mi nistere d 
c o nc urre ntl y i n 
t he o p p os ite ar m 
t o QI V 
Ass oci ate d 
I nter ve nti o n 
L a bels qI R V/ bi vale nt 
B N T 1 6 2 b 2 
(ori gi nal / O mi 
B A. 4/ B A. 5) qI R V/ bi vale nt 
B N T 1 6 2 b 2 
(ori gi nal / O mi 
B A. 4/ B A. 5) qI R V/ bi vale nt 
B N T 1 6 2 b 2 
(ori gi nal / O mi 
B A. 4/ B A. 5) qI R V qI R V Bi vale nt 
B N T 1 6 2 b 2 
(ori gi nal / O mi 
B A. 4/ B A. 5) 
a n d QI V 
[ADDRESS_371028] u d y  i nter ve nti o n at Vi sit 1 i n a n 
o pe n -la bel ma n ner i n acc or da nce wit h t he S o A ( Secti o n 1 0. 1 1. 1 ).  Ot her t ha n QI V, a ll st u d y  
i nter ve nti o ns f or Su bst u d y  A s h o ul d be a d mi nistere d i ntra m usc ularl y i nt o t he delt oi d m uscle 
of t he ri g ht ar m; w he n QI V is c oa d mi nistere d wit h bi vale nt B N T 1 6 2 b 2 
(ori gi nal / O mi B A. 4/ B A. 5), QI V s h o ul d be a d mi nistere d i ntra m usc ularl y i nt o t he delt oi d 
m uscle of t he left ar m. 
[ADDRESS_371029] u d y A 
See Secti o n 6. 2 .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI C CI 
C CI C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371030] u d y A 
See Secti o n 6. 8. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371031] u d y  A, t he f oll o wi n g c o nc o mita nt me dicati o ns a n d vacci nati o ns will be rec or de d i n 
t he C R F: 
Pri or recei pt of a n y C O VI D -1 9 vacci ne. 
Pri or recei pt of a n y p ne u m oc occal vacci ne. 
Lice nse d i nfl ue nza vacci ne, if recei ve d d uri n g t he 1 2 m o nt hs pri or t o e nr oll me nt .
A n y  vacci nati o ns recei ve d fr o m [ADDRESS_371032] visit 
( Visit 6). 
Pr o hi bite d me dicati o ns liste d i n Secti o n [ADDRESS_371033] u d y A 
Recei pt of t he f oll o wi n g vacci nes a n d me dicati o ns d uri n g t he ti me peri o ds liste d bel o w ma y  
e xcl u de a partici pa nt fr o m t he per - pr ot oc ol a nal ysis fr o m t hat p oi nt o n war d; h o we ver, it is 
a ntici pate d t hat t he partici pa nt w o ul d n ot be wit h dra w n fr o m t he st u d y  (s ee Secti o n 7) .  
Me dicati o ns s h o ul d n ot be wit h hel d if re q uire d f or a partici pa nt’s me dical care. 
U nless c o nsi dere d me dicall y  necess ar y , n o vacci nes ot her t ha n st u d y  i nter ve nti o n s h o ul d 
be a d mi nistere d wit hi n [ADDRESS_371034] u d y  vacci nati o n at Visit 1. 
Recei pt of a n y ot her ( no nst u d y ) c or o na vir us vacci ne fr o m e nr oll me nt t hr o u g h Visit 5 
( 8 - w ee k foll o w - u p v isit) is pr o hi bite d. 
Recei pt of a n y ot her ( no nst u d y ) seas o nal i nfl ue nza vacci ne fr o m e nr oll me nt t hr o u g h 
Visit 5 ( 8 - w ee k foll o w -u p visit) is pr o hi bite d. 
Recei pt of c hr o nic s ys te mic treat me nt wit h k n o w n i m m u n os u p pressa nt me dicati o ns, or 
ra di ot hera p y, wit hi n [ADDRESS_371035] u d y  is 
pr o hi bite d. 
Recei pt of s ys te mic c ortic oster oi ds ( ≥ 2 0 m g/ da y  of pre d nis o ne or e q ui vale nt) f or 
≥ [ADDRESS_371036] u d y  i nte r ve nti o n. 
Recei pt of bl o o d/ plas ma pr o d ucts, i m m u n o gl o b uli ns, or m o n ocl o nal a nti b o dies, fr o m 
[ADDRESS_371037] u d y .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 3 6 Pr o p h y lactic a nti p y retics a n d ot her pai n me dicati o n t o pre ve nt s y m pt o ms ass ociate d wit h 
st u d y  i nter ve nti o n a d mi nistrati o n are n ot per mitte d.  H o we ver, if a partici pa nt is ta ki n g a 
me dicati o n f or a n ot her c o n diti o n, e ve n if it ma y  ha ve a nti p y retic or pai n -relie vi n g 
pr o perties, it s h o ul d n ot be wit h hel d pri or t o st u d y vacci nati o n. 
[ADDRESS_371038] u d y A 
Me dicati o n ot her t ha n t hat descri be d as pr o hi bite d i n Secti o n 1 0. 1 1. 6. 7. 1 re q uire d f or 
treat me nt of pree xisti n g c o n diti o ns or ac ute ill ness is per mitte d. 
I n hale d, t o pi[INVESTIGATOR_2855], or l ocalize d i njecti o ns of c ortic oster oi ds (e g, i ntra -artic ular or i ntra b ursal 
a d mi nistrati o n) are per mitte d. 
[ADDRESS_371039] u d y A I nter ve nti o n a n d P artici p a nt 
Disc o nti n u a ti o n/ Wit h dr a w al 
See Secti o n [ADDRESS_371040] u d y A 
Sa m ples will be c ollecte d at ti me p oi nts as s pecifi e d i n Secti o n 1 0. 1 1. 1 fr o m all partici pa nts, 
a n d t he f oll o wi n g assa y s r u n: 
H AI titers f or t he matc he d seas o nal strai ns ( ) rec o m me n de d b y W H O 
S A R S -C o V -2 ne utralizati o n assa y  (refere nce strai n) 
S A R S -C o V -2 ne utralizati o n assa y s ( O micr o n B A. 4, O micr o n B A. 5; ot her V O Cs of 
i nterest, i ncl u di n g ot her O micr o n s u bli nea ges, ma y  als o be e val uate d) 
[ADDRESS_371041] u d y A 
See Secti o n 8. 2. 1 .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371042] u d y  A, l ocal reacti o ns will be assesse d at t he i njecti o n site o n t he ri g ht ar m 
o nl y  (see Secti o n 8. 3. 5 ). 
[ADDRESS_371043] 1 0 mi n utes i n a s u pi [INVESTIGATOR_050] p ositi o n.  T he E C Gs s h o ul d be o btai ne d pri or t o bl o o d 
c ollecti o n, meas ure me nt of bl o o d press ure, a n d meas ure me nt of p ulse rate.  E C Gs will be 
perf or me d i n tri plicate. 
E C G data will be s u b mitte d t o a ce ntral la b orat or y f or e val uati o n .  T he fi nal E C G re p ort fr o m 
t he ce ntral la b orat or y  s h o ul d be mai ntai ne d i n t he partici pa nt’s s o urce d oc u me ntati o n a n d be 
t he fi nal i nter pretati o n of t he E C G rec or di n g.  A n y cli nicall y  si g nif ica nt c ha n ges fr o m t he 
baseli ne/ Da y  1 E C G ma y p ote ntiall y  be A Es ( see Secti o n 1 0. 3 ) a n d s h o ul d be e val uate d 
f urt her, as cli nicall y warra nte d. 
I n s o me cases, it ma y  be a p pr o priate t o re peat a b n or mal E C Gs t o r ule o ut i m pr o per lea d 
place me nt as c o ntri b uti n g t o t he E C G a b n or malit y.  It is i m p orta nt t hat lea d place me nt be i n 
t he sa me p ositi o n eac h ti me d uri n g eac h assess me nt visit i n or der t o ac hie ve precise E C G 
rec or di n gs. 
E C G a b n or malities c o nsiste nt wit h pr o ba ble or p ossi ble m y ocar ditis or pericar ditis are t h ose 
j u d ge d as s uc h b y a car di ol o gist, i ncl u di n g :
S ustai ne d atrial or ve ntric ular arr h yt h mias 
Sec o n d -de gree M o bitz T y pe II or w orse A V bl oc k, ne w b u n dle bra nc h bl oc k 
Diff use S T -se g me nt ele vati o n or P R -se g me nt i n versi o n, c o m pati ble wit h pericar ditis 
Ec h ocar di o gra ms ma y  be perf or me d as detaile d i n Secti o n [ADDRESS_371044] of cli nical safet y 
la b orat or y  tests t o be perf or me d a n d t he S o A f or t he ti mi n g a n d fre q ue nc y .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371045] f or partici pa nts i n gr o u ps recei vi n g c o m bi nati o n 
bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) a n d qI R V i n Su bst u d y A , base d o n A E, 
E C G, a n d la b orat or y  data re vie w .  T hese data will be re vie we d o n a n o n g oi n g basis b y t he 
i n vesti gat or ( or me dicall y q ualifie d desi g nee) a n d s p o ns or i n or der t o pr o m ptl y  i de ntif y  a n d 
fla g a n y e ve nt t hat p ote ntiall y c o ntri b utes t o a st o p pi n g r ule. 
T he s p o ns or st u d y  tea m will be u n bli n de d, s o will be a ble t o assess w het her or n ot a st o p pi n g 
r ule has bee n met o n t he basis of a partici pa nt’s i n di vi d ual st u d y  i nter ve nti o n all ocati o n. 
I n t he e v e nt t hat s p o ns or pers o n nel c o nfir m t hat a st o p pi n g r ule is met, t he f oll o wi n g acti o ns 
will c o m me nce: 
T he I R C will re vie w all a p pr o priate data. 
T he st o p pi n g r ule will P A U S E ra n d o mizati o n a n d st u d y  i nter ve nti o n a d mi nistrati o n 
f or t he bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5)/ qI R V vacci ne gr o u p(s) at t he 
affecte d a n d, if a p plica ble, hi g her t otal d ose le vel  or  µ g ). 
St u d y  i nter ve nti o n a d mi nistrati o n ma y  c o nti n ue d uri n g t he pa use i n vacci ne gr o u ps 
recei vi n g qI R V al o ne ,or QI V a d mi nistere d c o nc urre ntl y wit h bi vale nt B N T 1 6 2 b 2 
(ori gi nal/ O mi B A. 4/ B A. 5 ). 
F or all partici pa nts alrea d y  vacci nate d, all ot her r o uti ne st u d y  c o n d uct acti vities, 
i ncl u di n g o n g oi n g data e ntr y , re p orti n g of A Es, partici pa nt e- diar y c o m pleti o n, bl o o d 
sa m ple c ollecti o n, a n d partici pa nt f oll o w - u p, will c o nti n ue d uri n g t he pa use. 
A st o p pi n g r ule is met if a n y  of t he f oll o wi n g r ules occ ur wit hi n 4 wee ks after a d mi nistrati o n 
of bi vale nt B N T 1 6 2 b 2 ( o ri gi nal/ O mi B A. 4/ B A. 5) /qI R V .Eac h bi vale nt B N T 1 6 2 b 2 
( o ri gi nal/ O mi B A. 4/ B A. 5)/ qI R V d ose le vel will be e val uate d f or c o ntri b uti o n t o st o p pi n g 
r ules i n de pe n de ntl y. 
St o p pi n g R ule Criteria: 
1. If a n y partici pa nt vacci nate d de vel o ps: 
A ne w E C G a b n or malit y  t hat a car di ol o gist j u d ges c o nsiste nt wit h pr o ba b le or 
p ossi ble m y ocar ditis or pericar ditis, i ncl u di n g: 
S ustai ne d atrial or ve ntric ular arr h yt h mias 
Sec o n d -de gree M o bitz T y pe II or w orse A V bl oc k, ne w b u n dle bra nc h bl oc k 
Diff use S T -se g me nt ele vati o n or P R -se g me nt i n versi o n, c o m pati ble wit h 
pericar ditis 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 3 9 A n a b n or mal tr o p o ni n I val ue t hat is c o nfir me d a b n or mal o n re peat testi n g, assesse d 
as relate d t o st u d y i nter ve nti o n b y t he i n vesti gat or. 
2. If ≥ 1 partici pa nt vacci nate d de vel o ps c o nfir me d m y ocar ditis or pericar ditis. 
3. If a n y partici pa nt vacci nate d dies. 
4. ≥ 1 part ici pa nt vacci nate d e x perie nces a Gra de 4 u ns olicite d A E, or S A E of a n y  se verit y, 
assesse d as relate d b y t he i n vesti gat or. 
5. ≥ 2 partici pa nts vacci nate d wit h bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4 / B A. 5) /qI R V at 
t he sa me d ose le vel de vel o p t he sa me or si milar Gra de 3 or hi g her u ns olicite d A E, ot her 
t ha n m y ocar ditis/ pericar ditis, assesse d as relate d t o st u d y  i nter ve nti o n b y t he i n vesti gat or.  
N ote t hat t he l ocal reacti o ns, s y ste mic e ve nts, a n d fe ver s pecifie d i n Secti o n 8. 3. [ADDRESS_371046] u d y A 
1 0. 1 1. 8. 8. 1. Scree ni n g ( 0 t o 2 8 D a ys Bef ore Visit 1) f or S u bst u d y A 
Bef ore e nr oll me nt a n d bef ore a n y st u d y- relate d pr oce d ures are perf or me d, v ol u ntar y , writte n, 
st u d y -s pecific i nf or me d c o nse nt will be o btai ne d fr o m t he partici pa nt.  Eac h si g nat ure o n t he 
I C D m ust be pers o nall y date d b y t he si g nat or y.  T he i n vesti gat or or his or her desi g nee will 
als o si g n t he I C D.  A c o p y  of t he si g ne d a n d date d I C D m ust be gi ve n t o t he partici pa nt.  T he 
s o urce data m ust reflect t hat t he i nf or me d c o nse nt was o btai ne d b ef ore partici pati o n i n t he 
st u d y .
It is a ntici pate d t hat t he pr oce d ures bel o w will be c o n d ucte d i n a ste p wise ma n ner. 
Assi g n a partici pa nt n u m ber usi n g t he I R T s ys te m.  
O btai n t he partici pa nt’s de m o gra p h y (i ncl u di n g date of birt h, se x, race, a n d et h nicit y ).  
T he f ull date of birt h will be c ollecte d t o criticall y e val uate t he i m m u ne res p o nse a n d 
safet y pr ofile b y a ge. 
O btai n me dical hist or y , i ncl u di n g c o nfir me d C O VI D -1 9 dia g n osis (see Secti o n 8. 4. 7 ) or 
as y m pt o matic p ositi ve S A R S -C o V -[ADDRESS_371047] res ult ( N A A T or a nti ge n test), a n d a n y  ot her 
me dical hist or y  of cli nical si g nifica nce. 
O btai n details of a n y me dicati o ns c urre ntl y ta ke n. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 4 0 Perf or m 1 2 -lea d tri plicate E C G. 
Perf or m p h ys ical e xa mi nati o n, i ncl u di n g vital si g ns ( wei g ht, hei g ht, oral te m perat ure, 
p ulse rate, a n d seate d bl o o d press ure), e val uati n g a n y  cli nicall y  si g nifica nt a b n or malities 
wit hi n t he f oll o wi n g b o d y  s y ste ms: ge neral a p peara nce; s ki n; hea d, e y es, ears, n ose, a n d 
t hr oat; heart; l u n gs; a b d o me n; m usc ul os keletal; e xtre mities; ne ur ol o gical; a n d l y m p h 
n o des. 
C ollect a bl o o d sa m ple of a p pr o xi matel y  2. 5 m L as detaile d i n t he la b orat or y  ma n ual f or 
tr o p o ni n I  la b orat or y  testi n g as descri be d i n Secti o n 8. 3. 4. 
Perf or m uri ne pre g na nc y test o n W O C B P as descri be d i n Secti o n 8. 3. 6 .
Disc uss c o ntrace pti ve use as descri be d i n Secti o n 5. 3. 1 .
Rec or d no nst u d y vacci nati o ns as descri be d i n Secti o n 1 0. 1 1. 6. 7 .
Re vie w d oc u me ntati o n of all pri or C O VI D - [ADDRESS_371048] be 
a ut h orize d f or use i n t he U S.  Rec or d pri or recei pt of a n y C O VI D -1 9 vacci ne as 
descri be d i n Secti o n 1 0. 1 1. 6. 7 .
Rec or d pri or recei pt of a n y  p ne u m oc occal vacci ne as descri be d i n Secti o n 1 0. 1 1. 6. 7 .
Rec or d details of a n y lice nse d i nfl ue nza vacci ne recei ve d i n t he pri or 1 2 m o nt hs, as 
descri be d i n Secti o n 1 0. 1 1. 6. 7 .
E ns ure a n d d oc u me nt t hat all of t he i ncl usi o n criteria a n d n o ne of t he e xcl usi o n criteria 
are met. 
Rec or d A Es as descri be d i n Secti o n 8. 4. 1 .
T he i n vesti gat or or a n a ut h orize d desi g nee c o m pletes t he C R F. 
1 0. 1 1. 8. 8. 2. Visit 1 – V acci n ati o n ( D a y 1) f or S u bst u d y A 
It is a ntici pate d t hat t he pr oce d ures bel o w will be c o n d ucte d i n a ste p wi se ma n ner. 
Disc uss c o ntrace pti ve use as descri be d i n Secti o n 5. 3. 1 .
Rec or d no nst u d y vacci nati o ns as descri be d i n Secti o n 1 0. 1 1. 6. 7 .
Re vie w scree ni n g la b orat or y  res ults (tr o p o ni n I) a n d E C G res ults. 
Perf or m 1 2 -lea d tri plicate E C G. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 4 1 Perf or m a cli nical assess me nt.  If t he cli nical assess me nt i n dicates t hat a p h y sical 
e xa mi nati o n is necessar y t o c o m pre he nsi vel y e val uate t he partici pa nt, perf or m a p h ys ical 
e xa mi nati o n a n d rec or d a n y  fi n di n gs i n t he s o urce d oc u me nts a n d, if cli nicall y  
si g nifica nt, rec or d o n t he me dical hist or y  C R F or o n t he A E C R F as per Secti o n 1 0. 3 .
Meas ure vital si g ns, i ncl u di n g oral te m perat ure, p ulse rate, a n d seate d bl o o d press ure. 
Perf or m uri ne pre g na nc y test o n W O C B P as descri be d i n Secti o n 8. 3. 6 .
E ns ure t hat t he partici pa nt c o nti n ues t o meet all of t he i ncl usi o n criteria a n d n o ne of t he 
e xcl usi o n criteria. 
E ns ure t hat t he partici pa nt meets n o ne of t he te m p orar y  dela y  criteria as descri be d i n 
Secti o n 5. 5 .
O btai n t he partici pa nt’s ra n d o mizati o n n u m ber a n d st u d y  i nter ve nti o n all ocati o n usi n g 
t he I R T s ys te m. 
O n t he da y  of a n d bef ore vacci nati o n, o btai n a nasal ( mi dt ur bi nate) s wa b (c ollecte d b y 
site staff). 
C ollect a bl o o d sa m ple of a p pr o xi matel y  2. 5 m L as detaile d i n t he la b orat or y  ma n ual f or 
tr o p o ni n I  la b orat or y  testi n g as descri be d i n Secti o n 8. 3. 4 .
C ollect a bl o o d sa m ple (a p pr o xi matel y  5 0 m L), bef ore a d mi nistrati o n of st u d y  
i nter ve nti o n, f or i m m u n o ge nicit y  assess me nt. 
Site staff me m ber(s) will dis pe nse/a d mi nister [ADDRESS_371049] u d y  A s h o ul d be a d mi nistere d 
i ntra m usc ularl y i nt o t he delt oi d m uscle of t he ri g ht ar m; w he n QI V is c oa d mi nistere d 
wit h bi vale nt B N T 1 6 2 b 2 ( ori gi nal / O mi B A. 4/ B A. 5) , QI Vs h o ul d be a d mi nistere d 
i ntra m usc ularl y i nt o t he delt oi d m uscle of t he left ar m.  Please refer t o t he I P Mf or f urt her 
i nstr ucti o n o n t his pr ocess. 
Site staff m ust o bser ve t he partici pa nt f or at least [ADDRESS_371050] u d y  i nter ve nti o n 
a d mi nistrati o n f or a n y  ac ute reacti o ns.  Rec or d a n y  ac ute reacti o ns (i ncl u di n g ti me of 
o nset) i n t he partici pa nt’s s o urce d oc u me nts a n d o n t he A E pa ge of t he C R F, a n d o n a n 
S A E f or m as a p plica ble. 
Iss ue a meas uri n g de vice t o meas ure l ocal reacti o ns at t he i njecti o n site a n d a 
t her m o meter f or rec or di n g dail y te m perat ures a n d pr o vi de i nstr ucti o ns o n t heir use. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 4 2 E x plai n t he e -diar y  c o m pleti o n re q uire me nt t o t he partici pa nt a n d assist t he partici pa nt 
wit h d o w nl oa di n g t he st u d y  a p plicati o n o nt o t he partici pa nt’s o w n de vice or iss ue a 
pr o visi o ne d de vice if re q uire d.  Pr o vi de i nstr ucti o ns o n e- diar y  c o m pleti o n a n d as k t he 
partici pa nt t o c o m plete t he react o ge nicit y e -diar y  fr o m Da y 1 t hr o u g h D a y  7, wit h Da y 1 
bei n g t he da y  of vacci nati o n. 
As k t he partici pa nt t o c o ntact t he site staff or i n vesti gat or i m me diatel y if he or s he 
e x perie nces a n y of t he f oll o wi n g fr o m Da y  1 t hr o u g h D a y  7 after vacci nati o n 
( w here Da y 1 is t he da y  of vacci nati o n) t o deter mi ne if a n u nsc he d ule d react o ge nicit y  
visit is re q uire d: 
Fe ver ≥3 9. 0° C ( ≥1 0 2. 1° F). 
Re d ness o r s welli n g at t he i njecti o n site meas uri n g greater t ha n 1 0 c m 
( > 2 0 meas uri n g de vice u nits). 
Se vere pai n at t he i njecti o n site. 
A n y  se vere s ys te mic e ve nt. 
Rec or d A Es as descri be d i n Secti o n 8. 4. 1 .
As k t he partici pa nt t o c o ntact t he site staff or i n vesti gat or if a me dicall y atte n de d e ve nt 
(e g, d oct or’s visit, e mer ge nc y  r o o m visit) or h os pi[INVESTIGATOR_1314] o n occ urs. 
As k t he partici pa nt t o c o ntact t he site staff or i n vesti gat or i m me diatel y if t he partici pa nt 
e x perie nces ac ute c hest pai n, s h ort ness of breat h, or pal pi[INVESTIGATOR_32455] o ns 
(see Secti o n 1 0. 1 1. 8. 8. 1 0 ). 
Sc he d ule a n a p p oi nt me nt f or t he partici pa nt t o ret ur n f or t he ne xt st u d y  visit. 
Re mi n d t he partici pa nt t o bri n g t he e -diar y  t o t he ne xt visit. 
C o m plete t he s o urce d oc u me nts. 
T he i n vesti gat or or a n a ut h orize d desi g nee c o m pletes t he C R Fs a n d u p dates t he st u d y  
i nter ve nti o n acc o u nta bilit y  rec or ds. 
T he i n vesti gat or or a p pr o priatel y  q ualifie d desi g nee re vie ws t he react o ge nicit y  
e- diar y  data o nli ne f oll o wi n g vacci nati o n t o e val uate partici pa nt c o m plia nce a n d as part 
of t he o n g oi n g safet y re vie w.  Dail y re vie w is o pti mal d uri n g t he acti ve diar y peri o d. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 4 3 1 0. 1 1. 8. 8. 3. Visit 2 – D a y 3 F oll o w -U p Visit ( After V acci n ati o n) – [ADDRESS_371051] u d y A 
Rec or d A Es as descri be d i n Secti o n 8. 4. 1 .
Rec or d no nst u d y vacci nati o ns as descri be d i n Secti o n 1 0. 1 1. 6. 7 .
Rec or d pr o hi bite d me dicati o n use as descri be d i n Secti o n 1 0. 1 1. 6. 7. 1 .
Verif y  u n dersta n di n g of a n d c o m plia nce wit h pr ot oc ol re q uire me nts f or c o ntrace pti o n as 
descri be d i n Secti o n 5. 3. 1 .
Re vie w la b orat or y  res ults (tr o p o ni n I) a n d E C G res ults.  A n y  a b n or mal tr o p o ni n I  le vel 
m ust res ult i n f urt her assess me nts as o utli ne d i n Secti o n 1 0. 1 1. 8. 8. 1 0 .
Perf or m 1 2 -lea d tri plicate E C G.  A n y  ne w E C G a b n or malit y  (c o m pare d t o baseli ne) 
c o nsiste nt wit h pr o ba ble or p ossi ble m y ocar ditis or pericar ditis (as liste d i n 
Secti o n 1 0. 1 1. 8. 4. 1 ) m ust res ult i n f urt her assess me nts as o utli ne d i n 
Secti o n 1 0. 1 1. 8. 8. 1 0 .
Meas ure vital si g ns, i ncl u di n g oral te m perat ure, p ulse rate, a n d seate d bl o o d press ure. 
C ollect a bl o o d sa m ple of a p pr o xi matel y  2. 5 m L as detaile d i n t he la b orat or y  ma n ual f or 
tr o p o ni n I  la b orat or y  testi n g as descri be d i n Secti o n 8. 3. 4 .
Re mi n d t he partici pa nt t o c o ntact t he site staff or i n vesti gat or i m me diatel y i f he or s he 
e x perie nces a n y of t he f oll o wi n g fr o m Da y  1 t hr o u g h D a y  7 after vacci nati o n 
( w here Da y 1 is t he da y  of vacci nati o n) t o deter mi ne if a n u nsc he d ule d react o ge nicit y  
visit is re q uire d: 
Fe ver ≥ 3 9. 0° C ( ≥ 1 0 2. 1° F). 
Re d ness or s welli n g at t he i njecti o n site meas uri n g greater t ha n 1 0 c m 
( > 2 0 meas uri n g de vice u nits ). 
Se vere pai n at t he i njecti o n site. 
A n y  se vere s ys te mic e ve nt. 
Re mi n d t he partici pa nt t o c o ntact t he site staff or i n vesti gat or if a me dicall y atte n de d 
e ve nt (e g, d oct or’s visit, e mer ge nc y r o o m visit) or h os pi[INVESTIGATOR_1314] o n occ urs. 
Re mi n d t he partici pa nt t o c o ntact t he site staff or i n vesti gat or i m me diatel yif t he 
partici pa nt e x perie nces ac ute c hest pai n, s h ort ness of breat h, or pal pi[INVESTIGATOR_32455] o ns 
(see Secti o n 1 0. 1 1. 8. 8. 1 0 ). 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 4 4 Sc he d ule a n a p p oi nt me nt f or t he partici pa nt t o ret ur n f or t he ne xt st u d y  visit. 
C o m plete t he s o urce d oc u me nts. 
T he i n vesti gat or or a n a ut h orize d desi g nee c o m pletes t he C R Fs. 
1 0. 1 1. 8. 8. 4. Visit 3 – 1- Wee k F oll o w- U p Visit ( After V acci n ati o n) –[ADDRESS_371052] u d y A 
Rec or d A Es as descri be d i n Secti o n 8. 4. 1 .
Rec or d no nst u d y vacci nati o ns as descri be d i n Secti o n 1 0. 1 1. 6. 7 .
Rec or d pr o hi bite d me dicati o n use as descri be d i n Sec ti o n 1 0. 1 1. 6. 7. 1 .
Verif y  u n dersta n di n g of a n d c o m plia nce wit h pr ot oc ol re q uire me nts f or c o ntrace pti o n as 
descri be d i n Secti o n 5. 3. 1 .
Re vie w la b orat or y  res ults (tr o p o ni n I) a n d E C G res ults.  A n y  a b n or mal tr o p o ni n I  le vel 
m ust res ult i n f urt her assess me nts as o utli ne d i n Secti o n 1 0. 1 1. 8. 8. 1 0 .
Perf or m 1 2 -lea d tri plicate E C G.  A n y  ne w E C G a b n or malit y  (c o m pare d t o baseli ne) 
c o nsiste nt wit h pr o ba ble or p ossi ble m y ocar ditis or pericar ditis (as liste d i n 
Secti o n 1 0. 1 1. 8. 4. 1 ) m ust res ult i n f urt her assess me nts as o utli ne d i n 
Secti o n 1 0. 1 1. 8. 8. 1 0 .
Meas ure vital si g ns, i ncl u di n g oral te m perat ure, p ulse rate, a n d seate d bl o o d press ure. 
C ollect a bl o o d sa m ple of a p pr o xi matel y  2. 5 m L as detaile d i n t he la b orat or y  ma n ual f or 
tr o p o ni n I  la b orat or y  testi n g as descri be d i n Secti o n 8. 3. 4 .
C ollect a bl o o d sa m ple of a p pr o xi matel y  5 0 m L  f or i m m u n o ge nicit y testi n g. 
Re vie w t he partici pa nt’s react o ge nicit y  e -diar y  data.  If t he e -diar y  c ollecti o n peri o d is 
c o m plete: 
C ollect st o p dates of a n y react o ge nicit y  e -diar y  e ve nts o n g oi n g o n t he last da y  
t hat t he react o ge nicit y e -diar y  was c o m plete d a n d rec or d st o p dates i n t he C R F if 
re q uire d. 
C ollect t he partici pa nt’s e- diar y  or assist t he partici pa nt wit h re m o vi n g t he st u d y  
a p plicati o n fr o m his or her o w n pers o nal de vice (if t he visit is c o n d ucte d after 
D a y  7). 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 4 5 Re mi n d t he partici pa nt t o c o ntact t he site staff or i n vesti gat or i m me diatel y i f he or s he 
e x perie nces a n y of t he f oll o wi n g fr o m Da y  1 t hr o u g h D a y  7 after vacci nati o n 
( w here Da y 1is t he da y  of vacci nati o n) t o deter mi ne if a n u nsc he d ule d react o ge nicit y  
visit is re q uire d: 
Fe ver ≥ 3 9. 0° C ( ≥ 1 0 2. 1° F). 
Re d ness or s welli n g at t he i njecti o n site meas uri n g greater t ha n 1 0 c m 
( > 2 0 meas uri n g de vice u nits). 
Se vere pai n at t he i njecti o n site. 
An y  se vere s ys te mic e ve nt. 
Re mi n d t he partici pa nt t o c o ntact t he site staff or i n vesti gat or if a me dicall y atte n de d 
e ve nt (e g, d oct or’s visit, e mer ge nc y  r o o m visit) or h os pi[INVESTIGATOR_1314] o n occ urs. 
Re mi n d t he partici pa nt t o c o ntact t he site staff or i n vesti gat or i m me diatel y if t he 
partici pa nt e x perie nces ac ute c hest pai n, s h ort ness of breat h, or pal pi[INVESTIGATOR_32455] o ns 
(see Secti o n 1 0. 1 1. 8. 8. 1 0 ). 
Sc he d ule a n a p p oi nt me nt f or t he partici pa nt t o ret ur n f or t he ne xt st u d y  visit. 
C o m plete t he s o urce d oc u me nts. 
T he i n vesti gat or or a n a ut h orize d desi g nee c o m pletes t he C R Fs. 
1 0. 1 1. 8. 8. 5. Visit 4 – 4- Wee k F oll o w- U p Visit ( After V acci n ati o n) – [ADDRESS_371053] u d y A 
Rec or d A Es as descri be d i n Secti o n 8. 4. 1 .
Rec or d no nst u d y vacci nati o ns as descri be d i n Secti o n 1 0. 1 1. 6. 7 .
Rec or d pr o hi bite d me dicati o n use as descri be d i n Secti o n 1 0. 1 1. 6. 7. 1 .
Verif y  u n dersta n di n g of a n d c o m plia nce wit h pr ot oc ol re q uire me nts f or c o ntrace pti o n as 
descri be d i n Secti o n 5. 3. 1 .
Re vie w la b orat or y  res ults (tr o p o ni n I) a n d E C G res ults.  A n y  a b n or mal tr o p o ni n I  le vel 
m ust res ult i n f urt her assess me nts as o utli ne d i n Secti o n 1 0. 1 1. 8. 8. 1 0 .
C ollect a bl o o d sa m ple of a p pr o xi matel y  5 0 m L  f or i m m u n o ge nicit y testi n g. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 4 6 Re vie w t he partici pa nt’s react o ge nicit y  e -diar y  data.  C ollect st o p dates of a n y  
react o ge nicit y  e -diar y  e ve nts o n g oi n g o n t he last da y  t hat t he react o ge nicit y  e -diar y  was 
c o m plete d a n d rec or d st o p dates i n t he C R F if re q uire d. 
If n ot alrea d y c o m plete d, c ollect t he partici pa nt’s e -diar y  or assist t he partici pa nt wit h 
re m o vi n g t he st u d y a p plicati o n fr o m his or her o w n p ers o nal de vice. 
Rec or d a n y A Es t hat occ ur wit hi n t he 4 8 h o urs after t he bl o o d dra w as descri be d i n 
Secti o n 8. 4. 1 .
1 0. 1 1. 8. 8. 6. Visi t 5 –8- Wee k F oll o w- U p Visit ( After V acci n ati o n) – [ADDRESS_371054] u d y A 
Rec or d no nst u d y vacci nati o ns as descri be d i n Secti o n 1 0. 1 1. 6. 7 .
Rec or d pr o hi bite d me dicati o n use as descri be d i n Secti o n 1 0. 1 1. 6. 7. 1 .
C ollect a bl o o d sa m ple of a p pr o xi matel y  5 0 m L  f or i m m u n o ge nicit y testi n g. 
Re mi n d t he partici pa nt t o c o ntact t he site staff or i n vesti gat or if a me dicall y atte n de d 
e ve nt (e g, d oct or’s visit, e mer ge nc y  r o o m visit) or h os pi[INVESTIGATOR_1314] o n occ urs. 
Rec or d A Es as descri be d i n Secti o n 8. 4. 1 .
Sc he d ule a n a p p oi nt me nt f or t he partici pa nt t o ret ur n f or t he ne xt st u d y  visit. 
C o m plete t he s o urce d oc u me nts. 
T he i n vesti gat or or a n a ut h orize d desi g nee c o m pletes t he C R Fs. 
Rec or d a n y A Es t hat occ ur wit hi n t he 4 8 h o urs after t he bl o o d dra w as descri be d i n 
Secti o n 8. 4. 1 .
Partici pa nts w h o ha ve n ot recei ve d lice nse d QI V at Visit 1 ma y  recei ve t his, if dee me d as 
re q uire d b y t he i n vesti gat or. 
1 0. 1 1. 8. 8. 7. Visit 6 – 6- M o nt h Tele p h o ne C o nt act –[ADDRESS_371055] u d y A 
C o ntact t he partici pa nt b y  tele p h o ne. 
Rec or d S A Es as descri be d i n Secti o n 8. 4. 1 .
Rec or d no nst u d y vacci nati o ns as descri be d i n Secti o n 1 0. 1 1. 6. 7 .
Rec or d pr o hi bite d me dicati o n use as descri be d i n Secti o n 1 0. 1 1. 6. 7. 1 .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 4 7 C o m plete t he s o urce d oc u me nts. 
T he i n vesti gat or or a n a ut h orize d desi g nee c o m pletes t he C R Fs. 
[ADDRESS_371056] u d y A 
A nasal ( mi dt ur bi nate) s wa b f or S A R S -C o V -2 N A A T is o btai ne d at t he vacci nati o n visit 
( Visit 1/ Da y  1). 
Researc h la b orat or y – ge nerate d p ositi ve res ults fr o m t he vacci nati o n visit s wa bs will be 
pr o vi de d t o t he site o nce a vaila ble, b ut t his will n ot be i n real ti me a n d ca n n ot be relie d u p o n 
t o direct cli nical c are.  T heref ore, t he partici pa nt s h o ul d be directe d t o see k a d diti o nal testi n g 
t hr o u g h his/ her pri mar y  healt hcare pr o vi der at a lice nse d cli nical la b orat or y  w he n e x hi biti n g 
p ote ntial C O VI D - [ADDRESS_371057] u d y A 
If a Gra de 3 l ocal reacti o n ( Secti o n 8. 3. 5. 2 ), s ys te mic e ve nt ( Secti o n 8. 3. 5. 3 ), or fe ver 
(Secti o n 8. 3. 5. 4 ) is re p orte d i n t he react o ge nicit y e -diar y , a tele p h o ne c o ntact s h o ul d occ ur t o 
ascertai n f urt her details a n d deter mi ne w het her a site visit is cli nicall y  i n dicate d.  If a 
s us pecte d Gra de 4 l ocal reacti o n ( Secti o n 8. 3. 5. 2 ), s y ste mic e ve nt ( Secti o n 8. 3. 5. 3 ), or fe ver 
(Secti o n 8. 3. 5. 4 ) is re p orte d i n t he react o ge nicit y e -diar y , a tele p h o ne c o ntact or site visit 
s h o ul d occ ur t o c o nfir m w het her t he e ve nt meets Gra de [ADDRESS_371058] be sc he d ul ed as s o o n as p ossi ble t o assess t he partici pa nt u nless a n y  of t he 
f oll o wi n g is tr ue: 
T he partici pa nt is u na ble t o atte n d t he u nsc he d ule d visit. 
T he l ocal reacti o n/s ys te mic e ve nt is n o l o n ger prese nt at t he ti me of t he tele p h o ne 
c o ntact. 
T he partici pa nt rec or de d a n i nc orrect val ue i n t he react o ge nicit y  e -diar y  (c o nfir mati o n of 
a react o ge nicit y e -diar y  data e ntr y  err or). 
T he PI  [INVESTIGATOR_1660] a ut h orize d desi g nee deter mi ne d it was n ot nee de d. 
T his tele p h o ne c o ntact will be rec or de d i n t he partici pa nt’s s o urce d oc u me ntati o n a n d t he 
C R F. 
If t he partici pa nt is u na ble t o atte n d t he u nsc he d ule d visit, or t he PI  [INVESTIGATOR_1660] a ut h orize d desi g nee 
deter mi ne d it was n ot nee de d, a n y o n g oi n g l ocal reacti o ns/s y ste mic e ve nts m ust be assesse d 
at t he ne xt st u d y  visit. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371059] u d y  n urse, as 
a p plica ble t o t he i n vesti gat or’s l ocal practice, w h o will: 
Meas ure b o d y t e m per at ure ( °F/ °C). 
Meas ure mi ni m u m a n d ma xi m u m dia meters of re d ness (if prese nt). 
Meas ure mi ni m u m a n d ma xi m u m dia meters of s welli n g (if prese nt). 
Assess i njecti o n site pai n (if prese nt) i n acc or da nce wit h t he gra des pr o vi de d i n 
Sec ti o n 8. 3. 5. 2 .
Assess s y ste mic e ve nts (if prese nt) i n acc or da nce wit h t he gra des pr o vi de d i n 
Secti o n 8. 3. 5. 3 .
Assess ot her fi n di n gs ass ociate d wit h t he reacti o n a n d rec or d t his o n t he A E pa ge of t he 
C R F if a p pr o priate. 
T he i n vesti gat or or a n a ut h orize d desi g nee will c o m plete t he u nsc he d ule d visit 
assess me nt pa ge of t he C R F. 
[ADDRESS_371060] pai n, s h ort ness of breat h, pal pi[INVESTIGATOR_32455] o ns, or a n y  
ot her s y m pt o m(s) t hat mi g ht be i n dicati ve of m y ocar ditis or pericar ditis wit hi n [ADDRESS_371061] f or p ossi ble m y ocar ditis or 
pericar ditis.  T he sa me a p plies f or a n y partici pa nt i n w h o m a ne w E C G a b n or malit y  
(c o m pare d t o ba seli ne) c o nsiste nt wit h pr o ba ble or p ossi ble m y ocar ditis or pericar ditis 
(as liste d i n Secti o n 1 0. 1 1. 8. 4. 1 ) or a b n or mal tr o p o ni n I  le v el is o bser ve d at Visit 2 or 3. 
I n a d diti o n t o a cli nical e val uati o n, t he f oll o wi n g s h o ul d be perf or me d: 
E C G a n d 
Meas ure me nt of t he tr o p o ni n le vel 
F or a n y partici pa nt i n w h o m a ne w E C G a b n or malit y  (c o m pare d t o baseli ne) c o nsiste nt wit h 
pr o ba ble or p ossi ble m y o car ditis or pericar ditis (as liste d i n Secti o n 1 0. 1 1. 8. 4. 1 ) or a b n or mal 
tr o p o ni n I  le vel is o bser ve d at Visit 2 or 3, t his s h o ul d be ac hie ve d b y  re peati n g t he 
assess me nts wit h t he ce ntral ve n d or(s). 
If m y ocar ditis or pericar ditis is s us pecte d base d u p o n t he i nitial e val uati o n, t he f oll o wi n g 
s h o ul d als o be perf or me d: 
Car diac ec h ocar di o gra m a n d/ or 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 4 9 Car diac ma g netic res o na nce st u d y 
Details of t he s y m pt o ms re p orte d, a n d res ults of t he i n vesti gati o ns perf or me d, will be 
rec or de d i n t he C R F. 
[ADDRESS_371062] atistic al C o n si der ati o ns –S u bst u d y A 
Met h o d ol o g y f or s u m mar y  a n d statistical a nal ys es of t he data c ollecte d i n t his s u b st u d y  is 
descri be d here a n d f urt her detaile d i n t he S A P, w hic h will be mai ntai ne d b y t he s p o ns or. T he 
S A P ma y  m o dif y  w hat is o utli ne d i n t he pr ot oc o l w here a p pr o priate; h o we ver, a n y maj or 
m o dificati o ns of t he pri mar y  e n d p oi nt defi niti o ns or t heir a nal ys es will als o be reflecte d i n a 
pr ot oc ol a me n d me nt. 
[ADDRESS_371063] u d y  A: 
P o p ul ati o n Descri pti o n 
Scree ne d All partici pa nts w h o si g n t he I C D. 
Ra n d o ml y  assi g ne d t o 
st u d y  i nter ve nti o n All partici pa nts w h o are assi g ne d a ra n d o mizati o n n u m ber i n 
t he I W R s y ste m re gar dless of w het her or n ot t he st u d y  
i nter ve nti o n was a d mi nistere d. 
E val ua ble i m m u n o ge nicit y All partici pa nts w h o are eli gi ble, recei ve t he st u d y 
i nter ve nti o n t o w hic h t he y  were ra n d o mize d, ha ve bl o o d 
dra w n f or assa y  testi n g wit hi n t he s pecifie d ti me fra me after 
vacci nati o n, ha ve at least [ADDRESS_371064] u d y  i nter ve nti o n. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371065] u d y A 
Refer t o Secti o n 9 f or ge neral c o nsi derati o ns of statistical a nal ys es. 
1 0. 1 1. 9. 3. 2. Pri m ar y E n d p oi nt(s)/ Esti m a n d(s) A n al ysis f or S u bst u d y A 
E n d p oi nt St atistic al A n al ysis Met h o ds 
S afet y P oi nt esti mates a n d t he ass ociate d e xact 2 -si de d 9 5 % CIs will be 
calc ulate d usi n g t he Cl o p per -Pears o n met h o d f or t he pr o p orti o n 
of partici pa nts re p orti n g eac h e ve nt (l ocal reacti o ns, s y ste mic 
e ve nts, A Es, a n d S A Es) f or eac h st u d yi nter ve nti o n b y  a ge 
strat u m (1 8 t hr o u g h 6 4 a n d ≥ 6 5 y ears of a ge ) a n d o verall 
(≥ 1 8 ye ars of a ge ). 
P oi nt esti mates a n d t he ass ociate d e xact 2 -si de d 9 5 % CIs will be 
calc ulate d usi n g t he Cl o p per -Pears o n met h o d f or t he pr o p orti o n 
of partici pa nts re p orti n g ab n or mal tr o p o ni n I la b orat or y  val ues 
f or eac h st u d y i nter ve nti o n at 2 d a y s a n d 1 wee k after 
vacci nati o n b y  a ge strat u m (1 8 t hr o u g h 6 4 a n d ≥ 6 5 y ears of 
a ge ) a n d o verall ( ≥ 1 8 y ears of a ge ). 
P oi nt esti mates a n d t he ass ociate d e xact 2- si de d 9 5 % CIs will be 
calc ulate d usi n g t he Cl o p per -Pears o n met h o d f or t he pr o p orti o n 
of partici pa nts wit h ne w E C G a b n or malities f or eac h st u d y 
i nter ve nti o n at 2 wee ks a n d 1 wee k after vacci nati o n b y  a ge 
strat u m ( 1 8 t hr o u g h 6 4 a n d ≥ 6 5 y ears of a ge ) a n d o v erall 
(≥ 1 8 ye ars of a ge ).
1 0. 1 1. 9. 3. 3. Sec o n d ar y E n d p oi nt(s)/ Esti m a n d(s) A n al ysis f or S u bst u d y A 
E n d p oi nt St atistic al A n al ysis Met h o ds 
Sec o n d ar y /
i m m u n o ge nicit y H AI G M Ts a n d t he ass ociate d 2 -si de d 9 5 % CIs will be pr o vi de d f or 
eac h strai n ,b y st u d y i nter ve nti o n ,bef ore vacci nati o n a n d [ADDRESS_371066] u d y i nter ve nti o n b y  a ge strat u m (1 8 t hr o u g h 6 4 
a n d ≥ 6 5 y ears of a ge ). 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371067] atistic al A n al ysis Met h o ds 
H AI G M F Rs fr o m bef ore vacci nati o n t o 4 wee ks after vacci nati o n 
a n d t he ass ociate d 2 -si de d 9 5 % CIs will be pr o vi de d f or eac h strai n ,
b y st u d y i nter ve nti o n ,f or eac h a ge strat u m (1 8 t hr o u g h 6 4 a n d 
≥ 6 5 y ears of a ge ). 
T he pr o p orti o n of partici pa nts ac hie vi n g H AI ser oc o n versi o n at 
4 a n d 8 wee ks after vacci nati o n, a n d t he pr o p orti o n of partici pa nts 
wit h H AI titers ≥ 1: 4 0 bef ore vacci nati o n a n d at 4 wee ks after 
vacci nati o n, a n d t he ass ociate d 2 -si de d Cl o p per- Pears o n 9 5 % CIs, 
will be pr o vi de d f or eac h strai n ,b y st u d y i nter ve nti o n ,f or eac h a ge 
strat u m ( 1 8 t hr o u g h 6 4 a n d ≥ 6 5 y ears of a ge ).
T he pr o p orti o n of partici pa nts ac hie vi n g H AI ser oc o n v ersi o n at 
4 a n d 8 wee ks after vacci nati o n a n d t he pr o p orti o n of partici pa nts 
wit h H AI titers ≥ 1: 4 0 bef ore vacci nati o n a n d at 4 wee ks after 
vacci nati o n, a n d t he ass ociate d 2 -si de d Cl o p per- Pears o n 9 5 % CIs, 
will be pr o vi de d f or all strai ns b y st u d y i nter ve nti o n f or eac h a ge 
strat u m (1 8 t hr o u g h 6 4 a n d ≥ 6 5 y ears of a ge ). 
T he strai ns me nti o ne d a b o ve refer t o t he matc he d seas o nal strai ns 
( ) rec o m me n de d b y  W H O .
G M Ts a n d t he ass ociate d 2 -si de d 9 5 % CIs will be pr o vi de d f or eac h 
strai n -s pecific ne utralizi n g titer bef ore vacci nati o n a n d 4wee ks after 
vacci nati o n b y  st u d y  i nter ve nti o n f or eac h a ge strat u m (1 8 t hr o u g h 
6 4 a n d ≥ 6 5 y ears of a ge ).
G M F R fr o m bef ore vacci nati o n t o 4 wee ks after vacci nati o n a n d t h e
ass ociate d 2- si de d 9 5 % CIs will be pr o vi de d f or eac h strai n -s pecific 
ne utralizi n g titer b y  st u d y  i nter ve nti o n f or eac h a ge strat u m 
(1 8 t hr o u g h 6 4 a n d ≥ 6 5 years of a ge ). 
Perce nta ges of partici pa nts wit h ser ores p o nse a n d t he ass ociate d 
2-si de d Cl o p per -Pears o n 9 5 % CI s will be pr o vi de d at [ADDRESS_371068] u d y  i nter ve nti o n ,f or eac h a ge 
strat u m (1 8 t hr o u g h 6 4 a n d ≥ 6 5 y ears of a ge ). 
T he strai n me nti o ne d a b o ve refer st o t he S A R S -C o V - 2 
O micr o n B A. 4/ B A. 5 or S A R S -C o V -2 refere nce strai n. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371069] or at or y E n d p oi nt(s)/ Esti m a n d(s) A n al ysis f or S u bst u d y A 
I m m u ne res p o nse 
t o e mer gi n g V O Cs G M Ts of S A R S- C o V - 2 ne utralizi n g titers f or V O Cs n ot alrea d y 
s pecifie d, al o n g wit h t he ass ociate d 2 -si de d 9 5 % C Is, will be 
pr o vi de d at s pecific ti me p oi nts f or eac h vacci ne gr o u p b y  a ge 
strat u m (1 8 t hr o u g h 6 4 a n d ≥6 5 y ears of a ge ).
G M F Rs fr o m baseli ne ( bef ore t he st u d y  vacci nati o n) t o eac h 
s u bse q ue nt ti me p oi nt, perce nta ge of partici pa nts wit h ser ores p o nse 
at eac h ti me p oi nt a fter vacci nati o n, al o n g wit h t he ass ociate d 
2- si de d 9 5 % CIs, ma y  als o be pr o vi de d f or eac h st u d y  i nter ve nti o n 
b y  a ge strat u m ( 1 8 t hr o u g h 6 4 a n d ≥ 6 5 y ears of a ge ). 
E x pl or at or y H AI G M Ts a n d t he ass ociate d 2 -si de d 9 5 % CIs will be pr o vi de d 
f or eac h strai n ,b y st u d y i nter ve nti o n ,bef ore vacci nati o n a n d 
1a n d 8wee k safter recei pt of t he st u d y i nter ve nti o n ,b y  a ge 
strat u m ( 1 8 t hr o u g h 6 4 a n d ≥6 5 y ears of a ge). 
H AI G M F Rs fr o m bef ore vacci nati o n t o 1 a n d 8 wee k safter 
vacci nati o n a n d t he ass ociate d 2- si de d 9 5 % CIs will be pr o vi de d 
f or eac h strai n ,b y st u d y i nter ve nti o n ,f or eac h a ge strat u m 
(1 8 t hr o u g h 6 4 a n d ≥ 6 5 years of a ge). 
T he pr o p orti o n of partici pa nts ac hie vi n g H AI ser oc o n versi o n at 
1a n d 8 wee k safter vacci nati o n, a n d t he pr o p orti o n of partici pa nts 
wit h H AI titers ≥1: 4 0 bef ore vacci nati o n a n d at 1 a n d 8 wee k s
after vacci nati o n, a n d t he ass ociate d 2 -si de d Cl o p per -Pears o n 
9 5 % CI s, will be pr o vi de d f or eac h strai n ,b y st u d y i nter ve nti o n ,
f or eac h a ge strat u m ( 1 8 t hr o u g h 6 4 a n d ≥6 5 y ears of a ge). 
T he pr o p orti o n of partici pa nts ac hie vi n g H AI ser oc o n versi o n at 
1a n d 8 wee k safter vacci nati o n a n d t he pr o p orti o n of partici pa nts 
wit h H AI titers ≥1: 4 0 bef ore vacci nati o n a n d at 1 a n d 8 wee k s
after vacci na ti o n, a n d t he ass ociate d 2- si de d Cl o p per -Pears o n 
9 5 % CI s, will be pr o vi de d f or all strai ns, b y st u d y i nter ve nti o n ,f or 
eac h a ge strat u m ( 1 8 t hr o u g h 6 4 a n d ≥6 5 y ears of a ge) .
T he strai ns me nti o ne d a b o ve refer t o t he matc he d seas o nal strai ns 
( ) rec o m me n de d b y  W H O. 
G M Ts a n d t he ass ociate d 2 -si de d 9 5 % CIs will be pr o vi de d f or 
eac h strai n -s pecific ne utralizi n g titer bef ore vacci nati o n a n d [ADDRESS_371070] u d y  i nter ve nti o n ,f or eac h a ge 
strat u m ( 1 8 t hr o u g h 6 4 a n d ≥ 6 5 ye ars of a ge) .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 5 3 G M F R fr o m bef ore vacci nati o n t o 1 a n d 8 wee k safter vacci nati o n 
a n d t he ass ociate d 2- si de d 9 5 % CIs will be pr o vi de d f or eac h 
strai n -s pecific ne utralizi n g titer ,b y  st u d y  i nter ve nti o n ,f or eac h 
a ge strat u m ( 1 8 t hr o u g h 6 4 a n d ≥ 6 5 y ears of a ge) .
Perce nta ges of partici pa nts wit h ser ores p o nse a n d t he ass ociate d 
2- si de d Cl o p per -Pears o n 9 5 % CI s will be pr o vi de d at 
1a n d [ADDRESS_371071] u d y  
i nter ve nti o n ,f or eac h a ge strat u m ( 1 8 t hr o u g h 6 4 a n d ≥6 5 y ears of 
a ge) .
T he strai n me nti o ne d a b o ve refers t o t he S A R S -C o V - 2 
O micr o n B A. 4/ B A. [ADDRESS_371072] u d y A 
Partici pa nts wit h E C G a b n or malit ies will be liste d. T he n u m ber a n d pr o p orti o n of 
partici pa nts wit h a n y ne w E C G a b n or malit ies after vacci nati o n will be pr o vi de d b y  vacci ne 
gr o u p b y  a ge strat u m (1 8 t hr o u g h 6 4 a n d ≥6 5 y ears of a ge ) a n d o verall ( ≥1 8 y ears of a ge ). 
[ADDRESS_371073] u d y  partici pa nts w h o re p ort a n y  s y m pt o m(s) t hat mi g ht be i n dicati ve 
of m y ocar ditis or pericar ditis wit hi n [ADDRESS_371074] u d y  vacci nati o n ( E C G, tr o p o ni n le vel, 
car diac ec h ocar di o gra m, a n d/ or car diac ma g netic res o na nce st u d y ) will be s u m marize d a n d 
liste d b y  vacci ne gr o u p b y  a ge strat u m (1 8 t hr o u g h 6 4 a n d ≥ 6 5 y ears of a ge ) a n d o verall 
(≥ 1 8 y ears of a ge ). 
[ADDRESS_371075] t o partici pa nts’ st u d y  i nter ve nti o n assi g n me nts (e xce pt f or staff 
r o uti nel y  i nteracti n g wit h sites), t he s p o ns or ma y  c o n d uct u n bli n de d re vie ws of t he data 
d uri n g t he c o urse of t he st u d y  f or t he p ur p ose of safet y assess me nt, facilitati n g 
d ose -escalati o n decisi o ns a n d/ or s u p p orti n g cli nical de vel o p me nt. 
[ADDRESS_371076] u d y  is n ot base d 
o n a n y  statistical h y p ot hesis testi n g. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 5 4 A p pr o xi matel y  3 0 partici pa nts will be e nr olle d f or eac h vacci ne gr o u p i n eac h a ge strat u m 
(1 8 t hr o u g h 6 4 a n d ≥ 6 5 years of a ge ); t heref ore, a t otal of a p pr o xi matel y [ADDRESS_371077] 1 A E 
3 0 0. 5 % 1 4. 0 % 
1. 0 % 2 6. 0 % 
2. 0 % 4 5. 5 % 
5. 0 % 7 8. 5 % 
7. 0 % 8 8. 7 % 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 5 5 1 0. 1 2. A p pe n di x 1 2: S u bst u d y B(P h ase 1/ 2 )
1 0. 1 2. 1. S o A –S u bst u d y B ( P h ase 1/ 2 )
Visit N u m ber Scree ni n g [ADDRESS_371078] 
Visit Wi n d o w ( D a ys) 0 t o 2 8 D a ys 
Bef ore 
Visit 2 0 1D a y 1 2 t o 4 
D a ys After 
Visit 2 0 16 t o 8 
D a ys After 
Visit 2 0 12 6 t o 3 0 
D a ys After 
Visit 2 0 11 7 5 t o 1 8 9 D a ys 
After Visit 2 0 1
Visit T y pe/ L oc ati o n Site Site Site or 
H o m e 
He alt h aSite or 
H o m e 
He alt haSite or 
H o m e 
He alt h aTele he alt h b
O btai n i nf or me d c o nse nt X
Assi g n partici pa nt n u m ber X
O btai n de m o gra p h y a n d me dical hist or y data (i ncl u di n g 
c o nfir me d C O VI D -[ADDRESS_371079] res ult [ N A A T or a nti ge n test]) X
O btai n details of me dicati o ns c urre ntl y ta ke n X
Perf or m p h ysical e xa mi nati o n X
Perf or m cli nical assess me nt cX
Meas ure hei g ht a n d w ei g ht X
Meas ure vital si g ns (i ncl u di n g oral te m perat ure) X X X  X 
Perf or m [ADDRESS_371080] bl o o d sa m ple f or tr o p o ni n I la b orat or y testi n g ~ 2. 5 m L ~ 2. 5 m L d~ 2. 5 m L ~ 2. [ADDRESS_371081] (if a p pr o priate) X X
C o nfir m use of c o ntrace pti ves (if a p pr o priate) X X X  X  X 
C ollect pri or C O VI D -[ADDRESS_371082] pr o hi bite d me dicati o n use X  X  X X
Re vie w tr o p o ni n I a n d E C G res ults X X  X  X 
C o nfir m eli gi bilit y X X0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371083] 
Visit Wi n d o w ( D a ys) 0 t o 2 8 D a ys 
Bef ore 
Visit 2 0 1D a y 1 2 t o 4 
D a ys After 
Visit 2 0 16 t o 8 
D a ys After 
Visit 2 0 12 6 t o 3 0 
D a ys After 
Visit 2 0 11 7 5 t o 1 8 9 D a ys 
After Visit 2 0 1
Visit T y pe/ L oc ati o n Site Site Site or 
H o m e 
He alt h aSite or 
H o m e 
He alt haSite or 
H o m e 
He alt h aTele he alt h b
O btai n ra n d o mizati o n n u m ber a n d st u d y i nter ve nti o n all ocati o n X
Re vie w t e m p or ar y  dela y criteria X
C ollect bl o o d sa m ple f or i m m u n o ge nicit y assess me nt ~ 1 5 or 
~ 5 0 m L d, e ~ 1 5 or 
~ [ADDRESS_371084] o ge nicit y e -diar y data ( dail y re vie w is o pti m al 
d uri n g t he acti ve diar y peri o d) 
Re vie w o n g oi n g react o ge nicit y e -diar y s y m pt o ms a n d o btai n st o p 
dates X  X 
C ollect A Es a n d S A Es as a p pr o priate f, d X X X  X  X X
C ollect e -diar y or assist t he partici pa nt wit h deleti n g a p plicati o n X  X 
a. Visit ma y be c o m plete d as a h o me healt h visit (see Secti o n 1 0. 1 2. 8. 2 ). 
b. Visit will be c o m plete d as a tele healt h visit (see Secti o n 1 0. 1 2. 8. 1 ). 
c. I ncl u di n g, if i n dicate d, a p h ysical e xa mi nati o n. 
d. Pri or t o vacci nati o n at Visit 2 0 1. 
e. O nl y u p t o 2 0 partici pa nts i n Gr o u ps 3, 4, a n d 5 w ill ha ve 5 0 m L dra w n (see Secti o n 1 0. 1 2. 4. 1 ). 
f.  A E s are c ollecte d fr o m t he c o m pleti o n of i nf or me d c o nse nt t hr o u g h Visit [ADDRESS_371085] be rec or de d. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371086] u d y BR ati o n ale 
T his P hase 1/ [ADDRESS_371087] u d y  will descri be t he safet y, t olera bilit y , a n d i m m u n o ge nicit y  of I R V
(qI R V, t I R V, or b I R V ) w he n a d mi nistere d i n c o m bi nati o n wit h bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) .Bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) will be use d 
d uri n g S u bst u d y  B ,as detaile d i n Ta ble 2.  S u bst u d y  B will be si n gle -bli n d 
(s p o ns or -u n bli n de d). 
[ADDRESS_371088] u d y B 
See Secti o n 2. 2 .
1 0. 1 2. 2. 3. Be nefit/ Ris k Assess me nt f or S u bst u d y B 
See Secti o n 2. 3. [ADDRESS_371089] u d y  B ma y  be: 
Recei pt of a d ose of a n efficaci o us or p ote ntiall y efficaci o us C O VI D -1 9 vacci ne. 
Recei pt of a p ote ntiall y efficaci o us i nfl ue nza vacci ne at n o c ost t o t he partici pa nt, a n d 
pr o visi o n of t he i m m u n o ge nicit y  res ults i n a s u bset of partic i pa nts. 
C o ntri b uti n g t o researc h t o hel p ot hers. 
Please see Secti o n 2. [ADDRESS_371090] u d y  B. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 5 8 1 0. 1 2. 3. O bjecti ves, E n d p oi nts, a n d Esti m a n ds ( S u bst u d y B) 
S u bst u d y B ( P h ase 1/ 2 )
O bjecti ves Esti m a n ds E n d p oi nts 
Pri m ar y S afet y Pri m ar y S afet y Pri m ar y S afet y 
To descri be t he safet y a n d 
tolera bilit y of st u d y 
i nter ve nti o ns i n partici pa nts 
[ADDRESS_371091] u d y i nter ve nti o n, 
t he perce nta ge of partici pa nts wit h: 
A b n or mal tr o p o ni n I la b orat or y val ues 
2 da ys a n d 1 wee k after vacci nati o n Tr o p o ni n I la b orat or y para meters 
detaile d i n Secti o n [ADDRESS_371092] u d y i nter ve nti o n, 
t he perce nta ge of partici pa nts wit h: 
Ne w E C G a b n or malities 2 da ys a n d 
1wee k after vacci nati o n E C G a b n or malities c o nsiste nt wit h 
pr o ba ble or p ossi ble m y ocar ditis or 
pericar ditis as defi ne d i n 
Secti o n [ADDRESS_371093] u d y i nter ve nti o n, 
t he perce nta ge of partici pa nts re p orti n g: 
L ocal reacti o ns f or u p t o 7 da ys f oll o wi n g 
vacci n ati o n i n t he ri g ht ar m o nl y 
S yste mic e ve nts f or u p t o 7 da ys f oll o wi n g 
vacci nati o n 
A E s fr o m vacci nati o n t hr o u g h 4   wee ks after 
vacci nati o n 
S A Es fr o m vacci nati o n t hr o u g h 6m o nt hs 
after vacci nati o n L ocal reacti o ns ( pai n at t he i njecti o n 
site, re d ness, a n d s welli n g) i n t he ri g ht 
ar m o nl y 
S yste mic e ve nts (fe ver, fati g ue, 
hea dac he, c hills, v o miti n g, diarr hea, 
ne w or w orse ne d m uscle pai n, a n d ne w 
or w orse ne d j oi nt pai n) 
A Es 
S A Es 
Sec o n d ar y I m m u n o ge nicit y a Sec o n d ar y I m m u n o ge nicit y Sec o n d ar y I m m u n o ge nicit y 
T o descri be t he i m m u ne 
res p o nses t o S A R S -C o V -[ADDRESS_371094] yi n g wit h t he ke y pr ot oc ol criteria 
(e val ua ble partici pa nts): 
G M Ts bef ore vacci nati o n a n d at eac h 
bl o o d sa m pli n g ti me p oi nt after i nfl ue nza 
vacci nati o n 
G M F R fr o m bef ore vacci nati o n t o eac h 
bl o o d sa m pli n g ti me p oi nt after i nfl ue nza 
vacci nati o n 
T he pr o p orti o n of partici pa nts ac hie vi n g 
H AI ser oc o n versi o n bf or eac h strai n at 
eac h bl o o d sa m pli n g ti me p oi nt af ter 
i nfl ue nza vacci nati o n 
T he perce nta ge of partici pa nts wit h H AI 
titers ≥ 1: 4 0 f or eac h strai n bef ore 
vacci nati o n a n d at eac h bl o o d sa m pli n g 
ti me p oi nt after i nfl ue nza vacci nati o n H AI titers f or t he matc he d seas o nal 
strai ns rec o m me n de d b y W H O 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371095] u d y B ( P h ase 1/ 2 )
O bjecti ves Esti m a n ds E n d p oi nts 
I n partici pa nts [ADDRESS_371096] yi n g wit h t he ke y pr ot oc ol criteria 
(e val ua ble partici pa nts): 
G M Ts bef ore vacci nati o n a n d at eac h 
bl o o d sa m pli n g ti me p oi nt after 
vacci nati o n f or eac h strai n 
G M F R fr o m bef ore S A R S -C o V - 2 
vacci nati o n t o eac h bl o o d sa m pli n g ti me 
p oi nt after S A R S -C o V - 2 vacci nati o n f or 
eac h strai n 
Perce nta ges of partici pa nts wit h 
ser ores p o nse cat eac h bl o o d sa m pli n g ti me 
p oi nt after S A R S -C o V - 2 vacci nati o n f or 
eac h strai n S A R S -C o V - 2 ne utralizi n g titers b y 
strai n 
Terti ar y/ E x pl or at or y Terti ar y/ E x pl or at or y Terti ar y/ E x pl or at or y 
T o descri be t he i m m u ne 
res p o nse t o e mer gi n g varia nts 
( u n der m o nit ori n g, of i nterest, 
a n d/ or of c o ncer n) i n 
partici pa nts 1 8 t hr o u g h 
6 4 years of a ge As detaile d i n t he S A P S A R S -C o V -2 ne utralizi n g titers f or 
varia nts ( u n der m o nit ori n g, of 
i nterest ,a n d/ or of c o ncer n ) 
T o descri be t he tr o p o ni n a n d 
E C G a b n or malities detecte d 
i n partici pa nts w h o are 
e val uate d f or p ossi ble car diac 
s y m pt o ms  As detaile d i n t he S A P Tr o p o ni n I la b orat or y para meters 
detaile d i n Secti o n 1 0. 2 
E C G a b n or malities c o nsiste nt wit h 
pr o ba ble or p ossi ble m y ocar ditis or 
pericar ditis as defi ne d i n 
Secti o n [ADDRESS_371097] u d y. 
b. Ser oc o n versi o n is defi ne d as a n H AI titer < 1: 1 0 pri or t o vacci nati o n a n d ≥ 1: [ADDRESS_371098], or a n H AI 
titer of ≥ 1: [ADDRESS_371099]. 
c. Ser ores p o nse is defi ne d as ac hie vi n g a ≥ 4 -f ol d rise fr o m baseli ne ( bef ore t he st u d y vacci nati o n). If t he baseli ne 
meas ure me nt is bel o w t he L L O Q, t he p ost vacci n ati o n meas ure of ≥ 4 × L L O Q is c o nsi dere d ser ores p o nse. 
[ADDRESS_371100] u d y B 
T his is a P hase 1/ [ADDRESS_371101] u d y  t o descri be t he safet y, t olera bilit y , a n d i m m u n o ge nicit y  of I R V 
( qI R V, tI R V, or bI R V) w he n a d mi nistere d i n c o m bi nati o n wit h bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) . Bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A . 4/ B A. 5) will be use d 
d uri n g S u bst u d y  B , as detaile d i n Ta ble 2. Bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) 
was rec o m me n de d b y A CI P i n [ADDRESS_371102] u d y will be si n gle -bli n d 
(s p o ns or -u n bli n de d). 
D uri n g S u bst u d y  B, u p t o a p pr o xi matel y  6 3 0 partici pa nts 1 8 t hr o u g h 6 4 ye ars of a ge will be 
e nr olle d. 
Ra n d o mizati o n will be c o n d ucte d acr oss 3 e nr oll me nt c o h orts i n de pe n de ntl y  d ue t o lice nse d 
QI V a vaila bilit y , wit h e nr oll me nt i n t hese c o h orts bei n g c o n d ucte d eit her c o nc urre ntl y or at 
differe nt ti mes as re q uire d base d o n o perati o nal c o nsi derati o ns as s h o w n i n Ta ble 8.0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371103] u d y B E nr oll me nt C o h orts 
E nr oll me nt 
C o h ort T ot al N u m ber 
of 
P artici p a nts N u m ber of 
P artici p a nts 
per V acci ne 
Gr o u p V acci ne 
Gr o u p 
N u m ber V acci ne Gr o u p Descri pti o ns 
1 6 0 3 0 1 Lice nse d QI V (Fl ucel va x )a d mi nistere d c o nc urre ntl y 
i n t he o p p osite ar m t o µ g bi vale nt B N T 1 6 2 b 2 
( ori gi nal */ O mi B A. 4/ B A. 5) 
2 Lice nse d QI V (Fl ucel va x )a d mi nistere d c o nc urre ntl y 
i n t he o p p osite ar m t o bI R V/ bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) 
2 3 6 0 U p t o 1 2 0 3 qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ 
O m i B A. 4/ B A. 5) at d ose -le vel c o m bi nati o n 1 a
4 qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ 
O m i B A. 4/ B A. 5) at d ose -le vel c o m bi nati o n 2 a
5 qI R V/ bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5) at d ose -le vel 
c o m bi nati o n 3 a
3 2 1 0 3 0 6 qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ 
O m i B A. 4/ B A. 5) at d ose -le vel c o m bi nati o n 4 a
7 qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ 
O m i B A. 4/ B A. 5) at d ose -le vel c o m bi nati o n 5 a
8 qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ 
O m i B A. 4/ B A. 5) at d ose -le vel c o m bi nati o n 6 a
9 qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ 
O m i B A. 4/ B A. 5) at d ose -le vel c o m bi nati o n 7 a
1 0 qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ 
O m i B A. 4/ B A. 5) at d ose -le vel c o m bi nati o n 8 a
1 1 tI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi \B A . 4/ B A. 5) 
1 2 qI R V 
a. C o m bi nati o ns as s h o w n i n Ta ble 2. 
N ote: *  Ori gi nal refers t o t he a ncestral strai n ( W u ha n -H u -1; U S A -W A 1/ 2 0 2 0), als o referre d t o i n t his pr ot oc ol as t he 
refere nce strai n. 
E nr oll me nt of partici pa nts [ADDRESS_371104] u d y  B ( G r o u ps 2, 6, 7, 8, 9, 1 0, 1 1, a n d 1 2), t he e nr oll me nt will be c o ntr olle d 
s uc h t hat n o m ore t ha n 1 0 partici pa nts (c o nsi dere d se nti nel partici pa nts) ca n be vacci nate d o n 
t he first da y ; vacci nati o n of t he re mai ni n g partici pa nts will c o m me nce n o s o o ner t ha n 
[ADDRESS_371105] orat or y  c o m bi nat i o ns of 
bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) wit h qI R V , tI R V, a n d bI R V ,as detaile d i n 
Secti o n 1 0. 1 2. 8. 7 .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371106] u d y  B will be re vie we d b y t he s p o ns or’s I R C ,a n d if t he se data are 
dee me d acce pta ble, t he I R C will e val uate w hic h gr o u ps (as detaile d i n Ta ble 2) are 
acce pta b le f or f urt her st u d y . 
I m m u n o ge nicit y Bl o o d Dr a ws i n S u bst u d y B :
Bl o o d sa m ples of a p pr o xi matel y  1 5 m L  will be c ollecte d f or i m m u n o ge nicit y  assess me nts 
pri or t o vacci nati o n a n d at 4 wee ks after vacci nati o n. U p t o 2 0 partici pa nts i n Gr o u ps 3, 4, 
a n d 5 f or t he 1 8 -t hr o u g h 6 4- ye ar a ge strat u m will be as ke d t o c o nse nt t o alter nati vel y 
pr o vi di n g 5 0 -m L , rat her t ha n 1 5 -m L , bl o o d sa m ples at t he sa me ti me p oi nts, w hic h will be 
use d f or i m m u n o ge nicit y assess me nts as well as assa y  de vel o p me nt / mai nte na nce . 
F or S u bst u d y  B bl o o d dra ws (as detaile d a b o ve) ,u p t o t he first [ADDRESS_371107] u d y  if he/s he has c o m plete d all 
peri o ds of t he s u bst u d y, i ncl u di n g t he last visit. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371108] y :
A ge a n d Se x: 
1. Male or fe male p artici pa nts 1 8 thr o u g h 6 4 ye ars of a ge ( or t he mi ni m u m a ge of c o nse nt 
i n acc or da nce wit h l ocal re g ulati o ns) at Visit 20 1 ( Da y  1). 
Refer t o A p pe n di x 5f or re pr o d ucti ve criteria f or male (Secti o n 1 0. 5. 1 )a n d 
fe male (Secti o n 1 0. 5. 2 ) partici pa nts. 
Dise ase C h ar acteristics: 
N ot a p plica ble. 
Ot her I ncl usi o n Criteri a: 
2. Partici pa nts w h o are willi n g a n d a ble t o c o m pl y wit h all sc he d ule d visits, i n vesti gati o nal 
pla n, la b orat or y  tests, lifest y le c o nsi derati o ns, a n d ot her st u d y  pr oce d ures. 
3. Healt h y partici pa nts w h o are deter mi ne d b y me dical hist or y, p h ys ical e xa mi nati o n 
(if re q uire d), a n d cli nical j u d g me nt of t he i n vesti gat or t o be eli gi ble f or i ncl usi o n i n t he 
st u d y .
N ote: Healt h y partici pa nts wit h pree xisti n g sta ble disease, defi ne d as disease n o t 
re q uiri n g si g nifica nt c ha n ge i n t hera p y or h os pi[INVESTIGATOR_1314] o n f or w orse ni n g disease d uri n g 
t he [ADDRESS_371109] d ose bei n g a n u p date d ( bi vale nt) vacci ne gi ve n at least 
1 5 0 da y s bef ore Visit 2 0 1. A n y  d ose of m o d R N A C O VI D - 1 9 vacci ne recei ve d after 
01 Se pte m ber 2 0 2 2 ma y  be c o nsi dere d t o be a bi vale nt vacci ne i n t he U S .
N ote: D oc u me nte d c o nfir mati o n of pri or d oses of S A R S -C o V -2vacci ne recei ve d m ust be 
o btai ne d pri or t o ra n d o mizati o n .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371110] y :
Me dic al C o n diti o ns: 
1. Me dical or ps yc hiatric c o n diti o n, i ncl u di n g rece nt ( wit hi n t he past year) or acti ve s uici dal 
i deati o n/ be ha vi or or la b orat or y  a b n or malit y , t hat ma y  i ncrease t he ris k of st u d y  
partici pati o n or, i n t he i n vesti gat or’s j u d g me nt, ma ke t he partici pa nt i na p pr o priate f or t he 
st u d y .
2. Hist or y  of se vere a d verse reacti o n ass ociate d wit h a n y  vacci ne a n d/ or se vere aller gic 
reacti o n (e g, a na p h yl a xis) t o a n y  c o m p o ne nt of t he st u d y  i nte r ve nti o n(s). 
3. I m m u n oc o m pr o mise d i n di vi d uals wit h k n o w n or s us pecte d i m m u n o deficie nc y , as 
deter mi ne d b y hist or y  a n d/ or la b orat or y / p h y sical e xa mi nati o n. 
4. Blee di n g diat hesis or c o n diti o n ass ociate d wit h pr ol o n ge d blee di n g t hat w o ul d, i n t he 
o pi [INVESTIGATOR_9384] o n of t he i n ves ti gat or, c o ntrai n dicate i ntra m usc ular i njecti o n. 
5. W o me n w h o are pre g na nt or breastfee di n g .
6. Hist or y  of m y o car ditis or pericar ditis .
Pri or/ C o nc o mit a nt T her a p y: 
7. Recei pt of c hr o nic me dicati o ns wit h k n o w n s y ste mic i m m u n os u p pressa nt effects 
(i ncl u di n g c y t ot o xic a ge nts or s y ste mic c ortic oster oi ds), or ra di ot hera p y , wit hi n [ADDRESS_371111] u d y. 
N ote: S y ste mic c ortic oster oi ds are defi ne d as t h ose a d mi nistere d f or ≥ 1 4 da y s at a d ose 
of ≥2 0 m g/ da y  of pre d nis o n e or e q ui vale nt (e g, f or ca ncer or a n a ut oi m m u ne disease) or 
pla n ne d recei pt t hr o u g h o ut t he st u d y .  I n hale d/ ne b ulize d, i ntra -artic ular, i ntra b ursal, or 
t o pi[INVESTIGATOR_2855] (s ki n or e y es) c ortic oster oi ds are per mitte d. 
8. Recei pt of bl o o d/ plas ma pr o d ucts, i m m u n o gl o b uli n, or m o n ocl o nal a nti b o dies use d f or 
t he treat me nt or pre ve nti o n of C O VI D -[ADDRESS_371112] u d y .
9. Vacci nati o n wit h a n y  i n vesti gati o nal o r lice nse d i nfl ue nza vacci ne wit hi n 6 m o nt hs 
( 1 7 5 d a y s) bef ore st u d y i nter ve nti o n a d mi nistrati o n, or o n g oi n g recei pt of c hr o nic 
a nti viral t hera p y wit h acti vit y  a gai nst i nfl ue nza. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 6 4 Pri or/ C o nc urre nt Cli nic al St u d y E x perie nce: 
[ADDRESS_371113] u d y  i nter ve nti o n wit hi n 
2 8 da y s pri or t o, a n d/ or d uri n g, partici pati o n i n t his st u d y .
N ote: I n a d diti o n t o a d mi nistrati o n of i n vesti gati o nal pr o d ucts, st u d y  i nter ve nti o ns ma y  
i ncl u de a d diti o nal pr oce d ures, s uc h as c ollecti o n o f bi ol o gical sa m ples. T heref ore, 
partici pa nts ma y  n ot be i n a n ot her st u d y  w here b y pr oce d ures, s uc h as res pi[INVESTIGATOR_1305] y ill ness 
visits, ma y  i nterfere wit h c o m plia nce wit h t his st u d y ’s pr ot oc ol. 
Di a g n ostic Assess me nts: 
N ot a p plica ble. 
Ot her E xcl usi o n Criteri a: 
[ADDRESS_371114] u d y  a n d t heir fa mil y  
me m bers. 
A d diti o n al E xcl usi o n Criteri a: 
[ADDRESS_371115] or y  of heart disease of c o ncer n: hist or y  of m y ocar ditis, pericar ditis, 
car di o m y o pat h y, c or o nar y arter y disease (i ncl u di n g hist or y of m y ocar d ial i nfarcti o n, 
u nsta ble a n gi na), N Y H A Class III a n d a b o ve heart fail ure, or si g nifica nt arr h y t h mias 
[ADDRESS_371116] u d y  res ults.  Partici pa nts wit h a 
scree ni n g 1 2 -lea d E C G t hat s h o ws a n a vera ge Q Tc F i nter val > [ADDRESS_371117] u d y  
partici pat i o n. 
1 0. 1 2. 5. 3. Criteri a f or Te m p or aril y Del a yi n g 
E nr oll me nt/ R a n d o miz ati o n/ A d mi nistr ati o n of St u d y I nter ve nti o n f or S u bst u d y B 
T he f oll o wi n g c o n diti o ns ma y  all o w a partici pa nt t o be ra n d o mize d o nce t he c o n diti o ns ha ve 
res ol ve d a n d t he partici pa nt is ot her wise eli gi ble.  Partici pa nts meeti n g t hese criteria at 
Visit 2 0 1 will be c o nsi dere d scree n fail ures if e nr oll me nt has cl ose d o nce t he c o n diti o n(s) 
has/ ha ve res ol ve d. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371118] res ult ( N A A T or ra pi d a nti ge n test) wit hi n t he pre vi o us 
2 8 da y s. 
2. C ur re nt fe brile ill ness ( oral te m perat ure ≥ 3 8. 0° C [ ≥1 0 0. 4° F]) or ot her ac ute ill ness wit hi n 
[ADDRESS_371119] u d y  i nter ve nti o n 
a d mi nistrati o n at Visit 2 0 1. 
5. Recei pt of s h ort -ter m ( 1 4 da y s) s y ste mic c ortic oster oi ds.  St u d y  i nter ve nti o n 
a d mi nistrati o n s h o ul d be dela y e d u ntil s y ste mic c ortic oster oi d use has bee n disc o nti n ue d 
f or at least 2 8 da y s.  I n hale d/ ne b ulize d, i ntra -artic ular, i ntra b ursal, or t o pi[INVESTIGATOR_2855] (s ki n or 
e y es) c ortic oster oi ds are per mitte d. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371120] u d y I nter ve nti o n(s) A d mi nistere d f or S u bst u d y B 
St u d y  i nter ve nti o ns f or S u bst u d y  B will i ncl u de: 
I nter ve nti o n N a me B N T 1 6 2 b 2 a
 qI R V qI R V b/ B N T 1 6 2 b 2 atI R V c/ B N T 1 6 2 b 2 abI R V c/ B N T 1 6 2 b 2 aQI V 
Ar m N a me 
( gr o u p of p artici p a nts 
recei vi n g a s pecific 
st u d y i nter ve nti o n or 
n o st u d y i nter ve nti o n) Lice nse d QI V + 
B N T 1 6 2 b 2 a  qI R V qI R V/ 
B N T 1 6 2 b 2 atI R V/ 
B N T 1 6 2 b 2 abI R V/ B N T 1 6 2 b 2 a+ 
lice nse d QI V Lice nse d QI V + 
B N T 1 6 2 b 2 a
or 
Lice nse d QI V + 
bI R V/ B N T 1 6 2 b 2 a
T ar gete d I nfl ue nz a 
Str ai ns N/ A Strai ns as 
rec o m me n de d b y 
W H O f or rec o m bi na nt 
or cell -base d i nfl ue nza 
vacci nes Strai ns as 
rec o m me n de d b y 
W H O f or rec o m bi na nt 
or cell -base d i nfl ue nza 
vacci nes Strai ns as 
rec o m me n de d b y 
W H O f or rec o m bi na nt 
or cell -base d i nfl ue nza 
vacci nes Strai ns as 
rec o m me n de d b y 
W H O f or rec o m bi na nt 
or cell -base d i nfl ue nza 
vacci nes F or eac h seas o nal strai n 
as rec o m me n de d b y 
W H O 
T y pe mo d R N A vacci ne mo d R N A vacci ne mo d R N A vacci ne mo d R N A vacci ne mo d R N A vacci ne Vacci ne 
D ose F or m ul ati o n m o d R N A m o d R N A m o d R N A m o d R N A m o d R N A 
U nit D ose Stre n gt h(s) µ g 
B N T 1 6 2 b 2 aµ g qI R V f or 
partici pa nts 
1 8 t hr o u g h 6 4 years of 
a ge (as detaile d i n t he 
I P M) µ g or µ g or 
µ g i n d ose -le vel 
c o m bi nati o ns as 
descri be d i n t he ta bles 
title d S u bst u d y B: All 
Vacci ne Gr o u ps  µ g tI R V/ µ g 
B N T 1 6 2 b 2 aµ g bI R V µ g 
B N T 1 6 2 b 2 aµ g bI R V/ µ g 
B N T 1 6 2 b 2 a
As detaile d i n t he I P M 
R o ute of 
A d mi nistr ati o n I ntra m usc ular i njecti o n I ntra m usc ular 
i njecti o n I ntra m usc ular 
i njecti o n I ntra m usc ular 
i njecti o n I ntra m usc ular 
i njecti o n I ntra m usc ular i njecti o n 
Use E x peri me ntal E x peri me ntal E x peri me ntal E x peri me ntal E x peri me ntal E x peri me ntal 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI C CI C CI C CI C CI C CI C CI C CI C CI C CI C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 6 7 I M P or NI M P/ A x M P I M P I M P I M P I M P I M P I M P 
P ac k a gi n g a n d 
L a beli n g St u d y i nter ve nti o n will be 
pr o vi de d i n a glass vial as 
o pe n -la bel s u p pl y.  Eac h 
vial will be la bele d per 
c o u ntr y re q uire me nt. St u d y i nter ve nti o n 
will be pr o vi de d i n a 
glass vial as 
o pe n -la bel s u p pl y.  
Eac h vial will be 
la bele d per c o u ntr y 
re q uire me nt. St u d y i nter ve nti o n 
will be pr o vi de d i n a 
glass vial as 
o pe n -la bel s u p pl y.  
Eac h vial will be 
la bele d per c o u ntr y 
re q uire me nt. St u d y i nter ve nti o n 
will be pr o vi de d i n a 
glass vial as 
o pe n -la bel s u p pl y.  
Eac h vial will be 
la bele d per c o u ntr y 
re q uire me nt. St u d y i nter ve nti o n 
will be pr o vi de d i n a 
glass vial as 
o pe n -la bel s u p pl y.  
Eac h vial will be 
la bele d per c o u ntr y 
re q uire me nt. St u d y i nter ve nti o n will 
be pr o vi de d as eit her a 
P F S or a glass/ plastic 
vial as o pe n -la bel 
s u p pl y.  Eac h P F S or vial 
will be la bele d per 
c o u ntr y re q uire me nt. 
a. Bi vale nt B N T 1 6 2 b 2 ( ori gi nal * / O mi B A. 4/ B A. 5) will be use d d uri n g S u bst u d y B . * O ri gi nal refers t o t he a ncestral strai n ( W u ha n -H u - 1; U S A- W A 1/ 2 0 2 0), als o referre d t o i n 
t his pr ot oc ol as t he refere nce strai n. 
b. Will ha ve f or m ulati o ns t hat are  per t he I P M a n d 
c. F or m ulati o ns will be .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI C CI 
C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371121] u d y i nter ve nti o n at Visit 2 0 1 as ra n d o mize d i n 
acc or da nce wit h t he S o A (Secti o n 1 0. 1 2. 1 ).  All s t u d y  i nter ve nti o n s h o ul d be a d mi nistere d 
i ntra m usc ularl y i nt o t he delt oi d m uscle of t he ri g ht ar m , ot her t ha n lice nse d QI V, w hic h 
s h o ul d be a d mi nistere d i ntra m usc ularl y i nt o t he de lt oi d m uscle of t he left ar m .
[ADDRESS_371122] u d y B 
N ot a p plica ble. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371123] u d y  B, t he f oll o wi n g c o nc o mita nt me dicati o ns a n d vacci nati o ns will be rec or de d i n 
t he C R F: 
Pri or recei pt of a n y C O VI D -1 9 vacci ne. 
Pri or recei pt of a n y p ne u m oc occal vacci ne. 
Lice nse d i nfl ue nza vacci ne, if recei ve d d uri n g t he 1 2 m o nt hs pri or t o e nr oll me nt .
A n y  vacci nati o ns recei ve d fr o m [ADDRESS_371124] visit ( Visit 2 0 4 ). 
Pr o hi bite d me dicati o ns liste d i n Secti o n [ADDRESS_371125] u d y B 
U nless c o nsi dere d me dicall y  necessar y , n o vacci nes ot her t ha n st u d y  i nter ve nti o n s h o ul d 
be a d mi nistere d wit hi n [ADDRESS_371126] u d y vacci nati o n at Visit 2 0 1. 
Recei pt of a n y ot her ( n o nst u d y ) c or o na vir us vacci ne fr o m e nr oll me nt t hr o u g h o ut t he 
e ntire st u d y  is pr o hi bite d. 
Recei pt of a n y ot her ( n o nst u d y ) seas o nal i nfl ue nza vacci ne fr o m e nr oll me nt t hr o u g h o ut 
t he e ntire st u d y is pr o hi bite d. 
Recei pt of c hr o nic me dicati o ns wit h k n o w n s y ste mic i m m u n os u p pressa nt effects , or 
ra di ot hera p y, wit hi n [ADDRESS_371127] u d y  is 
pr o hi bite d. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 7 0 Recei pt of s ys te mic c ortic oster oi ds ( ≥ 2 0 m g/ da y  of pre d nis o ne or e q ui vale nt) f or 
≥ [ADDRESS_371128] u d y i nter ve nti o n. 
Recei pt of bl o o d/ plas ma pr o d ucts, i m m u n o gl o b uli ns, or m o n ocl o nal a nti b o dies, fr o m 
[ADDRESS_371129] u d y .
Pr o p h y lactic a nti p y retics a n d ot her pai n me dicati o n t o pre ve nt s y m pt o ms ass oc iate d wit h 
st u d y  i nter ve nti o n a d mi nistrati o n are n ot per mitte d.  H o we ver, if a partici pa nt is ta ki n g a 
me dicati o n f or a n ot her c o n diti o n, e ve n if it ma y  ha ve a nti p y retic or pai n -relie vi n g 
pr o perties, it s h o ul d n ot be wit h hel d pri or t o st u d y vacci nati o n. 
[ADDRESS_371130] u d y B 
Me dicati o n ot her t ha n t hat descri be d as pr o hi bite d i n Secti o n 1 0. 1 2. 6. 7. 1 re q uire d f or 
tre at me nt of pree xisti n g c o n diti o ns or ac ute ill ness is per mitte d. 
I n hale d, t o pi[INVESTIGATOR_2855], or l ocalize d i njecti o ns of c ortic oster oi ds (e g, i ntra -artic ular or i ntra b ursal 
a d mi nistrati o n) are per mitte d. 
[ADDRESS_371131] u d y B I nter ve nti o n a n d P artici p a nt 
Disc o nti n u ati o n/ Wit h dr a w al 
See Secti o n [ADDRESS_371132] u d y  B, t he mi ni mal bl o o d sa m pli n g v ol u me is a p pr o xi matel y  4 0 m L  
( 1 5 m L  at Visits 2 0 1 a n d 2 0 4a n d a p pr o xi matel y 2 . 5 m L  at scree ni n g a n d Visits 2 0 1, 2 0 2, 
a n d 2 0 3 ). U p t o [ADDRESS_371133] data p oi nts. Tele healt h i ncl u des t he e xc ha n ge of healt hcare i nf or mati o n a n d ser vices 
via telec o m m u nicati o n tec h n ol o gies (e g, a u di o, vi de o, vi de oc o nfere nci n g s oft ware) re m otel y, 
all o wi n g t he partici pa nt a n d t he i n vesti gat or t o c o m m u nicate o n as pects of cli nical care, 
i ncl u di n g me dical a d vice, re mi n ders, e d ucati o n, a n d safet y m o nit ori n g. T he f oll o wi n g 
assess me nts m ust be perf or me d d uri n g a tele healt h visit (see t he S o A ): 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 7 1 Re vie w a n d rec or d a n y A Es a n d S A Es si nce t he last c o ntact. Refer t o Secti o n 8. 4 .
Re vie w a n d rec or d a n y ne w c o nc o mita nt me dicati o ns or c ha n ges i n c o nc o mita nt 
me dicati o ns si nce t he last c o ntact. 
Pr oce d ures as i n dicate d f or Visit 2 0 5 ( Secti o n 1 0. 1 2. 8. 9. 6 ). 
St u d y  partici pa nts m ust be re mi n de d t o pr o m ptl yn otif y site staff a b o ut a n y c ha n ge i n t heir 
healt h stat us. 
[ADDRESS_371134] u d y  visit at t he partici pa nt’s l ocati o n, 
rat her t ha n a n i n -pers o n st u d y  visit at t he site. T he f oll o wi n g ma y  be perf or me d d uri n g a 
h o me healt h visit (see t he S o A ): 
Pr oce d ures as i n dicate d f or Visits 2 0 2, 2 0 3, a n d 2 0 4 (see Secti o n 1 0. 1 2. 8. 9. 3 ,
Secti o n 1 0. 1 2. 8. 9. 4 ,a n d Secti o n 1 0. 1 2. 8. 9. 5 ,res pecti vel y) .
[ADDRESS_371135] u d y B 
Sa m ples will be c ollecte d at t he ti me p oi nts s pecifi e d i n Secti o n 1 0. 1 2. 1 fr o m all partici pa nts, 
a n d t he f oll o wi n g assa y s will be perf or me d :
H AI titers a gai nst seas o nal s trai ns ( ), ( ) , a n d ( 
rec o m me n de d b y W H O .
S A R S -C o V -2 ne utralizati o n assa y (refere nce strai n) .
S A R S -C o V -2 ne utralizati o n assa y s ( O micr o n B A. 4, O micr o n B A. 5 , a n d ot her e mer gi n g 
varia nts [u n der m o nit ori n g, of i nterest ,a n d/ or of c o ncer n ], i ncl u di n g ot her O micr o n 
s u bli nea ges, ma y  als o be e val uate d) .
[ADDRESS_371136] u d y B 
See Secti o n 8. 3 .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI C CI C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371137] 1 0 mi n utes i n a s u pi [INVESTIGATOR_050] p ositi o n.  T he E C Gs s h o ul d be o btai ne d pri or t o bl o o d 
c ollecti o n, meas ure me nt of bl o o d press ure, a n d meas ure me nt of p ulse rate.  E C Gs will be 
perf or me d i n tri plicate. 
E C G data will be s u b mitte d t o a ce ntral la b orat or y f or e val uati o n.  T he fi nal E C G re p ort fr o m 
t he ce ntral la b orat or y  s h o ul d be mai nta i ne d i n t he partici pa nt’s s o urce d oc u me ntati o n a n d be 
t he fi nal i nter pretati o n of t he E C G rec or di n g.  A n y cli nicall y  si g nifica nt c ha n ges fr o m t he 
baseli ne/ Da y  1 E C G ma y p ote ntiall y  be A Es (see Secti o n 1 0. 3 ) a n d s h o ul d be e val uate d 
f urt her, as cli nicall y warra nte d. 
I n s o me cases, it ma y  be a p pr o priate t o re peat a b n or mal E C Gs t o r ule o ut i m pr o per lea d 
place me nt as c o ntri b uti n g t o t he E C G a b n or malit y .  It is i m p orta nt t hat lea d place me nt be i n 
t he sa me p ositi o n eac h ti me d uri n g eac h assess me nt visit i n or der t o ac hie ve precise E C G 
rec or di n gs. 
E C G a b n or malities c o nsiste nt wit h pr o ba ble or p ossi ble m y ocar ditis or pericar ditis are t h ose 
j u d ge d as s uc h b y a car di ol o gist, i ncl u di n g :
S ustai ne d atrial or ve ntric ular arr h yt h mias 
Sec o n d -de gree M o bitz T y pe II or w orse A V bl oc k, ne w b u n dle bra nc h bl oc k 
Diff use S T -se g me nt ele vati o n or P R -se g me nt i n versi o n, c o m pati ble wit h pericar ditis 
Ec h ocar di o gra ms ma y  be perf or me d as detaile d i n Secti o n [ADDRESS_371138] u d y A: qI R V/ bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5), t I R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5), or 
bI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5) c o nc urre ntl y wit h lice ns e d QI V i n 
S u bst u d y  B , base d o n A E, E C G, a n d la b orat or y  data re vie w. T hese data will be re vie we d o n 
a n o n g oi n g basis b y  t he i n vesti gat or ( or me dicall y q ualifie d desi g nee) a n d s p o ns or i n or der t o 
pr o m ptl y  i de ntif y  a n d fla g a n y e ve nt t hat p ote ntiall y  c o ntri b utes t o a st o p pi n g r ule. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371139] o p pi n g 
r ule has bee n met o n t he basis of a partici pa nt’s i n di vi d ual st u d y  i nter ve nti o n all ocati o n. 
I n t he e ve nt t hat s p o ns or pers o n nel c o nfir m t hat a st o p pi n g r ule is met, t he f oll o wi n g acti o ns 
will c o m me nce: 
T he I R C will re vie w all a p pr o priate data. 
T he st o p pi n g r ule will P A U S E ra n d o mizati o n a n d st u d y  i nter ve nti o n a d mi nistrati o n 
i n all vacci ne gr o u ps acr oss b ot h a ge strat a
F or all partici pa nts al rea d y  vacci nate d, all ot her r o uti ne st u d y  c o n d uct acti vities, 
i ncl u di n g o n g oi n g data e ntr y , re p orti n g of A Es, partici pa nt e -diar y  c o m pleti o n, bl o o d 
sa m ple c ollecti o n, a n d partici pa nt f oll o w - u p, will c o nti n ue d uri n g t he pa use. 
A st o p pi n g r ule is met if a n y  of t he c o n diti o ns liste d i n t he st o p pi n g r ule criteria bel o w occ ur 
wit hi n [ADDRESS_371140] o p pi n g R ule Criteri a: 
1. If a n y vacci nate d partici pa nt de vel o p s: 
A ne w E C G a b n or malit y  t hat a car di ol o gist j u d ges c o nsiste nt wit h pr o ba ble or 
p ossi ble m y ocar ditis or pericar ditis, i ncl u di n g b ut n ot li mite d t o :
S ustai ne d atrial or ve ntric ular arr h yt h mias 
Sec o n d -de gree M o bitz T y pe II or w orse A V bl oc k, ne w b u n dle bra nc h bl oc k 
Diff use S T -se g me nt ele vati o n or P R -se g me nt i n versi o n, c o m pati ble wit h 
pericar ditis 
A n a b n or mal tr o p o ni n I val ue t hat is c o nfir me d a b n or mal o n re peat testi n g, assesse d 
as relate d t o st u d y i nter ve nti o n b y t he i n vesti gat or. 
2. If ≥ 1 vacci nate d partici pa nt de vel o ps a c o nfir me d cli nical dia g n osis of m y ocar ditis or 
pericar ditis. 
3. If a n y vacci nate d partici pa nt dies. 
4. If ≥ 1 vacci nate d partici pa nt e x perie nces a Gra de 4 u ns olicite d A E, or S A E of a n y 
se verit y, assesse d as relate d b y t he i n vesti gat or. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 7 4 5. If ≥ 2 partici pa nts vacci nate d wit h qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5), 
tI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5), or b I R V/ bi vale nt B N T 1 6 2 b 2 
( ori gi nal/ O mi B A. 4/ B A. 5 )gi ve n c o nc urre ntl y wit h lice nse d QI V , at t he sa me d ose le vel ,
de v el o p t he sa me or si milar Gra de 3 or hi g her u ns olicite d A E, ot her t ha n 
m y ocar ditis/ pericar ditis, assesse d as relate d t o st u d y  i nter ve nti o n b y  t he i n vesti gat or.  
N ote t hat t he l ocal reacti o ns, s y ste mic e ve nts, a n d fe ver s pecifie d i n Secti o n 8. 3. [ADDRESS_371141] u d y B 
1 0. 1 2. 8. 9. 1. Scree ni n g ( 0 t o 2 8 D a ys Bef ore Visit 2 0 1) f or S u bst u d y B 
Bef ore e nr oll me nt a n d bef ore a n y st u d y-relate d pr oce d ures are perf or me d, v ol u ntar y , writte n, 
st u d y -s pecific i nf or me d c o nse nt will be o btai ne d fr o m t he partici pa nt.  Eac h si g nat ure o n t he 
I C D m ust be pers o nall y date d b y t he si g nat or y.  T he i n vesti gat or or his or her desi g nee will 
als o si g n t he I C D.  A c o p y  of t he si g ne d a n d date d I C D m ust be gi ve n t o t h e partici pa nt.  T he 
s o urce data m ust reflect t hat t he i nf or me d c o nse nt was o btai ne d bef ore partici pati o n i n t he 
st u d y .
It is a ntici pate d t hat t he pr oce d ures bel o w will be c o n d ucte d i n a ste p wise ma n ner 
Assi g n a partici pa nt n u m ber usi n g t he I R T s ys te m.  
O b tai n t he partici pa nt’s de m o gra p h y (i ncl u di n g date of birt h, se x, race, a n d et h nicit y).  
T he f ull date of birt h will be c ollecte d t o criticall y e val uate t he i m m u ne res p o nse a n d 
safet y pr ofile b y a ge. 
O btai n me dical hist or y , i ncl u di n g c o nfir me d C O VI D -1 9 dia g n osis (see Secti o n 8. 4. 7 ) or 
as y m pt o matic p ositi ve S A R S -C o V -[ADDRESS_371142] res ult ( N A A T or a nti ge n test), a n d a n y  ot her 
me dical hist or y  of cli nical si g nifica nce. 
O btai n t he details of a n y me dicati o ns c urre ntl y  ta ke n. 
Perf or m 1 2 -lea d tri plicate E C G. 
Perf or m p h ys ical e xa mi nati o n, i ncl u di n g vital si g ns ( wei g ht, hei g ht, oral te m perat ure, 
p ulse rate, a n d seate d bl o o d press ure), e val uati n g a n y  cli n icall y  si g nifica nt a b n or malities 
wit hi n t he f oll o wi n g b o d y  s y ste ms: ge neral a p peara nce; s ki n; hea d, e y es, ears, n ose, a n d 
t hr oat; heart; l u n gs; a b d o me n; m usc ul os keletal; e xtre mities; ne ur ol o gical; a n d l y m p h 
n o des. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 7 5 C ollect a bl o o d sa m ple of a p pr o xi matel y  2. 5 m L as detaile d i n t he la b orat or y  ma n ual f or 
tr o p o ni n I  la b orat or y  testi n g as descri be d i n Secti o n 8. 3. 4. 
Perf or m uri ne pre g na nc y test o n W O C B P as descri be d i n Secti o n 8. 3. 6 .
Disc uss c o ntrace pti ve use as descri be d i n Secti o n 5. 3. 1 .
Rec or d n o nst u d y vacci nati o ns as descri be d i n Secti o n 1 0. 1 2. 6. 7 .
Re vie w d oc u me ntati o n of all pri or C O VI D -[ADDRESS_371143] be 
a ut h orize d f or use i n t he U S.  Rec or d pri or recei pt of a n y C O VI D -1 9 vacci ne as 
descri be d i n Secti o n 1 0. 1 2. 6. 7 .
Rec or d pri or recei pt of a n y  p ne u m oc occal vacci ne as descri be d i n 
Secti o n 1 0. 1 2. 6. 7 .
Rec or d details of a n y lice nse d i nfl ue nza vacci ne recei ve d i n t he pri or 1 2 m o nt hs, as 
descri be d i n Secti o n 1 0. 1 2. 6. 7 .
E ns ure a n d d oc u me nt t hat all of t he i ncl usi o n criteria a n d n o ne of t he e xcl usi o n criteria 
are met. 
Rec or d A Es as descri be d i n Secti o n 8. 4. 1 .
T he i n vesti gat or or a n a ut h orize d desi g nee c o m pletes t he C R F. 
1 0. 1 2. 8. 9. 2. Visit 2 0 1 – V acci n ati o n ( D a y 1) f or S u bst u d y B 
It is a ntici pate d t hat t he pr oce d ures bel o w wil l be c o n d ucte d i n a ste p wise ma n ner. 
Disc uss c o ntrace pti ve use as descri be d i n Secti o n 5. 3. 1 .
Rec or d n o nst u d y vacci nati o ns as descr i be d i n Secti o n 1 0. 1 2. 6. 7 .
Re vie w scree ni n g ce ntral la b orat or y  res ults (tr o p o ni n I ) a n d ce ntral E C G re p orts .
Perf or m 1 2 -lea d tri plicate E C G. 
Perf or m a cli nical assess me nt.  If t he cli nical assess me nt i n dicates t hat a p h y sical 
e xa mi nati o n is necessar y t o c o m pre he nsi vel y e val uate t he partici pa nt, perf or m a p h ys ical 
e xa mi nati o n a n d rec or d a n y  fi n di n gs i n t he s o urce d oc u me nts a n d, i f cli nicall y  
si g nifica nt, rec or d o n t he me dical hist or y  C R F or o n t he A E C R F as per Secti o n 1 0. 3 .
Meas ure vital si g ns, i ncl u di n g or al te m perat ure, p ulse rate, a n d seate d bl o o d press ure. 
Perf or m uri ne pre g na nc y test o n W O C B P as descri be d i n Secti o n 8. 3. 6 .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 7 6 E ns ure t hat t he partici pa nt c o nti n ues t o meet all of t he i ncl usi o n criteria a n d n o ne of t he 
e xcl usi o n criteria. 
E ns ure t hat t he partici pa nt meets n o ne of t he te m p orar y  dela y  criteria as descri be d i n 
Secti o n 5. 5 .
O btai n t he partici pa nt’s ra n d o mizati o n n u m ber a n d st u d y  i nter ve nti o n all ocati o n usi n g 
t he I R T s ys te m. 
C ollect a bl o o d sa m ple of a p pr o xi matel y  2. 5 m L as detaile d i n t he la b orat or y  ma n ual f or 
tr o p o ni n I  la b orat or y  testi n g as descri be d i n Secti o n 8. 3. 4 .
C ollect a bl o o d sa m ple (a p pr o xi matel y  1 5 m L or 5 0 m L ), bef ore a d mi nistrati o n of st u d y  
i nter ve nti o n, f or i m m u n o ge nicit y  assess me nt. 
Site staff me m ber(s) will dis pe nse/a d mi nister [ADDRESS_371144] u d y  i nter ve nti o n i nt o t he delt oi d 
m uscle per Secti o n 1 0. 1 2. 6. 1. 1 .
Site staff m ust o bser ve t he partici pa nt f or at least [ADDRESS_371145] u d y  i nter ve nti o n 
a d mi nistrati o n f or a n y ac ute reacti o ns.  Rec or d a n y ac ute reacti o ns (i ncl u di n g ti me of 
o nset) i n t he partici pa nt’s s o urce d oc u me nts a n d o n t he A E pa ge of t he C R F, a n d o n a n 
S A E f or m as a p plica ble. 
Iss ue a meas uri n g de vice t o meas ure l ocal reacti o ns at t he i njecti o n site a n d a 
t her m o meter f or rec or di n g dail y te m perat ures a n d pr o vi de i nstr ucti o ns o n t hei r use. 
E x plai n t he e -diar y  c o m pleti o n re q uire me nt t o t he partici pa nt a n d assist t he partici pa nt 
wit h d o w nl oa di n g t he st u d y  a p plicati o n o nt o t he partici pa nt’s o w n de vice or iss ue a 
pr o visi o ne d de vice if re q uire d.  Pr o vi de i nstr ucti o ns o n e- diar y  c o m pleti o n a n d as k t he 
partici pa nt t o c o m plete t he react o ge nicit y e -diar y  fr o m Da y 1 t hr o u g h Da y  7, wit h Da y 1 
bei n g t he da y  of vacci nati o n. 
As k t he partici pa nt t o c o ntact t he site staff or i n vesti gat or i m me diatel y if he or s he 
e x perie nces a n y of t he f oll o wi n g fr o m D a y  1 t hr o u g h Da y  7 after vacci nati o n 
( w here Da y 1 is t he da y  of vacci nati o n) t o deter mi ne if a n u nsc he d ule d react o ge nicit y  
visit is re q uire d: 
Fe ver ≥ 3 9. 0° C ( ≥1 0 2. 1° F). 
Re d ness or s welli n g at t he i njecti o n site meas uri n g greater t ha n 1 0 c m 
( > 2 0 meas uri n g d e vice u nits). 
Se vere pai n at t he i njecti o n site. 
A n y  se vere s ys te mic e ve nt. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 7 7 Rec or d A Es as descri be d i n Secti o n 8. 4. 1 .
As k t he partici pa nt t o c o ntact t he site staff or i n vesti gat or if a me dicall y atte n de d e ve nt 
(e g, d oct or’s visit, e mer ge nc y  r o o m visit) or h os pi[INVESTIGATOR_1314] o n occ urs. 
As k t he partici pa nt t o c o ntact t he site staff or i n vesti gat or i m me diatel y if t he partici pa nt 
e x perie nc es ac ute c hest pai n, s h ort ness of breat h, or pal pi[INVESTIGATOR_32455] o ns (see Secti o n 1 0. 1 2. 8. 1 0 ). 
Sc he d ule a n a p p oi nt me nt f or t he partici pa nt t o ret ur n f or t he ne xt st u d y  visit. 
Re mi n d t he partici pa nt t o bri n g t he e -diar y  t o t he ne xt visit. 
C o m plete t he s o urce d oc u me nts. 
T he i n vesti g at or or a n a ut h orize d desi g nee c o m pletes t he C R Fs a n d u p dates t he st u d y  
i nter ve nti o n acc o u nta bilit y  rec or ds. 
T he i n vesti gat or or a p pr o priatel y  q ualifie d desi g nee re vie ws t he react o ge nicit y  
e-diar y  data o nli ne f oll o wi n g vacci nati o n t o e val uate partici pa nt c o m plia nce a n d as part 
of t he o n g oi n g safet y re vie w.  Dail y re vie w is o pti mal d uri n g t he acti ve diar y peri o d. 
1 0. 1 2. 8. 9. 3. Visit 2 0 2 – D a y 3 F oll o w -U p Visit ( After V acci n ati o n) – [ADDRESS_371146] u d y B 
Rec or d A Es as descri be d i n Secti o n 8. 4. 1 .
Rec or d n o nst u d y vacci nati o ns as descri be d i n Secti o n 1 0. 1 2. 6. 7 .
Rec or d pr o hi bite d me dicati o n use as descri be d i n Secti o n 1 0. 1 2. 6. 7. 1 .
Verif y  u n dersta n di n g of a n d c o m plia nce wit h pr ot oc ol re q uire me nts f or c o ntrace pti o n as 
descri be d i n Secti o n 5. 3. 1 .
Re vie w scree ni n g ce ntral la b orat or y  res ults (tr o p o ni n I ) a n d ce ntral E C G re p orts .  A n y  
a b n or mal tr o p o ni n I le vel m ust res ult i n f urt her assess me nts as o utli ne d i n 
Secti o n 1 0. 1 2. 8. 1 0 .
Perf or m 1 2 -lea d tri plicate E C G.  A n y  ne w E C G a b n or malit y  (c o m pare d t o baseli ne) 
c o nsiste nt wit h pr o ba ble or p ossi ble m y ocar ditis or pericar ditis (as liste d i n 
Secti o n 1 0. 1 2. 8. 5. 1 ) m ust res ult i n f urt her assess me nts as o utli ne d i n 
Secti o n 1 0. 1 2. 8. 1 0 .
Meas ure vital si g ns, i ncl u di n g oral te m perat ure, p ulse rate, a n d seate d bl o o d press ure. 
C ollect a bl o o d sa m ple of a p pr o xi matel y  2. 5 m L as detaile d i n t he la b orat or y  ma n ual f or 
tr o p o ni n I  la b orat or y  testi n g as descri be d i n Secti o n 8. 3. 4 .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 7 8 Re mi n d t he partici pa nt t o c o ntact t he site staff or i n vesti gat or i m me diatel y i f he or s he 
e x perie nces a n y of t he f oll o wi n g fr o m Da y  1 t hr o u g h Da y  7 after vacci nati o n 
( w here Da y  1 is t he d a y  of vacci nati o n) t o deter mi ne if a n u nsc he d ule d react o ge nicit y  
visit is re q uire d: 
Fe ver ≥ 3 9. 0° C ( ≥ 1 0 2. 1° F). 
Re d ness or s welli n g at t he i njecti o n site meas uri n g greater t ha n 1 0 c m 
( > 2 0 meas uri n g de vice u nits). 
Se vere pai n at t he i njecti o n site. 
A n y  se ve re s y ste mic e ve nt. 
Re mi n d t he partici pa nt t o c o ntact t he site staff or i n vesti gat or if a me dicall y atte n de d 
e ve nt (e g, d oct or’s visit, e mer ge nc y r o o m visit) or h os pi[INVESTIGATOR_1314] o n occ urs. 
Re mi n d t he partici pa nt t o c o ntact t he site staff or i n vesti gat or i m me dia tel y i f t he 
partici pa nt e x perie nces ac ute c hest pai n, s h ort ness of breat h, or pal pi[INVESTIGATOR_32455] o ns 
(see Secti o n 1 0. 1 2. 8. 1 0 ). 
Re mi n d t he par tici pa nt t o c o m plete t he e -diar y ,w hic h s h o ul d be re vie we d dail y  b y  t he 
site. 
Sc he d ule a n a p p oi nt me nt f or t he partici pa nt t o ret ur n f or t he ne xt st u d y  visit. 
C o m plete t he s o urce d oc u me nts. 
T he i n vesti gat or or a n a ut h orize d desi g nee c o m pletes t he C R Fs. 
1 0. 1 2. 8. 9. 4. Visit 2 0 3 – 1- Wee k F oll o w- U p Visit ( After V acci n ati o n) – [ADDRESS_371147] u d y B 
Rec or d A Es as descri be d i n Secti o n 8. 4. 1 .
Rec or d n o nst u d y vacci nati o ns as descri be d i n Secti o n 1 0. 1 2. 6. 7 .
Rec or d pr o hi bite d me dicati o n use as descri be d i n Secti o n 1 0. 1 2. 6. 7. 1 .
Verif y  u n dersta n di n g of a n d c o m plia nce wit h pr ot oc ol re q uire me nts f or c o ntrace pti o n as 
descri be d i n Secti o n 5. 3. 1 .
Re vie w scree ni n g ce ntral la b orat or y  res ults (tr o p o ni n I ) a n d ce ntral E C G re p orts .  A n y  
a b n or mal tr o p o ni n I le vel m ust res ult i n f urt her assess me nts as o utli ne d i n 
Secti o n 1 0. 1 2. 8. 1 0 .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 7 9 Perf or m 1 2 -lea d tri plicate E C G.  A n y  ne w E C G a b n or malit y  (c o m pare d t o baseli ne) 
c o nsiste nt wit h pr o ba ble or p ossi ble m y ocar ditis or pericar ditis (as liste d i n 
Secti o n 1 0. 1 2. 8. 5. 1 ) m ust res ult i n f urt her assess me nts as o utli ne d i n Secti o n 1 0. 1 2. 8. 1 0 .
Meas ure vital si g ns, i ncl u di n g oral te m perat ure, p ulse rate, a n d seate d bl o o d press ure. 
C ollect a bl o o d sa m ple of a p pr o xi matel y  2. 5 m L as detaile d i n t he la b orat or y  ma n ual f or 
tr o p o ni n I  la b orat or y  testi n g as descri be d i n Secti o n 8. 3. 4 .
Re vie w t he partici pa nt’s react o ge nicit y  e -diar y  data.  If t he e - d iar y  c ollecti o n peri o d is 
c o m plete: 
C ollect st o p dates of a n y react o ge nicit y  e -diar y  e ve nts o n g oi n g o n t he last da y  t hat t he 
react o ge nicit y  e -diar y  was c o m plete d a n d rec or d st o p dates i n t he C R F if re q uire d. 
C ollect t he partici pa nt’s e- diar y  or assist t he partici pa nt wit h re m o vi n g t he st u d y  
a p plicati o n fr o m his or her o w n pers o nal de vice (if t he visit is c o n d ucte d after Da y  7). 
Re mi n d t he partici pa nt t o c o ntact t he site staff or i n vesti gat or i m me diatel y i f he or s he 
e x perie nces a n y of t he f oll o wi n g fr o m Da y 1 t hr o u g h Da y  7 after vacci nati o n 
( w here Da y 1 is t he da y  of vacci nati o n) t o deter mi ne if a n u nsc he d ule d react o ge nicit y  
visit is re q uire d: 
Fe ver ≥ 3 9. 0° C ( ≥ 1 0 2. 1° F). 
Re d ness or s welli n g at t he i njecti o n site meas uri n g greater t ha n 1 0 c m 
( > 2 0 meas uri n g de v ice u nits). 
Se vere pai n at t he i njecti o n site. 
A n y  se vere s ys te mic e ve nt. 
Re mi n d t he partici pa nt t o c o ntact t he site staff or i n vesti gat or if a me dicall y atte n de d 
e ve nt (e g, d oct or’s visit, e mer ge nc y  r o o m visit) or h os pi[INVESTIGATOR_1314] o n occ urs. 
Re mi n d t he partic i pa nt t o c o ntact t he site staff or i n vesti gat or i m me diatel y i f t he 
partici pa nt e x perie nces ac ute c hest pai n, s h ort ness of breat h, or pal pi[INVESTIGATOR_32455] o ns 
(see Secti o n 1 0. 1 2. 8. 1 0 ). 
Sc he d ule a n a p p oi nt me nt f or t he partici pa nt t o ret ur n f or t he ne xt st u d y  visit. 
C o m plete t he s o urce d oc u me nts. 
T he i n vesti gat or or a n a ut h orize d desi g nee c o m pletes t he C R Fs. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 8 0 1 0. 1 2. 8. 9. 5. Visit 2 0 4 – 4- Wee k F oll o w- U p Visit ( After V acci n ati o n) – [ADDRESS_371148] u d y B 
Rec or d A Es as descri be d i n Secti o n 8. 4. 1 .
Rec or d n o nst u d y vacci nati o ns as descri be d i n Secti o n 1 0. 1 2. 6. 7 .
Rec or d pr o hi bite d me dicati o n use as descri be d i n Secti o n 1 0. 1 2. 6. 7. 1 .
Verif y  u n dersta n di n g of a n d c o m plia nce wit h pr ot oc ol re q uire me nts f or c o ntrace pti o n as 
descri be d i n Secti o n 5. 3. 1 .
Re vie w scree ni n g ce ntral la b orat or y  res ults (tr o p o ni n I ) a n d ce ntral E C G re p orts .  A n y  
a b n or mal tr o p o ni n I le vel m ust res ult i n f urt her assess me nts as o utli ne d i n 
Secti o n 1 0. 1 2. 8. 1 0 .
C ollect a bl o o d sa m ple of a p pr o xi matel y  1 5 m L or 5 0 m L f or i m m u n o ge nicit y  testi n g. 
Re vie w t he partici pa nt’s react o ge nicit y  e -diar y  data.  C ollec t st o p dates of a n y  
react o ge nicit y  e -diar y  e ve nts o n g oi n g o n t he last da y  t hat t he react o ge nicit y  e -diar y  was 
c o m plete d a n d rec or d st o p dates i n t he C R F if re q uire d. 
If n ot alrea d y c o m plete d, c ollect t he partici pa nt’s e -diar y  or assist t he partici pa nt wit h 
re m o vi n g t he st u d y a p plicati o n fr o m his or her o w n pers o nal de vice. 
Rec or d a n y A Es t hat occ ur wit hi n t he 4 8 h o urs after t he bl o o d dra w as descri be d i n 
Secti o n 8. 4. 1 .
1 0. 1 2. 8. 9. 6. Visit 2 0 5 – 6- M o nt h Tele p h o ne C o nt act –[ADDRESS_371149] u d y B 
C o ntact t he partici pa nt b y  tele p h o ne. 
Rec or d S A Es as descri be d i n Secti o n 8. 4. 1 .
Rec or d n o nst u d y vacci nati o ns as descri be d i n Secti o n 1 0. 1 2. 6. 7 .
Rec or d pr o hi bite d me dicati o n use as descri be d i n Secti o n 1 0. 1 2. 6. 7. 1 .
C o m plete t he s o urce d oc u me nts. 
T he i n vesti gat or or a n a ut h orize d desi g nee c o m pletes t he C R Fs. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371150] u d y B 
If a Gra de 3 l ocal reacti o n ( Secti o n 8. 3. 5. 2 ), s ys te mic e ve nt ( Secti o n 8. 3. 5. 3 ), or fe ver 
(Secti o n 8. 3. 5. 4 ) is re p orte d i n t he react o ge nicit y e -diar y , a tele p h o ne c o ntact s h o ul d occ ur t o 
ascertai n f urt her d etails a n d deter mi ne w het her a site visit is cli nicall y  i n dicate d.  If a 
s us pecte d Gra de 4 l ocal reacti o n ( Secti o n 8. 3. 5. 2 ), s y ste mic e ve nt ( Secti o n 8. 3. 5. 3 ), or fe ver 
(Secti o n 8. 3. 5. 4 ) is re p orte d i n t he react o ge nicit y e -diar y , a tele p h o ne c o ntact or site visit 
s h o ul d occ ur t o c o nfir m w het her t he e ve nt meets Gra de [ADDRESS_371151] be sc he d ule d as s o o n as p ossi ble t o assess t he pa rtici pa nt u nless a n y  of t he 
f oll o wi n g is tr ue: 
T he partici pa nt is u na ble t o atte n d t he u nsc he d ule d visit. 
T he l ocal reacti o n/s ys te mic e ve nt is n o l o n ger prese nt at t he ti me of t he tele p h o ne 
c o ntact. 
T he partici pa nt rec or de d a n i nc orrect val ue i n t he react o ge nicit y  e -diar y  (c o nfir mati o n of 
a react o ge nicit y e -diar y  data e ntr y  err or). 
T he PI  [INVESTIGATOR_1660] a ut h orize d desi g nee deter mi ne d it was n ot nee de d. 
T his tele p h o ne c o ntact will be rec or de d i n t he partici pa nt’s s o urce d oc u me ntati o n a n d t he 
C R F. 
If t he partici pa nt is u na ble t o atte n d t he u nsc he d ule d visit, or t he PI  [INVESTIGATOR_1660] a ut h orize d desi g nee 
deter mi ne d it was n ot nee de d, a n y o n g oi n g l ocal reacti o ns/s y ste mic e ve nts m ust be assesse d 
at t he ne xt st u d y  visit. 
D uri n g t he u nsc he d ule d visit, t he reacti o ns s h o ul d be assesse d b y t h e i n vesti gat or or a 
me dicall y  q ualifie d me m ber of t he st u d y  staff, s uc h as a st u d y  p h y sicia n or a st u d y  n urse, as 
a p plica ble t o t he i n vesti gat or’s l ocal practice, w h o will: 
Meas ure b o d y t e m perat ure ( °F/ ° C). 
Meas ure mi ni m u m a n d ma xi m u m dia meters of re d ness (if prese nt). 
Meas ure mi ni m u m a n d ma xi m u m dia meters of s welli n g (if prese nt). 
Assess i njecti o n site pai n (if prese nt) i n acc or da nce wit h t he gra des pr o vi de d i n 
Secti o n 8. 3. 5. 2 .
Assess s y ste mic e ve nts (if prese nt) i n acc or da nce wit h t he gra des pr o vi de d i n 
Secti o n 8. 3. 5. 3 .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 8 2 Assess ot her fi n di n gs ass ociate d wit h t he reacti o n a n d rec or d t his o n t he A E pa ge of t he 
C R F if a p pr o priate. 
T he i n vesti gat or or a n a ut h orize d desi g nee will c o m plete t he u nsc he d ule d visit 
assess me nt pa ge of t he C R F. 
[ADDRESS_371152] pai n, s h ort ness of breat h, pal pi[INVESTIGATOR_32455] o ns, or a n y  
ot her s y m pt o m(s) t hat mi g ht be i n dicati ve of m y ocar ditis or pericar ditis w it hi n 6wee ks after 
st u d y  vacci nati o n m ust be s pecificall y  e val uate d i n cli nic b y  a car di ol o gist f or p ossi ble 
m y ocar ditis or pericar ditis.  T he sa me a p plies f or a n y  partici pa nt i n w h o m a ne w E C G 
a b n or malit y  (c o m pare d t o baseli ne) c o nsiste nt wit h pr o ba ble or p ossi ble m y ocar ditis or 
pericar ditis (as liste d i n Secti o n 1 0. 1 2. 8. 5. 1 ) or a b n or mal tr o p o ni n I le vel is o bser ve d at 
Visit 2 0 2 or Visit 2 0 3. 
I n a d diti o n t o a cli nical e val uati o n, t he f oll o wi n g s h o ul d be perf or me d: 
E C G a n d 
Meas ure me nt of t he tr o p o ni n le vel 
F or a n y partici pa nt i n w h o m a ne w E C G a b n or malit y  (c o m pare d t o baseli ne) c o nsiste nt wit h 
pr o ba ble or p ossi ble m y o car ditis or pericar ditis (as liste d i n Secti o n 1 0. 1 2. 8. 5. 1 ) or a b n or mal 
tr o p o ni n I  le vel is o bser ve d at Visit 2 0 2 or Visit 2 0 3, t his s h o ul d be ac hie ve d b y  re peati n g t he 
assess me nts wit h t he ce ntral ve n d or(s). 
If m y ocar ditis o r pericar ditis is s us pecte d base d u p o n t he i nitial e val uati o n, t he f oll o wi n g 
s h o ul d als o be perf or me d: 
Car diac ec h ocar di o gra m a n d/ or 
Car diac ma g netic res o na nce st u d y 
Details of t he s y m pt o ms re p orte d, a n d res ults of t he i n vesti gati o ns perf or me d, will be 
rec or de d i n t he C R F. 
A n y  dia g n osis of m y o car ditis or pericar ditis is c o nsi dere d a n i m p orta nt me dical e ve nt a n d 
m ust be re p orte d as a n S A E (refer t o Secti o ns 8. 4. 1. 1 a n d 8. 4. 3 ). Ot her dia g n oses s h o ul d be 
rec or de d as A Es or S A Es, as a p pr o priate. Ref er als o t o Sect i o n 8. 4. 7 .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371153] ur ba nce of 
t heir n or mal me nstr ual c ycle (i ncl u di n g, b ut n ot e xcl usi vel y , hea v y  me nstr ual blee di n g, 
a me n orr hea, a n d irre g ular peri o ds) f oll o wi n g recei pt of st u d y  i nter ve nti o n u ntil [ADDRESS_371154] or y ,a n d res ults of a n y i n vesti gati o ns perf or me d will be rec or de d i n 
t he C R F. 
1 0. 1 2. 8. 1 1. 1. U nsc he d ule d Visit f or a Gr a de 3 or S us pecte d Gr a de 4 Re acti o n f or 
S u bs t u d y B 
If a Gra de 3 l ocal reacti o n (Secti o n 8. 3. 5. 2 ), s ys te mic e ve nt (Secti o n 8. 3. 5. 3 ), or fe ver 
(Secti o n 8. 3. 5. 4 ) is re p orte d i n t he react o ge nicit y e -diar y , a tele p h o ne c o ntact s h o ul d occ ur t o 
ascertai n f urt her details a n d deter mi ne w het her a site visit is cli nicall y  i n dicate d. If a 
s us pecte d Gra de 4 l ocal reacti o n (Secti o n 8. 3. 5. 2 ), s y ste mic e ve nt (Secti o n 8. 3. 5. 3 ), or fe ver 
(Secti o n 8. 3. 5. 4 ) is re p orte d i n t he react o ge nicit y e -diar y , a tele p h o ne c o ntact or site visit 
s h o ul d occ ur t o c o nfir m w het her t he e ve nt meets Gra de [ADDRESS_371155] be sc he d ule d as s o o n as p os si ble t o assess t he partici pa nt u nless a n y  of t he 
f oll o wi n g is tr ue: 
T he partici pa nt is u na ble t o atte n d t he u nsc he d ule d visit. 
T he l ocal reacti o n/s ys te mic e ve nt is n o l o n ger prese nt at t he ti me of t he tele p h o ne 
c o ntact. 
T he partici pa nt rec or de d a n i nc orre ct val ue i n t he react o ge nicit y  e -diar y  (c o nfir mati o n of 
a react o ge nicit y e -diar y  data e ntr y  err or). 
T he PI  [INVESTIGATOR_1660] a ut h orize d desi g nee deter mi ne d it was n ot nee de d. 
T his tele p h o ne c o ntact will be rec or de d i n t he partici pa nt’s s o urce d oc u me ntati o n a n d t he 
C R F. 
If t he partici pa nt is u na ble t o atte n d t he u nsc he d ule d visit, or t he PI  [INVESTIGATOR_1660] a ut h orize d desi g nee 
deter mi ne d it was n ot nee de d, a n y o n g oi n g l ocal reacti o ns/s y ste mic e ve nts m ust be assesse d 
at t he ne xt st u d y  visit. 
D uri n g t he u nsc he d ule d visit, t he reacti o ns s h o ul d be assesse d b y t he i n vesti gat or or a 
me dicall y  q ualifie d me m ber of t he st u d y  staff, s uc h as a st u d y  p h y sicia n or a st u d y  n urse, as 
a p plica ble t o t he i n vesti gat or’s l ocal practice, w h o will: 
Meas ure oral te m perat ure ( °F/ ° C). 
Meas ure mi ni m u m a n d ma xi m u m dia meters of re d ness (if prese nt). 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 8 4 Meas ure mi ni m u m a n d ma xi m u m dia meters of s welli n g (if prese nt). 
Assess i njecti o n site pai n (if prese nt) i n acc or da nce wit h t he gra des pr o vi de d i n 
Secti o n 8. 3. 5. 2 .
Assess s y ste mic e ve nts (if prese nt) i n acc or da nce wit h t he gra des pr o vi de d i n 
Secti o n 8. 3. 5. 3 .
Assess f or ot her fi n di n gs ass ociate d wit h t he reacti o n a n d rec or d t hese o n t he A E pa ge of 
t he C R F if a p pr o priate. 
T he i n vesti gat or or a n a ut h orize d desi g nee will c o m plete t he u nsc he d ule d visit 
assess me nt p a ge of t he C R F. 
[ADDRESS_371156] u d y  B, partici pa nt s1 8 t hr o u g h 6 4 ye ars of a ge will be cl osel y m o nit ore d f or 
p ote ntial as y m pt o matic a n d s y m pt o matic m y ocar ditis/ pericar ditis ,i ncl u di n g t he use of 
r o uti ne E C Gs a n d tr o p o ni n testi n g. 
A n y  st u d y  partici pa nt w h o re p orts ac ute c hest pai n, s h ort ness of breat h, pa l pi[INVESTIGATOR_32455] o ns, or a n y  
ot her s y m pt o m(s) t hat mi g ht be i n dicati ve of m y ocar ditis or pericar ditis wit hi n 6wee ks after 
st u d y  vacci nati o n m ust be s pecificall y  e val uate d i n cli nic b y  a car di ol o gist f or p ossi ble 
m y ocar ditis or pericar ditis : 
Ac ute c hest pai n, 
S h or t ness of breat h, 
Pal pi[INVESTIGATOR_32455] o ns, or 
A n y  ot her s y m pt o m(s) t hat mi g ht be i n dicati ve of m y ocar ditis or pericar ditis .
I n a d diti o n t o a cli nical e val uati o n, t he f oll o wi n g s h o ul d be perf or me d: 
E C G a n d 
Meas ure me nt of t he tr o p o ni n le vel. 
If m y ocar ditis or pericar ditis is s us pecte d base d u p o n t he i nitial e val uati o n, t he f oll o wi n g 
s h o ul d als o be perf or me d: 
Car diac ec h ocar di o gra m a n d/ or 
Car diac ma g netic res o na nce st u d y .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 8 5 Details of t he s y m pt o ms re p orte d, a n d res ults of t he i n vesti gati o ns perf or me d, will be 
rec or de d i n t he C R F. A n y  dia g n osis ma de (e g, m y ocar ditis, pericar ditis, or ot her) s h o ul d be 
rec or de d as a n A E or S A E, as a p pr o priate . Refer als o t o Secti o n 8. 4. [ADDRESS_371157] ur ba nce of 
t heir n or mal me nstr ual c ycle (i ncl u di n g, b ut n ot e xcl usi vel y , hea v y  me nstr ual blee di n g, 
a me n orr hea, a n d irre g ular peri o ds) f oll o wi n g recei pt of st u d y  i nter ve nti o n u nti l [ADDRESS_371158] atistic al C o nsi de r ati o ns –S u bst u d y B 
Met h o d ol o g y  f or s u m mar y  a n d statistical a nal ys es of t he data c ollecte d i n t his s u bst u d y  is 
descri be d here a n d f urt her detaile d i n t he S A P, w hic h will be mai ntai ne d b y t he s p o ns or.  T he 
S A P ma y  m o dif y  w hat is o utli ne d i n t he pr ot oc ol w h ere a p pr o priate; h o we ver, a n y maj or 
m o dificati o ns of t he pri mar y  e n d p oi nt defi niti o ns or t heir a nal ys es will als o be reflecte d i n a 
pr ot oc ol a me n d me nt. 
[ADDRESS_371159] u d y B 
1 0. 1 2. 9. 1. 1. 1. Pri m ar y Esti m a n ds/ C o pri m ar y Esti m a n ds f or S u bst u d y B 
T he esti ma n ds t o e val uate t he safet y o bjecti ve are base d o n t he safet y p o p ulati o n. T hese 
esti ma n ds esti mate vacci ne safet y after st u d y i nter ve nti o n. C o m pletel y  missi n g e -diar y  data 
will n ot be i m p ute d; missi n g A E dates a n d missi n g A E i nte nsit y  will be ha n dle d acc or di n g t o 
[COMPANY_007] safet y r ules. Missi n g e -diar y  data n ot rec or de d i n t he e- diar y will be rec or de d o n t he 
A E C R F. T heref ore, t he pri mar y  a nal ys is will use react o ge nicit y  rec or de d as A Es i n t he 
C R F t o i m p ute t he missi n g e-diar y  data. 
[ADDRESS_371160] vi olati o n o bser vati o ns will be 
ce ns ore d. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 8 6 I m m u n o ge nicit y res ults t hat are bel o w t he L L O Q will be set t o 0. 5 × L L O Q i n t he a nal ys es. 
[ADDRESS_371161] u d y  B: 
P o p ul ati o n Descri pti o n 
Scree ne d All partici pa nts w h o si g n t he I C D. 
Ra n d o mize d All partici pa nts w h o are assi g ne d a ra n d o mizati o n n u m ber i n 
t he I R T s ys te m. 
E val ua ble i m m u n o ge nicit y All partici pa nts w h o are eli gi ble, recei ve t he st u d y 
i nter ve nti o n (s) t o w hic h t he y  were ra n d o mize d, ha ve bl o o d 
dra w n f or assa y  testi n g wit hi n t he s pecifie d ti me fra me after 
vacci nati o n (s) , ha ve at least [ADDRESS_371162] u d y  peri o d (starti n g fr o m t he 
ti me of vacci nati o n/ Da y  1) ma y  be re m o ve d fr o m t he e val ua ble i m m u n o ge nicit y  p o p ulati o n 
f or i nfl ue nza or C O VI D -[ADDRESS_371163] u d y  B will be de vel o pe d a n d fi nalize d bef ore a n y a nal ys es are perf or me d 
a n d will descri be t he a nal y s e s a n d pr oce d ures f or acc o u nti n g f or missi n g, u n use d, a n d 
s p uri o us data. T his secti o n is a s u m mar y  of t he pla n ne d statistical a nal ys es of t he pri mar y , 
sec o n dar y , a n d tertiar y /e x pl orat or y  e n d p oi nts. 
[ADDRESS_371164] u d y B 
Refer t o Secti o n 9 f or ge neral c o nsi derati o ns of statistical a nal ys es. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 8 7 1 0. 1 2. 9. 3. 2. Pri m ar y E n d p oi nt(s)/ Esti m a n d(s) A n al ysis f or S u bst u d y B 
E n d p oi nt St atistic al A n al ysis Met h o ds 
Pri mar y  safet y  P oi nt esti mates a n d t he ass ociate d e xact 2 -si de d 9 5 % CI swill 
be calc ulate d usi n g t he Cl o p per -Pears o n met h o d f or t he 
pr o p orti o n of partici pa nts [ADDRESS_371165] u d y 
i nter ve nti o n at 2 da y s a n d 1 wee k after vacci nati o n, f or all 
partici pa nts .
P oi nt esti mates a n d t he ass ociate d e xact 2 -si de d 9 5 % CI swill 
be calc ulate d usi n g t he Cl o p per -Pears o n met h o d f or t he 
pr o p orti o n of partici pa nts [ADDRESS_371166] u d y i nter ve nti o n at 2 wee ks a n d 
1 wee k after vacci nati o n, f or all partici pa nts .
P oi nt esti mates a n d t he ass ociate d e xact 2 -si de d 9 5 % CI swill 
be calc ulate d usi n g t he Cl o p per -Pears o n met h o d f or t he 
pr o p orti o n of partici pa nts re p orti n g eac h e ve nt (l ocal reacti o ns 
a n d s y ste mic e ve nts )f or eac h vacci ne gr o u p , i n partici pa nts 
1 8 t hr o u g h 6 4 ye ars of a ge .
P oi nt esti mates a n d t he ass ociate d e xact 2 -si de d 9 5 % CI swill 
be calc ulate d usi n g t he Cl o p per -Pears o n met h o d f or t he 
pr o p orti o n of partici pa nts re p orti n g eac h e ve nt (A Es a n d 
S A Es) f or eac h vacci ne gr o u p , i n partici pa nts 1 8 t hr o u g h 
6 4 y ears of a ge .
A Es a n d S A Es will be cate g orize d acc or di n g t o Me d D R A 
ter ms. 
1 0. 1 2. 9. 3. 3. Sec o n d ar y E n d p oi nt(s)/ Esti m a n d(s) A n al ysis f or S u bst u d y B 
E n d p oi nt St atistic al A n al ysis Met h o ds 
Sec o n dar y  
i m m u n o ge nicit y 
( partici pa nts 
1 8 t hr o u g h 
6 4 ye ars of a ge )I nfl ue nz a: 
H AI G M Ts, a n d t he ass ociate d 2 -si de d 9 5 % CI s, will be pr o vi de d 
f or eac h strai n ,b y st u d y i nter ve nti o n , bef ore vacci nati o n a n d at 
4wee ks after vacci nati o n ( pri mar y )a n d at ot her p ost vacci nati o n 
ti me p oi nts (sec o n dar y ), f or all partici pa nts. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371167] atistic al A n al ysis Met h o ds 
H AI G M F Rs fr o m bef ore vacci nati o n t o 4 wee ks after vacci nati o n 
( pri mar y ) a n d t o ot her p ost vacci nati o n ti me p oi nts (sec o n dar y ), 
a n d t he ass ociate d 2 -si de d 9 5 % CI s, will be pr o vi de d f or eac h 
strai n ,b y st u d y i nter ve nti o n ,f or all partici pa nts .
T he pr o p orti o n of partici pa nts ac hie vi n g H AI ser oc o n versi o n at 
4wee ks after vacci nati o n ( pri mar y )a n d at ot her p ost vacci nati o n 
ti me p oi nts (sec o n dar y ) a n d t he pr o p orti o n of partici pa nts wit h 
H AI titers ≥1: 4 0 bef ore vacci nati o n a n d at 4 wee ks a n d 6 m o nt hs 
after vacci nati o n, a n d t he ass ociate d 2 -si de d Cl o p per -Pears o n 
9 5 % CI s, will be pr o vi de d f or eac h strai n ,b y  st u d y  i nter ve nti o n ,
f or all partici pa nts .
T he strai ns me nti o ne d a b o ve f or qI R V or QI V -relate d st u d y  
i nter ve nti o ns refer t o t he matc he d seas o nal strai ns rec o m me n de d 
b y  W H O .
S A R S -C o V - 2: 
G M Ts ,a n d t he ass ociate d 2 -si de d 9 5 % CI s, will be pr o vi de d b y 
st u d y i nter ve nti o n f or eac h strai n-s pecific ne utralizi n g titer bef ore 
vacci nati o n a n d at 4wee ks after vacci nati o n ( pri mar y )a n d at ot her 
p ost vacci nati o n ti me p oi nts (sec o n dar y ), f or all partici pa nts .
G M F R fr o m bef ore vacci nati o n t o 4 wee ks after vacci nati o n 
( pri mar y )a n d t o ot her p ost vacci nati o n ti me p oi nts (sec o n dar y ), 
a n d t he ass ociate d 2- si de d 9 5 % CI s, will be pr o vi de d b y st u d y 
i nter ve nti o n f or eac h strai n- s pecific ne utralizi n g titer ,f or all 
partic i pa nts .
Perce nta ges of partici pa nts wit h ser ores p o nse, a n d t he ass ociate d 
2- si de d Cl o p per -Pears o n 9 5 % CI s, will be pr o vi de d b y st u d y 
i nter ve nti o n at 4 wee ks after vacci nati o n ( pri mar y) a n d at ot her 
p ost vacci nati o n ti me p oi nts (sec o n dar y ) f or eac h strai n ,f or all 
partici pa nts .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 8 9 1 0. 1 2. 9. 3. 4. Terti ar y/ E x pl or at or y E n d p oi nt(s) f or S u bst u d y B 
Pla n ne d a nal ys es of e x pl orat or y  e n d p oi nts are i n dicate d bel o w. 
I m m u ne res p o nse 
t o e mer gi n g 
varia nts ( u n der 
m o nit ori n g, of 
i nterest ,a n d/ or of 
c o ncer n) G M Ts of S A R S- C o V - 2 varia nt ( u n der m o nit ori n g, of i nterest ,
a n d/ or of c o ncer n) ne utralizi n g titers f or varia nts ( u n der 
m o nit ori n g , of i nterest ,a n d/ or of c o ncer n) n ot alrea d y  s pecifie d, 
al o n g wit h t he ass ociate d 2 -si de d 9 5 % CIs, will be pr o vi de d at 
s pecific ti me p oi nts f or eac h st u d y i nter ve nti o n. 
G M F Rs fr o m baseli ne ( bef ore t he st u d y  vacci nati o n) t o eac h 
s u bse q ue nt ti me p oi nt, a n d t he perce nta ge of partici pa nts wit h 
ser ores p o nse at eac h ti me p oi nt after vacci nati o n, al o n g wit h t he 
ass ociate d 2 -si de d 9 5 % CI s, ma y  als o be pr o vi de d f or eac h st u d y  
i nter ve nti o n. 
T o descri be t he 
tr o p o ni n a n d E C G 
a b n or malities 
detecte d i n 
partici pa nts w h o 
are e val uate d f or 
p ossi ble car diac 
s y m pt o ms  A d diti o nal s u m maries a n d/ or listi n gs of tr o p o ni n a n d E C G 
a b n or malities relate d t o pri mar y  safet y  e n d p oi nts f or partici pa nts 
[ADDRESS_371168] u d y  partici pa nts w h o re p ort a n y  s y m pt o m(s) t hat mi g ht be i n dicati ve 
of m y ocar ditis or pericar ditis wit hi n [ADDRESS_371169] u d y  vacci nati o n ( E C G, tr o p o ni n le vel, 
car diac ec h ocar di o gra m, a n d/ or car diac ma g netic res o na nce st u d y)  will be s u m marize d a n d 
liste d b y  st u d y  i nter ve nti o n. 
[ADDRESS_371170] u d y B 
A nal y ses (i m m u n o ge nicit y  or safet y) ma y be perf or me d at a n y ti me (e g, safet y data t hr o u g h 
a p pr o xi matel y  1 wee k after vacci nati o n) f or all partici pa nts .  
C o m plete sa fet ya n d i m m u n o ge nicit ya nal ys is will be perf or me d at t he e n d of t his su bst u d y .0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371171] atistical h y p ot hesis testi n g. 
Ap pr o xi matel y  3 0 partici pa nts / u p t o [ADDRESS_371172] 1 A E 
3 0 0. 5 % 1 4. 0 % 
1. 0 % 2 6. 0 % 
2. 0 % 4 5. 5 % 
5. 0 % 7 8. 5 % 
7. 0 % 8 8. 7 % 
1 2 0 0. 5 % 4 5. 2 %
1. 0 % 7 0. 1 %
2. 0 % 9 1. 1 %
5. 0 % 9 9. 8 %
7. 0 % > 9 9. 9 9 %0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 9 1 1 0. 1 3. A p pe n di x 1 3 : Pr ot oc ol A me n d me nt Hist or y 
T he Pr ot oc ol A me n d me nt S u m mar y  of C ha n ges Ta ble f or t he c urre nt a me n d me nt is l ocate d 
directl y  bef ore t he T O C.  T he pr ot oc ol a me n d me nt s u m mar y  of c ha n ges ta bles f or past 
a me n d me nt(s) ca n be f o u n d bel o w: 
A m e n d me nt 5 ( [ADDRESS_371173] 2 0 2 3) 
O ver all R ati o n ale f or t he A me n d me nt:   
Pr ot oc ol re visi o ns i n res p o nse t o partial cli nical h ol d. 
Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
T hr o u g h o ut A d de d m o n o vale nt B N T 1 6 2 b 2 ( O mi 
X B B. 1. 5) A d diti o n of ne w 
m o n o vale nt 
B N T 1 6 2 b 2 X B B. 1. 5 
i n t he vacci ne gr o u ps S u bsta ntial 
Secti o n 1. 1 : S y n o psis Rati o nale was u p date d T o ali g n wit h 
X B B. 1. 5 a d diti o n S u bsta ntial 
Secti o n 1. 1 : S y n o psis O bjecti ves w ere u p date d T o c o nsi der t he 
m o n o vale nt 
B N T 1 6 2 b 2 ( O mi 
X B B. 1. 5) a n d t he 
se parati o n of t he [ADDRESS_371174] u d y B S u bsta ntial 
Secti o n 1. 1 S y n o psis T he o verall desi g n was s u m marize d 
as a para gra p h; t he b ullet p oi nts were 
r e m o ve d T o bri n g clarit y i n t he 
desi g n N o ns u bsta ntial 
Secti o n 1. 1 : S y n o psis The ta ble title d “ S u bst u d y B: All 
Vacci ne Gr o u ps” was u p date d t o 
“ S u bst u d y B: All I nitial -E nr oll me nt 
Vacci ne Gr o u ps f or Partici pa nts 
1 8 T hr o u g h 6 4 Years of A ge” T o ali g n wit h t he 
desi g n Su bsta ntial 
Secti o n 1. 1 : S y n o psis A d de d a ne w ta ble title d “ S u bst u d y 
B: All E x pa n de d -E nr oll me nt Vacci ne 
Gr o u ps f or Partici pa nts ≥6 5 Years of 
A ge” t o r e place 3ta ble stitle d 
“S u bst u d y B: qI R V/ Bi vale nt 
B N T 1 6 2 b 2 ( Ori gi nal/ O mi 
B A. 4/ B A. 5) D ose -Le vel 
Co m bi nati o n s,” “ S u bst u d y B: 
tI R V/ Bi vale nt B N T 1 6 2 b 2 
( Ori gi nal/ O mi B A. 4/ B A. 5),” a n d 
“ S u bst u d y B: b I R V/ Bi vale nt 
B N T 1 6 2 b 2 ( Ori gi nal/ O mi 
B A. 4/ B A. 5) ”T o ali g n wit h t he ne w 
desi g n a n d bri n g 
clarit y i n t he na mi n g 
of t he vari o us vacci ne 
gr o u ps Su bsta ntial 
Secti o n 1. 1 : S y n o ps is Vacci ne pre parati o n ta ble w as 
r e m o ve d T o i m pr o ve 
rea da bilit y of t he 
s y n o psis N o ns u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 9 2 Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n 1. 1 : S y n o psis Ta ble title d “I nitial -E nr oll me nt Sta ge 
C o h orts i n Partici pa nts 1 8 T hr o u g h 
6 4 Years of A ge” was u p date d T o bri n g detail o n 
lice nse d QI V N o ns u bsta ntial 
Secti o n 1. 1 : S y n o psis U p date d I R C re vie w t o [ADDRESS_371175] u d y A Su bsta ntial 
Secti o n 1. 1 : S y n o psis Secti o n was re vise d t o al i g n wit h 
c ha n ges t o t he st u d y desi g n T o ali g n wit h st u d y 
desi g n S u bsta ntial 
Secti o n 1. 1 : S y n o psis Clarificati o n o n t he S u bst u d y B 
e nr oll me nt strate g y f or b ot h i nitial 
a n d e x pa n de d p hases E nr oll me nt of t he 
partici pa nts 1 8 
t hr o u g h 6 4 y ears of 
a ge a n d safet y re vie w 
pri or t o e nr olli n g t he 
partici pa nts ≥6 5 years 
of a ge S u bsta ntial 
Secti o n 1. 1 : S y n o psis U p date d t he n u m ber of partici pa nts T o ali g n wit h t he 
u p date d e nr oll me nt 
strate g y S u bsta ntial 
Secti o n 1. 1 : S y n o psis E xcl usi o n criteria were a d de d t o 
S u bst u d y B T o bri n g clarit y S u bsta ntial 
Secti o n 1. 1 : S y n o psis S u bst u d y B st u d y ar m ta ble was 
u p date d T o reflect X B B. 1. 5, 
place b o, a n d 
c o m parat or S u bsta ntial 
Secti o n 1. 2 : Sc he ma Sc he ma was u p date d T o reflect t he ne w 
e nr oll me nt strate g y 
a n d safet y re vie w S u bsta ntial 
Secti o n 2. 1 : St u d y 
Rati o nale Te xt w as e dite d T o ali g n wit h t he 
st u d y desi g n S u bsta ntial 
Secti o n 2. 2 : 
Bac k gr o u n d Te xt a n d refere nces were re vise d T o ali g n wit h t he 
st u d y desi g n S u bsta ntial 
Secti o n 2. 2. 3 : Cli nical 
O ver vie wTe xt w as e dite d T o ali g n wit h t he 
st u d y desi g n S u bsta ntial 
Secti o n 2. 3 : 
Be nefit/ Ris k 
Assess me nt Te xt w as e dite d T o ali g n wit h t he 
st u d y desi g n S u bsta ntial 
Secti o n 4. 3 : 
J ustificati o n f or D ose Te xt w as e dite d; a d diti o n of 
B N T 1 6 2 b 2 ( O mi X B B. 1. 5) T o ali g n wit h t he 
st u d y desi g n S u bsta nti al 
Secti o n 6 : St u d y 
I nter ve nti o n(s) a n d 
C o nc o mita nt T hera p y Te xt w as e dite d; m ore details were 
a d de d T o bri n g clarit y o n t he 
vacci ne gr o u ps S u bsta ntial 
Secti o n 6 : St u d y 
I nter ve nti o n(s) a n d 
C o nc o mita nt T hera p y Te xt w as e dite d; Ta ble 2 w as e dite d 
a n d s plit i nt o 2 ta bles ( n o w  Ta bles 2 
a n d 3); pre vi o us Ta bles 3 a n d 4 w ere 
r e m o ve d T o bri n g clarit y o n t he 
vacci ne gr o u ps S u bsta ntial 
Secti o n 7. 1 : 
Disc o nti n uati o n of 
St u d y I nter ve nti o n Details were a d de d f or partici pa nts i n 
Gr o u p [ADDRESS_371176] u d y i nter ve nti o n a d mi nistrati o n T o ali g n wit h t he 
a d diti o n of 2 -d ose 
gr o u ps N o ns u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 9 3 Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n 8. 3. 5 :Electr o nic 
Diar y A d de d i nstr ucti o n t hat misse d e -diar y 
e ntries s h o ul d be i ncl u de d i n t he A E 
C R F T o ali g n wit h 
re g ulat or y 
e x pectati o ns N o ns u bsta ntial 
Secti o n 8. 4. 1 : Ti me 
Peri o d a n d Fre q ue nc y 
f or C ollecti n g A E a n d 
S A E I nf or mati o n Te xt a d de d t o details of A E 
c ollecti o n re q uire me nts f or 
partici pa nts recei vi n g [ADDRESS_371177] u d y i nter ve nti o n T o e ns ure a de q uate 
safet y f oll o w -u p f or 
t h ose w h o recei ve 
2d oses S u bsta ntial 
Secti o n 8. 4. 7 : A d verse 
E ve nts of S pecial 
I nterest M y ocar ditis a n d pericar ditis are n o w  
c o nsi dere d A E SIs f or u p t o 6 wee ks 
( pre vi o usl y 4 wee ks) after 
vacci nati o n T o ali g n wit h 
re g ulat or y 
re q ui r e m e nts f or 
C O VI D -1 9 vacci nes S u bsta ntial 
Secti o n 9. 3. 1 : Ge neral 
C o nsi derati o ns Te xt w as e dite d T o ali g n wit h t he 
o bjecti ves N o ns u bsta ntial 
Secti o n 1 0. 1. 5. 1 :Data 
M o nit ori n g C o m mittee D M C will r e vie w safet y data a n d 
i m m u n o ge nicit y acc u m ulate d f or at 
least [ADDRESS_371178] u d y B , w as 
pre vi o usl y 1 we e k T o ali g n wit h 
re g ulat or y 
e x pectati o ns S u bsta ntial 
Secti o n 1 0. 2 : 
A p pe n di x 2: Cli nical 
La b orat or y Tests Te xt w as e dite d T o ali g n wit h t he 
st u d y desi g n N o ns u bsta ntial 
Secti o n 1 0. 1 1. 4 : 
S u bst u d y A Desi g n Te xt w as e dite d T o bri n g clarit y N o ns u bsta ntial 
Secti o n 1 0. 1 2. 1 : S o A –
S u bst u d y B ( P hase 1/ 2) Sc he d ule of acti vities was e dite d A visit was a d de d S u bsta ntial 
Secti o n 1 0. 1 2. 2. 1 : 
S u bst u d y B Rati o nale Te xt w as e dite d T o ali g n wit h t he 
st u d y desi g n S u bsta ntial 
Secti o n 1 0. 1 2. 2. 3 : 
O bjecti ves, E n d p oi nts, 
a n d Esti ma n ds 
( S u bst u d y B) O bjecti ves w ere u p date d T o ali g n wit h t he 
st u d y desi g n S u bsta ntial 
Secti o n 1 0. 1 2. 4. 1 : 
O verall Desi g n 
( S u bst u d y B) Te xt a n d Ta ble [ADDRESS_371179] u d y desi g n S u bsta ntial 
Secti o n 1 0. 1 2. 5. 2 : 
S u bst u d y B E xcl usi o n 
Criteria E xcl usi o n criteria were a d de d; 
pri or/c o nc o mita nt t hera p y was e dite d T o bri n g clarit y S u bsta ntial 
Secti o n 1 0. 1 2. 6. 1 : 
St u d y I nter ve nt i o n(s) 
A d mi nistere d 
(S u bst u d y B 
I nter ve nti o n a n d 
C o nc o mita nt T hera p y )S u bst u d y B st u d y i nter ve nti o n ta ble 
wa s e dite d; pre vi o us Ta ble [ADDRESS_371180] u d y desi g n; 
Ta bles 1 0 a n d 2 w ere 
c o m bi ne d i nt o 1 ta ble 
( Ta ble 2) S u bsta ntial 
Secti o n 1 0. 1 2. 6. 1. 1 : 
A d mi nistrati o n Te xt w as e dite d a n d pre vi o us 
Ta ble [ADDRESS_371181] d b y te xt T o a d d clarit y o n 
a d mi nistrati o n of t he 
vacci nes Su bsta ntial 
Secti o n 1 0. 1 2. 6. 7. 1 : 
Pr o hi bite d D uri n g t he 
St u d y W or di n g has bee n c ha n ge d T o bri n g clarit y o n t he 
pr o hi bite d me dicati o n 
d uri n g t he st u d y N o ns u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 9 4 Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n 1 0. 1 2. 6. 7. 2 : 
Per m itte d D uri n g t he 
St u d y A d de d n o nst u d y c or o na vir us a n d 
n o nst u d y i nfl ue nza vacci ne 
all o w a nce at t he 4- wee k f oll o w -u p 
visit All o wi n g partici pa nts 
t o recei ve c or o na vir us 
a n d/ or i nf l ue nza 
vacci nes [ADDRESS_371182] u d y i nter ve nti o n S u bsta ntial 
Secti o n 1 0. 1 2. 8 : 
S u bst u d y B 
Assess me nts a n d 
Pr oce d ures Te xt w as re vise d T o ali g n wit h t he 
st u d y desi g n S u bsta ntial 
Secti o n 1 0. 1 2. 8. 1 : 
Tele healt h Visits Te xt w as e dite d T o clarif y t he visits N o ns u bsta ntial 
Secti o n 1 0. 1 2. 8. 7 : 
St o p pi n g R ules Re vise d st o p pi n g r ules te xt a n d 
a d diti o n of st o p pi n g r ules criteria T o all o w  a better 
safet y s ur veilla nce 
after st u d y 
i nter ve nti o n 
a d mi nistrati o n S u bsta ntial 
Secti o n 1 0. 1 2. 8. 1 0 : 
A d diti o nal Pr oce d ures 
f or M o nit ori n g of 
P ote ntial M y ocar ditis or 
Pericar ditis Te xt w as u p date d T o bri n g clarit y N o ns u bsta ntial 
Secti o n 1. 1. 1. 1. 1 : 
Visit 3 0 2 – 4- Wee k 
F oll o w -U p Visit ( After 
Vacci nati o n) Te xt w as re m o ve d T here is n o P B M C N o ns u bsta ntial 
Sec ti o n 1. 1. 1. 1. 1 : 
Visit 3 0 2 – 4- Wee k 
F oll o w -U p Visit ( After 
Vacci nati o n) A d diti o nal st u d y i nter ve nti o n f or 
selecte d gr o u ps. Re mi n der a d de d t o 
alert partici pa nt t o o pti o n f or 
a d mi nistrati o n of n o nst u d y vacci nes T o ali g n wit h t he 
st u d y desi g n S u bsta ntial 
Secti o n 1. 1. 1. 1. 1 : 
Visit 3 0 3 – 8- Wee k 
F oll o w -U p Visit ( After 
Vacci nati o n) Te xt w as re m o ve d T here is n o P B M C N o ns u bsta ntial 
Secti o n 1. 1. 1. 1. 1 : 
Visit 3 0 3 – 8- Wee k 
F oll o w -U p Visit ( After 
Vacci nati o n) A d diti o n of Visit [ADDRESS_371183] u d y desi g n S u bsta ntial 
Secti o n 1. 1. 1. 1. 1 : 
Visit 3 0 4 – 6- M o nt h 
F oll o w -U p Visit ( After 
Vacci nati o n) Visit [ADDRESS_371184] u d y 
desi g n S u bsta ntial 
Secti o n 1 0. 1 2. 8. 1 0 : 
A d diti o nal Pr oce d ures 
f or M o nit ori n g of 
P ote ntial M y ocar ditis or 
Pericar ditis Te xt w as e dite d T o bri n g clarit y N o ns u bsta ntial 
Secti o n 1 0. 1 2. 9. 1. 1. 1 
Pri mar y 
Esti ma n ds/ C o pri mar y 
Esti ma n ds I ncl u de d i nf or mati o n o n t he a nal ysis 
of m issi n g e -diar y data rec or de d o n 
t he A E C R F. T o clarif y a nal ysis 
pla n N o ns u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 9 5 Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n 1 0. 1 2. 9. 3. 2 : 
Pri mar y 
E n d p oi nt(s)/ Esti ma n d(s) 
A nal ysis Te xt w as e dite d T o ali g n wit h t he 
st u d y desi g n S u bsta ntial 
Secti o n 1 0. 1 2. 9. 6. 1 : 
I m m u n o ge nicit y 
( Sa m ple Size 
Deter mi nati o n) Te xt w as a d de d T o ali g n wit h t he 
st u d y desi g n S u bsta ntial 
A m e n d me nt 4 ( 1 6 A pril 2 0 2 3) 
O ver all R ati o n ale f or t he A me n d me nt: 
T o reflect c ha n ges t o t he st u d y  desi g n of S u bst u d y B f oll o wi n g s p o ns or re vie w of S u bst u d y  
A data fr o m partici pa nts 1 8 t hr o u g h 6 4 ye ars of a ge, a n d t o re m o ve refere nces t o P hase 3. 
Pr ot oc ol A me n d me nt S u m m ar y of C h a n ges T a ble: 
Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
T hr o u g h o ut Re m o ve d refere nces t o 
P hase [ADDRESS_371185] u d y desi g n 
c ha n ges N o ns u bsta ntial 
Secti o n 2. 2. 3. 3 C o m bi ne d 
I nfl ue nza a n d S A R S -C o v - 2 
Vacci nes A d de d secti o n f or clarit y T o pr o vi de clarit y N o ns u bsta ntial 
Secti o n 2. 3 Be nefit/ Ris k 
Assess me nt U p date d QI V fr o m Fl uz o ne 
t o Fl ucel va x T o u p date per t he st u d y desi g n S u bsta ntial 
Secti o n 2. 3. [ADDRESS_371186] u d y desi g n 
c ha n ges N o ns u bsta ntial 
Secti o n 4. 3. 3 
qI R V/ Bi vale nt B N T 1 6 2 b 2 
( Ori gi nal/ O mi B A. 4/ B A. 5) Re vise d per t he u p date d 
S u bst u d y B st u d y desi g n T o acc o m m o date st u d y desi g n 
c ha n ges N o ns u bsta ntial 
Secti o n 4. 3. 4 
tI R V/ Bi vale nt B N T 1 6 2 b 2 
( Ori gi nal/ O mi B A. 4/ B A. 5) A d de d a secti o n f or 
j ustificati o n f or t he a d d iti o n 
of st u d y i nter ve nti o ns T o acc o m m o date st u d y desi g n 
c ha n ges N o ns u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 9 6 Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n 4. 3. 5 
bI R V/ Bi vale nt B N T 1 6 2 b 2 
( Ori gi nal/ O mi B A. 4/ B A. 5) A d de d a secti o n f or 
j ustificati o n f or t he a d diti o n 
of st u d y i nter ve nti o ns T o acc o m m o date st u d y desi g n 
c ha n ges N o ns u bsta ntial 
Secti o n 6 St u d y 
I nter ve nti o n(s) a n d 
C o nc o mita nt T hera p y U p date d wit h ne w st u d y 
i nter ve nti o ns a n d ta bles; 
u p date d ta ble hea ders T o u p date per t he ne w  st u d y 
desi g n S u bsta ntial 
Secti o n 7. 2 Partici pa nt 
Disc o nti n uati o n/ Wit h dra w 
al Fr o m t he St u d y U p date d t o refere nce 
S u bst u d y B i nf or mati o n U p date d f or t he ne w st u d y 
desi g n N o ns u bsta ntial 
Secti o n 8. 2. [ADDRESS_371187] u d y B –
s pecific i nf or mati o n U p date d f or t he ne w st u d y 
desi g n S u bsta ntial 
Secti o n 8. 3. [ADDRESS_371188] u d y B –
s pecific i nf or mati o n U p date d f or t he ne w st u d y 
desi g n S u bsta ntial 
Secti o n 8. 3. [ADDRESS_371189] u d y desi g n U p date d f or clarit y S u bsta ntial 
Secti o n title d Disease -
Relate d E ve nts a n d/ or 
Disease -Relate d O utc o mes 
N ot Q ualif yi n g as A Es or 
S A Es ( S u bst u d y B) Secti o n re m o ve d as it n o 
l o n ger fits wit h t he ne w 
st u d y desi g n U p date d f or t he ne w st u d y 
desi g n S u bsta ntial 
Secti o n 8. 4. [ADDRESS_371190] u d y 
desi g n S u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 9 7 Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n [ADDRESS_371191] u d y a n d 
Site Start a n d Cl os ure U p date d la n g ua ge t o ali g n 
wit h t he ne w pr ot oc ol 
t e m plate U p date d t o ali g n wit h t he 
u pc o mi n g te m plate N o ns u bsta ntial 
Secti o n 1 0. 2 A p pe n di x 2: 
Cli nical La b orat or y Tests U p date d refere nce S u bst u d y 
B a n d i ncl u de d ne w 
h y perli n k U p date d f or t he ne w st u d y 
desi g n N o ns u bsta ntial 
Secti o n [ADDRESS_371192] u d y 
I nter ve nti o n(s) 
A d mi nistere d U p date d wit h ta bles wit h 
ne w li n ks f or clarit y T o pr o vi de clarit y N o ns u bsta ntial 
Secti o n 1 0. 1 1. 8. 8. 1 
Scree ni n g ( 0 t o 2 8 Da ys 
Bef ore Visit 1) U p date d t o re m o ve refere nce 
t o c ollecti o n of pre vi o us 
st u d y partici pa nt n u m bers T o pr o vi de clarit y N o ns u bsta ntial 
Secti o n 1 0. 1 2. 1. 1 S o A —
I nitial -E nr oll me nt ( P hase 
1/ 2) A d de d a ne w secti o n a n d 
S o A ta ble d ue t o t he ne w 
S u bst u d y B desi g n U p date d f or t he ne w st u d y 
desi g n S u bsta ntial 
Secti o n 
Secti o n 1 0. 1 2. 1. 2 S o A —
E x pa n de d -E nr oll me nt 
( P hase 2) A d de d a ne w secti o n a n d 
u p date d t he pre vi o us S o A 
ta ble d ue t o t he ne w 
S u bst u d y B desi g n U p date d f or t he ne w st u d y 
desi g n S u bsta ntial 
Secti o n [ADDRESS_371193] u d y 
desi g n S u bsta ntial 
Secti o n 1 0. 1 2. 2. 3 
Be nefit/ Ris k Assess me nt U p date d t o ali g n wit h t he 
ne w st u d y desi g n U p date d f or t he ne w st u d y 
desi g n S u bsta ntial 
Secti o n 1 0. 1 2. 3 O bjecti ves, 
E n d p oi nts, a n d Esti ma n ds 
( S u bst u d y B) A d de d ne w o bjecti ves, 
esti ma n ds, a n d e n d p oi nts t o 
reflect t he ne w S u bst u d y B 
desi g n a n d re m o ve o bs olete 
i nf or mati o n; re m o ve d 
pre vi o us defi niti o ns of L CI, 
C CI, I LI, c o nfir me d 
C O VI D -[ADDRESS_371194] u d y 
desi g n S u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 9 8 Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n [ADDRESS_371195] u d y B E xcl usi o n 
Criteria Re m o ve d pre vi o us e xcl usi o n 
criteria 5 a n d 8; a d de d ne w  
e xcl usi o n criteria [ADDRESS_371196] u d y 
desi g n S u bsta ntial 
Secti o n 1 0. 1 2. 5. 3 Criteria 
f or Te m p oraril y Dela yi n g 
E nr oll me nt/ Ra n d o mizati o n 
/ A d mi nistrati o n of St u d y 
I nter ve nti o n U p date d wit h ne w visit 
i n f or mati o n d ue t o t he ne w 
st u d y desi g n U p date d f or t he ne w st u d y 
desi g n N o ns u bsta ntial 
Secti o n [ADDRESS_371197] u d y 
I nter ve nti o n(s) 
A d mi nistere d U p date d t he ta ble w it h ne w 
i nter ve nti o ns a n d a d de d t he 
S u bst u d y B: All Vacci ne 
Gr o u ps ta ble U p date d f or t he ne w st u d y 
desi g n S u bsta ntial 
Secti o n [ADDRESS_371198] u d y 
desi g n S u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 1 9 9 Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n [ADDRESS_371199] orat or y Gr o u ps: 
2, 6, 7, 8, 9, [ADDRESS_371200] u d y 
Pr oce d ures –I nitial -
E nr oll me nt Gr o u p A d de d a ne w secti o n a n d 
s u bsecti o ns t o ali g n wit h t he 
ne w st u d y desi g n a n d ne w 
pr oce d ures A d de d f or t he ne w st u d y 
desi g n S u bsta ntial 
Secti o n [ADDRESS_371201] u d y 
Pr oce d ures –E x pa n de d -
E nr oll me nt Gr o u p A d de d a ne w secti o n a n d 
s u bsecti o ns t o ali g n wit h t he 
ne w st u d y desi g n a n d ne w 
pr oce d ures A d de d f or t he ne w st u d y 
desi g n S u bsta ntial 
Secti o n [ADDRESS_371202] u d y 
desi g n S u bsta ntial 
Secti o n 1 0. 1 2. 9. 3. 2 
Pri mar y 
E n d p oi nt(s)/ Esti ma n d(s) 
A nal ysis U p date d t he secti o n per t he 
ne w st u d y desi g n U p date d per t he ne w st u d y 
desi g n S u bsta ntial 
Secti o n 1 0. 1 2. 9. 3. 3 
Sec o n dar y 
E n d p oi nt(s)/ Esti ma n d(s) 
A nal ysis U p date d t he secti o n per t he 
ne w st u d y des i g n U p date d t he secti o n per t he 
ne w st u d y desi g n S u bsta ntial 
Secti o n 1 0. 1 2. 9. 3. 4 
Tertiar y/ E x pl orat or y 
E n d p oi nt(s) U p date d t he secti o n per t he 
ne w st u d y desi g n U p date d t he secti o n per t he 
ne w st u d y desi g n S u bsta ntial 
Secti o n [ADDRESS_371203] u d y 
desi g n S u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 2 0 0 Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n [ADDRESS_371204] u d y desi g n S u bsta ntial 
A m e n d me nt 3 ( 1 5 Fe br u ar y 2 0 2 3) 
O ver all R ati o n ale f or t he A me n d me nt: 
I n cl usi o n of S u bst u d y  B: A P hase 2/ 3 st u d y  t o descri be t he safet y, t olera bilit y , a n d 
i m m u n o ge nicit y of qI R V/ bi vale nt B N T 1 6 2 b 2 ( ori gi nal/ O mi B A. 4/ B A. 5). 
Pr ot oc ol A me n d me nt S u m m ar y of C h a n ges T a ble: 
Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n [ADDRESS_371205] u d y B 
( P hase 2/ 3) S u bsta ntial 
Secti o n 2. 1 St u d y Rati o nale Re vise d wit h u p date d 
i nf or mati o n A vaila bilit y of m ore 
c urre nt i nf or mati o n S u bsta ntial 
Secti o n 2. 2. 1 S A R S -C o V - 2 Re vise d wit h u p date d 
i nf or mati o n A vaila bilit y of m ore 
c urre nt i nf or mati o n S u bsta ntial 
Secti o n 2. 2. 3 Cli nical 
O ver vie wRe vise d wit h u p date d 
i nf o r m ati o n A vaila bilit y of m ore 
c urre nt i nf or mati o n S u bsta ntial 
Secti o n 2. 3 Be nefit/ Ris k 
Assess me nt S pecifie d S R S D f or 
QI V is Fl uz o ne 
Q ua dri vale nt T o pr o vi de 
clarificati o n N o ns u bsta ntial 
Secti o n 2. 3. 1 Ris k Assess me nt A d de d a ris k assess me nt 
f or QI V a n d 
mi dt ur bi nate s wa bs, a n d 
u p date d t he 
B N T 1 6 2 b 2 O micr o n 
( B A. 4/ B A. 5 s u bli nea ge ) 
ris ks T o a d d a d diti o nal 
i nf or mati o n a n d 
clarif y p ote ntial 
ris ks S u bsta ntial 
Secti o n 2. 3. [ADDRESS_371206] u d y B 
( P hase 2/ 3) N o ns u bsta ntial 
Secti o n [ADDRESS_371207] u d y B 
( P hase 2/ 3) N o ns u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 2 0 1 Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n 4. 3 J ustificati o n f or 
D ose Re m o ve d i nf or mati o n 
u n der t his hea der a n d 
u p date d t he 
c orres p o n di n g 
s u bsecti o ns A vaila bilit y of m ore 
c urre nt i nf or mati o n S u bs ta ntial 
Secti o n 4. 3. 1 Bi vale nt 
B N T 1 6 2 b 2 
( Ori gi nal/ O mi B A. 4/ B A. 5) Re vise d j ustificati o n t o 
n ote t he F D A’s E U A as 
t he reas o n f or t he 
c h ose n d ose A vaila bilit y of m ore 
c urre nt i nf or mati o n S u bsta ntial 
Secti o n 4. 3. 2 qI R V Re vise d j ustificati o n of 
d ose base d o n P hase 3 
data i n differe nt a ge 
gr o u ps ( 1 8 t hr o u g h 6 4 
a n d ≥6 5 years of a ge) A vaila bilit y of m ore 
c urre nt i nf or mati o n S u bsta ntial 
Secti o n [ADDRESS_371208] u d y B 
( P hase 2/ 3) S u bsta ntial 
Secti o n 5. 5 Criteria f or 
T e m p oraril y Dela yi n g 
E nr oll me nt/ Ra n d o mizati o n/ 
A d mi nistrati o n of St u d y 
I nter ve nti o n A d de d t he S u bst u d y 
A a n d B li n k s
M o ve d t he secti o n 
c o nte nt t o t he 
S u bst u d y Aa p pe n di x T o better ali g n t o 
t he master pr ot oc ol 
f or mat N o ns u bsta ntial 
Secti o n 6 St u d y 
I nter ve nti o n(s) a n d 
C o nc o mita nt T hera p y A d de d li n ks t hr o u g h o ut 
t he secti o n t o ne w 
c orres p o n di n g S u bst u d y 
B secti o ns T o acc o m m o date 
t he a d diti o n of 
S u bst u d y B 
( P hase 2/ 3) S u bsta ntial 
Secti o n 6 St u d y 
I nter ve nti o n(s) a n d 
C o nc o mita nt T hera p y Clarifie d i nter ve nti o ns 
acr oss b ot h s u bst u dies T o acc o m m o date 
t he a d diti o n of 
S u bst u d y B 
( P hase 2/ 3) S u bsta ntial 
Secti o n 8. 2. 1 Bi ol o gical 
Sa m ples A d de d ver bia ge 
re gar di n g partici pa nts 
w h o pr o vi de c o nse nt f or 
ge netic testi n g T o a d d e xce pti o ns 
f or t h ose t hat a gree 
t o ge netic testi n g of 
P B M C sa m ples S u bsta ntial 
Secti o n 8. 2 Efficac y a n d/ or 
I m m u n o ge nicit y Assess me nts A d de d li n k t o t h e 
c orres p o n di n g S u bst u d y 
B secti o n T o acc o m m o date 
t he a d diti o n of 
S u bst u d y B 
( P hase 2/ 3) S u bsta ntial 
Secti o n 8. 3. [ADDRESS_371209] u d y B S u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 2 0 2 Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n 8. 3. [ADDRESS_371210] u d y B 
( P hase 2/ 3) S u bsta ntial 
Secti o n 8. 4. [ADDRESS_371211] u d y B 
( P hase 2/ 3) S u bsta ntial 
Secti o n 8. 4. 7 Disease -Relate d 
E ve nts a n d/ or Disease -Relate d 
O utc o mes N ot Q ualif yi n g as 
A E s or S A Es ( S u bst u d y B) A d de d i nf or mati o n 
detaili n g A RI visits T o acc o m m o date 
t he a d diti o n of 
S u bst u d y B 
( P hase 2/ 3) S u bsta ntial 
Secti o n 8. 4. [ADDRESS_371212] u d y B 
( P hase 2/ 3) S u bsta ntial 
Secti o n 8. 4. [ADDRESS_371213] u d y B 
( P hase 2/ 3) S u bsta ntial 
Secti o n 8. [ADDRESS_371214] u d y B 
( P hase 2/ 3) S u bsta ntial 
Secti o n [ADDRESS_371215] u d y B 
( P hase 2/ 3) S u bsta ntial 
Secti o n 9. 3. [ADDRESS_371216] u d y B 
( P has e2/ 3) S u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 2 0 3 Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n [ADDRESS_371217] u d y Data A d de d li n ks t o 
Cli nical Trials. g o v a n d 
[COMPANY_007].c o m T o pr o vi de li n ks t o 
areas of accessi n g 
data N o ns u bsta ntial 
Secti o n 1 0. 4 A p pe n di x 4: 
Ge netics A d de d secti o n as it is 
a p plica ble wit h t he 
a d diti o n of S u bst u d y B T o acc o m m o date 
t he a d diti o n of 
S u bst u d y B 
( P hase 2/ 3) S u bsta ntial 
Secti o n 1 0. 5. 1 
Male Partici pa nt Re pr o d ucti ve 
I ncl usi o n Criteria U p date d a n d s pecifie d 
c o ntrace pti o n use T o ali g n wit h 
c urre nt 
rec o m me n dati o ns S u bsta ntial 
Secti o n 1 0. 5. 2 Fe male 
Partici pa nt Re pr o d ucti ve 
I ncl usi o n Criteria U p date d li n k t o re vise d 
secti o n n u m ber Secti o n n u m bers 
ha ve c ha n ge d N o ns u bsta ntial 
Secti o n 1 0. 8 A p pe n di x 8: 
Criteria f or All o wi n g 
I ncl usi o n of Partici pa nts Wit h 
C hr o nic Sta ble HI V, H C V, or 
H B V I nfecti o n A d de d a secti o n t o 
clarif y t he all o wa nce of 
partici pa nts wit h c hr o nic 
sta ble HI V, H C V, or 
H B V i nfecti o ns T o pr o vi de clarit y S u bsta ntial 
Secti o n 1 0. 1 1. 1 S o A –
S u bst u d y A ( P hase 1) U p date d t he or der of 
bl o o d dra ws T o pr o vi de clarit y N o ns u bsta n tial 
Secti o n 1 0. 1 1. 3 O bjecti ves, 
E n d p oi nts, a n d Esti ma n ds 
( S u bst u d y A) U p date d t he o bjecti ves 
a n d esti ma n ds t o i ncl u de 
t he ne w a ge strat u m T o acc o m m o date 
t he ne w a ge strat u m S u bsta ntial 
Secti o n 1 0. 1 1. 4. 1 O verall 
Desi g n U p date d t he desi g n 
secti o n t o i ncl u de t he 
≥[ADDRESS_371218] u d y A 
I ncl usi o n Criteria U p date d t he i ncl usi o n 
criteria t o re m o ve t he 
1 8 t hr o u g h 6 4 years 
of a ge ra n ge a n d als o 
clarifie d t he a d diti o n 
of partici pa nts wit h 
c hr o nic sta ble HI V, 
H C V, a n d H B V 
i nfecti o ns 
U p date d i ncl usi o n 
criteri o n 5 t o detail 
t he 2a ge strata 
A d de d i ncl usi o n 
criteri o n [ADDRESS_371219] u d y A 
E xcl usi o n Criteria U p date d e xcl usi o n 
criteri o n 9 T o acc o m m o date 
t he ne w a ge strat u m S u bsta ntial 
Secti o n 1 0. 1 1. 5. 3 Criteria f or 
T e m p oraril y Dela yi n g 
E nr oll me nt/ Ra n d o mizati o n/ 
A d mi nistrati o n of St u d y 
I nter ve nti o n M o ve d t he c o nte nt 
pre vi o usl y i n 
Secti o n 5. 5 here t o ali g n 
wit h t he master pr ot oc ol 
f or mat T o ali g n secti o ns t o 
t he master pr ot oc ol 
f or mat N o ns u bsta n tial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 2 0 4 Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n [ADDRESS_371220] u d y I nter ve nti o n(s) 
A d mi nistere d A d de d a r o w  f or 
tar gete d i nfl ue nza 
strai ns T o pr o vi de clarit y N o ns u bsta ntial 
Secti o n 1 0. 1 1. 8. 8. 2 Visit 1 –
Vacci nati o n ( Da y 1) U p date d t he or der of 
bl o o d dra ws T o pr o vi de clarit y N o ns u bsta ntial 
Secti o n 1 0. 1 1. 8. 8. 2 Visit 1 –
Vacci nati o n ( Da y 1) U p date d t he i njecti o n 
site i n t he delt oi d 
m uscle b y re m o vi n g 
refere nce t o t he 
n o n d o mi na nt ar m T o u p date per t he 
P A C L N o ns u bsta ntial 
Secti o n 1 0. 1 1. 8. 8. 6 Visit 5 –
8- Wee k F oll o w -U p Visit 
( After Vacci nati o n) –5 2 t o 
6 0 Da ys After Visit 1 U p date d visit t o all o w  
f or partici pa nts w h o ha d 
n ot recei ve d lice nse d 
QI V at Visit 1 t o recei ve 
it at Visit 5, if dee me d 
as re q uire d b y t he 
i n vesti gat or T o acc o m m o date 
t he ne w a ge strat u m S u bsta ntial 
Secti o n 1 0. 1 1. 9. 3. 2 Pri ma r y  
E n d p oi nt(s)/ Esti ma n d(s) 
A nal ysis U p date d t he secti o n t o 
i ncl u de a ge 
stratificati o ns T o acc o m m o date 
t he ne w a ge strat u m S u bsta ntial 
Secti o n 1 0. 1 1. 9. 3. 3 Sec o n dar y 
E n d p oi nt(s)/ Esti ma n d(s) 
A nal ysis U p date d t he o bjecti ves 
a n d esti ma n ds t o i ncl u de 
t he ne w a ge strat u m a n d 
matc h t he u p date d 
la n g ua ge t hr o u g h o ut t he 
pr ot oc ol T o acc o m m o date 
t he ne w a ge strat u m N o ns u bsta ntial 
Secti o n [ADDRESS_371221] orat or y 
E n d p oi nt(s)/ Esti ma n d(s) 
A nal ysis U p date d t he o bjecti ves 
a n d esti ma n ds t o i ncl u de 
t he ne w a ge strat u m a n d 
matc h t he u p date d 
la n g ua ge t hr o u g h o ut t he 
pr ot oc ol T o acc o m m o date 
t he ne w a ge strat u m N o ns u bsta ntial 
Secti o n 1 0. 1 1. 9. 3. 5. 1 
Electr ocar di o gra m A nal yses U p date d t he secti o n t o 
i ncl u de a ge 
stratificati o ns T o acc o m m o date 
t he ne w a ge strat u m N o ns u bsta ntial 
Secti o n 1 0. 1 1. 9. 3. 5. 2 Ot her 
A nal yses U p date d t he secti o n t o 
i ncl u de a ge 
stratificati o ns T o acc o m m o date 
t he ne w a ge strat u m N o ns u bsta ntial 
Secti o n 1 0. 1 1. 9. 5 Sa m ple Size 
Deter mi nati o n U p date d t he secti o n t o 
i ncl u de a ge 
stratificati o ns T o acc o m m o date 
t he ne w a ge strat u m N o ns u bsta ntial 
Secti o n 1 0. 1 2 A p pe n di x 1 2: 
S u bst u d y B ( P hase 2/ 3) Secti o n (a n d all 
s u bsecti o ns) create d t o 
a d d P hase 2/ [ADDRESS_371222] u d y B 
( P hase 2/ 3) S u bsta ntial 
Secti o n [ADDRESS_371223] u d y B 
( P hase 2/ 3) S u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 2 0 5 Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n [ADDRESS_371224] u d y B 
( P hase 2/ 3) S u bsta ntial 
Secti o n [ADDRESS_371225] ur ba nces A d de d secti o n per ne w 
A E SI T o acc o m m o date 
ne w A E SI S u bsta ntial 
Secti o n 1 0. 1 3A p pe n di x 1 3: 
Pr ot oc ol A me n d me nt Hist or y A d de d t he a p pe n di x o n 
t he pr ot oc ol a me n d me nt 
hist or y T o u p date per t he 
pr ot oc ol te m plate N o ns u bsta ntial 
T hr o u g h o ut Re m o ve d ( 2 2/ 2 3) after 
qI R V T o all o w  f or 
u p dates as t his 
pr ot oc ol ma y later 
i ncl u de s u bst u dies 
wit hi n ot her 
i nfl ue nza seas o ns N o ns u bsta ntial 
T hr o u g h o ut U p date d a ge ra n ges 
t hr o u g h o ut t he pr ot oc ol T o acc o m m o date 
t he ne w a ge strat u m N o ns u bsta ntial 
A m e n d me nt 2 ( 0 9 Dece m ber 2 0 2 2) 
O ver all R ati o n ale f or t he A me n d me nt: 
Partici pa nts ≥[ADDRESS_371226] u d y A. 
Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n 1. [ADDRESS_371227] u d y A Re visi o ns were ma de t o matc h u p dates 
t hr o u g h o ut t he b o d y of t he pr ot oc ol T o acc o m m o date t he 
ne w a ge strat u m S u bsta ntial 
Secti o n 2. 3. 1 
Ris k Assess me nt A d de d a ris k assess me nt f or QI V, 
mi dt ur bi nate s wa bs, a n d u p date d 
B N T 1 6 2 b 2 O micr o n ( B A. 4/ B A. 5 
s u bli nea ge) ris ks T o a d d a d diti o nal 
i nf or mati o n a n d clarif y 
p ote ntial ris ks S u bsta ntial 
Secti o n 2. 2. 3 
Cli nical O ver vie w U p date d t he secti o n wit h ne w 
i nf or mati o n T o a d d a d diti o nal 
i nf or mati o n S u bsta ntial 
Secti o n 1 0. 5. 1 
Male Partici pa nt 
Re pr o d ucti ve I ncl usi o n 
Criteria U p date d a n d s pecifie d c o ntrace pti o n 
use T o ali g n wit h c urre nt 
rec o m me n dati o ns S u bsta ntial 
Secti o n 1 0. 8 
A p pe n di x 7: Criteria f or 
All o wi n g I ncl usi o n of 
Partici pa nts Wit h 
C hr o nic Sta ble HI V, 
H C V, or H B V I nfecti o n A d de d a secti o n t o clarif y t he 
all o w a nce of partici pa nts wit h c hr o nic 
sta ble HI V, H C V, or H B V i nfecti o ns T o pr o vi de clarit y S u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 2 0 6 Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n 1 0. 1 1. 3 
O bjecti ves, E n d p oi nts, 
a n d Esti ma n ds 
( S u bst u d y A) U p date d t he o bjecti ves a n d esti ma n ds 
t o i ncl u de t he ne w a ge strat u m T o acc o m m o date t he 
ne w a ge strat u m S u bsta ntial 
Secti o n 1 0. 1 1. 4. 1 
O verall Desi g n U p date d t he desi g n secti o n t o i ncl u de 
t he ≥[ADDRESS_371228] u d y A I ncl usi o n 
Criteria U p date d t he i ncl usi o n criteria t o 
r e m o ve t he 1 8 t hr o u g h 6 4 years of 
a ge ra n ge a n d als o clarifie d t he 
a d diti o n of partici pa nts wit h 
c hr o nic sta ble HI V, H C V, a n d 
H B V i nfecti o ns 
U p date d i ncl usi o n criteri o n 5 t o 
detail t he t w o a ge strata 
A d de d i ncl usi o n criteri o n [ADDRESS_371229] u d y A E xcl usi o n 
Criteria U p date d e xcl usi o n criteri o n 9 T o acc o m m o date t he 
ne w a ge strat u m S u bsta ntial 
Secti o n 1 0. 1 1. 8. 8. 6 
Visit 5 – 8- Wee k 
F oll o w -U p Visit ( After 
Vacci nati o n) –5 2 t o 
6 0 Da ys After Visit 1 U p date d visit t o all o w  f or partici pa nts 
w h o ha d n ot recei ve d lice nse d QI V at 
Visit 1 t o recei ve it at Visit 5, if 
dee me d as re q uire d b y t he i n vesti gat or T o acc o m m o date t he 
ne w a ge strat u m S u bsta ntial 
Secti o n 1 0. 1 1. 9. 3. 2 
Pri mar y E n d p oi nt(s)/ 
Esti ma n d(s) A nal ysis U p date d t he secti o n t o i ncl u de a ge 
stratificati o ns T o acc o m m o date t he 
ne w a ge strat u m S u bsta ntial 
Secti o n 2. 3 Be nefit/ Ris k 
Assess me nt S pecifie d S R S D f or QI V is Fl uz o ne 
Q ua dri vale nt T o pr o vi de 
clarificati o n N o ns u b sta ntial 
T hr o u g h o ut Re m o ve d ( 2 2/ 2 3) after qI R V T o all o w  f or u p dates 
as t his pr ot oc ol ma y 
later i ncl u de 
s u bst u dies wit hi n ot her 
i nfl ue nza seas o ns N o ns u bsta ntial 
T hr o u g h o ut U p date d a ge ra n ges t hr o u g h o ut t he 
pr ot oc ol T o acc o m m o date t he 
ne w a ge strat u m N o ns u bsta ntial 
Secti o n 5. 5 Criteria f or 
T e m p oraril y Dela yi n g 
E nr oll me nt/ 
Ra n d o mizati o n/ 
A d mi nistrati o n of St u d y 
I nter ve nti o n A d de d S u bst u d y A li n k 
M o ve d t he secti o n c o nte nt t o t he 
S u bst u d y A a p pe n di x T o better ali g n t o t he 
master pr ot oc ol f or mat N o ns u bst a ntial 
Secti o n 7. 2 Partici pa nt 
Disc o nti n uati o n/ Wit h dra 
wal Fr o m t he St u d y A d de d ne w la n g ua ge f or w he n 
partici pa nts w o ul d be disc o nti n ue d i n 
S u bst u d y A T o pr o vi de clarit y N o ns u bsta ntial 
Secti o n 8. 4. [ADDRESS_371230] Clarifie d t hat a c o nfir me d C O VI D -1 9 
dia g n osis is a n A E SI after Visit 1 T o pr o vi de clarit y N o ns u bsta ntial 
Secti o n 1 0. 1 1. 1 U p date d or der of bl o o d dra ws T o pr o vi de clarit y N o ns u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 2 0 7 Secti o n # a n d N a m e Descri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n 1 0. 1 1. 8. 8. 2 
Visit 1 –Vacci nati o n 
( Da y  1) U p date d or der of bl o o d dra ws T o pr o vi de clarit y N o ns u bsta ntial 
Secti o n 1 0. 1 1. 5. 3 
Criteria f or Te m p oraril y 
Dela yi n g E nr oll me nt/ 
Ra n d o mizati o n/ A d mi nist 
rati o n of St u d y 
I nter ve nti o n M o ve d t he c o nte nt pre vi o usl y i n 
Secti o n 5. [ADDRESS_371231] u d y I nter ve nti o n(s) 
A d mi nistere d A d de d a r o w  f or tar gete d i nfl ue nza 
strai ns T o pr o vi de clarit y N o ns u bsta ntial 
Secti o n 1 0. 1 1. 9. 3. 3 
Sec o n dar y E n d p oi nt(s)/ 
Esti ma n d(s) A nal ysis U p date d t he o bjecti ves a n d esti ma n ds 
t o i ncl u de t he ne w a ge strat u m a n d 
matc h t he u p date d la n g ua ge 
t hr o u g h o ut t he pr ot oc ol T o acc o m m o date t he 
ne w a ge strat u m N o ns u bsta ntial 
Secti o n [ADDRESS_371232] orat or y E n d p oi nt(s)/ 
Esti ma n d(s) A nal ysis U p date d t he o bjecti ves a n d esti ma n ds 
t o i ncl u de t he ne w a ge strat u m a n d 
matc h t he u p date d la n g ua ge 
t hr o u g h o ut t he pr ot oc ol T o acc o m m o date t he 
ne w a ge strat u m N o ns u bsta ntial 
Secti o n 1 0. 1 1. 9. 3. 5. 1 
Electr ocar di o gra m 
A nal yses U p date d t he secti o n t o i ncl u de a ge 
stratificati o ns T o acc o m m o date t he 
ne w a ge strat u m N o ns u bsta ntial 
Secti o n 1 0. 1 1. 9. 3. 5. 2 
Ot her A nal yses U p date d t he secti o n t o i ncl u de a ge 
stratificati o ns T o acc o m m o date t he 
ne w a ge strat u m N o ns u bsta ntial 
Secti o n 1 0. 1 1. 9. 5 
Sa m ple Size 
Deter mi nati o n U p date d t he secti o n t o i ncl u de a ge 
stratificati o ns T o acc o m m o date t he 
ne w a ge strat u m N o ns u bsta ntial 
Secti o n 1 0. 1 1. 8. 8. 2 
Visit 1 –Vacci nati o n 
( Da y  1) U p date d t he i njecti o n site i n t he 
delt oi d m uscle b y re m o vi n g refere nce 
t o t he n o n d o mi na nt ar m T o u p date per t he 
P A C L N o ns u bsta ntial 
Secti o n 1 0. 1 2 
A p pe n di x 1 1: Pr ot oc ol 
A me n d me nt Hist or y A d de d t he a p pe n di x o n t he pr ot oc ol 
a m e n d me nt hist or y T o u p date per t he 
pr ot oc ol te m plate N o ns u bsta ntial 
A m e n d me nt 1 ( [ADDRESS_371233] o ber 2 0 2 2) 
O ver all R ati o n ale f or t he A me n d me nt: 
T he st o p pi n g r ules f or t he bi vale nt B N T 1 6 2 b 2 ( o ri gi nal/ O mi B A. 4/ B A. 5)/ qI R V ar ms ha ve 
bee n u p date d t o i ncl u de t he µ g d ose le vels. T his c ha n ge was i n res p o nse t o a C B E R 
re q uest. 
Secti o n # a n d 
N a m eDescri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n 1. [ADDRESS_371234] u d y A 
( P hase 1) U p date d la n g ua ge re gar di n g st o p pi n g r ules t o 
be i ncl usi ve of µ g d ose le vels T o ali g n wit h c urre nt 
rec o m me n dati o ns S u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 2 0 8 Secti o n # a n d 
N a m eDescri pti o n of C h a n ge Brief R ati o n ale S u bst a nti al or 
N o ns u bst a nti al 
Secti o n 
[ADDRESS_371235] o p pi n g r ules f or 
clarit y beca use of t he a d diti o nal ar ms bei n g 
i ncl u de d T o ali g n wit h c urre nt 
rec o m me n dati o ns S u bsta ntial 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) C CI 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 2 0 9 1 0. 1 4. A p pe n di x 1 4 : A b bre vi ati o ns 
T he f oll o wi n g is a list of a b bre viati o ns t hat ma y  be use d i n t he pr ot oc ol .
A b bre vi ati o n Ter m 
A CI P A d vis or y  C o m mittee o n I m m u nizati o n Practices ( U nite d States) 
A D E a d verse de vice effect 
A E a d verse e ve nt 
A E SI a d verse e ve nt of s pecial i nterest 
A KI ac ute ki d ne y  i nj ur y 
A L T ala ni ne a mi n otra nsferase 
A RI ac ute res pi[INVESTIGATOR_1305] y  i ll ness 
A S T as partate a mi n otra nsferase 
A V atri o ve ntric ular 
A x M P a u xiliar y  me dici nal pr o d uct 
B C R B- cell rece pt or 
bI R V bi vale nt i nfl ue nza m o d R N A vacci ne 
B L Q bel o w t he li mit of q ua ntitati o n 
B N T 1 6 2 b 2 [COMPANY_007] / Bi o N Tec h C O VI D - 1 9 vacci ne 
C B E R Ce nter f or Bi ol o gics E val uati o n a n d Researc h ( U nite d States) 
C CI c ult ure -c o nfir me d i nfl ue nza 
CD C Ce nters f or Disease C o ntr ol a n d Pre ve nti o n ( U nite d States) 
C F R C o de of Fe deral Re g ulati o ns 
C h A d O x 1 - S C h A d O x 1 -S (rec o m bi na nt) S A R S -C o V -2 vacci ne ( Astra Ze neca) 
CI c o nfi de nce i nter val 
CI O M S C o u ncil f or I nter nati o nal Or ga nizati o ns of Me dical Scie nces 
C K creati ne ki nase 
C K D -E PI [INVESTIGATOR_303619] o nic ki d ne y  d isease epi [INVESTIGATOR_32450] o g y 
C O N S O R T C o ns oli date d Sta n dar ds of Re p orti n g Trials 
C O VI D - [ADDRESS_371236] u g -i n d uce d li ver i nj ur y 
D M C data m o nit ori n g c o m mittee 
D N A de o x yri b o n ucleic aci d 
E C et hics c o m mittee 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371237] u g Re g ulati n g A ut h orities Cli nical Trials 
(E ur o pea n Cli nical Trials Data base )
F D A F o o d a n d Dr u g A d mi nistrati o n ( U nite d States) 
Fi O [ADDRESS_371238] me nt t hera p y
I B i n vesti gat or’s br oc h ure 
I C D i nf or me d c o nse nt d oc u me nt 
I C H I nter nati o nal C o u ncil f or Har m o nisati o n of Tec h nical 
Re q uire me nts f or P har mace uticals f or H u ma n Use 
I C U i nte nsi ve care u nit 
I D i de ntificati o n 
I g G i m m u n o gl o b uli n G 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371239] ma n ual 
I R B i nstit uti o nal re vie w b oar d 
I R C i nter nal re vie w c o m mittee 
I R T i nteracti ve res p o nse tec h n ol o g y 
IR V i nfl ue nza m o d R N A vacci ne ( bI R V, mI R V, or tI R V) 
I S O I nter nati o nal Or ga nizati o n f or Sta n dar dizati o n 
I V i ntra ve n o us(l y) 
I W R i nteracti ve We b -base d res p o nse 
K DI G O Ki d ne y  Disease I m pr o vi n g Gl o bal O utc o mes 
L B B B left b u n dle bra nc h bl oc k 
L C I la b orat or y -c o nfir me d i nfl ue nza 
L F T li ver f u ncti o n test 
L L O Q l o wer li mit of q ua ntitati o n 
L N P li pi d na n o particle 
M C A R missi n g c o m pletel y at ra n d o m 
M D R me dical de vice re g ulati o n 
Me d D R A Me dical Dicti o nar y  f or Re g ulat or y  Acti vities 
mI R V m o n o vale nt i nfl ue nza m o d R N A vacci ne 
mI T T m o difie d i nte nt -t o -treat 
m o d R N A n ucle osi de -m o difie d messe n ger ri b o n ucleic aci d 
M QI me dicall y  q ualifie d i n di vi d ual 
m R N A messe n ger ri b o n ucleic aci d 
m R N A - 1 2 7 3 m R N A -1 2 7 3 S A R S -C o V -2 vacci ne ( M o der na) 
N A ne ura mi ni dase 
N/ A n ot a p plica ble 
N A A T n ucleic aci d a m plificati o n test 
N- bi n di n g S A R S -C o V -2 n ucle o pr otei n –bi n di n g 
NI n o ni nferi orit y 
NI M P n o ni n vesti gati o nal me dici nal pr o d uct 
NY H A Ne w Y or k Heart Ass ociati o n 
Omi O micr o n 
P A C L pr ot oc ol a d mi nistrati ve c ha n ge letter 
Pa O 2 partial press ure of o x y ge n, arterial 
P B M C peri p heral bl o o d m o n o n uclear cell 
P C R p ol y merase c hai n reacti o n 
P F S prefille d s yri n ge(s) 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 2 1 2 A b bre vi ati o n Ter m 
PI [INVESTIGATOR_32449] i n vesti gat or 
P P E pers o nal pr otecti ve e q ui p me nt 
P S S A [COMPANY_007]’ sSe ri o us A d verse E v e nt S u b missi o n Assista nt 
P T pr ot hr o m bi n ti me 
P V C pre mat ure ve ntric ular c o ntracti o n 
qI R V q ua dri vale nt i nfl ue nza m o d R N A vacci ne 
QI V q ua dri vale nt i nfl ue nza vacci ne 
Q Tc F Q T i nter val c orrecte d usi n g Fri dericia ’s f or m ula 
Q T L q ualit y  t olera nce li mit 
R C D C re verse c u m ulati ve distri b uti o n c ur ve 
R N A ri b o n ucleic aci d 
R R res pi[INVESTIGATOR_1305] y  rate 
R S V res pi[INVESTIGATOR_1305] y  s y n c y tial vir us 
R T -P C R re verse tra nscri pti o n – p ol y merase c hai n reacti o n 
S A E seri o us a d verse e ve nt 
S A D E seri o us a d verse de vice effect 
S A P statistical a nal y sis pla n 
S A R S se vere ac ute res pi[INVESTIGATOR_1305] y  s y n dr o me 
S A R S -C o V se vere ac ute res pi[INVESTIGATOR_1305] y  s y n dr o me c or o na vir us 
S A R S -C o V - [ADDRESS_371240] 
U S PI U nite d States pac ka ge i nsert 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 2 1 3 A b bre vi ati o n Ter m 
V E vacci ne efficac y 
VO C varia nt of c o ncer n 
VR B P A C Vacci nes a n d Relate d Bi ol o gical Pr o d ucts A d vis or y  C o m mittee 
W H O W orl d Healt h Or ga nizati o n 
W O C B P w o ma n/ w o me n of c hil d beari n g p ote ntial 
W T wil d t y pe 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 2 1 4 1 1. R E F E R E N C E S 
1Vi per Gr o u p C O VI D -1 9 Vacci ne Trac ker Tea m. C O VI D -1 9 vacci ne trac ker: 
[COMPANY_007]/ Bi o N Tec h: C o mir nat y.  A vaila ble fr o m: 
htt ps://c o vi d 1 9.trac k vacci nes. or g/ vacci nes/ 6/ .  Accesse d: [ADDRESS_371241] u g A d mi nistrati o n. F D A ro u n d u p: J ul y  8, 2 0 2 2. A vaila ble fr o m: 
htt ps:// w w w.f da. g o v/ ne ws -e ve nts/ press -a n n o u nce me nts/f da -r o u n d u p -j ul y- 8- 2 0 2 2. 
Accesse d: [ADDRESS_371242] u g A d mi nistrati o n. [COMPANY_007] -Bi o N Tec h C O VI D - 1 9 v acci nes. A vaila ble 
fr o m: htt ps:// w w w.f da. g o v/ vacci nes -bl o o d -bi ol o gics/c or o na vir us -c o vi d - 1 9- c ber -
re g ulate d -bi ol o gics/ pfizer -bi o ntec h -c o vi d - 1 9- vacci nes . Accesse d: [ADDRESS_371243] u g A d mi nistrati o n. Re vie w me m ora n d u m, 2 8 Mar 2 0 2 2: C B E R 
assess me nt of a sec o n d b o oster d ose of t he [COMPANY_007] Bi o N Tec h C O VI D -1 9 vacci ne 
( 0. 3 m L ) a d mi nistere d f oll o wi n g a first b o oster d ose of a n y F D A a ut h orize d or a p pr o ve d 
C O VI D -1 9 vacci ne i n certai n i n di vi d uals. A vaila ble fr o m: 
htt ps:// w w w.f da. g o v / me dia/ 1 5 7 3 6 4/ d o w nl oa d. Accesse d :0 2 J u n 2 0 2 2. 
5[COMPANY_007] a n d Bi o N Tec h. B N T 1 6 2 b 2 [ C O MI R N A T Y ( C O VI D -1 9 vacci ne, m R N A)] 
e val uati o n of a b o oster d ose (t hir d d ose). Vacci nes a n d Relate d Bi ol o gical Pr o d ucts 
A d vis or y  C o m mittee meeti n g briefi n g d oc u me nt, 1 7 Se p 2 0 2 1. A vaila ble fr o m: 
htt ps:// w w w.f da. g o v/ me dia/ 1 5 2 1 6 1/ d o w nl oa d. Accesse d :[ADDRESS_371244] of vacci nati o n o ne year after pa n de mic 
decl are d [ press release]. A vaila ble fr o m: htt ps:// w w w. pfizer.c o m/ ne ws/ press -
release/ press -release -detail/real -w orl d -e vi de nce -c o nfir ms -hi g h -effecti ve ness -pfizer.  
P u blis he d: 1 1 Mar 2 0 2 1. Accesse d: 0 2 J u n 2 0 2 2. 
7W orl d Healt h Or ga nizati o n. Wee kl y  e pi [INVESTIGATOR_32450] o gical u p date o n C O VI D- 1 9 -
2 9 Mar 2 0 2 2. A vaila ble fr o m: htt ps:// w w w. w h o.i nt/ p u blicati o ns/ m/ite m/ wee kl y -
e pi [INVESTIGATOR_32450] o gical -u p date - o n- c o vi d - 1 9 --- 2 9 -marc h - 2 0 2 2. Accesse d: 0 5 A pr 2 0 2 2. 
8W orl d Healt h Or ga nizati o n. Rec o m me n dati o ns an n o u nce d f or infl ue nza vacci ne 
co m p ositi o n f or t he 2 0 2 3- 2 0 2 4 n ort her n he mis p here infl ue nza seas o n . A vaila ble fr o m: 
htt ps:// w w w. w h o.i nt/ ne ws/ite m/ 2 4 - 0 2- 2 0 2 3 -rec o m me n dati o ns -a n n o u nce d -f or -i nfl ue nza -
vacci ne -c o m p ositi o n -f or -t he - 2 0 2 3- 2 0 2 4- n ort her n -he mis p here -i nfl ue nza -seas o n . 
Accesse d :[ADDRESS_371245] o ber 5, 2 0 2 3 
meeti n g su m mar y  m i n utes .A vaila ble fr o m: 
htt ps:// w w w.f da. g o v/ me dia/ 1 7 3 6 5 4/ d o w nl oa d . Accesse d: 0 6 Fe b 2 0 2 4. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge 2 1 5 1 0 C o he n K W, L i n der ma n S L, M o o die Z, et al. L o n git u di nal a nal y si s s h o ws d ura ble a n d 
br oa d i m m u ne me m or y  after S A R S -C o V -2 i nfecti o n wit h persisti n g a nti b o d y  res p o nses 
a n d me m or y  B a n d T cells. Cell Re p Me d. 2 0 2 1; 2( 7): 1 0 0 3 5 4. 
1 1 D u L , He Y, Z h o u Y, et al. T he s pi [INVESTIGATOR_303616] n of S A R S -C o V -- a tar get f or vacci ne a n d 
t hera pe utic de vel o p me nt. Nat Re v Micr o bi ol. 2 0 0 9; 7( 3): 2 2 6 - 3 6. 
1 2 C u n ha B A. I nfl ue nza: hist orical as pects of e pi [INVESTIGATOR_303620] a n d pa n de mics. I nfect Dis Cli n 
N ort h A m. 2 0 0 4; 1 8( 1): 1 4 1 - 5 5. 
1 3 M o nt o A S, Gra ve nstei n S, Elli ott M, et al. Cli nical si g ns a n d s y m pt o ms pre dicti n g 
i nfl ue nza i nfecti o n. Arc h I nter n Me d. 2 0 0 0; 1 6 0( 2 1): 3 2 4 3 - 7. 
1 4 C o wli n g BJ, C ha n K H, Fa n g VJ, et al. C o m parati ve e pi [INVESTIGATOR_32450] o g y  of pa n de mic a n d 
seas o nal i nfl ue nza A i n h o use h ol ds. N E n gl J Me d. 2 0 1 0; 3 6 2( 2 3): 2 1 7 5 - 8 4. 
1 5 Hall E. I nfl ue nza. C ha pter 1 2. I n: Ce nters f or Disease C o ntr ol a n d Pre ve nti o n. Hall E, 
W o di A P, Ha m b ors k y  J, et al, e ds. E pi [INVESTIGATOR_32450] o g y  a n d pre ve nti o n of vacci ne -pre ve nta ble 
diseases. 1 4t h e d. Was hi n gt o n, D C: P u blic Hea lt h F o u n dati o n; 2 0 2 1: 1 7 9 -9 2. 
1 6 I ulia n o A D, R o g us ki K M, C ha n g H H, et al. Esti mates of gl o bal seas o nal i nfl ue nza -
ass ociate d res pi[INVESTIGATOR_1305] y  m ortalit y : a m o delli n g st u d y. La n cet. 2 0 1 8; 3 9 1( 1 0 1 2 7): 1 2 8 5 - 3 0 0. 
1 7 C o x NJ, S u b bara o K. I nfl ue nza. La ncet. 1 9 9 9; 3 5 4( 9 1 8 6): 1 2 7 7- 8 2. 
1 8 P olac k F P, T h o mas SJ, Kitc hi n N, et al. Safet y a n d efficac y of t he B N T 1 6 2 b 2 m R N A 
C o vi d -1 9 vacci ne. N E n gl J Me d. 2 0 2 0; 3 8 3( 2 7): [ADDRESS_371246] u d y [ press release]. A vaila ble fr o m: 
htt ps:// w w w. pfizer.c o m/ ne ws/ press -release/ press- release -detail/ pfizer -a n d -bi o ntec h -
c o nfir m -hi g h -efficac y -a n d - n o-seri o us. P u blis he d: 0 1 A pr 2 0 2 1. Accesse d: [ADDRESS_371247] u g A d mi nistrati o n. E mer ge nc y  use a ut h orizati o n ( E U A) f or a n 
u na p pr o ve d pr o d uct: re vie w me m ora n d u m. [COMPANY_007] -Bi o N Tec h C O VI D -1 9 vacci ne 
B N T 1 6 2 b 2 as a si n gle b o oster d ose. A vaila ble fr o m: 
htt ps:// w w w.f da. g o v/ me dia/ 1 5 2 4 3 2/ d o w nl oa d. Accesse d: 0 2 J u n 2 0 2 2. 
2 1 [COMPANY_007]. [COMPANY_007] a n d Bi o N Tec h recei ve e x pa n de d U. S. F D A e mer ge nc y  use a ut h orizati o n 
of C O VI D -1 9 vacci ne b o oster t o i ncl u de i n di vi d uals 1 8 a n d ol der [ press release]. 
A vaila ble fr o m: htt ps:// w w w. pfizer.c o m/ ne ws/ press -releas e/ press -release -detail/ pfizer -
a n d -bi o ntec h -recei ve -e x pa n de d - us- f da -e mer ge nc y - use. P u blis he d: 1 9 N o v 2 0 2 1. 
Accesse d: 0 2 J u n 2 0 2 2. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
P F -0 7 9 2 6 3 0 7 ( C o m bi nati o n C O VI D -1 9 a n d I nfl ue nza m o d R N A Vacci ne) 
Pr ot oc ol C 5 2 6 1 0 0 1 
Fi nal Pr ot oc ol A me n d me nt 6, 0 9 Fe br uar y 2 0 2 4 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical Pr ot oc ol Te m plate P hase 1 2 3 4 ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_371248] u g A d mi nistrati o n. C or o na vir us ( C O VI D -1 9) up date: F D A rec o m me n ds 
incl usi o n of O micr o n B A. 4/ 5 co m p o ne nt f or C O VI D -1 9 v acci ne bo oster doses . 
A vaila ble fr o m :
htt ps:// pr o of p oi ntis olati o n.c o m/ br o wser? url = htt p % 3 A % 2 F % 2 F we b.arc hi ve. or g % 2 F we b 
% 2 F 2 0 2 4 0 1 2 4 0 3 2 0 2 0 % 2 F htt ps % 3 A % 2 F % 2 F w w w.f da. g o v % 2 F ne ws -e ve nts % 2 F press -
a n n o u nce me nts % 2 Fc or o na vir us -c o vi d - 1 9- u p date -f da -r ec o m me n ds -i ncl usi o n -o micr o n -
ba 4 5 -c o m p o ne nt -c o vi d -1 9 -vacci ne . Accesse d :[ADDRESS_371249] u g A d mi nistrati o n. G ui da nce f or i n d ustr y :t o xicit y gra di n g scale f or 
healt h y a d ult a n d a d olesce nt v ol u nteers e nr olle d i n pre ve nti ve vacci ne cli nical trials. 
R oc k ville, M D: Ce nter f or Bi ol o gics E val uati o n a n d Researc h; Se pte m ber 2 0 0 7. 
A vaila ble fr o m: htt ps:// w w w.f da. g o v/ me dia/ 7 3 6 7 9/ d o w nl oa d. Accesse d: 1 0 A u g 2 0 2 3. 
2 4 Fl uz o ne Q ua dri vale nt (i nfl ue nza vacci ne). U S prescri bi n g i nf or mati o n: Marc h 2 0 2 3. 
A vaila ble fr o m: htt ps:// w w w.f da. g o v/ me dia/ 1 7 0 0 1 9/ d o w nl oa d . Accesse d: 0 6 N o v 2 0 2 3. 
2 5 Fl ucel va x Q ua dri vale nt (i nfl ue nza vacci ne). U S prescri bi n g i nf or mati o n; Oct o ber 2 0 2 1. 
A vaila ble fr o m: htt ps:// w w w.f da. g o v/ me dia/ 1 1 5 8 6 2/ d o w nl oa d. Accesse d: 2 9 Mar 2 0 2 3. 
2 6 Fl uz o ne Hi g h -D ose Q ua dri vale nt. U S prescri bi n g i nf or mati o n: Marc h 2 0 2 3. A vaila ble 
fr o m: htt ps:// w w w.f da. g o v/ me dia/ 1 3 9 7 3 1/ d o w nl oa d?attac h me nt . Accesse d: 
0 1 N o v 2 0 2 3. 
2 7 [COMPANY_007]. [COMPANY_007] a n d Bi o N Tec h gra nte d F D A e mer ge nc y  use a ut h orizati o n of O micr o n 
B A. 4/ B A. 5 -a da pte d bi vale nt C O VI D -1 9 vacci ne b o oster f or a ges 1 2 y ears a n d ol der 
[ press release]. A vaila ble fr o m: htt ps:// w w w. pfizer.c o m/ ne ws/ press -release/ press- 
release -detai l/ pfizer -a n d -bi o ntec h -gra nte d -f da -e mer ge nc y -use -a ut h orizati o n. P u blis he d: 
3 1 A u g 2 0 2 2. Accesse d: 1 6 Se p 2 0 2 2. 
2 8 Ce nters f or Disease C o ntr ol a n d Pre ve nti o n. S y m pt o ms of C O VI D- 1 9. A vaila ble fr o m: 
htt ps:// w w w.c dc. g o v/c or o na vir us/ 2 0 1 9- nc o v/s y m pt o ms -testi n g/s y m pt o ms. ht ml. 
Accesse d: [ADDRESS_371250] 2 0 2 2 . A vaila ble fr o m : 
htt ps:// w w w. h hs. g o v/sites/ defa ult/files/secretarial -directi ve -c o vi d - 1 9- bi vale nt -vacci ne -
b o osters -y o u n ger -pe ds. p df . Accesse d: 2 2 Ja n 2 0 2 4. 
3 0 U S De part me nt of Healt h a n d H u ma n Ser vices. C O VI D - 1 9 v acci nes . 1 5 Dec 2 0 2 3. 
A vaila ble fr o m: htt ps:// w w w. h hs. g o v/c or o na vir us/c o vi d - 1 9- vacci nes/i n de x. ht ml . 
Accesse d: 2 2 Ja n 2 0 2 4. 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) 
D o c u m e nt A p pr o v al R e c or d 
D o c u m e nt N a m e: 
D o c u m e nt Titl e: 
Si g n e d B y: D at e( G M T) Si g ni n g C a p a cit y 0 9 0 1 7 7 e 1 9f e 5ff 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 2- F e b- 2 0 2 4 1 2: 2 7 ( G M T) P P D 
P P D 